Unorthodox Antimicrobial Combination Therapies for the Treatment of Multi-drug Resistant Gram-negative Infections by Phee, Lynette
 1 
Unorthodox Antimicrobial 1 
Combination Therapies for the 2 
Treatment of Multi-drug 3 




Lynette Phee  8 
Centre for Immunobiology 9 
Blizard Institute 10 
Barts and The London School of Medicine and Dentistry 11 
Queen Mary University of London 12 
 13 
Submitted in partial fulfilment of the requirements of the Degree of Doctor of Philosophy by 14 
the University of London 15 
 16 
Supervisor – Dr David Wareham 17 
  18 
 2 
Statement of Originality 19 
I, Lynette Mingyu Phee, confirm that the research included within this thesis is my own 20 
work or that where it has been carried out in collaboration with, or supported by others, 21 
that this is duly acknowledged below and my contribution indicated. Previously published 22 
material is also acknowledged below. 23 
I attest that I have exercised reasonable care to ensure that the work is original, and does 24 
not to the best of my knowledge break any UK law, infringe any third party’s copyright or 25 
other Intellectual Property Right, or contain any confidential material. 26 
I accept that the College has the right to use plagiarism detection software to check the 27 
electronic version of the thesis. 28 
I confirm that this thesis has not been previously submitted for the award of a degree by 29 
this or any other university. 30 
The copyright of this thesis rests with the author and no quotation from it or information 31 
derived from it may be published without the prior written consent of the author. 32 
 33 
Signature: Lynette M. Phee 34 
Date:  11/05/2018 35 
 3 
Details of collaboration and publications 36 
Systematic review of colistin combination therapies for the treatment of Gram-negative 37 
infections 38 
• Selection of studies for inclusion and critical appraisal of papers – Dr Frederick Pink 39 
(FP), Lynette Phee (LP) 40 
• Third party arbitrator for study inclusion/exclusion – Dr David Wareham (DW) 41 
• Search protocol, database search, data extraction and data analysis – Lynette 42 
Phee 43 
Unorthodox colistin combinations – in vitro experiments 44 
• In vitro susceptibility of A. baumannii to colistin – Comparison of methods against 45 
population analysis profile 46 
o Zone of inhibition measurements for disc diffusion assays (colistin 47 
susceptibility testing) – Muhd Haziq Fikry Abdul Momin, Lynette Phee 48 
o All other experimental design/work and data analysis – Lynette Phee 49 
• Screening colistin combinations in vitro 50 
o Etest synergy screening for colistin-daptomycin combination – Dr Michael 51 
Hornsey, Lynette Phee 52 
o All other experimental design/work and data analysis – Lynette Phee 53 
• In vitro confirmation of colistin-fusidic acid activity in time-kill assays 54 
o Determination of viable bacterial colony counts – Dr Jonathan Betts, 55 
Lynette Phee 56 
o All other experimental design/work and data analysis – Lynette Phee 57 
In vivo activity of colistin and fusidic acid combination therapy against A. baumannii 58 
infections 59 
• G. mellonella model 60 
o G. mellonella larvae injections – Dr Jonathan Betts, Dr David Wareham, 61 
Lynette Phee 62 
o Assessment of larval survival – Dr Jonathan Betts, Muhd Haziq Fikry Abdul 63 
Momin, Dr David Wareham, Lynette Phee 64 
o Ascertainment of purity of colistin solutions for G. mellonella treatment 65 
assays – Analytical chemistry department, GlaxoSmithKline, Stevenage, UK 66 
(as part of an ongoing collaboration with Dr John Barrett [Medicines 67 
Research Centre, GSK] and Dr Joseph Standing [Institute of Child Health, 68 
University College London] to study in vitro and in vivo pharmacokinetics of 69 
colistin and fusidic acid combination) 70 
o All other experimental design/work and data analysis – Lynette Phee 71 
 4 
• Murine lung infection model 72 
o Murine model design and experiment – Dr Crystal L. Jones and Dr Daniel V. 73 
Zurawski (Centre for Infectious Disease Research, Walter Reed Army 74 
Institute of Research, Silver Springs, USA). Done in collaboration, for the 75 
purposes of comparing G. mellonella model with muring lung infection 76 
model.  77 
• All Illustrations and assistance with G. mellonella injection video clip – Dr Charles 78 
Henn 79 
Publications (for details, please refer to appendix A and B): 80 
Phee L, Hornsey M, Wareham DW. In vitro activity of daptomycin in combination with low- 81 
dose colistin against a diverse collection of Gram-negative bacterial pathogens. Eur J Clin 82 
Microbiol Infect Dis. 2013 Oct;32(10):1291-4.  83 
Phee LM, Betts JW, Bharathan B, Wareham DW. Colistin and Fusidic Acid, a Novel Potent 84 
Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii 85 
Infections. Antimicrob Agents Chemother. 2015 Aug;59(8):4544-50.  86 
 87 
 88 
  89 
 5 
Abstract 90 
The rise of antimicrobial resistance (AMR) has culminated in the most pressing problem in 91 
modern medicine. The situation is most acute with regards to the management of multi- 92 
drug resistant Gram-negative infections (MDRGNB) with common infections increasingly 93 
untreatable due to rapidly dwindling therapeutic options. A solution to the problem of AMR 94 
is unlikely to be easily found, but revisiting and re-purposing existing antimicrobials is a 95 
viable approach in the medium term.  This study investigated the use of unorthodox 96 
antimicrobial combination therapies for the treatment of MDRGNB, with particular focus on 97 
agents of last resort. A systematic review of clinical studies highlighted the potential for 98 
polymyxin (colistin) combination therapies (e.g. colistin-rifampicin, colistin-carbapenems), 99 
although this could not be supported in a formal meta-analysis. A systematic approach for 100 
screening MDRAB for susceptibility to novel colistin combinations using multiple methods 101 
was employed and uncovered a number that were more potent than those previously 102 
identfied. The most potent combination that was consistently identified was colistin when 103 
combined with fusidic acid, despite this drug having no useful activity against MDRGNB on 104 
its own. The combination was further evaluated in static time-kill assays against a range of 105 
Gram-negative pathogens with defined resistance mechanisms, including to polymyxins 106 
and using invertebrate (Galleria mellonella) and murine models of MDRGNB infection. 107 
Colistin and fusidic acid combination therapy was subsequently used to successfully treat a 108 
case of ventilator-associated pneumonia due to MDR A. baumannii. This work highlights 109 
how older drugs can be re-purposed to tackle the problem of AMR using a precision 110 
medicine approach. Further studies to elucidate the mechanism of action of the colistin- 111 
fusidic acid combination and a formal clinical trial are warranted to investigate the potential 112 
utility of this combination in the treatment of MDRGNB with the expressed goal of bridging 113 
the current antimicrobial development gap.  114 
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1.1 Background 587 
1.1.1 Antimicrobial resistance – The problem 588 
Antimicrobial resistance (AMR) has risen to become the foremost pressing issue facing 589 
healthcare today. The number of publications in PubMed related to the key phrase 590 
‘antimicrobial resistance’ has increased exponentially since the 1950s (see Figure 1-1), 591 
highlighting the interest this area has received in the wider scientific community. The 592 
problem has been listed by policy makers as one of the biggest threats to society in current 593 
times, leading to the formation of national (e.g. The Review on Antimicrobial Resistance in 594 
the United Kingdom, The Interagency Taskforce for Antimicrobial Resistance (ITFAR) in the 595 
United States of America) and international (World Health Organisation, WHO) efforts to 596 
tackle the problem. (1, 2)  597 
Figure 1-1 Publications in PubMed with key phrase 'antimicrobial resistance'. 598 
(Statistics generated using data extracted from http://dan.corlan.net/medline-trend.html) (3) 599 
 600 
The former Prime Minister of the United Kingdom (UK), David Cameron, commissioned a 601 
review on AMR led by an economist, Jim O’Neill to delineate the impact of antimicrobial 602 
resistance and to put forth a structured plan to combat the problem. The commission 603 
estimated if antimicrobial resistance was left unchecked, it would claim 10 million lives per 604 
year by 2050, (2) which is more than the number of deaths due to all forms of cancer in 605 
2015 (8.8 million deaths), (4) and cost the global economy £66 trillion (more than 10 times 606 

































































would be impossible if we were to enter into a so-called ‘Post-Antibiotic Era’, when even 608 
trivial and common infections become untreatable. (6, 7) 609 
Antibiotics, together with improvement in living standards, sanitation, nutrition, public 610 
health infrastructure and vaccination programmes, have dramatically changed the 611 
landscape of human society, with fewer premature deaths and rising life expectancy. (8) As 612 
an illustration of the burden of infectious diseases on mortality, the top 3 causes of death in 613 
the USA in 1900 (before the discovery of antibiotics) were pneumonia, tuberculosis and 614 
‘diarrhoea and enteritis’ respectively. These accounted for almost a third of all causes of 615 
death registered in that year alone. In contrast, by 1997, the top 3 causes of mortality were 616 
heart disease, cancer and stroke accounting for more than half of all deaths, and the top 3 617 
causes of deaths from infectious diseases (pneumonia, influenza, HIV) accounting for less 618 
than 5%. (9) 619 
A similar trend in decline of mortality rates was observed in England and Wales. At the turn 620 
of the 20th century, a third of all deaths were attributed to infectious diseases. Furthermore, 621 
a third of these deaths were due to tuberculosis alone. (10) By 2000, only 11% of all 622 
diseases were attributed to infectious diseases. This trend over the course of the 20th 623 
century is somewhat more marked in childhood mortality. In the year 1901, more than half 624 
of deaths from infectious diseases were in children under the age of 15 (25% from 625 
gastrointestinal causes and 13% from tuberculosis). In 2000, only 0.5% of all deaths were 626 
in children under the age of 15, and only 0.6% of all deaths from infectious diseases were 627 
attributed to tuberculosis (all ages). (11) Likewise, the leading causes of mortality between 628 
the start of the 20th and 21st centuries are remarkably different. Whilst infectious disease 629 
was a leading cause of death in the former, cancer (albeit, diagnosis of cancer was difficult 630 
then, and life expectancy shorter) and circulatory diseases (coronary artery disease was 631 
only beginning to gain recognition at this point, and circulatory diseases included rheumatic 632 
fever and its complications) represented less than 1% and 6% of all deaths respectively. 633 
(10) 634 
By 2015, infectious diseases did not feature in the leading 5 causes of mortality in England 635 
and Wales. Dementia (11.6%), ischaemic heart disease (11.5%), stroke (6.5%), chronic lung 636 
disease and lung cancer were the top 5 causes of death in 2015, accounting for 41.5% of 637 
all deaths. (12) 638 
Though it is often difficult to delineate the extent of the impact of clinical use of antibiotics 639 
on mortality trends, (13-15) it is undeniable that antibiotics currently play a fundamental role 640 
in modern medicine, without which many “medical marvels” of our times including life- 641 
changing surgery and advances in cancer medicine would not be possible. Without 642 
efficacious agents to combat pathogenic infectious organisms, we might not only see the 643 
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return of the 19th century’s mortality trends, there may be indirect excess mortality due to 644 
the inability to deliver care (e.g. surgery). (7, 16)  645 
Despite the relentless march of antimicrobial resistance, and the repeated calls by medical 646 
professionals and policy makers to address the problem of our dwindling therapeutic 647 
options, we have now entered a period of ‘antimicrobial discovery void’, where the last 648 
novel class of antibacterial agent discovered was back in the 1980s. Indeed, the number of 649 
novel classes of antibacterials discovered has been declining decade upon decade since 650 
the 1950s. See Figure 1-2. Multiple problems compound the issues behind antibacterial 651 
discovery and development, and these include lack of financial incentive (from the point of 652 
view of pharmaceutical companies) as antibacterial screening programmes and relevant 653 
clinical trials require a large amount of time, effort and resources, and the returns are much 654 
smaller (antibacterials tend to be short course treatments, and resistance may render them 655 
useless before long) compared with treatments for chronic illness (e.g. hypertension, 656 
diabetes mellitus) or cancer therapy. (1, 2, 6, 7, 17) 657 
Clinical trials for new antibacterial agents are often very expensive, and the goal is often to 658 
show that the new agent is non-inferior to the established standard of care, as ethically 659 
speaking, all trials have to adhere to the rule of ‘do no harm’, and superiority trials, in most 660 
cases, would be unethical to perform. (18, 19)  661 
Moreover, it has been postulated that the ‘Golden Age’ of antibacterial discovery has come 662 
and gone, with suitable agents (efficacious and non-toxic compounds) for clinical use 663 
having already been discovered by either deliberate screening programmes or serendipity. 664 
It is widely opined that complete overhaul in the way we look for candidate novel agents is 665 
required if the antibacterial development pipeline were to be revitalised. (7)  666 
The situation is particularly acute where therapeutic options for Gram-negative bacterial 667 
(GNB) infections are concerned. In a 2009 report released by the European Centre for 668 
Disease Prevention and Control (ECDC) and European Medicines Agency (EMEA) Joint 669 
Working Group, (20) emphasised the contrast between the contribution of antibiotic- 670 
resistant Gram-positive and Gram-negative pathogens. Data from the European 671 
Antimicrobial Resistance Surveillance Network (EARS-net) were analysed for the year of 672 
2007 (includes data collected from EU member states, Iceland and Norway), to highlight the 673 
burden of antibiotic resistance. Analyses performed were restricted to the 4 main types of 674 
infection, namely bloodstream infections, respiratory tract infections, skin and soft tissue 675 
infections and urinary tract infections. Representative antibiotic-resistant pathogens 676 
included were methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 677 
Enterococcus faecium (VRE) and penicillin-resistant Streptococcus pneumoniae (PRSP) for 678 
Gram-positive organisms; and 3rd-generation cephalosporin resistant Escherichia coli 679 
(3GCREC), 3rd-generation cephalosporin resistant Klebsiella pneumoniae and carbapenem- 680 
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resistant Pseudomonas aeruginosa for Gram-negative organisms. Although the total 681 
number of cases of infection were similar in both groups – 192 800 for Gram-positives, and 682 
193 300 for Gram-negatives, the number of excess deaths due to antibiotic-resistance was 683 
nearly treble for Gram-negatives (n = 18 200) compared with that of Gram-positives (n = 6 684 
900). Excess inpatient days were approximately 18% higher due to antibiotic-resistant 685 
Gram-negative compared to Gram-positive infections. Taking into account healthcare- 686 
related costs and loss of productivity due to absence or mortality, the estimated cost 687 
attributed to antibiotic-resistant Gram-negative infections (€867 million) was 30% higher 688 
than that of Gram-positives (€666 million) for the year of 2007. 689 
Figure 1-2 Antibacterial discovery time-line – novel agents. 690 
 691 
An observational study by Abe et al in 2010 of 259 intensive care unit (ICU) patients in a 692 
teaching hospital in Japan between 2000 – 2008, investigating the differences between 693 
septic patients with Gram-positive and Gram-negative bacteraemia revealed that Gram- 694 
negative bacteraemia, whilst being less common than Gram-positive bacteraemia (n = 70 695 
and n = 168 respectively), was more likely to be associated with septic shock (signs and 696 
symptoms of sepsis with evidence of multi-organ failure and severe hypotension despite 697 
supportive measures; 36%), and Gram-positive bacteraemic patients being less critically ill 698 
(15%). (21) Similarly, mortality was higher in those with Gram-negative bacteraemia (40%) 699 
compared with Gram-positive (28%), which may be due in part to the latter presenting in 700 
younger patients (mean 56.2 years) compared with the former (mean 61.7 years). Mean 701 
levels of inflammatory markers, C-reactive protein (CRP) and interleukin-6 (IL-6) were 702 
similarly higher amongst the Gram-negative group compared with the Gram-positive group, 703 






























outcomes associated with Gram-negative sepsis, with the higher incidence in the elderly, is 705 
considerably more concerning as the entire global population continues to age. (21) 706 
Despite this, the development pipeline landscape for antibacterials over the past decade 707 
appear to address problems for antibiotic-resistant Gram-positives rather than Gram- 708 
negatives. (22) 709 
There has been an uptick in the number of systemic antibacterials brought to market in the 710 
past few years, likely buoyed by the concerted efforts of academia, healthcare 711 
professionals, policy makers, industry and the media. See Figure 1-3 for the antibacterial 712 
approval trends over the past 3 decades in the United States (USA).  713 
Figure 1-3 United States (US) Food and Drug Administration (FDA) systemic antibacterial 714 
approvals. 715 
(23, 24) 716 
 717 
However, a closer look at the antibacterial spectra of activity of the new agents reveals a 718 
preponderance towards Gram-positive organisms (see  719 
Figure 1-4), with only 1 agent approved in the past 15 years from an entirely novel class – 720 
Daptomycin (only active against Gram-positive organisms). Of the 4 antibacterials with 721 
Gram-negative activity, 3 (ceftazidime/avibactam, ceftolozane/tazobactam, 722 
meropenem/vaborbactam) were marketed to specifically target MDR Gram-negative 723 
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It is important to note that whilst components of these drug/inhibitor combinations may be 725 
novel, the overall antibacterial effect remains rooted in the b-lactam ring, and dependent on 726 
binding to penicillin-binding proteins. This may potentially see these drugs falling foul to 727 
adaptive processes generated by the target bacteria, rendering the new compounds 728 
useless. Indeed, within a mere few years of use, despite instituting strict antimicrobial 729 
stewardship and sparing usage of the new agents, reports of resistance have already 730 
surfaced. (25-28)  731 
Figure 1-4 U.S. FDA approvals for systemic antibacterials by spectrum of activity.  732 
Others include antimicrobials with only anaerobic activity (fidaxomicin, secnidazole), gut 733 
decontamination only (rifaximin) and anti-tuberculosis activity only (bedaquiniline). 734 
 735 
The argument that most “easily discoverable” antimicrobial compounds have already been 736 
found and put through the rigor of research and development, either failing to reach market 737 
due to lack of potency, stability and/or efficacy, or excessive toxicity in animal or human 738 
studies, or being the fortunate few that enter the clinical antibacterial armoury, has been 739 
repeatedly offered as the fundamental problem behind the lack of novel antimicrobial 740 
discovery. (29) This is evident from the tailing off of the number of novel classes of 741 
antibacterials discovered over the past few decades. The hurdles facing discovery of new 742 
classes possessing new mechanisms of action against Gram-negative bacteria are even 743 
higher still, given the exceptional protection the Gram-negative outer membrane affords 744 
these organisms. (30) Finding new ways to traverse this barrier, whilst maintaining overall 745 
antibacterial potency and minimising toxicity to eukaryotic cells is a tall order indeed, likely 746 



























development. Coupling this with the well-established high cost of bringing a potential 748 
antibacterial compound (proven to be effective in vitro) to market, often in excess of USD$1 749 
billion, (31) novel class anti-Gram-negative agents are a tough sell to pharmaceutical 750 
companies, which are the only institutions with the ability to undertake the task. 751 
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1.1.2 Antibacterials – Mechanism of action 752 
Bacteria, being prokaryotes, are significantly different from human eukaryotic cells, thus 753 
providing a number of suitable specific targets for effective anti-infective chemotherapy 754 
that remain relatively safe to use in humans. This is evident by the stark contrast in the 755 
number of efficacious antibacterial agents discovered and introduced into clinical medicine 756 
compared with anti-fungal agents (fungi, being eukaryotes, with many similar cellular 757 
characteristics to human cells).  758 
The mechanisms of antibacterial activity may be broadly classified in groups based on its 759 
target site – (a) biosynthesis of bacterial cell wall, (b) bacterial protein synthesis, (c) bacterial 760 
nucleic acid synthesis, (d) bacterial cell membrane. Antibacterial mechanisms of action by 761 
their respective classes are summarised in Figure 1-5. 762 




1.1.2.1 Target site: Cell wall 766 
Antibacterials can be broadly divided into their site or target of action. Perhaps the best 767 
known of all antibacterials, and the most widely used to date in clinical practice are the 768 
beta-lactams. These include the so called 'grandfather' of all antibiotics, penicillin, as well 769 
as broader spectrum cephalosporins and one of the 'agents of last resort', carbapenems. 770 
Beta-lactams target the synthesis of the bacterial cell wall, which are unique to these 771 
prokaryotes. It is thus unsurprising that they possess superior safety profiles compared 772 
with some of the more toxic agents, and being a class of antibacterials that have been used 773 
for decades, the collective knowledge of their efficacy, toxicity, mechanism of action and 774 
safety in specific patient population groups are unrivalled. Targeting the unique bacterial 775 
cell wall provides a reasonable strategy for effective antibacterial action.  776 
The cell wall comprises of a peptidoglycan layer, which is unique to bacteria, and provides 777 
rigidity to the cell and protects it from trauma. The peptidoglycan polymer is formed of 778 
repeated disaccharide subunits comprising N-acetyle-glucosamine (NAG) and N- 779 
acetylmuramic acid (NAM). Parallel polymers are bound together by cross-linking adjacent 780 
NAM peptide chains by a process known as transpeptidation. This is the final stage of cell 781 
wall biosynthesis and forms the target site of beta-lactams (competitive inhibition, whereby 782 
the 4-member beta-lactam ring acts as an analogue to the peptide chain preventing the 783 
formation of the peptide bond). (32) 784 
Other antibacterials that target the bacterial cell wall include potent Gram-positive biocide 785 
glycopeptides (forms a complex with terminal D-alanyl-D-alanine on NAM thus preventing 786 
transpeptidation (33, 34)), topical antibiotic bacitracin (inhibits lipid phosphatase, preventing 787 
the release of the peptidoglycan from its C55-isoprenyl pyrophosphate transport carrier, 788 
which brings the molecule to the periplasmic space (35)), broad-spectrum agent fosfomycin 789 
(irreversibly inhibits MurA, which catalyses the early phase of peptidoglycan synthesis - 790 
conversion of uridine diphosphatase N-glucosamine [UDPGlcNAc] to uridine diphosphatase 791 
N-acetylmuramic acid [UDPMurNAc], both of which form the basic building blocks of 792 
peptidoglycan (36)) and anti-mycobacterial agent cycloserine (inhibits conversion of L- 793 
alanine to D-alanine, and the formation of D-alanyl-D-alanine (32)).  794 
1.1.2.2 Target site: Cell membrane 795 
Polymyxins and daptomycin disrupt the cell membrane. Additionally, polymyxins are active 796 
against the Gram-negative outer membrane. The loss of the integrity of these membranes 797 
eventually leads to cell death.  798 
Daptomycin is a cyclic lipopeptide antimicrobial, which inserts its lipophilic tail into the 799 
bacterial cell membrane, thereby resulting in rapid depolarisation of the cell membrane and 800 
efflux of potassium ions, culminating in cell death. (37, 38) 801 
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The exact mechanism of action of polymyxins is not fully understood. Polymyxins are 802 
amphipathic polypeptides consisting cationic hydrophilic heads and lipophilic fatty acid 803 
tails. This allows high affinity for the negatively charged outer membrane, and following 804 
successful binding, disruption of the lipid bilayer membrane with the fatty acid tail. 805 
Additionally, it has been proposed that polymyxins promote contact between the inner 806 
leaflets of the outer and inner membranes, allowing rapid exchange of phospholipids 807 
between them, effectively destabilising the integrity of the cell membrane. This cumulative 808 
‘detergent’ effect on the cell membrane leads to leakage of the cell contents, and the 809 
induction of the intracellular hydroxyl radical pathway, ultimately resulting in rapid cell 810 
death. (39-41) 811 
1.1.2.3 Target site: Protein synthesis 812 
Bacterial protein synthesis is essential to cell function and is broadly subdivided into 3 813 
stages. Initiation - the attachment of tRNA to corresponding amino acids by specific 814 
aminoacyl tRNA synthases, followed by the transpeptidation phase whereby an initiation 815 
complex is first formed by assembly of the necessary components including the 30S 816 
ribosome-mRNA complex (the former bound to the start codon of the latter), the 817 
formylmethionyl tRNA (which binds to the peptidyl, P site), and finally a 50S ribosomal 818 
subunit completes the functional initiation complex. Elongation - A tRNA corresponding 819 
with the next triplicate codon binds to the empty aminoacyl, A site, following which, 820 
transpeptidation occurs, linking the amino acids, creating a growing peptide chain. The 821 
chain moves to the P site, allowing the next tRNA to occupy the A site and continue the 822 
process. This is known as translocation. Termination - the cycle continues until a stop 823 
codon is introduced at the A site. This terminates the process, and the peptide chain is 824 
released and the ribosomal subunits detaches from the mRNA. (42) 825 
The prokaryotic bacterial ribosome (70S) being rather distinct from eukaryotic human 826 
ribosome (80S, comprising 40S and 60S subunits), affords a wealth of potential targets for 827 
antibacterial activity. It is thus unsurprising that this is the site of action for a number of 828 
unique classes of antimicrobial agents discovered to date. 829 
Aminoglycosides exert their antimicrobial activity by binding the A-site of the 30S subunit, 830 
thus interfering with the translocation step leading to errors in proofreading (misreads, 831 
premature termination). The resultant aberrant protein, when incorporated into the cell 832 
membrane, disrupts its integrity thereby allowing further cellular uptake of the antimicrobial. 833 
(43, 44) 834 
Tetracyclines (e.g. doxycycline) inhibit the binding aminoacyl-tRNA to the A-site by 835 
interacting with the A-site codon on the mRNA of the 30S subunit. (45, 46) 836 
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Multiple classes of antimicrobials inhibit the transpeptidation phase of elongation. 837 
Chloramphenicol, lincosamides (e.g. clindamycin) and type A streptogrammins inhibit the 838 
peptidyl transferase reaction. Chloramphenicol prevents the binding of tRNA to the A-site, 839 
(47, 48) whilst linconsamides and type A streptogramins interact with both the peptidyl 840 
group at the P-site and aminoacyl group at the A-site of the 50S subunit. (49-51) 841 
Macrolides and type B streptogramins prevent the formation of the growing peptide chain, 842 
and subsequently lead to the formation of incomplete peptide chains. (48, 51, 52) Type A 843 
(e.g. pristinamycin II) and Type B (e.g. pristinamycin I) streptogrammins act synergistically 844 
against susceptible Gram-positive organisms (e.g. S. aureus) as Type A streptogrammins 845 
binding aminoacyl-tRNA-free A-site result in a conformational change leading to an 846 
increase affinity for Type B streptogrammins. (51) Additionally, macrolides, lincosamides 847 
and streptogrammins are collectively known as the MLS group of antimicrobials due to the 848 
similarities in their resultant antimicrobial activity.  849 
The mode of action of oxazolidinones (e.g. linezolid) is not fully elucidated to date, though 850 
the common consensus suggests inhibition of an early stage of protein synthesis, possibly 851 
the formation of the initiation complex and/or the interaction with either the P-site or A-site 852 
of the 50S subunit. (53, 54) 853 
Fusidic acid, together with elongation factor G (EF-G) and guanosine diphosphate (GDP) 854 
form a stable complex after one round of translocation (guanosine triphosphate, GTP 855 
hydrolyses to GDP to provide energy for translocation from A-site to P-site), thereby 856 
preventing subsequent translocation and halting protein synthesis. (55, 56) 857 
1.1.2.4 Target site: Bacterial DNA synthesis 858 
Quinolones, metronidazole and nitrofurantoin inhibit bacterial DNA synthesis. Quinolones 859 
bind, and thereby inhibit the actions of DNA topoisomerase IV and DNA gyrase, which are 860 
integral to the synthesis of DNA. (57) 861 
Metronidazole, undergoes reduction in anaerobic bacteria. This metabolite disrupts the 862 
helical DNA structure, thus inhibiting DNA synthesis, resulting in cell death. (58) 863 
Sulphonamides were discovered in the early parts of the 20th century, and introduced into 864 
clinical practice at approximately the same time as penicillin. (59) They target a different 865 
part of the bacterial cell, namely the folate synthesis. Folate metabolism is an essential part 866 
of DNA synthesis, as such, inhibition of this activity is not limited to the antibacterial 867 
spectrum. Depending on the concentration of the drug given, cells affected by folate 868 
inhibitors include fungi (e.g. Pneumocystis jiroveci), protozoa (e.g. Plasmodium spp., 869 
Leishmania spp., Toxoplasma gondii), and mammalian cells. (60) The latter may manifest as 870 
toxicity in clinical use (e.g. bone marrow suppression).  (60-62) 871 
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As bacteria are unable to absorb folic acid, synthesis of folate from para-aminobenzoic acid 872 
(PABA) is integral to and interruption of this fundamental pathway is the basis of 873 
antimicrobial activity asserted by sulphonamides (inhibition of dihydropteroate synthase as 874 
a structural analogue of PABA) and trimethoprim (inhibition of dihydrofolate reductase). (60, 875 
61) Potent synergy between the 2 drugs, which exert their antibacterial effects on 876 
sequential steps in the folate synthesis pathway, led to the introduction of the combination 877 
cotrimoxazole in the 1980s. (62) Cotrimoxazole is still widely used as both a therapeutic 878 
and prophylactic agent for a range of infections including those caused by a variety of 879 
Gram-negative (e.g. urinary tract infections caused by Enterobacteriaceae) and Gram- 880 
positive (e.g. S. aureus cellulitis including methicillin-resistant strains such as USA300 881 
clone) organisms, fungal pathogen P. jiroveci (causes atypical pneumonia in 882 
immunosuppressed patients particularly those with HIV) and gastrointestinal protozoan 883 
pathogens (e.g. Cyclospora spp. and Isospora spp.). (62)  884 
1.1.2.5 Other/multiple target sites 885 
Nitrofurantoin belongs to a class of antimicrobials, nitrofurans, is a synthetic compound 886 
which is almost exclusively used for the treatment of urinary tract infections. Despite being 887 
in clinical use for over half a century, the mechanism of action of nitrofurantoin remains 888 
incompletely understood to this day. An initial intracellular reduction step is important, as 889 
the metabolites appears to confer its antimicrobial activity. (63) The reduced metabolites 890 
bind to a variety of intracellular macromolecules including ribosomal proteins (inhibiting 891 
translation) and DNA (resulting in DNA strand breaks). (64, 65)  892 
Rifamycins (e.g. rifampicin), another old antimicrobial with broad-spectrum activity against 893 
Gram-positive (e.g. S. aureus) and Gram-negative organisms (e.g. Neisseria meningitides), 894 
is also the lynchpin of anti-tuberculous therapy. Rifamycins bind to the b-subunit of DNA- 895 
dependent RNA-polymerase, thus impeding the synthesis of messenger RNA (mRNA), one 896 
of the crucial ingredients of protein synthesis. (66) 897 
 38 
1.1.3 Antibacterials – Mechanisms of resistance 898 
Figure 1-6 Antimicrobial resistance mechanisms. 899 
 900 
AMR is commonly subdivided into the following 5 categories – Enzymatic deactivation, 901 
decreased permeability, efflux of antimicrobial, interfering with binding of target site, and 902 
adaptive alternative to inhibited process. (67) See Figure 1-6 for a general depiction of 903 
these mechanisms. Enzymatic deactivation of antimicrobials may involve modification of 904 
the compound (e.g. aminoglycoside modifying enzymes (AME)) thereby interfering with their 905 
ability to bind with the target site, (68) or disintegration of the molecule (e.g. b-lactamases). 906 
(69, 70) Decreased permeability or uptake of an antibacterial is an effective way of 907 
excluding antimicrobials, often resulting in high level phenotypic resistance (elevated MICs). 908 
This mechanism is usually employed by Gram-negative bacteria, where its outer membrane 909 
already serves to exclude several classes of antimicrobials (e.g. macrolides, glycopeptides), 910 
and the passage of many antimicrobials (e.g. aminoglycosides, carbapenems) through the 911 
outer membrane hinges on the presence of compatible porin channels (water-filled 912 
channels found within the lipid bilayer membrane allowing the passage of hydrophilic 913 
molecules otherwise excluded by the hydrophobic membrane). (71) Decreased permeability 914 
may be due to reduction (72) or modification of these porins (e.g. OmpF/OmpC found in E. 915 
coli, OprD in P. aeruginosa), or change in type of porin expressed (e.g. downregulation of 916 
OmpF and upregulation of OmpC in nutrient-rich environments leading to decreased 917 
uptake of b-lactams). (73) Additionally, efflux pumps remove antimicrobials from the 918 
bacterial cell. A number of efflux pumps are involved in the removal of multiple classes of 919 
compounds, conferring multi-drug resistance (e.g. AcrAB-TolC, best described in E. coli, 920 
expels a variety of compounds including chloramphenicol, quinolones, tetracyclines, 921 
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rifampicin, fusidic acid and b-lactams). AMR may also be attained by interfering with the 922 
binding of the molecule with the target site. The target site may be modified (e.g. reduction 923 
or neutralisation of charge of the lipopolysaccharide (LPS) component on the Gram- 924 
negative outer membrane through mutations in PmrAB/PhoPQ/LpxACD reduces binding of 925 
polymyxins (74-76)), protected (e.g. plasmidic Qnr genes encode of DNA homologue for the 926 
fluoroquinolone target sites DNA gyrase and topoisomerase IV) or overexpressed thereby 927 
bypassing the otherwise deleterious effect of the antimicrobial (e.g. increased production of 928 
dihydrofolate reductase and dihydropteroic acid synthase raises the concentration of 929 
trimethoprim and sulfamethaxazole required to inhibit the bacterium, resulting in resistance 930 
(77, 78)). Finally, an alternative metabolic pathway may act as a bypass route to an 931 
essential task undertaken by the bacterium, for which the antibiotic targets (e.g. the action 932 
of b-lactams on peptidoglycan production in cell wall synthesis - mecA encodes for 933 
alternative penicillin-binding protein, PBP2’, with reduced affinity for b-lactam antibiotics in 934 
S. aureus resulting in MDR strain commonly known MRSA (79)). 935 
AMR determinants may be chromosomally encoded or acquired from mobile elements. 936 
Chromosomally encoded resistance determinants are usually passed on vertically, to 937 
daughter cells. The spread of the resistance determinants in this fashion is generally limited 938 
to clonal expansion, restricting the rate of transmission to the doubling time of host 939 
organism. This is in stark contrast to resistance encoded on mobile elements. Mobile 940 
elements (i.e. plasmids, transposons, integrons, integrated sequences) are pieces of DNA 941 
that have the ability to move from one host to another without having to undergo cell 942 
division. This is also known as horizontal transmission. Mobile elements may engage in 943 
horizontal transmission by 3 routes – transformation (uptake and integration of ‘naked’ DNA 944 
sequences by competent host cell), transduction (via a bacteriophage), and conjugation 945 
(cell to cell transfer of plasmids). (80)  946 
Plasmids are closed circular loops of DNA, which can be transferred from one bacterium to 947 
another by conjugation. (81) Additionally, plasmids are able to replicate independently of 948 
the host bacterium, allowing for a rapid expansion and thus, exponential transmission of 949 
resistance determinants it harbours.  950 
Bacteriophages are viruses that infect bacteria, which may subsequently carry away pieces 951 
of donor bacterial DNA and inserted into a recipient thereafter. DNA sequences transferred 952 
in this manner may be naked DNA sequences or plasmids.  953 
Transposons are a type of mobile DNA element that are capable of random recombination 954 
outside of the usual recA system of homologous recombination. Transposons carrying 955 
resistance determinants are thus able to confer antimicrobial resistance to a wide array of 956 
recipient cells via bacteriophages or conjugative plasmids. A subset of transposons, 957 
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conjugative transposons (e.g. Tn916 from Enterococcus faecalis carrying tet(M) conferring 958 
resistance to tetracycline-minocycline), are able to transfer without bacteriophages or 959 
plasmids. (82)   960 
Furthermore, resistance determinants might be expressed phenotypically or may be 961 
quiescent (where the presence of the molecular gene does not translate into real world 962 
resistance). The latter may be ‘switched on’ or induced in the presence of specific 963 
antimicrobials, potentially resulting in treatment failure. An example of this is the 964 
constitutive Type I b-lactamase gene, AmpC, carried on the chromosome of some 965 
Enterobacteriaceae (e.g. Enterobacter cloacae, Citrobacter freundii, Serratia marcescens). 966 
AmpC is expressed at low levels, under the inhibitory regulation of ampR. On exposure to 967 
b-lactams, notably penicillins, cefoxitin or imipenem, a conformational change in ampR 968 
leads to the overexpression of AmpC, resulting in high level resistance to a range of b- 969 
lactams including penicillins, older and 3rd generation cephalosporins (e.g. cefuroxime, 970 
ceftriaxone). (83, 84) 971 
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1.1.4 Examples of multi-drug resistant Gram-negative 972 
bacteria 973 
1.1.4.1 Multi-drug resistant mechanism – extended-spectrum b- 974 
lactamases 975 
In a perfect storm of circumstances, many successful pathogenic strains of Gram-negative 976 
bacteria carry multiple resistance determinants, which are expressed phenotypically, and 977 
most worryingly of all, as virulent as their antibiotic-susceptible wild-type counterparts. (85) 978 
Multi-drug resistance is described in a tier-wise fashion to denote their relative in vitro 979 
resistance to antimicrobial agents and hence the number of viable therapeutic options. 980 
Multi-drug resistance (MDR) refers to bacteria that are resistant (or not susceptible) to at 981 
least one member from 3 or more classes of antibacterials; extensively drug resistant (XDR) 982 
bacteria are only susceptible to 2 or fewer classess of antibacterials (being resistant to at 983 
least one agent from the rest); pan-drug resistant (PDR) bacteria are resistant to all known 984 
classes of antibacterials. (86) 985 
Some of the best described MDR Gram-negative bacteria in clinical medicine are known by 986 
their b-lactamase component, reflecting perhaps how successful b-lactamase enzymes are 987 
in establishing infection in spite of the vast array of antimicrobial treatments at our 988 
disposable, and widespread geographically. b-lactamases are a large family of enzymes, 989 
which may be found on the bacterial chromosome (intrinsic) or on mobile genetic elements, 990 
and exist in both Gram-positive and Gram-negative bacteria, displaying their ubiquity, 991 
versatility and adaptability.  992 
Of the vast array of MDR mechanisms described to date, perhaps the most ‘infamous’ in 993 
clinical medicine belong to the b-lactamase family – extended-spectrum b-lactamases 994 
(ESBLs) and carbapenemases (organisms carrying these enzymes are known collectively as 995 
carbapenemase-producing organisms or CPO). ESBLs are typically resistant to penicillins 996 
(excluding b-lactam/b-lactamase inhibitor combinations in most instances), with variable 997 
resistance to cephalosporins depending on the specific subtype of ESBL. In the 1980s and 998 
1990s, TEM and SHV dominated the ESBL landscape, largely a problem in hospital- 999 
acquired infections (usually in K. pneumoniae), necessitating broader-spectrum b-lactam 1000 
therapy due to efficient hydrolysis of penicillins including aminopenicillins and early 1001 
generation cephalosporins (e.g. cefalexin). Variants of TEM and SHV have been described 1002 
and the subfamily number in the hundreds (based on specific amino acid substitutions), 1003 
with variable activity against cephalosporins. This precipitated a practice of the use of 1004 
newer cephalosporins (e.g. cephamycins and 3rd generation cephalosporins), which 1005 
retained activity against most of these ESBLs (some strains with loss of non-specific outer 1006 
membrane porins OmpK35 and OmpK36 in K. pneumoniae may lead to resistance to 1007 
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cephamycins (87)), for treatment of nosocomially acquired infections. (88) It was not till the 1008
late 1990s and early 2000s, with the rise of CTX-M, that ESBLs shifted from a niche 1009
problem in hospitals to a tangible threat affecting the wider population. CTX-M was first 1010
described in the early 1990s, having mobilised from chromosomal b-lactamase genes in 1011
Kluyvera spp. onto mobile genetic elements, and transferred by horizontal gene transfer, 1012
into other Gram-negative bacteria, notably the ubiquitous Enterobacteriaceae. CTX-M 1013
differs from the earlier TEM and SHV ESBLs due to their ability to hydrolyse the newer 1014
cephalosporins, including 3rd generation agents, cefotaxime, ceftazidime and ceftriaxone. 1015
(89) These broad-spectrum agents were, at the time, used widely in treatment of wide 1016
variety of infections from pneumonia to pyelonephritis and a cornerstone of the sepsis 1017



























spectrum of activity (active against both Gram-positive and Gram-negative bacteria), 
superior pharmacometric parameters (compared with non b-lactam antibiotics) and 
simplicity of the dosing regimen, they have risen to become ‘work-horse’ antibiotics, used 
either empirically or as second line therapy, singly or in combination. (90, 91) The rise of 
CTX-M in hospital-acquired infections, and eventually with the integration into successful 
clone E. coli sequence type 131 (ST131) carrying plasmids (most notably IncF) with 
numerous genes encoding for both virulence factors and antibiotic resistance determinants 
including blaCTX-M-15 and aac(6’)-lb-cr and into the community, with resistance to penicillins 
and cephalosporins (due to the former) and fluoroquinolones and aminoglycosides (from 
the latter), (92) driving the use of last-line antimicrobials, carbapenems, in routine clinical 
practice.
Carbapenems, comprising ertapenem, imipenem, meropenem and doripenem, are broad-
spectrum b-lactam agents, stable against the hydrolytic activity of ESBLs (including TEM, 
SHV, OXA-1, CTX-M and AmpC), eventually displacing cephalosporins and increasingly 
used routinely in clinical practice. (93) Despite continued efforts, no further new subclasses 
with extended activity have been discovered since the discovery of the carbapenems in 
1976 (thienamycin (94)). In essence, carbapenems are the last-line b-lactam antibiotics, and 
the continued rise of carbapenemases (b-lactamases that hydrolyse, among other b-
lactams, carbapenems), has led to widespread concern regarding the end of the age of b-
lactam agents, a long-held stalwart of antimicrobial therapy and our battle against 
pathogenic Gram-negative bacteria. Numerous carbapenemases have been described in 
Enterobacteriaceae since the first description in 1994 of NmcA, a class A serine-b-
lactamse, on the chromosome of Enterobacter cloacae by Naas et al. (95) The widely 
adopted molecular classification scheme for b-lactamases, which is based on amino acid 
homology, categorises them into 4 classes, A through D. Classes A (penicillinases), C 
(cephalosporinases) and D (oxacillinases) comprise serine b-lactamases, due to a serine 
residue at its active site (where hydrolysis of the b-lactam ring takes place), whereas class 1045
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B metallo-b-lactamases require a zinc ion at its active site for hydrolysis. (96) The 4 most 1046
common carbapenemases in the UK are Klebsiella pneumoniae carbapenemases (KPC), 1047
OXA-48-like carbapenemases (OXA-48), New Delhi metallo-b-lactamases (NDM) and 1048
Verona integron-encoded metallo-b–lactamases (VIM). (97) See Figure 1-7 for a trend of 1049
laboratory confirmed cases of carbapenemases referred to the Public Health England 1050
reference laboratory from 2008-2015. KPC belongs to class A, OXA-48 to class D, NDM 1051
and VIM to class B from the Ambler classification system.  1052
CPO are a heterogenous group, with varying activity against different b-lactam and 1053
monobactam (e.g. aztreonam) agents. Phenotypic expression of resistance may vary widely 1054
within a single subtype of carbapenemases, and the minimum inhibitory concentration 1055
(MIC) to individual carbapenems may be sufficiently low to display in vitro susceptibility. 1056
(98, 99) Whilst these compounds may be unreliable for the in vitro detection of CPOs in the 1057
clinical microbiology laboratory, thus hindering efficient infection prevention and control, 1058
(100) there may be appreciable susceptibility to carbapenems in vivo. In small observational 1059
studies, carbapenems in combination with another viable antimicrobial may be used with 1060
reasonable treatment success against carbapenemase-producing organisms if the 1061
carbapenem MICs to the candidate carbapenem are low, and a high-dose regimen is used, 1062
with clear advocates for the use of continuous infusions. (101) However, this is not always 1063
the case, and there are lingering concerns regarding potential treatment failure with 1064
carbapenems due to selection pressure driving the catalytic activity of the carbapenemase. 1065
(102) Additionally, co-production of carbapenemases with other b-lactamases (e.g. CTX-M) 1066
and resistance to other classes of antimicrobials (e.g. fluoroquinolones, aminoglycosides), 1067
CPOs unlike ESBLs, are rather more resistant to antimicrobials, often XDR or PDR. 1068
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Figure 1-7 Laboratory confirmed cases of carbapenemases from 2008 – 2015 in the UK by molecular subtype. 1069


































1.1.4.2 Multi-drug resistant Gram-negative organisms – ESKAPE 1073 
pathogens 1074 
As previously mentioned in Section 1.1.1, the need for new therapeutic antimicrobial 1075 
options is most crucial with regards to Gram-negative pathogens. The Infectious Diseases 1076 
Society of America (IDSA) highlighted a list of pathogens in 2009(103), first given the 1077 
acronym “ESKAPE” by Rice, (104) so named for their ability to “escape” the effects of most 1078 
antimicrobial agents (i.e. multi-drug resistant, or MDR): 1079 
1) Enterococcus faecium 1080 
2) Staphylococcus aureus 1081 
3) Klebsiella pneumoniae 1082 
4) Acinetobacter baumannii 1083 
5) Pseudomonas aeruginosa 1084 
6) Enterobacter species 1085 
It should be noted, that the only novel antimicrobial approved in the past 15 years, 1086 
daptomycin, a cyclic lipopeptide, is only active against the first 2 pathogens on this list 1087 
(Gram-positive pathogens E. faecium and S. aureus), with the rest being intrinsically 1088 
resistant as daptomycin is unable to cross the Gram-negative outer membrane. 1089 
Being successful nosocomial pathogens, with the ability to infect a wide array of native (e.g. 1090 
bloodstream infections, pneumonia, urinary tract infections, wound infection) and prosthetic 1091 
sites (e.g. prosthetic joints, intravascular-catheter associated infections) in humans, and 1092 
evade the action of multiple classes of antimicrobials, the ESKAPE pathogens have 1093 
become attractive candidates to study when investigating the management of MDR 1094 
infections. (105) Of bacteraemia isolates caused by ESKAPE Gram-negative organisms, K. 1095 
pneumoniae was the most frequently isolated, and A. baumannii, the least susceptible to 1096 
frontline antimicrobials. See Figure 1-8 for the relative frequency of isolation of the ESKAPE 1097 
organisms from Gram-negative bacteraemia isolates in the UK, and Figure 1-9 for the 1098 
differences in resistance rates using 4 indicator antimicrobials. K. pneumoniae and A. 1099 
baumannii in greater detail in sections 1.1.4.2.1 and 1.1.4.2.2. 1100 
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 Figure 1-8 Gram-negative bacteraemia rates per 100,000 population in England, Wales and Northern Ireland (England & Wales only between 1101
1999-2001) by organism, 1999-2016. 1102
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Figure 1-9 Percentage of bacteraemia isolates with resistance to (a) gentamicin, (b) 1105 
ciprofloxacin, (c) 3rd generation cephalosporins and (d) carbapenems, from 2001 and 2014, 1106 
in England, Wales and Northern Ireland. 1107 
Data extracted from voluntary surveillance data reports 1108 



































































































1.1.4.2.1 Klebsiella pneumoniae 1114 
K. pneumoniae is a Gram-negative bacillus, belonging to the Enterobacteriaecae group of 1115 
organisms. Though, unlike E. coli (mainly an enteric organism), it is found both in the 1116 
environment (e.g. soil, water) and on mucosal surfaces, which it colonises, just like E. coli. It 1117 
rose to prominence in the latter part of the 20th century, where growing K. pneumoniae 1118 
colonisation and infection rates in hospitalised patients coupled with increasing detection 1119 
of antibiotic-resistant strains (ESBL strains carrying TEM and SHV enzymes in the 1980s, to 1120 
CTX-M producers first reported in the 1990s with rapid spread in the UK in 2000s), began 1121 
to raise alarm bells. (106) See Figure 1-8  for burden of ESKAPE Gram-negative 1122 
bacteraemia compared with E. coli (the most common cause of bacteraemia) in the UK 1123 
over the past 17 years, where the rates of both K. pneumoniae and E. coli bacteraemia has 1124 
risen almost 3 fold since the start of this century.  1125 
Figure 1-10 Comparison of (a) gentamicin, (b) ciprofloxacin and (c) 3rd generation 1126 
cephalosporin resistance rates amongst Klebsiella spp. and E. coli bacteraemia isolates 1127 
from England, Wales and Northern Ireland, 2001-2016. 1128 
Data extracted from voluntary surveillance data reports 1129 



























The capacity of K. pneumoniae to acquire large amounts of mobile genetic elements and 1134
efficiently transfer them to other strains including the more abundant E. coli, was of chief 1135
concern. (107) Trends of resistance to key antimicrobials amongst E. coli and Klebsiella 1136
spp. bacteraemia isolates, namely gentamicin, ciprofloxacin and 3rd generation 1137
cephalosporins, show overall increase for all bug-drug combinations between 2001 and 1138
2016 (see Figure 1-10  for details). It is interesting to note that whilst resistance rates in 1139
Klebsiella spp. were higher for all 3 indicator antimicrobials in 2001, a rapid shift occurs a 1140













































(c) 3rd generation cephalosporin resistance
Klebsiella spp. E. coli
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ciprofloxacin resistance. This trend might be explained by the rise of CTX-M type ESBL 1142 
(CTX-M-15 is common in the UK, (106) which confers 3rd generation cephalosporin 1143 
resistance, and encoded plasmids that commonly carry ciprofloxacin resistance genes. 1144 
ESBL was rare in 2001, with only a handful of reports in bloodstream infections, rising to 1145 
12% by 2006(108). This likely accounts for the rise in resistance to all 3 antimicrobials, and 1146 
in turn driven by the widespread use of these agents in clinical practice. A decline of 1147 
consumption of both ciprofloxacin and extended-spectrum cephalosporins followed soon 1148 
after, due to their implication in the rising Clostridium difficile infection problem in the UK. 1149 
(109, 110) This may explain the marginal fall and eventual plateau in the 3rd generation 1150 
cephalosporin and ciprofloxacin resistance rates from 2008 onwards. Moreover, K. 1151 
pneumoniae possess a number of virulence determinants, including polysaccharide 1152 
capsules (thick fibrin-rich structures allowing the bacterium to resist phagocytosis and 1153 
inhibit immunological pathways, most notably in capsular serotypes that lack 1154 
mannose/rhamnose (allowing macrophage recognition), for example the K2 serotype), 1155 
fimbriae (host cell adherence) and lipopolysaccharide (possessing endotoxin, which 1156 
mediates sepsis). (107) The combination of the innate pathogenicity and ease with which K. 1157 
pneumoniae acquires and accumulate plasmids (on which genetic determinants for 1158 
virulence factors or antimicrobial resistance may reside) has led to its success as the 1159 
forerunner organism in the rise of carbapenemase-producing enterobacteriaceae infections. 1160 
Indeed, the first reports and outbreaks involving OXA-48-like, NDM and KPC enzymes, 1161 
were caused by K. pneumoniae. From that starting point, spread to other species such as 1162 
E. coli and Enterobacter spp. have since been reported, (111) once again emphasising its 1163 
ability as a “vehicle” to effect rapid dissemination of MDR and XDR resistance 1164 
determinants. 1165 
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1.1.4.2.2 Acinetobacter baumannii 1166 
Amongst the Gram-negative ESKAPE pathogens, A. baumannii has gained relative 1167 
notoriety due to its intrinsic resistance to most classes of antimicrobials (See Figure 1-9), 1168 
generally MDR, and frequently XDR or PDR, and ability to survive harsh conditions both in 1169 
vivo and in the environment, affording it unique advantages for driving nosocomial 1170 
outbreaks and consequently, endemic status in the hospital environment. A. baumannii is 1171 
an opportunistic pathogen, often causing infection of mucous membranes following 1172 
disruption of its natural integrity or immunity (e.g. trauma, surgery, insertion of prosthetic 1173 
devices). (112) A. baumanni infections tend to affect patients who have been in hospital for 1174 
prolonged periods, often receiving critical care, or trauma victims in zones of conflict. 1175 
Numerous sites of infection have been reported to date, with a vast majority being 1176 
pneumonia, urinary tract infection, bloodstream infection and wound infections, most are 1177 
device-related. (113)  1178 
Pathogenicity islands have been discovered that carry genes encoding virulence factors 1179 
including cell envelope biogenesis, iron uptake/metabolism, biofilm formation, heavy metal 1180 
processing, type IV secretion systems and fimbrial formation. (114) Smith et al also found 1181 
that A. baumannii has acquired a large amount of foreign DNA in clusters encoding 1182 
virulence factors and resistance determinants, indicating the dedication the organism has 1183 
to disease pathogenesis, of which antimicrobial resistance plays a major role. (115) 1184 
Additionally, A. baumannii possessed an outer membrane protein, Omp38, which binds to 1185 
mitochondria of epithelial cells, and subsequently leads to the release of cytochrome c and 1186 
apoptosome, ultimately resulting in apoptosis of the epithelial cell. (116) A unique pilus 1187 
assembly system and biofilm-associated protein contribute to A. baumannii’s ability to 1188 
persist on surfaces, including inorganic environmental material.  1189 
Along with the wide array of virulence factors carried in pathogenicity islands, A. baumannii 1190 
possesses a number of “intrinsic” antimicrobial resistance determinants. Many of these are 1191 
chromosomally borne, likely acquired from foreign sources, much like its virulence factors. 1192 
A. baumannii carries a chromosomally encoded class C AmpC, Acinetobacter-derived 1193 
cephalosporinase (ADC), whose expression is determined by upstream elements. (112) The 1194 
presence of chromosomally located b-lactamase genes, encoding OXA-51-like enzymes 1195 
(belonging to class D oxacillinases), confers resistance to most other b-lactams including 1196 
penicillins and carbapenems. The expression of these chromosomal b-lactam genes is 1197 
associated with the upstream promoter sequence. Insertion sequence ISAba1 has a strong 1198 
promoter sequence, and is usually associated with phenotypic cephalosporin and 1199 
carbapenem resistance. Other oxacillinases, OXA-23-like, OXA-24-like and OXA-58-like 1200 
enzymes may be encoded on the chromosome or on plasmids (plasmidic carriage more 1201 
often with OXA-23 and OXA-58). (112) MDR A. baumannii often possess efflux pumps, the 1202 
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best described being the RND efflux mechanism, AdeABC, unique to A. baumannii, which 1203 
results in resistance to b-lactams, aminoglycosides, erythromycin, chloramphenicol, 1204 
trimethoprim, fluoroquinolones and tetracyclines. (117) Furthermore, multiple resistance 1205 
determinants have been found on integrons, most notably class 1 integrons, encoding 1206 
metallo-b-lactamases (MBL; e.g. VIM, IMP (118)), aminoglycoside resistance (e.g. aacC1, 1207 
aphA1)(119), chloramphenicol acetyltransferases (cat), alternative dihydropteroate synthase 1208 
(encoded by sul genes) and trimethoprim resistance from mutations in dhfr genes due to 1209 
overproduction of dihydroflate reductase or trimethoprim-insensitive enzyme. (120)  1210 
The MDR profile of A. baumannii, together with its pathogenicity, and the ability to 1211 
continually update its genetic make-up, makes this organism ideal for AMR study and 1212 
research. In addition to its use in vitro and clinical studies for studying new, existing or 1213 
repurposed antimicrobial regimens, a number of pre-clinical animal models have been 1214 
developed with reproducible results. In particular, optimisation of antimicrobial therapy 1215 
against A. baumannii has been well described in mice/rats (pneumonia, meningitis, wound, 1216 
septicaemia and osteomyelitis models), rabbits (meningitis and endocarditis models), as 1217 
well as non-mammalian models (e.g. C. elegans, G. mellonella) of infection. (121) 1218 
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1.1.5 Colistin therapy 1219 
The precipitous rise of MDR infections has plunged modern medicine into a desperate time 1220 
– with dwindling efficacious therapeutic options active against them, the threat of a ‘Post- 1221 
Antibiotic Era’ is more tangible now than ever before.  1222 
The success of MDR Gram-negative organisms epitomises the threat, where the 1223 
developmental pipeline for novel antimicrobial agents is dry, thereby rendering common 1224 
infections (e.g. urinary tract infections) untreatable or extremely difficult to treat currently 1225 
and for the foreseeable future. Physicians all around the world have been forced to use 1226 
older antimicrobial agents, some of which were previously abandoned due to toxicity (e.g. 1227 
polymyxins), in ad hoc efforts to treat MDR infections. (122) 1228 
Colistin (polymyxin E) was first discovered in 1947, during the ‘Golden Age’ of antibiotic 1229 
discovery. (123-125) Owing to their unique structure as amphipathic polypeptides, 1230 
polymyxins have a novel mechanism of action, targeting the negatively charged cell 1231 
membrane (including the Gram-negative outer membrane), effectively creating ‘pores’, 1232 
eventually leading to leakage of cell contents, cell lysis and death (126). This mechanism of 1233 
action, made it particularly useful against a wide variety of Gram-negative organisms, which 1234 
are substantially more resistant to antimicrobials due to the possession of a very effective 1235 
outer barrier, the outer membrane. (127) However, colistin therapy is not without its costs. 1236 
The non-specificity in which the drug targets cell membranes has led to unwanted side 1237 
effects against eurkaryotic human cell membranes. The most notable of which is 1238 
nephrotoxicity, likely due to the drug’s ability to concentrate in the renal tract. Increasing 1239 
reports of toxicity, and the discovery of safer viable alternatives (e.g. aminoglycosides, 1240 
quinolones), saw polymyxins fall out of favour in the 1970s, when its continued use was 1241 
largely confined to niche areas of medicine (e.g. treatment of multi-drug resistant P. 1242 
aeruginosa infections in cystic fibrosis populations) wherein safer alternatives were non- 1243 
existent. (128-132)  1244 
In a similar tale, albeit on a much larger scale, the renaissance colistin (COL) has enjoyed in 1245 
recent years has been borne of necessity. Once again, clinicians have found themselves 1246 
without viable alternatives for the treatment of MDR Gram-negative infections (e.g. 1247 
carbapenemase-producing Enterobacteriaceae, XDR A. baumannii), and are turning to 1248 
older agents (e.g. polymyxins, fosfomycin) in the hope of finding an agent with useful 1249 
activity. (17) Figure 1-11 displays the number of articles published on ‘colistin’ or ‘colistin 1250 
resistance’ since 1950, demonstrating the recent renewed interest in this old agent. 1251 
Theoretically, the unique mechanism of action of COL, coupled with its lack of general use 1252 
in clinical medicine over the past few decades, ought to see to a general susceptibility of 1253 
human pathogenic strains to the antimicrobial (sans for those which are inherent resistant 1254 
to the action of the drug e.g. Gram-positive and anaerobic agents). (130, 132, 133) 1255 
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However, as seen in Figure 1-11, trends of increasing resistance (or concerns of resistance) 1256 
often follow rising consumption of an antimicrobial. 1257 
However, even for this agent of last resort, the reality of drug resistance has culminated in 1258 
reports of treatment failure. This is in part due to the problem of bioavailability of the active 1259 
compound COL, when given as colistimethate sodium, the pro-drug of colistin. The 1260 
hydrolysis of colistimethate sodium to COL is a variable process, and difficult to predict. 1261 
Older clinical trials done to assess the efficacy of COL when it was first introduced into 1262 
clinical use more than half a century ago, utilised colistin sulphate, rather than the pro-drug. 1263 
Due to the paucity of contemporary studies assessing the 1264 
pharmacokinetics/pharmacodynamics of COL therapy, treatment failure on COL therapy 1265 
has been ascribed to problems with under dosing. (128, 134, 135) Another potential 1266 
problem with COL lays with the production of the antimicrobial itself.  1267 
COL is a polypeptide antimicrobial (consisting of colistin A and B, and approximately 30 1268 
other peptides with similar structure and varying antimicrobial activity profiles in vivo (136, 1269 
137)) derived from soil bacterium, Paenibacillus polymyxa, via a complex fermentation 1270 
process. The pro-drug, colistimethate sodium (CMS) is inactive, and synthesised by 1271 
sulfomethylation of COL (substitution of the 5 primary amine groups with methylsulfonate). 1272 
CMS, being an inactive pro-drug has a superior safety profile compared with colistin sulfate 1273 
(with approximately 100% COL base activity, or CBA). The sulfomethylation process is 1274 
complicated, and may result in incomplete substitution of the 5 amine groups, with the 1275 
formation of tetra, tri and di-sulfomethylated products in varying percentages between 1276 
batches. This process, coupled with the varied colistin A and B ratios have resulted in 1277 
legitimate concerns regarding the batch to batch variability of CMS. (136, 138-140) 1278 
The pharmacokinetics (PK) of COL therapy is complex, with a number of issues 1279 
surrounding it. Firstly, being an old antimicrobial that has largely fallen into disuse over the 1280 
decades since its discovery and introduction, it has not benefited from detailed study with 1281 
regards to its optimisation for clinical application as its contemporaries (e.g. 1282 
aminoglycosides). Indeed, confusion over the units used and naming convention in dosing 1283 
regimens, has led to an international panel of experts recommending a consensus in this 1284 
matter. The Prato consensus proposes to use a standard “international units” to dose CMS, 1285 
or milligrams to express its corresponding colistin base activity, clearly stating to which 1286 
compound one refers. 1 million international units (miu, or mu) of CMS (approximately 80 1287 
mg CMS), equates to 30 mg CBA, and approximates 80 mg CMS. (140) Furthermore, the 1288 
delivery of COL as its pro-drug CMS, results in the inevitable mixture of CMS and all its 1289 
possible derivatives, including colistin A and B, in vivo. The hydrolysis of CMS is 1290 
unpredictable, and varies between individuals, and under different conditions. This makes 1291 
its pharmacokinetics difficult to predict. Moreover, CMS and colistin differ in their 1292 
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elimination profile. It was a long-held belief that COL is predominantly renally excreted, 1293 
using bioassays to measures drug levels in the urine and blood following therapy. However, 1294 
modern bioanalysis (using high-performance liquid chromatography (HPLC) or liquid 1295 
chromatography/tandem mass-spectrometry (LC-MS/MS) methods) have revealed that this 1296 
is not quite the case, and there has been an overestimation of the relative urinary 1297 
concentration of COL largely due to the continued hydrolysis of CMS into COL after sample 1298 
collection.  1299 
Whilst CMS was largely excreted unchanged in the urine of healthy volunteers with normal 1300 
renal function, very little COL was found to be renally excreted, in a study by Couet et al. 1301 
(141) This is due in part, to the reabsorption of colistin by the renal tubules, likely involving 1302 
organic cationic transporters (OCTN1), peptide transporters (PEPT2) and megalin (receptor 1303 
for macromolecule reabsorption) found on the luminal surface of the renal proximal 1304 
convoluted tubules. (142, 143) The reabsorption of COL is associated with increased 1305 
membrane permeability of these renal tubules, leading to influx of water and electrolytes, 1306 
ultimately resulting in cell swelling and lysis. This often manifests as acute tubular necrosis, 1307 
and the severity is dependent on the concentration and length of exposure to COL. (144) In 1308 
patients with impaired renal function, renal excretion of CMS is reduced, thus increasing its 1309 
non-renal elimination, a major pathway being the conversion of CMS to COL. Hence, 1310 
necessitating CMS dose reduction in renal impairment. However, due to the efficiency of 1311 
removal of both CMS and COL by haemofiltration and haemodialysis, relative dose 1312 
increments are recommended. (145) Recent clinical pharmacokinetics studies have 1313 
highlighted the need for revising the dosing regimen of CMS to ensure the target serum 1314 
concentration is achieved quickly and maintained throughout therapy. From the Couet 1315 
study of COL PK in healthy individuals, the terminal half-life of CMS (single dose of 80 mg 1316 
or 1 miu given over 1 h infusion) was 2 h (peak serum concentration, Cmax 4.8 mg/L), 1317 
whereas that of colistin was 50% longer, at 3 h (Cmax 0.83 mg/L). (141) Interestingly, 1318 
Plachouras et al noted that this is not the case in the critically ill population, with 1319 
considerable reduction in colistin Cmax (0.6 mg/L), and increase in colistin half-life (t1/2) to   1320 
14 h, following treble the dose used in Couet’s study (1 h infusion of 3 miu CMS every 8 h). 1321 
The authors advocated for a loading dose of CMS to attain the target serum concentration 1322 
(at or above the clinical susceptibility breakpoint of 2 mg/L, as set by both EUCAST and 1323 
CLSI) of 2 mg/L rapidly, and an increase in maintenance doses thereafter to ensure the 1324 
steady state concentration remains above 2 mg/L. Assessment of these recommendations 1325 
(134, 146) were made by several authors including Karaiskos et al, who noted an average 1326 
Cmax of 2.65 mg/L (0.96 – 5.1 mg/L) with a time-to-Cmax (Tmax) of 8 h, from 19 critically ill 1327 
patients following a 9 mu loading dose (4-6 mu in patients with reduced creatinine 1328 
clearance 29-48 mL/min). Of note, only 4 of the 12 patients with normal renal function 1329 
(creatinine clearance ≥ 80 mL/min) attained steady state serum concentrations >2 mg/L. 1330 
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(147) The optimisation of COL dosing is made more challenging still, with the observation of 1331 
acute kidney injury associated with COL concentrations of > 2.5 mg/L. (148) This narrow 1332 
therapeutic index for COL, and the wide variability in serum concentration following 1333 
administration calls for more stringent look at this therapeutic agent of last resort. 1334 
Strategies to address these issues include close therapeutic drug monitoring (TDM) of COL 1335 
levels from target sites (e.g. blood, urine, bronchial alveolar lavage) using accurate and 1336 
reliable bioanalytical methods (e.g. LC-MS/MS), continual update of current predictive 1337 
models with increasing data from real world observations for better information on dosing 1338 
regimens for individual patients, rapid and accurate information of organism identification 1339 
and susceptibility from in vitro diagnostics, reduction in colistin doses by synergistic 1340 
combination with other antimicrobial agents to ameliorate the burden of toxicity, 1341 
international collaboration to ensure dissemination of pragmatic and reliable guidance for 1342 




Figure 1-11 Articles published from 1950 – 2016 as indexed in PubMed using search terms ‘colistin’ or ‘colistin resistance’. 1346 

























1.1.6 Colistin in vitro susceptibility – current methods and 1349 
prevailing issues 1350 
The observation of inhibition of bacterial growth on artificial media by various compounds 1351 
was first described in the latter part of the 19th century (149). In the 1920s, Fleming 1352 
illustrated the use of antiseptic solution filled “ditches” in agar to study the effects of 1353 
antimicrobial activity across a solid artificial medium, and the idea of using turbidity in 1354 
bacterial suspension as a marker of microbial growth. (150, 151) These observations would 1355 
later be refined into commonly used antimicrobial susceptibility test (AST) techniques that 1356 
are still employed today – namely disc diffusion and broth dilution.  1357 
The importance of AST in the treatment of infections has never been more important than it 1358 
is today. The selection of the optimal antimicrobial regimen is paramount not just for 1359 
treatment efficacy and success, there is furthermore a wider issue of antimicrobial 1360 
stewardship, or the combined effort of the health services to use the best treatment 1361 
approach in a timely fashion to preserve the current antimicrobial agents we possess. The 1362 
preservation of COL, an agent of last resort, is clearly crucial. It follows that it is critical to 1363 
have reliable colistin AST method(s). However, this is unfortunately not the case, and COL 1364 
AST has historically been plagued with problems.  1365 
Firstly, inconsistencies in reported antibacterial activity of COL due to variations of the 1366 
compound used for testing (see Section 1.1.5 for details regarding problems in the 1367 
manufacturing process of COL and CMS) has led to legitimate concerns regarding the 1368 
reliability of COL AST and its utility in guiding clinical management. In addition to the 1369 
aforementioned batch to batch variability of COL, older in vitro studies including those cited 1370 
in product literature have utilised CMS for susceptibility testing, rather than colistin 1371 
sulphate. (129, 152) Contemporary studies (mostly conducted since the recent renaissance 1372 
of COL) have taken into account the recommendations made by international guidelines 1373 
(e.g. Clinical and Laboratory Standards Institute (CLSI), The European Committee on 1374 
Antimicrobial Susceptibility Testing (EUCAST)) regarding the importance of using the active 1375 
COL base in the form of its sulphate salt. (153) 1376 
In vitro susceptibility methods vary from laboratory to laboratory, and agar-based methods, 1377 
particularly disc diffusion, remains the predominant method used in clinical laboratories 1378 
worldwide. (154) COL, however, diffuses poorly across agar (155) and AST by disc diffusion 1379 
has been reported to be unreliable for predicting susceptibility. (156, 157) Likewise, the 1380 
costlier and widely used gradient strip method (e.g. Etest) for determination of MIC, 1381 
preferred due to its ease of use compared with other MIC AST methods (e.g. agar dilution, 1382 
broth microtitre dilution) has fallen out of favour as concerns regarding its reliability (with 1383 
potential impact on treatment outcomes) have surfaced. (158) CLSI and EUCAST have 1384 
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more recently issued a joint statement recommending the use of broth microtitre dilution as 1385 
the method of choice for colistin AST. (153, 159) Broth microtitre dilution is a costly and 1386 
labour-intensive method, and usually reserved for use in reference laboratories. The 1387 
introduction of automated AST systems (e.g. Vitek, Phoenix, MicroScan) have enabled 1388 
clinical laboratories, albeit precluding resource-poor settings, to undertake a “surrogate 1389 
broth microtitre dilution” method for the determination of COL susceptibility. However, it is 1390 
worth mentioning that few automated systems are validated for COL AST (159). A number 1391 
of recent studies have compared the performance of various AST methods against broth 1392 
microtitre dilution as the gold standard with varying results, with most reporting categorical 1393 
agreement (accuracy of predicting susceptibility or resistance) >90%, excepting a few 1394 
reports where agreement with agar diffusion methods (including disc and gradient strip 1395 
diffusion methods) may be as low as 50%. (158, 160-162) This, however, is based on the 1396 
assumption that COL susceptibility can be best predicted by broth microtitre dilution or 1397 
similar broth-based methods. End-point broth-based methods, such as broth microtitre 1398 
dilution, whilst better than their agar diffusion counterparts at predicting MICs and 1399 
susceptibility, are compounded with problems relating to the detection of heteroresistance. 1400 
The conventional AST methods poorly predict heteroresistance, raising questions about the 1401 
potential of treatment failure in “falsely COL -susceptible” Gram-negative infections. (163, 1402 
164) Multiple reports in literature have highlighted the “regrowth” of COL -resistant 1403 
subpopulations (after an initial decrease in bacterial load) in the presence of COL, including 1404 
concentrations exceeding the susceptible clinical breakpoint (2 mg/L by EUCAST, and 4 1405 
mg/L by CLSI). (163, 165, 166) COL heteroresistance has hitherto only been reliably 1406 
detected via techniques involving observations of bacterial load over an extended period of 1407 
time. These techniques are extremely time-consuming and labour-intensive, and do not 1408 
conform to the constraints of a clinical microbiology laboratory, often only performed in 1409 
academic settings. These studies highlighting the detection of heteroresistance may only 1410 
be the tip of the iceberg, as most heteroresistant strains isolated in the clinical setting 1411 
would go unnoticed due to the inadequacies of the AST methods used in the clinical 1412 
microbiology laboratory for the purpose of accurate detection of heteroresistance. It would 1413 
be vital to perform parallel studies utilising a time-series method and broth microtitre 1414 
dilution to delineate the extent of the problem, and develop potential method that would 1415 
accurately detect heteroresistance and be logistically and practically feasible in the clinical 1416 
setting. 1417 
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1.1.7 Colistin combination therapies 1418 
COL is often used in combination with other antimicrobial agents. This may be as part of 1419 
targeted therapy, where the additional agents are thought to enhance the antibacterial 1420 
effect of colistin, or part of empirical therapy, where the spectrum of activity afforded by 1421 
COL is broadened as COL lacks activity against Gram-positive and anaerobic bacteria.  1422 
Due to the potential of treatment failure with polymyxin monotherapy, (167) as well as the 1423 
intention of preserving the activity of colistin as an active agent of last resort, the addition of 1424 
a potentially synergistic agent is a rational strategy undertaken by clinicians to combat 1425 
MDR infections. (129)  1426 
Combination therapy strategies targeting pathogenic infections have been around for 1427 
decades, and have shown to combat certain infections very effectively (e.g. HIV infection, 1428 
Mycobacterium tuberculosis). Though there have been suggestions of the advantage of 1429 
using combination therapy approaches to treat bacterial infections (e.g. P. aeruginosa), this 1430 
belt and braces approach to antimicrobial chemotherapy has fallen by the wayside due to 1431 
the glut of safe, efficacious and broad-spectrum monotherapy options (e.g. cephalosporins, 1432 
carbapenems, fluoroquinolones) available for clinical use over the past few decades. The 1433 
reversion of thought about combination therapy, much like the renaissance of COL, has 1434 
been borne out of necessity once again, as we contemplate strategies to combat 1435 
antimicrobial resistance, specifically, MDR infections. (168)  1436 
Targeted COL combination therapy can be considered in a couple of distinct ways. Firstly, 1437 
the agents in the combination may be fully or partially active (in the case of raised MICs to 1438 
one or multiple components of the regimen) against the target organism. This is the 1439 
conventional idea of combination therapy, and perhaps the underlying reason for the 1440 
“negative press” surrounding combination therapy, where legitimate concern has been 1441 
repeatedly expressed regarding the burden of excessive toxicities with no apparent gain in 1442 
positive clinical outcomes. (169) As previously mentioned here (see Section 1.1.2.2), COL 1443 
has a rather unique mode of action, whereby it inserts its fatty acid tail into the Gram- 1444 
negative outer membrane, disrupting its integrity and allowing the passage of otherwise 1445 
excluded molecules into the cell. This specific “permeabilising” feature of its mechanism of 1446 
action enables COL to be an excellent “vehicle” for a multitude of antimicrobial compounds 1447 
to traverse the Gram-negative outer membrane, presenting potential novel antimicrobial 1448 
effects. Interest in the investigation of this particular property of polymyxins has grown 1449 
considerably, and a good example of this is the combination of colistin and rifampicin for 1450 
the treatment of MDR A. baumannii infections. Rifampicin, a relatively large hydrophobic 1451 
molecule (823 Da), is unable to efficiently traverse the Gram-negative outer membrane 1452 
(either by diffusion or through porin channels) on its own, hence Gram-negative organisms 1453 
are said to be “intrinsically resistant” to rifampicin. However, numerous in vitro and clinical 1454 
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studies have noted the synergistic effect of the addition of colistin to rifampicin. The 1455 
hypothesis being that COL acts as a permeabiliser in this context. (170-172)  1456 
Though COL has been shown to act synergistically with a number of antimicrobial agents in 1457 
vitro, (173) there is a relative lack of evidence to recommend COL combination therapy. 1458 
(174-177) This is in large part due to the paucity of good quality evidence for the clinical use 1459 
of COL combinations. The difficulties (e.g. ethical dilemma surrounding performing double- 1460 
blind randomised trials in septic patients, relative heterogeneity of the population 1461 
susceptible to MDR infections, lack of general consensus regarding the definition/diagnosis 1462 
of sepsis and consequently the definition of “positive clinical outcome”) inherent to 1463 
performing “gold-standard” clinical trials in the field of anti-infectives is a major factor in the 1464 
lack of said evidence in the public domain. As part of the efforts in combating antimicrobial 1465 
resistance, agencies across the globe have advocated for the adoption of alternative trial 1466 
designs to a) drive trial outcome data closer to the “real world” (e.g. pragmatic trial design) 1467 
and b) enable gathering of good quality trial data without having to meet the burden 1468 
proposed by the standard double-blind randomised-controlled trial. (18, 19, 178-180) 1469 
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1.2 Study objectives 1470 
The UK’s Department of Health released a report in September 2013 outlining strategies to 1471 
combat antimicrobial resistance, (181) with focussing on 7 key areas: 1472 
1) Improving infection prevention and control practices 1473 
2) Optimising prescribing practices 1474 
3) Improving professional education and training, and public engagement 1475 
4) Developing new drugs, treatments and diagnostics 1476 
5) Better access and use of surveillance data 1477 
6) Better identification and prioritisation of AMR research needs 1478 
7) Strengthened international collaboration 1479 
Identification of efficacious antimicrobial combination therapies have been identified by this 1480 
report as pragmatic strategies to combat antimicrobial resistance, specifically in line with 1481 
key area 6, as an alternative to novel therapies. Additionally, timely identification and 1482 
delivery of antimicrobial therapies (singly or in combination), would play a large part in 1483 
optimisation of prescribing practices. (168, 182)  1484 
The purpose of this study was to investigate potential unorthodox antimicrobial 1485 
combination therapies for the treatment of MDR Gram-negative infections. The unique 1486 
property of COL, as previously discussed will serve as the underlying lynchpin of the study. 1487 
It is postulated that more adjuvants may be discovered that will act synergistically with COL 1488 
against MDR Gram-negative pathogens. 1489 
The study will comprise a number of key stages to first describe the prevailing knowledge 1490 
we possess regarding COL combinations in clinical medicine, as well as susceptibility 1491 
testing methodologies given the myriad problems encountered with COL. Subsequently, a 1492 
systematic screening programme will be used to assess a series of potential licensed 1493 
antimicrobials for synergy with COL. This will then be further examined by way of 1494 
pharmacometrics and in an invertebrate model of infection. Finally, in full circle, description 1495 







Details of these stages are as follows: 1502 
1) Systematic review of comparative clinical outcomes of COL combination therapies 1503 
versus prevailing standard therapies for the treatment of Gram-negative bacterial 1504 
infections 1505 
2) COL in vitro susceptibility – assessment of current methods for detection of 1506 
resistance 1507 
3) Screening COL combinations in vitro, with further investigation of novel 1508 
combinations for synergistic activity 1509 
4) Assessment of novel COL combinations in vivo 1510 
5) Case studies of use of unorthodox COL combinations  1511 
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2 A Systematic Review of Colistin 1512 
Combination Therapies for Gram- 1513 
negative infections 1514 
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2.1 Introduction 1515 
2.1.1 Rationale 1516 
The global rise of antimicrobial resistance has been a relentless march, threatening to 1517 
herald in a new ‘Post-antibiotic Era’ where common infections are untreatable. (1, 2, 7) The 1518 
situation is particularly acute with regards to Gram-negative infections, where the 1519 
antimicrobial developmental pipeline has run dry and agents of last resort (e.g. 1520 
carbapenems) can no longer be relied upon due to the success of CPO (e.g. KPC- 1521 
producing K. pneumoniae) and XDR Gram-negative organisms (e.g. XDR A. baumannii). (1, 1522 
2, 86) Refer to Section 1.1.4.1 for details of carbapenemases and Section 1.1.4.2.2 for 1523 
details about XDR A. baumannii. 1524 
Physicians are increasingly turning to older antimicrobial agents (e.g. polymyxins) to treat 1525 
these MDR infections, with varying success. (17) COL (polymyxin E), whilst retaining activity 1526 
against many MDR strains, is a therapeutic option that is fraught with problems. COL in 1527 
vitro susceptibility testing produces widely variable results, making it difficult to identify 1528 
resistance in the laboratory. (158, 160) This problem is further compounded by 1529 
heteroresistance, which is unlikely to be observed with routine susceptibility tests. 1530 
Moreover, COL is commonly delivered as a pro-drug, CMS, in the clinical setting. CMS is 1531 
metabolised to produce colistin in vivo, as well as multiple other products with varying 1532 
levels of antimicrobial activity. (129) This unpredictability as well as batch-to-batch variation 1533 
of CMS had led to further problems with the therapeutic use of COL. (127)  1534 
Many clinical outcome studies investigating the use of COL were done decades ago with 1535 
poor or nonexistent trial design. (131) As such, physicians have been using the drug in 1536 
many ways with varying dosing regimens and in combination with numerous other agents. 1537 
(Refer to Section 1.1.5 for further details regarding problems surrounding COL dosing.) 1538 
There have been recent efforts made to assess the efficacy of a number of these COL 1539 
combinations, however, properly designed randomised controlled trials for COL- 1540 
combination therapies remain a rarity.  1541 
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2.1.2 Objectives 1542 
Given the complexity of the problem the first aim was to undertake a systematic review 1543 
comparing COL-combination therapies with comparators used in various clinical studies, 1544 
namely COL monotherapy and non- COL therapies. Due to the paucity of randomised 1545 
controlled trials (RCTs) studying these regimens, non-RCT studies were assessed in this 1546 
study, but considered separately from RCTs for the purposes of pooled data synthesis, to 1547 
investigate the impact of controlled trial design on summative outcomes where appropriate. 1548 
Clinical outcomes assessed in this study were as follows - all-cause and infection-related 1549 
mortality rates, clinical response rates and occurrence of nephrotoxicity. 1550 
Subgroup analysis were performed where possible, to assess the impact of particular 1551 
attributes on outcome measures including: 1552 
1) Class of antimicrobial combined with COL (e.g. carbapenems, tetracyclines, 1553 
rifampicin) 1554 
2) Comparator regimen (i.e. non- COL containing therapies, COL monotherapy) 1555 
As well as the impact of colistin combination therapies on the following: 1556 
1) Site of infection (e.g. bacteraemia, respiratory tract infection) 1557 
2) Infecting organism (e.g. A. baumannii, K. pneumoniae) 1558 
3) Infections caused by CPO 1559 
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2.2 Methods 1560 
2.2.1 Eligibility criteria and selection of studies 1561 
All studies reporting clinical outcomes of infections following treatment with COL (or 1562 
polymyxins) based therapy were included. All clinical studies were included, regardless of 1563 
study design with the exception of single case reports.  1564 
Exclusion criteria included articles limited to a paediatric population and those not 1565 
published in English. 1566 
2.2.2 Search protocol 1567 
PubMed and Scopus databases were screened using the following search terms and their 1568 
related keywords – “colistin”, “combination” and “trial” from all published works from 1569 
1/11/1950 through to 1/11/2015. Additionally, ClinicalTrials.gov was searched for any 1570 
completed studies with publicly available results for any colistin-based trials. Reference 1571 
lists from relevant previously published systematic reviews and included studies were also 1572 
hand-searched.  1573 
2.2.3 Study selection 1574 
Selection of papers included in the meta-analysis was performed by two independent 1575 
reviewers (LP and FP) using standardised critical appraisal questionnaires adapted from the 1576 
CONSORT 2010 checklist (183) for randomised-controlled trials (RCTs) and the Newcastle- 1577 
Ottawa Scale (184) for non-RCT studies (all assessed using the appraisal tool for cohort 1578 
studies). Any disagreement that arose between the 2 reviewers was resolved with 1579 
discussion or with the assistance of a third independent reviewer (DW). 1580 
The CONSORT (consolidated standards of reporting trials) checklist is a guideline of a core 1581 
set of criteria (25 items) for the conduct and report of randomised clinical trials to ensure 1582 
validity and quality of the results and standardisation across studies. The Newcastle- 1583 
Ottawa scale (NOS) was developed to perform a similar function for non-randomised 1584 
controlled clinical trials (e.g. cohort studies and case-control trials).  1585 
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2.2.4 Risk of bias in individual studies 1586 
The risk of bias of the eligible studies was considered separately for RCTs and non-RCTs. 1587 
The RCT studies were assessed on 6 criteria as described by Deverereaux et al. (185): 1588 
1) Concealment of randomisation 1589 
2) Early termination of the trial 1590 
3) Blinding of participants (patients) 1591 
4) Blinding of healthcare providers 1592 
5) Blinding of data collectors 1593 
6) Blinding of outcome assessors 1594 
The non-RCT studies were assessed for validity in 3 broad categories, based on the 1595 
Newcastle-Ottawa scale (184): 1596 
1) Selection of study cohort 1597 
2) Comparability of colistin combination treatment arm and comparator regimen(s) 1598 
3) Determination of clinical outcomes, including missing data handling (where 1599 
appropriate) and duration of follow-up (28 days for mortality, 14 days for clinical 1600 
response and 1 year for nephrotoxicity) 1601 
2.2.5 Synthesis of results and assessment of heterogeneity 1602 
Quantitative data, where possible, was pooled in statistical meta-analysis using a random 1603 
effects model (DerSimonian and Laird), and represented on Forest plots. For the purposes 1604 
of comparison, all formulations of polymyxins were collectively named ‘colistin’, whether 1605 
they belonged to the polymyxin-combination or comparator arms. All results were subject 1606 
to double data entry to ensure accuracy. 1607 
Effect sizes were expressed as odds ratios, and their 95% confidence intervals and p 1608 
values (derived from z test, which examines the significance of the difference between the 1609 
odds, if any) were calculated for analysis.  1610 
Data syntheses were performed in Stata (StataCorp. 2011. Stata Statistical Software: 1611 
Release 12. College Station, TX: StataCorp LP.) using a random effects model 1612 
(DerSimonian and Laird, D+L). Random effects model was chosen due to the heterogeneity 1613 
of the populations included (e.g. variations in age distributions, geography, underlying 1614 
infection, severity of illness) in the various studies, and the true effect from each study 1615 
would vary. The random effects model, unlike a fixed effects model, assumes random 1616 
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sampling of populations across the studies in the meta-analysis, as opposed to a fixed 1617 
population with a fixed true effect across the board. Additionally, heterogeneity was 1618 
assessed using the I2 statistic and interpreted as described in the Cochrane Handbook 1619 
(186). 1620 
2.2.6 Additional analyses 1621 
Subgroup analyses were performed to assess the impact on clinical outcomes made by 1622 
specific colistin combination therapies compared with colistin monotherapy and non- 1623 
colistin therapies respectively. 1624 
Data collected was also stratified by site of infection and type of infecting pathogen to 1625 
investigate any potential differences in clinical outcomes between the pooled estimates of 1626 
the colistin combination therapies and those of the comparator regimens.  1627 
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2.3 Results 1628 
2.3.1 Search results 1629 
A total of 563 citations were retrieved from the PubMed and Scopus databases. After 1630 
excluding papers irrelevant to the study (including duplicates) by screening titles and 1631 
abstracts, 138 full-text papers were subject to data extraction and independent review. 1632 
Eventually, 51 studies were included in the data syntheses. See Figure 2-1 for a flowchart 1633 
of the study selection process as per the Preferred Reporting Items for Systematic Reviews 1634 
and Meta-Analyses (PRISMA) guidelines. (187)  1635 
Figure 2-1 PRISMA flowchart of the study selection process. 1636 
 1637 
Database search (n=563) Title screen excluded:
- Duplicates (28)
- Irrelevant to topic (213)
- Review/editorial/guidelines (31)
Abstracts for screening (n=291)
Abstract screen excluded:
- Paediatric only (57)
- Epidemiology/surveillance (33)
- Laboratory/Animal research  (9)
- Non-colistin therapies (36)
- Review/Protocol (3)
- Case reports (3)
- Monotherapy only (5)
- Nebulised or gut decolonisation 
   only (13)





(n=6) Full-text screen excluded:
- Lack of description of outcomes for
   colistin combination group (59)
- No comparator group (16)
- Quality assessment, exclude (1)
- Monotherapy only (7)
- No systemic polymyxin therapy (1)
- Only single case outcomes (3)







2.3.2 Study characteristics 1638 
A total of 4 RCTs were identified. 3 studies each reported outcomes for mortality, clinical 1639 
response and nephrotoxicity respectively. The descriptions of the studies are detailed in  1640 
Table 2-1. 1641 
Among the eligible non-RCT studies, 41 reported mortality outcomes, 22 with clinical 1642 
response rates, and 11 with nephrotoxicity rates. The characteristics of these studies are 1643 
illustrated in Table 2-2. 1644 
 1645 
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 Table 2-1 Description of RCT studies. 1646 
Unless otherwise stated, age either expressed as a range (years) or mean age ± standard deviation (years).  1647 
HAP – hospital-acquired pneumonia; VAP – ventilator-associated pneumonia; cIAI – complicated intra-abdominal infection. 1648 
Study ID First author Year Follow-up duration  Population  Age  Inclusion criteria / Intervention 
743 Sirijatuphat 2014 Mortality: 28 days 
Clinical response: 28 days 
after end of therapy 
Nephrotoxicity: unclear 
Inpatients from a single 
centre in Thailand. 
30-97y  Carbapenem-resistant A. baumannii 
infection patients, who are to 
commence colistin therapy. 
Colistin monotherapy or colistin-
fosfomycin combination therapy (7-14 




2013 30 days 
 
 ICU patients from 5 
centres in Italy 
62 ± 15.4y  Life-threatening nosocomial XDR A. 
baumannii infection (HAP, VAP, 
bacteraemia or cIAI), susceptible to 
colistin 
Colistin monotherapy or colistin-
rifampicin combination therapy (10-21 
days) 
760 Aydemir 2013 Unclear (till death or 
discharge from 
hospital) 
 ICU patients from a 
single centre in Turkey 
61 ± 20y  Carbapenem-resistant A. baumannii 
VAP (with susceptibility results known 
≤48h of onset) 
Colistin monotherapy or colistin-
rifampicin combination (rifampicin 
stopped if resistant and no evidence 





Study ID First author Year Follow-up duration Population Age  Inclusion criteria / Intervention 
857 Conway 1997 12 days  Adult cystic fibrosis 
patients from a single 
centre in UK. 
Colistin monotherapy: 
21.7 ± 4.2y 
Colistin combinations: 
21.2 ± 4.25y 
Respiratory tract 
infection/exacerbation on background 
of chronic colonisation with P. 
aeruginosa (susceptible to colistin) 
Colistin monotherapy or colistin 
combination with another anti-
pseudomonal agent (aztreonam, 
azlocillin, piperacillin, ceftazidime, 
imipenem or ciprofloxacin). 
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Table 2-2 Description of non-RCT studies. 1651 
Unless otherwise stated, age either expressed as a range (years) or mean age ± standard deviation (years). ICU – Intensive care unit; MHT – modified Hodge 1652 
test; HAP – hospital-acquired pneumonia; VAP – ventilator-associated pneumonia; cIAI – complicated intra-abdominal infection. Col – colistin; Carb – 1653 
carbapenems; Rif – rifampicin; Sulb – sulbactams; SXT – cotrimoxazole; Tig - tigecycline 1654 
a) Mortality 1655 
Study ID First author Year Follow-up Population   Age   Inclusion criteria 
744 Lopez-Cortes 2014 30 days Inpatients from 28 
hospitals in Spain 
 
Median: 60y, IQR: 52-
75y 
 
A. baumannii sepsis 
≥48h therapy active in vitro 
747 Batirel 2014 5-497 days Inpatients from 27 




58.3 ± 20.5y, Colistin-
combinations: 59.1 ± 
19.6y 
 
XDR A. baumannii 
bacteraemia 
Colistin-based therapy ≥72h 
752 Petrosillo 2014 30 days ICU patients from 3 
tertiary centres in 
Italy 
 




753 Crusio 2014 6 months Patients from a 
single centre in USA 
 
77 ± 12.9y 
 
Carbapenem-resistant P. 
aeruginosa or A. baumannii 
infection. 
 
Polymyxin B based therapy 
≥72h 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
755 Kontopidou 2014 14 days ICU patients from 19 






≥48h therapy active in vitro 
756 Kalin 2014 14 days ICU patients from a 





MDR A. baumannii 
ventilator-associated 
pneumonia 
Colistin or Col/Sulb therapy 
758 Capone 2013 unclear Patients from 9 
hospitals in Italy 
 





763 Tumbarello 2012 30 days Patients from 3 
hospitals in Italy 
 
Non-survivors: 61.5 ± 





≥48h therapy active in vitro 
 
765 Ku 2012 3 months Patients from a 
single centre in USA 
 
59 ± 18y 
 
A. baumannii or 
carbapenem-resistant 
Enterobacteriaceae infection 
≥2 doses of colistin or 
tigecycline therapy 
795 Tascini 2006 unclear Patients from a 




MDR P. aeruginosa diabetic 
foot infection 
Colistin based therapy 
796 Falagas 2006 unclear Inpatients from a 




56.2 ± 19.8y, Colistin-





Colistin based therapy ≥72h 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
990 Yilmaz 2015 28 days ICU patients from a 
single centre in 
Turkey 
 
No Abx: 59.8 ± 21.5y, 
Colistin-carbapenem 
59.6 ± 20.5y, Colistin-
sulbactam 70.6 ± 
14.7y 
 
MDR or XDR A. baumannii 
ventilator-associated 
pneumonia 
Colistin based therapy ≥48h 
1005 de Oliveira 2015 30 days Inpatients from 3 
centres in Brazil 
 
Non-survivors: 59.7 ± 
16.1y, Survivors: 53 ± 
19.5y 
 
Infections caused by KPC 
producers 
1009 Chang 2015 30 days ICU patients from 17 





pneumoniae or E. coli 
≥48h of therapy 
1026 Samonis 2014 unclear Cancer patients 





P. aeruginosa infection 
1030 Porwal 2014 30 days Inpatients from a 
single centre in India 
 




1031 Pontikis 2014 28 days ICU patients from 11 
centres in Greece 
 
56.7 ± 17.2y 
 
XDR or PDR bacterial 
infection 
≥1 dose of fosfomycin 
disodium based therapy 
1033 Papadimitriou-Olivgeris 2014 30 days ICU patients from a 
single centre in 
Greece 
 
Non-survivors: 65.2 ± 
10.4y 





≥7 days of therapy 
1040 Lubbert 2014 unclear Liver transplant 
receipients from a 








Study ID First author Year Follow-up Population   Age   Inclusion criteria 
1044 Khawcharoenporn 2014 28 days Inpatients from a 





XDR A. baumannii 
nosocomial pneumonia 
Receiving therapy active in 
vitro 
1055 Garnacho-Montero 2014 28 days ICU patients from a 
single centre in 
Spain 
 
Col without vanc: 63 ± 
11.6y 





associated pneumonia or 
bacteraemia 
Colistin based therapy 
with/without vancomycin 
for >4 days 
1063 Daikos 2014 28 days Inpatients from 2 





K. pneumoniae bacteraemia 
1066 Chuang 2014 unclear ICU patients from a 
single centre in 
Taiwan 
 
 63.8 ± 18.5y 
 
MDR A. baumannii 
pneumonia 
Colistin or tigecycline based 
therapy 
1069 Balkan 2014 28 days Inpatients from a 
single hospital in 
Turkey 
 





≥24 h therapy active in vitro 
1074 Tuon 2013 2 - 365 days Inpatients from a 








1081 Rocco 2013 unclear ICU patients from 2 
centres in Italy 
 
Median: 61y, IQR: 43-
74y 
 
XDR bacterial infection 
Colistin based therapy 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
1088 Navarro-San Francisco 2013 30 days Inpatients from a 








1115 Şimsek 2012 28 days Inpatients from a 





A. baumannii (only 
susceptible to colistin in 
vitro) infection 
Colistin based therapy ≥24 
h 
1142 Brigante 2012 20 - 156 days Inpatients from 2 




MDR A. baumannii infection 
1146 Zarkotou 2011 unclear Inpatients from a 
single centre in 
Greece 
 




1160 Lim 2011 30 days Inpatients from a 





MDR A. baumannii 
bacteraemia 
Receiving therapy ≥72h 
1173 Souli 2010 unclear Inpatients from a 







1180 Korbila 2010 unclear Inpatients from a 
single centre in 
Greece 
 
Colistin (IV): 60.9 ± 
15.7y 
Colistin (IV+nebs): 
59.6 ± 19.2y 
 
MDR Gram-negative 
(susceptible to colistin) 
ventilator-associated 
pneumonia 
≥72h IV colistin-based 
therapy 
1186 Huang 2010 unclear Surgical ICU 
patients from a 





MDR or PDR Gram-negative 
bacterial infection 
Colistin based therapy ≥72h 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
1208 Souli 2008 1 - 132 days Inpatients from a 







1231 Parkins 2007 unclear Inpatients from 3 
centres in Canada 
 




≥5 days of anti-
pseudomonal therapy 
(unless death occurs) 
1248 Micol 2006 unclear Haemato-oncology 
inpatients from a 





P. aeruginosa bacteraemia 
1302 Bryant 1971 unclear Patients from a 





1307 Schafer 2007 unclear Inpatients from a 








Tigecycline based therapy 
1308 Bergamasco 2012 30 days Solid-organ 
transplant 
receipients from a 












b) Clinical response 1660 
Study ID First author Year Follow-up Population   Age   Inclusion criteria 
747 Batirel 2014 5 - 497 days Inpatients from 27 




58.3 ± 20.5y 
Colistin-combination: 
59.1 ± 19.6y 
 
XDR A. baumannii 
bacteraemia 
Colistin based therapy ≥72h 
753 Crusio 2014 unclear Patients from a 
single centre in USA 
 
77 ± 12.9y 
 
Carbapenem-resistant K. 
pneumoniae, P. aeruginosa 
or A. baumannii infection 
Polymyxin B based therapy 
≥72h 
755 Kontopidou 2014 14 days ICU pateints from 







≥48h therapy active in vitro 
756 Kalin 2014 14 days ICU patients from a 









sulbactam) based therapy 
795 Tascini 2006 unclear Patients from a 




MDR P. aerguinosa diabetic 
foot infection 
Colistin based therapy 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
796 Falagas 2006 unclear Inpatients from a 




56.2 ± 19.8y 
Colistin-combination: 





Colistin based therapy ≥72h 
853 Ledson 1998 unclear Cystic fibrosis 
patents from a 




P. aeruginosa respiratory 
infection 
≥1 dose colistin based 
therapy 
990 Yilmaz 2015 unclear ICU patients from a 
single centre in 
Turkey 
 
No Abx: 59.8 ± 21.5y, 
Colistin-carbapenem 
59.6 ± 20.5y, Colistin-
sulbactam 70.6 ± 
14.7y 
 
MDR or XDR A. baumannii 
ventilator-associated 
pneumonia 
Colistin based therapy ≥48h 
1031 Pontikis 2014 14 days ICU patients from 
11 centres in 
Greece 
 
56.7 ± 17.2y 
 
XDR or PDR bacterial 
infection 
≥1 dose fosfomycin 
disodium based therapy 
 
1055 Garnacho-Montero 2014 unclear ICU patients from a 
single centre in 
Spain 
 
Col without vanc: 63 ± 
11.6y 





associated pneumonia or 
bacteraemia 
Colistin based therapy 
with/without vancomycin 
for >4 days 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
1115 Simsek 2012 unclear Inpatients from a 





A. baumannii (susceptible in 
vitro only to colistin) 
infection 
Colistin based therapy ≥24 
h 
 
1118 Rihani 2012 unclear Inpatients from a 
single centre in USA 
 




1141 Dalfino 2012 unclear ICU patients froma 
single centre in Italy 
 




Colistin based therapy ≥72h 
1142 Brigante 2012 20 - 156 days Inpatients from 2 




MDR A. baumannii infection 
1173 Souli 2010 7 days Inpatients from a 







1180 Korbila 2010 unclear Inpatients from a 
single centre in 
Greece 
 
Colistin (IV): 60.9 ± 
15.7y 
Colistin (IV+nebs): 
59.6 ± 19.2y 
 
MDR Gram-negative 
(susceptible to colistin) 
ventilator-associated 
pneumonia 
≥72h IV colistin-based 
therapy 
1186 Huang 2010 unclear Surgical ICU 
patients from a 





MDR or PDR Gram-negative 
bacterial infection 
Colistin based therapy ≥72h 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
1188 Falagas 2010 unclear Inpatients from a 







Colistin based therapy ≥72h 
1208 Souli 2008 7 days Inpatients from a 








1238 Hachem 2007 unclear Cancer patients 





MDR P. aeruginosa 
Colistin based or other anti-
pseudomonal therapy 
1239 Furtado 2007 unclear Inpatients from a 





MDR P. aeruginosa 
nosocomial pneumonia 
Polymyxin B based therapy 
≥48h 
1307 Schafer 2007 unclear Inpatients from a 








Tigecycline based therapy 
 1661 
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c) Nephrotoxicity 1662 
Study ID First author Year Follow-up Population   Age   Inclusion criteria 
747 Batirel 2014 9 - 497 days Inpatients from 27 




58.3 ± 20.5y 
Colistin-combination: 
59.1 ± 19.6y 
 
XDR A. baumannii 
bacteraemia 
Colistin based therapy 
≥72h 
752 Petrosillo 2014 unclear ICU patients from 3 
tertiary centres in 
Italy 
 
Median: 62y, IQR: 46-
73.2y 
 
Colistin based therapy 
753 Crusio 2014 unclear Patients from a single 
centre in USA 
 




aeruginosa or A. 
baumannii infection 
Polymyxin B based 
therapy ≥72h 
796 Falagas 2006 unclear Inpatients from a 




56.2 ± 19.8y 
Colistin-combination: 




Colistin based therapy 
≥72h 
990 Yilmaz 2015 unclear ICU patients from a 
single centre in 
Turkey 
 
No Abx: 59.8 ± 21.5y, 
Colistin-carbapenem 
59.6 ± 20.5y, Colistin-
sulbactam 70.6 ± 14.7y 
 
MDR or XDR A. baumannii 
ventilator-associated 
pneumonia 
Colistin based therapy 
≥48h 
1055 Garnacho-Montero 2014 unclear ICU patients from a 
single centre in Spain 
 
Col without vanc: 63 ± 
11.6y 





associated pneumonia or 
bacteraemia 
Colistin based therapy 
with/without vancomycin 
for >4 days 
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Study ID First author Year Follow-up Population   Age   Inclusion criteria 
1079 Sbrana 2013 unclear Trauma inpatients 
from a single centre 
in Italy 
 




1081 Rocco 2013 unclear ICU patients from 2 
centres in Italy 
 
Media: 61y, IQR: 43-
74y 
 
XDR bacterial infection 
Colistin based therapy 
(either monotherapy or in 
combination with other 
nephrotoxic agents) ≥7 
days 
1141 Dalfino 2012 unclear ICU patients from a 
single centre in Italy 
 




Colistin based therapy 
≥72h 
1248 Micol 2006 unclear Haemato-oncology 
patients from a single 
centre in France 
 20-80y  P. aeruginosa 
bacteraemia 
1302 Bryant 1971 unclear Patients from a single 








2.3.3 Risk of bias 1664 
Of the eligible papers with sufficient information regarding COL-combination therapy 1665 
clinical outcomes, 51 included comparators’ outcomes within the same publication/study. 1666 
Only 4 of these studies were randomised controlled trials (RCT), none of which were 1667 
double-blinded studies. The remaining 47 studies included cohort studies and case series. 1668 
The COL-combination and comparator groups were unmatched in the non-RCT studies for 1669 
either disease severity or potential confounding baseline demographics. Post-hoc 1670 
multivariate analyses were rarely done, with only 3 (Petrosillo #752, Kontopidou #755, 1671 
Tumbarello #763) of the non-RCT studies reporting adjusted odds ratio for mortality with 1672 
COL-combination therapy (none for either clinical response or nephrotoxicity). All the 1673 
studies were subject to investigator and assessor biases to varying levels, and case series 1674 
in particular, carried a rather substantial reporting bias due to the pre-selection of patients 1675 
being treated with COL-combination therapies, often due to previous failure of 1676 
monotherapy (i.e. as rescue or salvage treatment), more severe sepsis or critical illness at 1677 
onset, or more significant underlying comorbid factors.  1678 
2.3.3.1 Risk of bias – RCTs 1679 
The risk of bias from the RCTs is shown in Table 2-3. As RCT studies represent the best 1680 
level of evidence currently available for the evaluation of clinical outcomes with COL 1681 
combination therapy, all identified RCTs (n = 4) have been included in the meta-analysis. 1682 
Perhaps due to the complexities of conducting trials in patients who are predominantly 1683 
critically ill, investigators have found that the constraints of the traditional double-blind RCT 1684 
design are in conflict with the greater priority of patient safety. Indeed, none of the 4 RCTs 1685 
available in literature have met all 6 criteria of validity. 1686 
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Table 2-3 Quality assessment – RCTs. 1687 











743 Sirijatuphat 2014 Unclear No No No Unclear No 
757 Durante-
Mangoni 
2013 No No No No Unclear No 
760 Aydemir 2013 No No No No Unclear No 
857 Conway 1997 Unclear No No No Yes Yes 
 1688 
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2.3.3.2 Risk of bias – Non-RCTs 1689 
The risk of bias from non-RCTs is detailed in Table 2-4. The Newcastle-Ottawa Scale’s star 1690 
system for cohort studies was used to assess all eligible studies (n = 47). Each study was 1691 
assessed for validity in each outcome separately. Not all studies reported all outcomes of 1692 
interest – mortality (n = 41), clinical response (n = 22), and nephrotoxicity (n = 11). A cut-off 1693 
minimum score of 4 was set for inclusion in the final data syntheses (1 study reporting 1694 
nephrotoxicity outcome was excluded).   1695 
Of the 41 studies which reported comparative mortality outcomes, 23 (56%) were judged to 1696 
be of acceptable quality overall, and 18 (44%) were good (score > 6). Quality assessments 1697 
of clinical response and nephrotoxicity outcomes revealed data garnered were 1698 
considerably less optimal. Only 1 study for clinical response and none for nephrotoxicity 1699 
were considered to be of good quality. The relative subjective nature of determining clinical 1700 
response as well as the variability in definitions (e.g. cure versus improvement, clinical 1701 
observations versus biochemical or radiological markers) compared with the binary nature 1702 
of mortality may account for the differences. Similarly, the different definitions used to 1703 
judge nephrotoxicity used by the various investigators (e.g. RIFLE, AKIN, individually 1704 
defined biochemical changes) contribute to the studies being judged of worse quality. Most 1705 
do not state the duration of follow-up of their cohort for the specific outcome measured.  1706 
 1707 
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Table 2-4 Quality assessment – Non-RCTs. 1708 
Quality assessments of each category – Green: Good, Yellow: Acceptable, Orange (not for 1709 
‘Comparability’): Borderline, Red: Poor. NOS – Newcastle-Ottawa scale (range 0-9; Low 0- 1710 
3, Acceptable 4-6, Good 7-9). 1711 
(a) Mortality 1712 

























744 Lopez-Cortes 2014 9     
752 Petrosillo 2014 8     
1066 Chuang 2014 8     
753 Crusio 2014 7     
763 Tumbarello 2012 7     
765 Ku 2012 7     
990 Yilmaz 2015 7     
1005 de Oliveira 2015 7     
1030 Porwal 2014 7     
1033 Papadimitriou-Olivgeris 2014 7     
1044 Khawcharoenporn 2014 7     
1055 Garnacho-Montero 2014 7     
1063 Daikos 2014 7     
1069 Balkan 2014 7     
1088 Navarro-San Francisco 2013 7     
1115 Simsek 2012 7     
1160 Lim 2011 7     
1304 Qureshi 2012 7     
747 Batirel 2014 6     
755 Kontopidou 2014 6     
756 Kalin 2014 6     
758 Capone 2013 6     
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796 Falagas 2006 6     
1009 Chang 2015 6     
1142 Brigante 2012 6     
1146 Zarkotou 2011 6     
1173 Souli 2010 6     
1208 Souli 2008 6     
1231 Parkins 2007 6     
1307 Schafer 2007 6     
1308 Bergamasco 2012 6     
789 Basetti 2008 6     
1026 Samonis 2014 5     
1040 Lubbert 2014 5     
1081 Rocco 2013 5     
1180 Korbila 2010 5     
1186 Huang 2010 5     
1248 Micol 2006 5     
1302 Bryant 1971 5     
740 Cheng 2015 5     
1010 Chaari 2015 5     
1056 Freire 2014 5     
1062 de Sanctis 2014 5     
1303 Shields 2011 5     
795 Tascini 2006 4     
1031 Pontikis 2014 4     
1074 Tuon 2013 4     
1104 Di Carlo 2013 4     
1175 Reddy 2010 4     
 1713 
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(b) Clinical response 1714 























753 Crusio 2014 7     
747 Batirel 2014 6     
755 Kontopidou 2014 6     
756 Kalin 2014 6     
796 Falagas 2006 6     
1055 Garnacho-Montero 2014 6     
1115 Simsek 2012 6     
1141 Dalfino 2012 6     
1173 Souli 2010 6     
1188 Falagas 2010 6     
1208 Souli 2008 6     
1239 Furtado 2007 6     
1307 Schafer 2007 6     
990 Yilmaz 2015 5     
1118 Rihani 2012 5     
1142 Brigante 2012 5     
1180 Korbila 2010 5     
1186 Huang 2010 5     
1238 Hachem 2007 5     
789 Basetti 2008 5     
1303 Shields 2011 5     
795 Tascini 2006 4     
853 Ledson 1998 4     
1031 Pontikis 2014 4     
1056 Freire 2014 3     
1305 Ostronoff 2006 3     
1306 Tascini 2004 3     
 93 























802 Motaouakkil 2006 2     
980 Thomas 1976 2     
 1715 
(c) Nephrotoxicity 1716 























747 Batirel 2014 6     
753 Crusio 2014 6     
1055 Garnacho-Montero 2014 6     
1141 Dalfino 2012 6     
1302 Bryant 1971 6     
1115 Simsek 2012 6     
752 Petrosillo 2014 5     
796 Falagas 2006 5     
1081 Rocco 2013 5     
1248 Micol 2006 5     
789 Basetti 2008 5     
1061 Dewan 2014 5     
990 Yilmaz 2015 4     
1044 Khawcharoenporn 2014 3     
1079 Sbrana 2013 2     
980 Thomas 1976 2     
802 Motaouakkil 2006 1     
1306 Tascini 2004 1     
 1717 
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2.3.4 Legend for forest plots 1718 
Organism  
AB A. baumannii 
EC E. coli 
EnA E. aerogenes 
EnCl E. cloacae 
Ent Enterobacteriaceae 
GNB Gram-negative bacteria 
KO K. oxytoca 
KP K. pneumoniae 
MM M. morganii 
PA P. aeruginosa 
SM S. marcescens 
StM S. maltophilia 
 1719 
Resistance  
CPO Carbapenemase-producing organism 
CR Carbapenem-resistant 
MDR Multi-drug resistant 
NS Not specified 
PDR Pan-drug resistant 
SOC Susceptible only to colistin 
SOF Susceptible only to fosfomycin 
XDR Extensively drug resistant 
 1720 




nebs Nebulised / Aerosolised 
 1721 
Comparators  
All comp All comparator groups 
Col Colistin monotherapy 
Mono All monotherapies (including colistin monotherapy) 
Non-col Non-colistin therapies 
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Mixed Mixed adjuvants (outcome given for all combinations) 









2x 2 adjuvants 
2-3x 2-3 adjuvants 
2-4x 2-4 adjuvants 
≥2x 2 or more adjuvants 
1722 
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2.3.5 Effect of colistin-combination therapies on mortality 1723 
Mortality data were consolidated into all-cause (or crude mortality) and infection-related 1724 
mortality. All time-courses were considered, and where a paper provided survival data at 1725 
varying time-points, the closest time-point to 28 days (or 4 weeks) was taken for inclusion 1726 
in the meta-analysis. COL was used in all RCTs comparing mortality rates, while in 3 non- 1727 
RCT studies polymyxin B (Crusio #753, Bergamasco #1308, Tuon #1074) was the sole 1728 
polymyxin used and in a further 3 studies (de Oliveira #1005, Qureshi #1304, Bryant #1302) 1729 
either colistin or polymyxin B was used.  1730 
The data syntheses were performed separately for RCT and non-RCT trials. The latter 1731 
group consisted of all studies that made a comparison between colistin-combinations and 1732 
any comparator, regardless of matching of baseline demographics. Case series were 1733 
included in this group, though single case reports were excluded. Studies with no 1734 
comparators (i.e. only had clinical outcomes described for colistin-combination therapy) 1735 
were excluded from the meta-analyses. 1736 
For mortality meta-analyses, odds ratio (OR) < 1 favoured (i.e. lower mortality rate 1737 
compared with alternative) colistin combination therapies, OR = 1 referred to equivalent 1738 
mortality in both groups, and OR > 1 favoured the comparator. 1739 
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2.3.5.1 Mortality – RCTs 1740 
3 RCTs reported mortality outcomes (total number of patients included, n = 346) and were 1741 
thus included in the data synthesis. For all-cause mortality, the odds of survival were 1742 
approximately increased 1.2 fold with colistin-combinations compared with the 1743 
comparator, which was colistin monotherapy in all 3 studies. This observation, however, 1744 
was not statistically significant (p = 0.455). 1745 
Infection-related mortality similarly was lower with colistin-combination therapies 1746 
(approximately 1.5 fold), though the trend was again, not statistically significant (p = 0.083). 1747 
The forest plots for both all-cause and infection-related mortality are shown in Figure 2-2. 1748 
The infecting pathogen in all 3 studies was A. baumannii, and 2 studies (Durante-Mangoni 1749 
#757 and Aydemir #760) used rifampicin as the colistin adjuvant, and the 3rd study 1750 
(Sirijatuphat #743) investigated colistin-fosfomycin combination therapy. Although colistin- 1751 
rifampicin combination therapy appeared to favour survival (compared with colistin 1752 
monotherapy) in the individual studies, particularly Aydemir et al. (study #760), neither 1753 
difference observed for all-cause mortality (odds ratio; OR 0.94, p = 0.81) nor infection- 1754 
related mortality was statistically significant (OR 0.62, p = 0.128).  1755 
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Forest plot of Colistin combination mortality rates vs monotherapy from RCTs
 lower with combination therapy lower with monotherapyOdds ratio
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2.3.5.2 Mortality – Non-RCTs 1759 
2.3.5.2.1 All colistin-combination versus all comparators 1760 
41 non-RCT studies were included in the meta-analyses of mortality rates. 37 studies 1761 
reported all-cause mortality (total number of patients included, n = 2868) and 11 studies (n 1762 
= 353) reported infection-related mortality. Mortality rates were similar in COL-combination 1763 
and comparator arms for both all-cause mortality (1.23 fold higher in comparator arm, p = 1764 
0.113) and infection-related mortality (OR 1.03, p = 0.903). See figure 5 for forest plots of all 1765 
COL-combinations versus all comparators.  1766 
2.3.5.2.2 Subgroup analysis – infection characteristics 1767 
The pooled all-cause mortality rate favoured the COL-combination arm in case of 1768 
bacteraemia (n = 890 from 11 studies) – mortality was 1.7 fold lower (p = 0.001) compared 1769 
with comparators. Subgroups analyses by infecting organism type showed that colistin- 1770 
combinations led to higher odds of survival in K. pneumoniae infections (2.5 fold, p < 1771 
0.001), including K. pneumoniae bacteraemia (2.4 fold, p < 0.001). Moreover, colistin 1772 
combination therapy for infections with carbapenemase-producing organisms (CPO; n = 1773 
798 from 14 studies) was associated with better survival (all-cause mortality) compared 1774 
with all comparators (1.9 fold, p = 0.017). See Figure 2-4 for all-cause mortality rates 1775 
subgroup analyses. 1776 
In contrast with observations for all-cause mortality, similar subgroup analyses of pooled 1777 
infection-related mortality data combining all COL combinations against all comparator 1778 
groups revealed no statistically significant trend towards one group or the other. See Figure 1779 
2-5 for details of the subgroup analyses for infection-related mortality. 1780 
 1781 
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Figure 2-4 Subgroup analyses – All-cause mortality rates comparison between all colistin combinations and all comparators. 1784 
 1785 
         - Bloodstream infection only
        Carbapenemase producer (CPO)
Specific resistance mechanism
         - Bloodstream infection only
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        P. aeruginosa
         - Bloodstream infection only
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Figure 2-5 Subgroup analyses – Infection-related mortality rates comparison between all colistin combinations and all comparators. 1786 
 1787 
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2.3.5.2.3 Subgroup analysis of all-cause mortality – specific colistin 1789 
combinations versus colistin monotherapy 1790 
Further comparisons were made between different comparator arms (i.e. COL 1791 
monotherapy, non- COL therapies), subdivided into specific categories based on the 1792 
antimicrobial class of the additional agent(s) within the COL-combination arms, for non- 1793 
RCT studies. 1794 
When compared with COL monotherapy, no differences in all-cause mortality rates 1795 
between COL-combination and monotherapy arms were statistically significant. COL- 1796 
combinations that did favour survival (all-cause) included COL-aminoglycosides (1.6 fold, p 1797 
= 0.17), colistin-quinolones (2.04 fold, p = 0.582), COL-tetracyclines (1.44 fold, p = 0.181), 1798 
colistin-rifampicin (1.95 fold, p = 0.578) and COL with 2 or more adjuvants (1.88 fold, p = 1799 
0.096). Combinations which included sulbactam (1.91 fold, p = 0.456), carbapenems (1.05 1800 
fold, p = 0.879) and glycopeptides (1.14 fold, p = 0.706) favoured the comparator arms. See 1801 
Figure 2-6 for details of the studies included. 1802 
The only significant difference between survival with a specific COL combination therapy 1803 
and COL monotherapy was for COL-tetracycline combinations (all COL-tigecycline 1804 
combinations) in the treatment of bacteraemia (2.38 fold, p = 0.04, n = 107). Coincidentally, 1805 
bacteraemia in these subgroups were caused by CPO (Tumbarello #763 KPC, 1806 
Papadimitriou-Olivgeris #1033 KPC, Daikos #1063 KPC ± VIM, Navarro-San Francisco 1807 
#1088 OXA-48, Qureshi #1304 KPC), with the majority of cases carried by K. pneumoniae. 1808 
See Figure 2-8 for details of the subgroup analyses for specific COL combinations. 1809 
2.3.5.2.4 Subgroup analysis of all-cause mortality – specific colistin 1810 
combinations versus non-colistin therapies 1811 
Assessment of specific colistin combinations against non-colistin therapies did not reveal 1812 
any statistically significant difference in all-cause mortality rates. Colistin combination 1813 
therapies that appeared to favour survival (p > 0.05) included colistin-aminoglycosides (1.42 1814 
fold, p = 0.287), colistin with non-carbapenem b-lactams (1.25 fold, p = 0.86), colistin- 1815 
fosfomycin (1.64 fold, p = 0.758), colistin-tetracyclines (here, represents colistin-tigecycline; 1816 
1.49 fold, p = 0.17) and colistin with 2 or more adjuvants (1.31 fold, p = 0.563). Colistin- 1817 
carbapenem combinations favoured the non-colistin therapies arm with 1.15 fold increase 1818 
in survival (p = 0.641). See Figure 2-7 for details of studies included in the specific colistin 1819 
combinations subgroup analyses. 1820 
Further analyses of subgroup data by site of infection and resistance mechanism did not 1821 
reveal any significant association of survival or mortality with any individual colistin 1822 
combination therapy. See Figure 2-8 for details of the analyses.  1823 
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Figure 2-6 Subgroup analyses – All-cause mortality rates comparison between specific 1824
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2.3.5.2.5 Subgroup analysis of infection-related mortality – specific colistin 1827 
combinations versus colistin monotherapy 1828 
The comparisons of infection-related mortality rates between specific colistin combinations 1829 
and colistin monotherapy was likewise not statistically significant (p > 0.05). Due to 1830 
relatively few studies reporting infection-related mortality (11 in total) as an outcome 1831 
measure, pooled estimates were only available for colistin-carbapenems (2.8 fold higher, p 1832 
= 0.424), colistin-tigecycline (2.9 fold lower, p = 0.461) and colistin with 2 or more adjuvants 1833 
(1.8 fold lower, p = 0.557). See Figure 2-9 for details of infection-related mortality rates 1834 
between these combinations and colistin monotherapy. 1835 
Further subgroup analyses by site of infection and resistance mechanism did not reveal any 1836 
meaningful association between any particular colistin combination and infection-related 1837 
mortality rates compared with colistin monotherapy alone. See Figure 2-11 for details. 1838 
2.3.5.2.6 Subgroup analysis for infection-related mortality – specific colistin 1839 
combinations versus non-colistin therapies 1840 
Infection-related mortality rates were once again not significantly different between specific 1841 
COL combinations and non-COL therapies. The mortality rate trends were as follows – for 1842 
COL-aminoglycosides (1.66 fold lower, p = 0.666), COL-carbapenems (1.28 fold higher, p = 1843 
0.698), COL-tigecycline (1.79 fold higher, p = 0.522) and COL with 2 or more adjuvants 1844 
(1.41 fold higher, p = 0.656). See Figure 2-10 details the forest plots of these comparisons. 1845 
Further subgroup analyses (i.e. by site of infection and resistance mechanism) did not yield 1846 
statistically significant associations mainly due to the number of studies per strata (n = 2-3) 1847 




Figure 2-7  Subgroup analyses – All-cause mortality rates comparison between specific 1851
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Figure 2-8 Subgroup analyses – All-cause mortality rates comparison between specific colistin combinations and colistin monotherapy or non-colistin 1854 
therapies by site of infection and resistance mechanism. 1855 
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Figure 2-11 Subgroup analyses – Infection-related mortality rates comparison between specific colistin combinations and colistin monotherapy or non- 1862 
colistin therapies by site of infection and resistance mechanism. 1863 
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2.3.6 Effect of colistin-combination therapies on clinical 1865 
response 1866 
Clinical response was reported in 25 studies (3 RCTs and 22 non-RCTs) with variations in 1867 
the definitions applied. Comparisons made in the meta-analyses included any study 1868 
reporting ‘clinical cure’ or ‘clinical improvement’, and in studies that only reported ‘clinical 1869 
failure’ rates, clinical response was taken to be those which were not considered to be 1870 
‘clinical failures’. Any time-line was included in the meta-analyses. 1871 
COL was the only polymyxin used in all the RCTs (n = 3), while 2 non-RCT studies 1872 
compared clinical response rates between polymyxin B combination therapy and other 1873 
therapeutic regimen. (188, 189) 1874 
Clinical response to therapy favoured COL combinations if OR >1, was equivalent in both 1875 
arms if OR = 1, and favoured the comparator if OR <1. 1876 
 112 
2.3.6.1 Clinical response - RCTs 1877 
3 RCTs (n = 199) reported clinical response as an outcome measure. Data from Conway et 1878 
al. (study ID 957) were excluded from data synthesis due to equivalence of clinical 1879 
response (in this case, all patients recovered from their infection by the end of the treatment 1880 
period). Therefore, 137 patients were included in the final data synthesis. The odds of 1881 
survival favoured COL combination therapy (OR 1.3), although this was not statistically 1882 
significant (p = 0.443). The comparator in all 3 studies was COL monotherapy, given 1883 
intravenously. COL combinations included COL-fosfomycin (Sirijatuphat #743) and COL- 1884 
rifampicin (Aydemir #760). The details of the comparisons are shown in Figure 2-12. 1885 
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Figure 2-12 Clinical response data from RCTs. 1886 
 1887 
 1888 
Test of OR=1 : z= 0.77 p = 0.443 
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2.3.6.2 Clinical response – Non-RCTs 1889 
2.3.6.2.1 All colistin-combinations versus all comparators 1890 
22 non-RCT studies (n = 1655) were analysed for differences in clinical response rates 1891 
between COL-combinations and other comparators. The study by Ledson et al was 1892 
excluded from the final data synthesis due to equivalence of effect in both arms (all patients 1893 
responded favourably to treatment), thus 21 non-RCT studies (n = 1520) were subject to 1894 
meta-analysis.  1895 
Clinical response rates were similar regardless of choice of therapy (all COL combinations 1896 
compared with all other therapeutic options), with OR 1.01, and this was not statistically 1897 
significant (p = 0.967). The forest plot illustrating these comparisons is shown in Figure 1898 
2-13. 1899 
2.3.6.2.2 Subgroup analysis – by infection characteristics 1900 
Subgroup analyses by site of infection and infecting organism did not reveal any valid (p < 1901 
0.05) differences between the clinical response rates of patients treated with COL 1902 
combinations compared with any other therapy. Clinical response rates for COL 1903 
combinations were as follows – A. baumannii (OR 0.85, p = 0.534), K. pneumoniae (OR 1904 
0.76, p = 0.683), P. aeruginosa (OR 1.01, p = 0.975), bacteraemia (OR 0.98, p = 0.965) and 1905 
respiratory tract infections (OR 1.12, p = 0.686). Likewise, no significant differences in 1906 
clinical response rates were noted between COL combinations and COL monotherapy for 1907 
the treatment of bacteraemia (OR 1.11, p = 0.785) or respiratory tract infections (OR 1.25, p 1908 
= 0.382); or between COL combinations and non-COL therapies for treatment of 1909 
bacteraemia (OR 0.53, p = 0.518) or respiratory tract infection (OR 0.14, p = 0.112).  1910 
2.3.6.2.3 Subgroup analysis – specific colistin combinations versus colistin 1911 
monotherapy 1912 
Treatment with specific COL combination therapies or COL monotherapy resulted in similar 1913 
clinical response rates (p > 0.05), with marginal benefit (if any) observed when treated with 1914 
COL-sulbactams (1.29 fold, p = 0.5) or COL-rifampicin (1.04 fold, p = 0.962). Combinations 1915 
with carbapenems (1.37 fold, p = 0.31), tetracyclines (2.23 fold, p = 0.203) or 2 or more 1916 
adjuvants (1.04 fold, p = 0.943), however, resulted in poorer clinical response. Details of 1917 
these results are shown in Figure 2-14. 1918 
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2.3.6.2.4 Subgroup analysis – specific colistin combinations versus non- 1919 
colistin therapies 1920 
Comparisons between specific COL combinations and non-COL therapies likewise did not 1921 
yield any statistically significant (p > 0.05) differences in clinical response rates. Whilst 1922 
COL-carbapenems led to better clinical response (1.7 fold, p = 0.771), COL-tetracyclines 1923 
(1.02 fold, p = 0.977) and COL with 2 or more adjuvants (1.15 fold, p = 0.831) led to poorer 1924 
clinical response over non-COL therapies. The comparisons are detailed in forest plots in 1925 
Figure 2-15. 1926 
 1927 
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Figure 2-13 Clinical response data from non-RCT studies – All colistin-combinations versus all comparators. 1928 
 1929 
 1930 
Test of OR=1 : z= 0.04 p = 0.967
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2.3.7 Effect of colistin combination therapies on 1936 
nephrotoxicity 1937 
14 studies were included in the meta-analyses for nephrotoxicity. Of theses, 3 were RCTs 1938 
and 11 were non-RCT studies. Definitions used for assessing nephrotoxicity varied 1939 
between studies, with most (n = 8; 2 RCTs and 6 non-RCTs) utilising the RIFLE (Risk, Injury, 1940 
Failure, Loss of kidney function, or End-stage kidney disease) or AKIN (Acute Kidney Injury 1941 
Network) classifications. (190) AKIN classification being a modification of the RIFLE system, 1942 
negating the need for availability of baseline renal function (or its potentially inaccurate 1943 
estimation). See Table 2-5 for RIFLE and Table 2-6 for AKIN classifications respectively. In 1944 
the current meta-analysis, any level of renal dysfunction (as defined by the trial 1945 
investigators) was included in the data synthesis. 1946 
Table 2-5 RIFLE classification. 1947 
For categories ‘Risk’, ‘Injury’ and ‘Failure’ – describes acute kidney injury states with rapid 1948 
onset (≤ 7 days) and lasts > 24 h. Fulfillment of any one criteria, with the worst outcome is 1949 
taken to be an individual’s risk category according to RIFLE. Adapted from Lopes et al, 1950 
(190) with definition of loss of kidney function from Biesen et al. (191) 1951 
Category Serum creatinine Glomerular 
filtration rate 
Urine output 
Risk 1.5x increase >25% decrease < 0.5 mL/kg/h for   
6 h 
 
Injury 2x increase >50% decrease < 0.5 mL/kg/h for 
12 h 
 
Failure Normal baseline: 3x increase 
 
Baseline ≥ 4mg/dL (354 
µmol/L):  
≥ 0.5 mg/dL (44 µmol/L) 
 
>75% decrease < 0.3 mL/kg/h for 
24 h 
OR 








Persistent loss of kidney 
function requiring renal 
replacement therapy  





Persistent loss of kidney 
function requiring renal 
replacement therapy  




Table 2-6 Acute Kidney Injury Network (AKIN) classification. 1953 
Diagnosis of acute kidney injury only after dehydration and/or urinary obstruction has been 1954 
corrected or excluded. Minimum of 2 measurements of serum creatinine within a 48 h 1955 
period is required. Stage 1 and 2 are approximately similar to categories ‘Risk’ and ‘Injury’ 1956 
from RIFLE scale, and Stage 3 similar to those fulfilling ‘Failure’ and anyone requiring renal 1957 
replacement therapy. Staging is based on fulfilment of any one criteria corresponding to the 1958 
most severe stage on the scale.  1959 
Stage Serum creatinine  
(by raw values) 




1 ≥ 0.3 mg/dL (26.4 µmol/L) 
increase 
 




> 2-3x increase 
 
 
< 0.5 mL/kg/h for 12 h 
 
3 If baseline/initial 
measurement  
≥ 4 mg/dL (354 µmol/L):  
 ≥ 0.5 mg/dL (44 µmol/L) 
increase 
> 3x increase < 0.3 mL/kg/h for 24 h 
OR 
Anuria for 12 h 
 1960 
COL was used as the only polymyxin in the RCT (n = 3) studies. In the non-RCT studies, 1961 
Crusio et al. (#753) observed nephrotoxicity rates with polymyxin B (with or without other 1962 
antimicrobial agents) therapy, and Bryant et al. (#1302) reviewed all polymyxins (including 1963 
colistin and polymyxins B).  1964 
Pooled OR < 1 favoured the COL combination (i.e. lower renal toxicity rates in COL 1965 
combination arm), OR = 1 denoted equivalence in both arms, and OR >1 favoured the 1966 
comparator (i.e. higher renal toxicity rates with COL combinations).  1967 
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2.3.7.1 Nephrotoxicity – RCTs 1968 
3 RCTs (total number of patients included, n = 358) were included in the nephrotoxicity 1969 
analysis. Occurrence of renal dysfunction was higher in the COL monotherapy arm (1.28 1970 
fold), although this finding was not statistically significant (p = 0.295). 2 of the 3 studies 1971 
(Durante-Mangoni #757 and Sirijatuphat #743) defined nephrotoxicity according to the 1972 
RIFLE criteria, and Conway et al. interpreted any fall in creatinine clearance at Day 12 of 1973 
therapy compared with baseline as renal toxicity. The details of the pooled estimate are 1974 
reflected in Figure 2-16. 1975 
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Figure 2-16 Nephrotoxicity data from RCTs. 1976 
 1977 
 1978 
Test of OR=1 : z= 1.05 p = 0.295 
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 123 
2.3.7.2 Nephrotoxicity – Non-RCTs 1979 
2.3.7.2.1 All colistin combinations versus all comparators 1980 
11 non-RCTs (n = 1092) were included in the nephrotoxicity analysis. Data synthesis was 1981 
done on 10 studies (n = 1074), as the study by Micol et al (#1248) was excluded due to 1982 
equivalence of odds in both arms (in this case, all 18 patients developed renal toxicity). The 1983 
definition of renal dysfunction used in the studies were as follows – RIFLE (Batirel #747, 1984 
Dalfino #1141, Falagas #796, Petrosillo #752, Rocco #1081), AKIN (Garnacho-Montero 1985 
#1055), ‘azotemia after COL therapy’ (Bryant #1302; defined as blood urea nitrogen > 40 1986 
mg/100 mL), ‘acute renal failure due to treatment as per RIFLE’ (Crusio #753) and 1987 
undefined renal toxicity (Yilmaz #990, Micol #1248). Renal dysfunction was marginally 1988 
higher in the COL-combination arm (1.14 fold) compared with any other antimicrobial 1989 
therapy, however, this was not statistically significant (p = 0.546). See the forest plot in 1990 
Figure 2-17 for details of the estimates. 1991 
2.3.7.2.2 Subgroup analysis – specific colistin combinations versus colistin 1992 
monotherapy 1993 
Similarly, higher nephrotoxicity rates were observed with COL combination compared with 1994 
COL monotherapy (OR 1.25), and this difference was not statistically significant (p = 0.341). 1995 
Compared with COL monotherapy, nephrotoxicity rates were higher when COL was given 1996 
with nephrotoxic agents such as glycopeptides (1.37 fold, p = 0.474) and when 2 or more 1997 
adjuvants were given (1.73 fold, p = 0.343). However, neither trend was statistically 1998 
significant. Lower renal toxicity rates were observed with COL-carbapenems (1.07 fold), 1999 





Figure 2-17 Nephrotoxicity data from non-RCTs – All colistin-combinations vs. all comparators. 2004 
 2005 
Test of OR=1 : z= 0.60 p = 0.546 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Figure 2-18 Subgroup analyses – Nephrotoxicity rates comparison between specific colistin combinations and colistin monotherapy. 2006 
 2007 
NOTE: Weights are from random effects analysis
Colistin−Aminoglycosides
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2.4 Discussion 2008 
2.4.1 Summary of evidence and discussion 2009 
The results of the meta-analyses performed here have highlighted the general indifference 2010 
in clinical outcomes between COL combinations and all other regimens (including COL 2011 
monotherapy, non-COL containing therapies and inactive/lack of antimicrobial therapy) – 2012 
all-cause mortality (RCTs p = 0.455, non-RCTs p = 0.113), infection-related mortality (RCTs 2013 
p = 0.083, non-RCTs p = 0.903), clinical response (RCTs p = 0.443, non-RCTs p = 0.967) 2014 
and nephrotoxicity (RCTs p = 0.295, non-RCTs p = 0.546) rates. See Table 2-7 for a 2015 
summary of the meta-analyses performed. 2016 
Further analyses by site of infection and identity of causative organism revealed that COL 2017 
combinations were associated with better odds of survival (all-cause) in bacteraemic 2018 
patients (n = 890 from 11 studies, OR 0.6, p = 0.001) or those infected with K. pneumoniae 2019 
(n = 546 from 10 studies, OR 0.41, p < 0.001). However, a similar trend was not observed 2020 
for infection-related mortality or clinical response. Of the various COL combinations 2021 
analysed, only COL-tigecycline yielded a difference over COL monotherapy in all-cause 2022 
mortality and only when looking at a subgroup of bacteraemic patients (n = 107 from 5 2023 
studies, OR 0.42, p = 0.04). No other COL combinations were significantly different from 2024 
the comparator group for any of the clinical outcomes investigated. Interestingly, despite 2025 
COL being used as an agent of last resort for the treatment of MDR Gram-negative 2026 
infections, COL-based combination therapies were not found to be superior to non-COL 2027 
therapies either.  2028 
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Non-RCT All comparators 0.808 0.62, 1.052 0.113 2868 744, 747, 752, 753, 755, 756, 763, 765, 
795, 796, 990, 1005, 1009, 1026, 1030, 
1031, 1033, 1040, 1044, 1055, 1063, 1066, 
1069, 1074, 1081, 1088, 1115, 1142, 1160, 






0.887 0.676, 1.165 0.389 1766 744, 747, 752, 753, 755, 756, 763, 765, 
795, 796, 990, 1005, 1009, 1026, 1030, 
1033, 1055, 1063, 1081, 1088, 1115, 1142, 






0.65 0.65, 1.058 0.083 346 743, 757, 760 
Infection-related 
mortality 
Non-RCT All comparators 0.968 0.571, 1.64 0.903 353 1040, 1074, 1088, 1142, 1146, 1173, 1208, 


















p value Total no. of 
cases (n) 
Studies included 
Clinical response RCT Colistin 
monotherapy 
1.304 0.662, 2.567 0.443 199 743, 760, (857 excluded) 
 
Clinical response Non-RCT All comparators 0.983 0.723, 1.338 0.915 1655 753, 755, 756, 795, 796, 990, 1031, 1055, 
1115, 1118, 1141, 1142, 1173, 1180, 1186, 
1188, 1208, 1238, 1239, 1307, (747 and 
853 excluded)  
Clinical response Non-RCT Colistin 
monotherapy 
1.038 0.737, 1.46 0.833 1455 753, 755, 756, 795, 796, 990, 1055, 1115, 
1118, 1141, 1142, 1180, 1186, 1188, 1208, 
1238, 1239, (747 and 853 excluded)  
Nephrotoxicity RCT Colistin 
monotherapy 
0.783 0.495, 1.238 0.295 358 743, 757, 857 
Nephrotoxicity Non-RCT All comparators 1.137 0.75, 1.724 0.546 1092 747, 752, 753, 796, 990, 1055, 1081, 1141, 
1302, (1248 excluded) 
Nephrotoxicity Non-RCT Colistin 
monotherapy 




2.4.1.1 Colistin-tigecycline for treatment of carbapenemase-producing 2032 
K. pneumoniae bacteraemia 2033 
Of the 5 studies comparing all-cause mortality rates for carbapenemase-producing K. 2034 
pneumoniae bacteraemia treated with COL-tigecycline combination therapy and COL 2035 
monotherapy, 3 reported lower all-cause mortality with COL-tigecycline therapy, with the 2036 
best odds by Daikos et al (#1063, OR 0.26) against KPC and/or VIM producing K. 2037 
pneumoniae. OR from 3 other studies for treatment of KPC-producing K. pneumoniae 2038 
bacteraemia demonstrated either indifference (Papadimitriou-Olivgeris #1033, OR 1), or 2039 
better survival with COL-tigecycline (Tumbarello, #763, OR 0.44; Qureshi #1304, OR 0.26). 2040 
Notably, the single study reporting worse all-cause mortality rates with COL-tigecycline in 2041 
bacteraemia were in patients infected with OXA-48-like K. pneumoniae or E. coli in a small 2042 
study of 7 patients by Navarro-San Francisco et al (#1088, OR 11). This may suggest a 2043 
particular use of COL-tigecycline combination for the treatment of KPC-producing 2044 
bacteraemia, although the small numbers and observational nature of the studies make it 2045 
difficult to draw a definitive conclusion from this association. Moreover, without clear and 2046 
consistent parallel in vitro testing of the COL-tigecycline combination, and th diversity of 2047 
the patient population included in these studies, it is not possible to ascertain if 2048 
antibacterial synergy between COL and tigecycline underlies the apparent lower all-cause 2049 
mortality rate observed in this subset of patients.  2050 
It is worth noting that the association of COL-tigecycline therapy with a positive outcome 2051 
was observed only for all-cause mortality, and did not translate to better clinical response, 2052 
or indeed lower mortality rates attributable to the infection being treated. This may be due 2053 
aforementioned problems encountered in trial design and conduct. The degree of 2054 
uncertainty and heterogeneity of ascertainment of clinical response and infection-related 2055 
mortality is clearly greater than for a strict binary outcome such as crude/all-cause 2056 
mortality. Furthermore, an unknown non-treatment or infection related link may exist 2057 
between selection of COL-tigecycline combination and survival. These factors may 2058 
contribute to the discrepancies observed.  2059 
 130 
2.4.1.2 Colistin-carbapenem combination therapy – flawed strategy? 2060 
Indeed, it is perhaps of some concern that the addition of carbapenems to COL was not 2061 
associated with better survival, the strategy appeared to be inferior (though OR not 2062 
statistically significant, p > 0.05) to either COL monotherapy or non-COL therapies. This is 2063 
somewhat surprising given the wealth of evidence suggesting in vitro synergy, (192) and 2064 
has been the focus of several contemporary clinical trials (including a recently conducted 2065 
multi-centre RCT). (193-195) Whilst it is likely that the poor quality of the currently available 2066 
evidence has led to worse pooled odds of survival with COL-carbapenem combinations, it 2067 
might be worth rethinking the use of carbapenems for the treatment of XDR Gram-negative 2068 
infections at all, particularly carbapenemase-producing organisms. It would seem prudent 2069 
for any rational treatment strategy to exclude known substrates (e.g. carbapenems, other b- 2070 
lactams) for enzymes (e.g. KPC, NDM, OXA-48) produced by the infecting or colonising 2071 
pathogen, as the burden of resistance will likely increase. Given that carbapenem use has 2072 
been consistently implicated as an independent risk factor for both colonisation and 2073 
infection with carbapenemase-producing organisms, (196-198) COL-carbapenem 2074 
combination therapies would likely lead to increases in these highly transmissible 2075 
organisms and resistance determinants. Although there is an argument that combination 2076 
therapies could hinder the development of resistance, COL-carbapenem strategy may not 2077 
be useful in the case of pre-existing colonisation or infection of carbapenemase-producing 2078 
organisms (even in low numbers) as the microbe need only to circumvent an additional 2079 
pathway, as opposed to the multiple antimicrobial pathways presented in combination 2080 
therapies against a naïve pathogen. Alternative combination strategies utilising several 2081 
unique pathways, where possible (this may be an impossible task when encountering a 2082 
PDR or XDR organism), with optimisation of dosing regimen for the site(s) of infection and 2083 
specific elimination kinetics of the individual patient, could potentially result in a far greater 2084 
antimicrobial effect in vivo. The permeabilising property of COL could thus aid in this 2085 
endeavour, by allowing the ‘co-transport’ of non-traditionally Gram-negative antimicrobial 2086 
agents, with possibilities of encountering new anti-Gram-negative modes of action. 2087 
 131 
2.4.2 Limitations 2088 
The main limitation of this study is the modest quality of evidence currently available in 2089 
literature investigating COL combination therapy. Most of the 51 included studies were 2090 
non-RCTs (4 RCTs), and all were observational in nature. Choice of therapy was selected 2091 
by the attending physician, and due to lack of consensus in guidelines for treatment of 2092 
multi-drug resistant Gram-negative infections, there was considerable variations in 2093 
treatment regimen, even within a single study cohort. The relative subjectivity and variability 2094 
involved in case/outcome definitions, particularly in critically ill patients, as well as the 2095 
subjectivity involved in determination of outcome measures including clinical response and 2096 
infection-associated mortality, further decreased the quality of the data generated. The 2097 
study populations were not always well defined (particularly in retrospective cohort studies 2098 
or case series), or similar between studies.  2099 
An attempt was made to stratify the meta-analyses based on level of evidence by type of 2100 
study conducted (i.e. RCT vs non-RCT). The RCTs (n = 4) however, though presented more 2101 
meaningful comparisons, were less than ideal. None of the 4 RCTs were double-blinded, 2102 
and concealment of randomisation was either not undertaken or not commented on. This 2103 
introduced considerable selection and performance bias to the studies, which unfortunately 2104 
were the best level of evidence currently available for COL combinations.  2105 
In an effort to include as many diverse studies (and cases) into the meta-analyses, all 2106 
available evidence was incorporated into the pooled data syntheses, except for single 2107 
patient case reports. Case series were included if the study population consisted of 2108 
patients treated with COL combinations as well as alternative antimicrobial regimens. The 2109 
cut-off for quality assessment was also intentionally set relatively low – all 4 RCTs were 2110 
included, and ≥ 4 for non-RCTs on the Newcastle-Ottawa scale. (184) The all-inclusive 2111 
nature of the pooled data may decrease the validity of comparisons due to potentially 2112 
increasing the likelihood of unaccounted confounding factors. 2113 
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2.4.3 Conclusions 2114 
Few well-designed RCTs have been performed to investigate the efficacy of therapeutic 2115 
options in Gram-negative bacterial infections due to a myriad of complex issues, not least 2116 
of which being ethical concerns. However, with the unrelenting rise of MDR and XDR Gram- 2117 
negative infections, there is a pressing need for this evidence to guide effective 2118 
management of these patients. (1, 2) 2119 
Unfortunately, not many comprehensive meta-analyses have been conducted to compile 2120 
the available evidence to date. This is largely hampered by the aforementioned lack of well- 2121 
designed trials, and the predominance of critically ill patients, (199) where strict adherence 2122 
to trial protocols might prove difficult, amongst those requiring COL-based therapies (often 2123 
MDR Gram-negative infections). Indeed, most studies reporting clinical outcomes for COL- 2124 
based therapies are observational (only 4 RCTs have been conducted thus far, and none 2125 
were double-blind studies), where decisions regarding therapeutic options are left to the 2126 
attending physician. This in turn introduces an intrinsic bias, where most patients who 2127 
receive COL combination therapies do not share with their comparator counterparts many 2128 
characteristics which have significant impact on clinical outcome (e.g. severity of illness, 2129 
comorbid factors, time to initiation of appropriate antimicrobial therapy). (200, 201) 2130 
Unsurprisingly, clear reports of these confounding factors are largely missing from the 2131 
published dataset. Another considerable source of bias is introduced when COL adjuvants 2132 
are commenced for treatment of another infecting pathogen, other than the organism being 2133 
investigated. This might be started empirically (to broaden the spectrum of antimicrobial 2134 
coverage of COL therapy alone in severe sepsis where the identification of the pathogen(s) 2135 
is awaited) or as part of targeted therapy for a secondary pathogen, often isolated from a 2136 
different site. Favourable clinical response might not, therefore, be due to the therapeutic 2137 
effect of the regimen described against the pathogen of interest.  2138 
3 recently published meta-analyses have focussed on the clinical outcomes of polymyxin 2139 
combination therapy compared with polymyxins monotherapy. Zusman et al (177) 2140 
compared pooled all-cause mortality rates between polymyxins combination therapies 2141 
against polymyxins monotherapy. The authors observed improved survival with polymyxin- 2142 
carbapenem (n = 7, OR 1.58, 95% CI 1.03 – 2.42) for any type of infection and polymyxin- 2143 
tigecycline or aminoglycoside therapy (n = 7, OR 2.09, 95% CI 1.21 – 3.6) in K. pneumoniae 2144 
bacteraemia patients from non-RCT studies. However, when only RCTs (n = 3) were 2145 
considered, no significant superiority of polymyxin-rifampicin (n = 2) and polymyxin- 2146 
fosfomycin (n = 1) therapy was observed over polymyxin monotherapy. Chen et al. (202) 2147 
compared COL combination therapy with COL monotherapy in A. baumannii infections, 2148 
and found that while treatment with monotherapy increased the microbiological response 2149 
rate by 2.1 fold (2 RCTs, 4 non-RCTs, 95% CI 1.46 – 3.03, p < 0.0001), there was no 2150 
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difference between the 2 groups in terms of clinical response (1 RCT, 4 non-RCTs, OR 1.37 2151 
favouring monotherapy, 95% CI 0.86 – 2.19, p = 0.18) and in-hospital all-cause mortality 2152 
rates (2 RCTs, 4 non-RCTs, RR 0.93 lower in combination therapy, 95% CI 0.74 – 1.17, p = 2153 
0.54). Vardakas et al compared pooled mortality between patients treated with COL 2154 
combination therapies and COL monotherapy (n = 32, including 3 RCTs and 29 non-RCTs) 2155 
– no significant difference was noted (RR 0.91, p = 0.1), although on stratification by COL 2156 
dosing regimen (high-dose: mean/median daily dose > 6 mu CMS, low-dose: all other 2157 
doses, unknown: no recorded COL doses) mortality was significantly lower in the 2158 
combination arm compared to monotherapy (RR 0.8, p = 0.005). (203) 2159 
This systematic review aimed to investigate any differences seen in mortality (both all- 2160 
cause and infection-related mortality), clinical response and nephrotoxicity rates between 2161 
COL combination therapies and other standard antimicrobial therapies, allowing for 2162 
previously mentioned baseline differences in patients’ characteristics and other inherent 2163 
bias associated with small retrospective observational studies. 2164 
The results of the meta-analyses performed were generally similar to those observed by 2165 
Zusman et al., Chen et al. and Vardakas et al. (177, 202, 203) Overall, there is a lack of 2166 
robust evidence to suggest an association between currently used COL combinations in 2167 
clinical practice and favourable outcomes. This may be due to the underlying bias towards 2168 
worse clinical outcomes in the COL combinations groups as this approach could be 2169 
employed as ‘salvage therapy’ when all else has failed. Indeed, some of the non-RCT 2170 
studies have stated that this is the case (Dalfino #1141, Huang #1186, Tascini #795, Tascini 2171 
#1306). COL combinations may not prove to be associated with superior clinical response 2172 
or greater odds of survival compared with other therapies, but it is important to note that 2173 
the meta-analyses performed have likewise demonstrated a lack of additional burden of 2174 
nephrotoxicity (RCTs p = 0.295, non-RCTs p = 0.412). COL combinations may be tried on 2175 
an individual basis as salvage therapy should other therapeutic options prove inadequate, 2176 
given the lack of evidence for increased adverse renal side effects (the most important 2177 
adverse effect of polymyxin therapy).  2178 
There is an urgent need to conduct properly designed trials investigating COL combination 2179 
therapy, which address the difficulties encountered in conducting studies within the 2180 
critically ill patient cohort (e.g. response-adaptive randomisation). (18) Designs should take 2181 
into account definitions used during the trial including what constitutes appropriate 2182 
‘standard of care therapy’ to aid comparisons. (18) The studies conducted have largely 2183 
been confined to single centres, and even multi centre trials are restricted to a single 2184 
country. Such limitation placed on the study cohort minimises the wider impact of the 2185 
results attained. Pragmatic trial designs could help to recruit patients into studies which 2186 
reflect ‘real life’ situations, thereby providing information with far greater generalisability and 2187 
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relevance globally. (180) Trial protocols should also endeavour to include in vitro synergy 2188 
testing strategies, preferably incorporating pharmacometric modelling either in a prior pilot 2189 
study or during the investigative phase, to enable optimal therapeutic management of 2190 
infection (including dosing regimens) as well as provide much needed legacy information 2191 
for the wider clinical community in the battle against multi-drug resistance. (134, 170, 204, 2192 
205) 2193 
While the lack of well-designed trials (of the 51 eligible studies for data synthesis, only 4 2194 
were RCTs, most were retrospective in nature – 34 for mortality comparisons, 18 for clinical 2195 
response and 10 for nephrotoxicity) with comparable treatment arms undermines the value 2196 
of the meta-analyses, it is notable that none of the 3 RCTs performed advocated for the use 2197 
of COL combinations (COL-rifampicin and COL-fosfomycin). There are currently 2 RCTs 2198 
underway to investigate COL-meropenem combination therapy versus COL monotherapy 2199 
for the treatment of carbapenem-resistant (193) and XDR Gram-negative infections (194) 2200 
respectively. However, there is a need to rethink our antimicrobial therapy strategies to best 2201 
utilise the agents we currently have. The unique property of polymyxins possess of 2202 
permeabilising the Gram-negative outer membrane could be exploited to allow for 2203 
previously unexplored combinations (206) that could lead to potential better rates of cure 2204 
compared with the marginal (if any) benefit of the combinations already attempted as 2205 
presented in the meta-analyses here. 2206 
Whilst acknowledging the drawbacks of the evidence presented in the meta-analyses 2207 
performed here, it is difficult to ignore the possibility of the lack of efficacy of the prevailing 2208 
COL combinations, and novel combinations should be explored in parallel with anti- 2209 
infective trial design optimisation and drug development. In concert with optimisation of 2210 
trial design, in vitro techniques for predicting in vivo synergy should be explored and fine- 2211 
tuned to aid definitive clinical management of multi-drug resistant infections as well as 2212 
development of new therapies.  2213 
 2214 
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3.1.1 Introduction 2497 
3.1.1.1 Background and rationale 2498 
Polymyxins were discovered in the late 1940s, (256) and two antimicrobials belonging to 2499 
this class, namely polymyxins B and polymyxins E (also known as colistin) were 2500 
subsequently introduced into clinical use in the 1960s. (131)  2501 
Polymyxins are polypeptides produced by Bacillus polymyxa, a soil bacterium. Formed 2502 
polymyxin B and COL compounds are mainly composed of polymyxin B1 and B2 (for 2503 
polymyxin B), and colistin A and B (for COL). (126) These components share many 2504 
similarities as depicted in Figure 3-1. 2505 
Polymyxins are amphipathic – two hydrophobic regions flank polar and cationic segments, 2506 
which lie on opposite faces in the three-dimensional structure. This property aids in its 2507 
interaction with the Gram-negative outer membrane, first with the polar head of the lipid A 2508 
subunit, and subsequently forming pores through its hydrophobic layer. Finally, displacing 2509 
the divalent Ca2+ and Mg2+ ions from the outer membrane, thereby disrupting its structural 2510 
integrity. A similar interaction with the cytoplasmic membrane, effectively creating ‘pores’ 2511 
and destruction of the protective membrane layers, eventually leading to cell death. This is 2512 
the most commonly cited putative mechanism of action of polymyxins. (126, 256)  2513 
Due to the importance of the interaction between polymyxins and the outer membrane, 2514 
most known mechanisms of colistin resistance are due to changes in the outer membrane, 2515 
thereby interrupting this interaction and prohibiting colistin’s antimicrobial activity. Perhaps 2516 
the best-described modifications are in the lipid A region of the lipopolysaccharide 2517 
component in the outer membrane, namely the addition of 4-amino-4-dexoy-L-arabinose 2518 
(L-Ara4N) and phosphoethanolamine (PetN), both of which serve to reduce the negative 2519 
charge in the membrane. This in turn reduced the binding affinity with the cationic portion 2520 
of polymyxins. (257) 2521 
Two-component systems, PmrA-PmrB and PhoP-PhoQ (the former regulated by the latter 2522 
via pmrD), in response to changes in the environment (e.g. encountering cationic 2523 
antimicrobial peptides), are activated to upregulate pmrCAB and arnBCADTEF-prmE 2524 
operons, which in turn modulate the production and addition of PetN and L-Ara4N in lipid 2525 
A, respectively. Mutations in these two-component systems may produce similar 2526 
modifications in the lipid A composition, resulting from the substitution of phosphate 2527 
groups in lipid A by L-Ara4N or PetN. (76, 257) 2528 
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Figure 3-1 Structure of colistin (A and B) and polymyxin B (B1 and B2). 2529 
Polymyxins are composed of a heptapeptide ring linked to a fatty acid tail via an exocyclic 2530 
side chain. Polymyxins B and E (i.e. colistin) differ by the amino acid occupying the 6th 2531 
position (R6) in the heptapeptide ring – D-phenylalanine for polymyxin B and D-leucine for 2532 
colistin. The 2 major components of the polymyxins [designated B1 and B2 for polymyxin B, 2533 
and E1 (or A) and E2 (or B) for polymyxin E (or colistin)] differ from each other by the N- 2534 
terminus (R1) of the fatty acid tail – B1 and A bearing fatty acyl group (S)-6-methyloctanoyl, 2535 
B2 and B with fatty acyl group 6-methylheptanoyl respectively. 2536 
 2537 
Additionally, the activity of PhoP-PhoQ has been found to be under negative feedback 2538 
control by mgrB in K. pneumoniae, and consequently mutations in mgrB has resulted in 2539 
COL resistance due to lipid A modifications by PetN. (258) mgrB mutations have also 2540 
resulted in upregulation of the arnBCADTEF operon, leading to insertion of L-Ara4N 2541 
moieties to lipid A. Both actions resulted in COL resistant phenotypes. (259) More recently, 2542 
a new plasmid-borne determinant, mcr-1, which encodes for PetN transferase (a lipid A 2543 
modification enzyme), has been identified in colistin-resistant Enterobacteriaceae. (260)  2544 
In A. baumannii, mutations in pmrA and pmrB, leading to upregulation of pmrC (encodes 2545 
for PetN transferase), have been reported as mechanisms of COL resistance. Additionally, 2546 
mutations in the genes involved in early phase lipid A biosynthesis (lpxACD) have been 2547 
shown to result in complete loss of lipid A production, often conferring high-level COL 2548 
resistance. (74, 261) COL heteroresistance have been observed on numerous occasions, 2549 
(165, 262) mainly in A. baumannii, however, the mechanism behind this phenomenon has 2550 
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There have been several studies investigating COL susceptibility methods, (158, 160-162, 2552 
264) and considerable variability has been observed amongst the commonly used 2553 
techniques giving rise to legitimate concerns about the impact this might have on optimal 2554 
utilisation of this agent of last resort. (164, 165) A major problem encountered in these 2555 
comparative studies is the choice of reference method or gold standard, namely broth 2556 
microtitre dilution (BMD) or agar dilution. Whilst these methods are relatively 2557 
straightforward to perform and can be easily automated in the modern microbiology 2558 
laboratory, they are likely to underperform when predicting resistance in isolates 2559 
comprising of heteroresistant subpopulations. (165, 265) Population analysis profile (PAP) 2560 
has the advantage of being able to detect these subpopulations, therefore allowing us more 2561 
accurate information regarding the likelihood of treatment success or failure (susceptibility 2562 
and resistance respectively) with COL, although the cost and labour required to perform 2563 
PAP precludes it from routine clinical use. (266)  2564 
3.1.1.2 Objectives 2565 
To the best of my knowledge, there has yet to be a comparative evaluation of COL 2566 
susceptibility methods utilising PAP as a gold standard, and this study sets out to 2567 
investigate the comparability of the following susceptibility methods with PAP to determine 2568 
their ability to predict colistin resistance (including heteroresistance) in A. baumannii strains 2569 
(as well as 5 type strains – E. coli (2), P. aeruginosa (1), K. pneumoniae (1), P. mirabilis (1)). 2570 
1) Disc diffusion 2571 
2) Gradient strip 2572 
3) Automated system, based on turbidity (MicroScan WalkAway system with Neg MIC 2573 
44 panel) 2574 
4) Agar dilution 2575 
5) BMD (currently recommended by CLSI and EUCAST) 2576 
Additionally, the following non-conventional (not routinely done within a clinical diagnostic 2577 
laboratory or reference laboratory) experimental methods were performed. 2578 
1) ‘Macro’ methods – Macro Etest (based on a ‘macro Etest’ method first proposed 2579 
by Wootton et al (267) for the detection of heterogeneous vancomycin-intermediate 2580 
Staphylococcus aureus (hVISA)), and macro disc diffusion 2581 




3.1.2 Methods 2585 
3.1.2.1 Strain selection 2586 
42 bacterial isolates were included in this comparative study. All isolates were stored at - 2587 
70°C on MicroBank™ beads (Pro-Lab Diagnostics, Austin, Texas, USA) and subcultured 2588 
onto Iso-Sensitest agar (ISA; Oxoid™, Basingstoke, UK) for each experimental run. Isolates 2589 
were incubated aerobically at 37°C for 18-24 h. 2590 
5 type strains were used for quality control purposes and were obtained from the National 2591 
Collection of Type Cultures (NCTC), held by Public Health England, UK. The type strains 2592 
used included A. baumannii NCTC 12156 (American Type Culture Collection; ATCC 19606), 2593 
Pseudomonas aeruginosa NCTC 12934 (ATCC 278853; a known COL heteroresistant type 2594 
strain (204, 268)), Escherichia coli NCTC 12241 (ATCC 25922), E. coli NCTC 10418 (ATCC 2595 
10536) and Proteus mirabilis NCTC 13376 (ATCC 14153; intrinsically colistin resistant). 36 2596 
clinical A. baumannii isolates, and a Klebsiella pneumoniae isolate (KP6 2014), carrying a 2597 
mutation in pmrB, which confers COL resistance, was also included in this study. See Table 2598 
3-1 for details of the strains used. 2599 
Table 3-1 Strains used in comparative study of different susceptibility methods versus 2600 
population analysis profile for the detection of colistin resistance. 2601 
Carb – Carbapenem; Tig – Tigecycline. 2602 
Isolate Organism Characteristics 
AB11 A. baumannii OXA-23-like, SE clone; MDR strain 
AB12 A. baumannii OXA-23-like, SE clone; MDR strain 
AB14 A. baumannii OXA-23, UK clone 1; MDR strain 
AB16 A. baumannii OXA-23, UK clone 2 
AB17 A. baumannii Carb R, MDR clinical strain 
AB25 A. baumannii OXA-23-like, EU clone 2 
AB26 A. baumannii OXA-23-like, EU clone 2 
AB183 A. baumannii Carb S, MDR clinical strain 
AB184 A. baumannii OXA-51-like, T strain 
AB186 A. baumannii OXA-51-like, Burn strain 
AB198 A. baumannii Carb R, MDR clinical strain 
AB199 A. baumannii Carb R, MDR clinical strain 
AB200 A. baumannii Carb R, MDR clinical strain 
AB202 A. baumannii XDR meningitis strain 
AB205 A. baumannii OXA-23, UK clone 1; XDR strain 
AB210 A. baumannii OXA-23-like, UK clone 1; Tig S 
AB211 A. baumannii OXA-23-like, UK clone 1; Tig R (pair of AB210) 
AB213 A. baumannii OXA-23-like, UK clone 1; XDR strain 
AB214 A. baumannii Carb R, MDR clinical strain 
AB215 A. baumannii Carb R, MDR clinical strain 
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Isolate Organism Characteristics 
AB216 A. baumannii Carb R, MDR clinical strain 
AB219 A. baumannii OXA-23-like, UK clone 1; XDR strain 
AB230 A. baumannii Carb R, MDR clinical strain 
AB231 A. baumannii Carb R, MDR clinical strain 
AB234 A. baumannii Carb R, MDR clinical strain 
AB235 A. baumannii Carb R, MDR clinical strain 
AB236 A. baumannii Carb R, MDR clinical strain 
AB238 A. baumannii Carb R, MDR clinical strain 
AB243 A. baumannii Carb R, MDR clinical strain 
AB244 A. baumannii Carb R, MDR clinical strain 
AB285 A. baumannii OXA-23-like, XDR strain 
AB287 A. baumannii OXA-23-like, XDR strain 
AB292 A. baumannii OXA-23-like, UK clone 1; MDR strain 
AB296 A. baumannii XDR clinical strain 
AB315 A. baumannii OXA-23-like, UK clone 1; XDR VAP strain 
AB5075 A. baumannii OXA-23, EU clone I; MDR strain 
NCTC 12156 A. baumannii Type strain 
NCTC 12934 P. aeruginosa Type strain (COL heteroresistant) 
NCTC 12241 E. coli Type strain 
NCTC 13376 P. mirabilis Type strain 
NCTC 10418 E. coli Type strain 
KP6(2014) K. pneumoniae pmrB mutant; COL resistant 
 2603 
3.1.2.2 Antimicrobial agent preparation 2604 
Colistin sulfate salt was obtained from Sigma-Aldrich (lot no. SLBD3111V; Dorset, UK). A 2605 
COL stock solution of 10,000 mg/L was freshly made up each day by dissolving the 2606 
compound in sterile distilled water. The stock solution was stored at 4°C and used within 2607 
24 h.  2608 
3.1.2.3 Media preparation 2609 
Iso-Sensitest agar (CM0471) was obtained from Oxoid™ (Basingstoke, UK), and used 2610 
unsupplemented for subcultures, bacterial colony counts and growth controls (where 2611 
appropriate). The agar was prepared as per manufacturer’s instructions. 31.4g of 2612 
compound was mixed with 1 L of distilled water and boiled at 121°C for 15 minutes. After 2613 
cooling the molten agar to 50°C in a water bath, it was poured into sterile 90 mm petri 2614 
dishes with or without COL supplementation. Agar plates were stored at 4°C. 2615 
Unsupplemented plates were used within 5 days, and COL-supplemented plates were used 2616 
within 24 h.  2617 
Iso-Sensitest broth (CM0473; Oxoid™, Baskingstoke, UK) was used in all comparative 2618 
experiments, with or without colistin supplementation. The broth was prepared using 2619 
manufacturer’s instructions. 23.4 g of the dehydrated product was mixed in 1 L of distilled 2620 
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water. After sterilisation at 121°C for 15 minutes in a steam autoclave, the broth was 2621 
allowed to cool to room temperature prior to use. COL supplementation was performed 2622 
immediately prior to each experiment, and freshly prepared for each run. Unsupplemented 2623 
Iso-Sensitest broth was stored at 4°C, and used within 5 days.  2624 
3.1.2.4 Disc diffusion 2625 
Isolates grown on Iso-Sensitest agar (ISA) were used to inoculate 10 mL aliquots of sterile 2626 
Iso-Sensitest broth (ISB) in 50 mL Falcon tubes. Broth cultures were then incubated 2627 
aerobically at 37°C, with shaking at 224 rpm, for 24 h. The overnight cultures were used for 2628 
all experiments, except for the automated system.  2629 
Bacterial suspensions in phosphate-buffered saline were prepared by first, diluting an 2630 
aliquot of the overnight broth culture to a turbidity equivalent to 0.5 McFarland standard, 2631 
followed by a 1:100 dilution step into 3 mL of sterile phosphate-buffered saline. The 2632 
prepared bacterial suspensions were used for both disc diffusion and Etest (see Section 2633 
3.1.2.5 below) experiments.  2634 
Even lawns of each isolate were obtained by applying the prepared suspension to 2635 
unsupplemented ISA agar plates with sterile cotton swabs. The lawns were allowed to air 2636 
dry for 5 minutes prior to application of COL discs (Oxoid™, Basingstoke, UK). 2 different 2637 
discs were used for each isolate – a COL 25 µg disc (CT0065B, Oxoid™) and a COL 50 µg 2638 
disc (CT0664B, Oxoid™). The agar plates were then incubated for 18 h under aerobic 2639 
conditions at 37°C. Following incubation, the diameter of the zones of inhibition were read 2640 
independently by 2 individuals, and the average recorded. The tests were done in triplicate, 2641 
and the mean taken for analysis and comparison with other methods. 2642 
3.1.2.5 Etest® method 2643 
Preparation of bacterial suspensions and lawns were performed as per disc diffusion (see 2644 
Section 3.1.2.4). COL Etest® strips were obtained from bioMérieux (Marcy l’Etoile, France) 2645 
and applied to the bacterial lawns. After appropriate incubation (conditions similar to disc 2646 
diffusion; See Section 3.1.2.4), the MIC for each strain was read and recorded. The tests 2647 
were done in triplicate, and the mean taken for analysis and comparison with other 2648 
methods. 2649 
3.1.2.6 Broth microtitre dilution 2650 
Overnight broth cultures were diluted in sterile ISB to yield final inocula of 5 x 105 cfu/mL.  2651 
COL was added to ISB to yield final concentrations of COL ranging from 0.125 – 256 mg/L in 2652 
doubling concentration series (prepared COL ISB was twice as concentrated, ranging 0.25 – 2653 
512 mg/L, for subsequent dilution with prepared inocula, eventually yielding final 2654 
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concentrations of 0.125 – 256 mg/L). 75 µL of each concentration was added to individual 2655 
wells in round-bottom 96-well microtitre plates. A further 75 µL of unsupplemented sterile 2656 
ISB was added to a well for each isolate tested as a growth control.  2657 
Prepared inocula were added in 75 µL aliquots into each well (except for sterility control 2658 
wells – where 75 µL of sterile broth were added instead), after which, the microtitre plates 2659 
were incubated aerobically at 37°C for 18 h.  2660 
The lowest COL concentration that prevented growth (growth determined by visible 2661 
turbidity) for each isolate was read and recorded. This corresponds to the MIC determined 2662 
by BMD. The tests were done in triplicate, and the mean taken for analysis and comparison 2663 
with other methods.  2664 
3.1.2.7 Agar dilution 2665 
Overnight broth cultures were diluted in sterile phosphate-buffered saline to yield inocula of 2666 
107 cfu/mL.  2667 
COL-supplemented ISA plates with concentrations ranging from 0.125 mg/L to 256 mg/L 2668 
were prepared for the agar dilution series. A multipoint inoculator, which delivers 2669 
approximately 1 µL spots, was used to apply the inocula to the doubling concentration 2670 
series as well as unsupplemented ISA plates used as growth controls. P. mirabilis 2671 
susceptibility was performed separately to avoid interference with other isolates due to its 2672 
swarming property on solid agar. Spots were allowed to air dry prior to incubation in air at 2673 
37°C for 18 h. 2674 
COL MICs were determined by the lowest COL concentration that prevented visible bacterial 2675 
growth. Agar dilution AST was done in triplicate, and the mean taken for analysis and 2676 
comparison. 2677 
3.1.2.8 Automated system – MicroScan WalkAway-96 plus 2678 
Colonies from fresh subcultures of the selected strains were prepared using the MicroScan 2679 
PromptTM Inoculation System-D platform (Beckman Coulter, Brea, CA, USA) as per 2680 
manufacturer’s instructions. Briefly, the inoculation wand was used to touch a minimum of 2681 
5 colonies before introducing into the sterile saline provided and mixed using a vortex 2682 
mixer. Purity plates of the suspension were set up on ISA, and incubated for 18 h in air at 2683 
37°C.  2684 
Neg MIC Type 44 panels were reconstituted with the prepared suspension using an 2685 
inoculator device. The panels were incubated in the MicroScan WalkAway-96 plus system 2686 
(Dade Behring, West Sacremento, California, USA).  The instrument recorded COL MICs 2687 
after appropriate incubation. The MicroScan WalkAway-96 plus system performed 2688 
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antimicrobial susceptibility tests based on the broth microtitre dilution method. Commercial 2689 
panels consisted of antimicrobial agents in Mueller-Hinton broth with any necessary growth 2690 
supplementation prior to dehydration (information from product literature for Neg MIC Type 2691 
44 panels). The panels were rehydrated as above, and incubated in the MicroScan 2692 
WalkAway-96 plus system, which detects growth by photometric measurement of turbidity 2693 
(although manual reading of panels was possible upon completion of relevant incubation 2694 
period). (269) A dedicated computer system using the LabPro software records the results. 2695 
2 concentrations of colistin were included in the Neg MIC Type 44 panels – 2 mg/L and 4 2696 
mg/L, and MIC measurements (range ≤ 2 mg/L to > 4 mg/L) were performed by the system 2697 
and checked manually. The tests were done in triplicate, and an average was taken.  2698 
3.1.2.9 Modified time-kill assays 2699 
Static time-kill assays study the antimicrobial effect on a microbe over time, typically 24 h 2700 
for aerobic Gram-negative bacteria, and are useful for determination of bacteriostatic (< 3 2701 
log10 cfu/mL decrease in colony count) and bactericidal (≥ 3 log10 cfu/mL decrease in 2702 
colony count) effect by measuring the difference in the viable bacterial count at the start 2703 
and end of the experiment. (270) COL has been shown to be rapidly bactericidal against A. 2704 
baumannii (usually within 2-4 h) in time-kill studies, with little post-antibiotic effect 2705 
thereafter, resulting in subsequent regrowth often attaining a similar viable bacterial count 2706 
at 24 h as antibiotic-naïve growth controls. (165) Conventional time-kill assays chart the 2707 
changes in bacterial load over time, usually at the start and at 2 h, 4 h, 6 h, and end of 2708 
experiment. Time-kill assays were modified in this experiment to assay the start and end 2709 
(24 h time-point) of the experiment to assess the overall/end-point bacteriostatic or 2710 
bactericidal effect. It was postulated that this would be a more reliable indicator of COL 2711 
resistance (including heteroresistance) compared with traditional MIC methods.  2712 
Overnight broth cultures were prepared as per Section 3.2.1.4. Each isolate was added to 2713 
50 mL Falcon tubes containing 10 mL of sterile ISB and COL ranging 0.125 mg/L to 256 2714 
mg/L in doubling concentrations, adjusted to starting inoculum of 106 cfu/mL. A growth 2715 
control was also set up for each isolate with a similar starting inoculum using 2716 
unsupplemented ISB. The cultures were incubated aerobically at 37°C with shaking (224 2717 
rpm) for 24 h.  2718 
100 µL aliquots were taken at 0 h and 24 h from each broth culture and plated onto 2719 
unsupplemented ISA (with serial dilution in phosphate-buffered saline where appropriate) to 2720 
obtain bacterial colony counts. MIC and minimum bactericidal concentrations (MBC) by 2721 
time-kill were determined by comparing the 24 h colony count with the starting inoculum. 2722 
The lowest concentration of COL that resulted in any or ≥ 3 log10 cfu/mL decrease in colony 2723 
counts, without any increase in higher concentrations, were determined as the MIC (TKMIC) 2724 
and MBC (TKMBC) respectively. 2725 
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Furthermore, 2 surrogate markers for TKMIC and TKMBC were determined. The difference in 2726 
bacterial colony counts between 0 h and 24 h reads at the colistin susceptible breakpoint 2727 
of 2 mg/L (271, 272) were recorded as MTKC (surrogate marker for TKMBC) and MTKCS 2728 
(surrogate marker for TKMIC). For MTKC, isolates were defined as susceptible if there was a 2729 
≥ 3 log10 cfu/mL decrease in the 24 h read. Any decrease in the 24 h read was defined as 2730 
susceptible for MTKCS. (273) The tests were done in triplicate, and the mean for TKMIC and 2731 
TKMBC measurements used for analysis and comparisons.  2732 
3.1.2.10 Macro method (disc and Etest®) 2733 
A ‘macro screening method’ was performed experimentally as proposed by Walsh et al for 2734 
the detection of vancomycin heteroresistant Staphylococcus aureus strains, with some 2735 
modifications. (267) Bacterial suspensions were prepared by diluting overnight broth 2736 
cultures (See Section 3.2.1.4) in ISB with turbidity equivalent to a 2 McFarland standard. 2737 
200 µL aliquots of the prepared suspensions were spread onto unsupplemented ISA plates 2738 
to create even lawns. COL Etest® strips (bioMérieux, Marcy l’Etoile, France) and COL 25 2739 
µg discs (Oxoid™, Basingstoke, UK) were applied to the lawns and incubated at 37°C in air 2740 
for 48 h. The tests were done in triplicate, and the mean MICs used for analysis and 2741 
comparisons. 2742 
3.1.2.11 Population analysis profile 2743 
Population analysis profile (PAP) was performed as per published protocol by Wootton et 2744 
al. (267) Overnight cultures were set up as described in Section 3.2.1.4. ISA plates 2745 
supplemented with COL were prepared as for agar dilution in Section 3.2.1.3. The COL 2746 
concentrations used included 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 mg/L. An unsupplemented 2747 
ISA plate was also used for each isolate as a growth control. Bacterial colony counts were 2748 
determined for each overnight broth culture (which was stored at 4°C for a maximum of 24 2749 
h). Sterile ISB was added to each overnight culture to yield of final inoculum of 1 x 109 2750 
cfu/mL. 100 µL aliquots of the inocula (or serial dilution in phosphate-buffered saline (PBS), 2751 
where appropriate) were evenly spread onto the prepared ISA plates for each strain. The 2752 
plates were incubated aerobically at 37°C for 48 h. 2753 
Bacterial colony counts were determined for each COL concentration and for the growth 2754 
control. The area under the curve (AUC) for each strain (log10 cfu/mL bacterial colony 2755 
counts against COL concentration) was determined using the trapezoidal rule in Stata 2756 
(StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp 2757 
LP). AUC-ratios against known COL hetero-resistant strain, NCTC 12934, (204, 268) were 2758 
determined for each strain in the study. Cut-offs for susceptibility and resistance were 2759 
established as follows: AUC-ratio < 0.9 were susceptible, and ratios of ≥ 0.9 were resistant.  2760 
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3.1.2.12 Data analysis 2761 
COL susceptible breakpoints for A. baumannii, Enterobacteriaceae (including E. coli, K. 2762 
pneumoniae and P. mirabilis) and P. aeruginosa published by both EUCAST (272) and CLSI 2763 
(272) were unanimously 2 mg/L, and was used as categorise each strain into 2764 
susceptible/resistant groups. Categorical agreement, very major error and major error were 2765 
then determined for each methodology versus the gold standard, PAP.  2766 
All MIC/MBC values were set to a fixed doubling concentration series ranging from 0.125 – 2767 
256 mg/L (see Table 3-2 for list of doubling concentrations) for consistency of analysis. All 2768 
experiments were done in triplicate, and the average (rounded up to the nearest doubling 2769 
concentration for MIC/MBC results, using log2 integer scale) used for analyses. 2770 
Table 3-2 Range of doubling concentrations for MIC/MBC measurements and 2771 
corresponding logarithmic values used for data analysis. 2772 














Categorical agreement attained when the classification confirmed when the test method 2774 
and the reference method classified the specified strain into the same susceptibility group 2775 
(i.e. truly susceptible and truly resistant strains). Very major errors were falsely susceptible 2776 
strains (susceptible by test method, but resistant by reference method), and major errors 2777 
were falsely resistant strains (resistant by test method, but susceptible by reference 2778 
method). (160) 2779 
Essential agreement amongst the MIC methods was defined as ≤ 2-fold (or within 1 2780 
doubling dilution) difference between the MIC of the test and reference methods. The 2781 
reference methods used include the conventional BMD (recommended by both EUCAST 2782 
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and CLSI for colistin susceptibility testing) and agar dilution, as well as minimum 2783 
bactericidal concentration (TKMBC) and a modified time-kill technique to determine minimum 2784 
inhibitory concentration (TKMIC).  2785 
Sensitivity and specificity (274) of the various test methods in detection of resistance, with 2786 
population analysis profile as the gold standard, were determined as follows: 2787 
Sensitivity = 
True resistance 
True resistance + False susceptible 
     
   
Specificity = 
True susceptible 
True susceptible + False resistance 
 2788 
Receiver-operator characteristic (ROC) curve analyses (274) were performed in Stata for 2789 
disc diffusion methods (disc diffusion using both 25 µg and 50 µg colistin discs and macro 2790 
disc diffusion) and macro Etest method. This was used to examine the suitability of these 2791 
methods for colistin susceptibility testing, by plotting the ‘true positive rate’ or sensitivity (y 2792 
axis) against the ‘false positive rate’ or ‘1-specificity’ (x axis) depicting relative trade-offs. 2793 
ROC values range 0 – 1, with values of 0.5 being equivalent to random chance, and 1 2794 
reflecting 100% agreement with the chosen gold standard, and 0 the complete inverse of 2795 
the gold standard. Where relevant (i.e. ROC values significantly better than 0.5, or random 2796 
chance), a cut-off point relating to the best trade-off of true positive and false positive rates 2797 
was determined. 2798 
3.1.2.13 Statistical analysis 2799 
Sensitivity and specificity of the different methods were compared with each other, where 2800 
appropriate, using paired McNemar’s  c2 in Stata to examine the significance of the 2801 
differences observed. (275) The exact McNemar’s test is used when the sum of the 2802 
discordant pairs (false positives and false negatives) is less than 10. McNemar’s test is 2803 
used to examine differences between pairs of categorical or binary data, with the null 2804 
hypothesis (p > 0.05) proposing that differences are due to random chance alone. 2805 
An assessment of the differences between the means of the susceptible population versus 2806 
the resistant population (as categorised by PAP) for each method was made using an 2807 
independent t test (Stata), and the results drawn on strip plots. The statistical significance 2808 
and magnitude of differences between the medians were studied using quantile regression 2809 
(Stata) and plotted using box and whisker plots. 2810 
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Differences between the best performing test by categorical agreement, very major error 2811 
and major error rates and all other test methods were compared using a two-sample test of 2812 
proportions. 1-tailed p values were used, with the assumption that the best performing test 2813 
yielded the highest categorical agreement and lowest very major and major error rates 2814 
respectively.  2815 
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3.1.3 Results 2816 
3.1.3.1 Susceptibility test results 2817 
The results from the various test methods are shown in Table 3-3. 38 of the 42 isolates 2818 
tested (90.5%) were susceptible by population analysis profile (highlighted in green in Table 2819 
3-3), compared with 38.1% (16/42) by MicroScan, 14.3% (6/42) by both Etest and agar 2820 
dilution and 11.9% (5/42) by BMD. Figure 3-2 shows the MIC distribution of each test and 2821 
their susceptibility category by PAP.  2822 
 2823 
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Table 3-3 Summary of colistin susceptibility test results.  2824 
S – susceptible, R – resistant. MTKC – Modified time-kill using colistin 2 mg/L (Susceptible ≥ 3 log10 cfu/mL decrease in colony counts from starting 2825 
inoculum); MTKCS – Modified time-kill using colistin 2 mg/L (Susceptible – no increase in colony counts from starting inoculum). 2826 



















AB11 A.	baumannii ≤2 0.5 0.5 0.5 4 16 1 16.6 17.2 12.8 R R R
AB12 A.	baumannii ≤2 0.5 0.5 0.5 2 16 2 16.3 17.1 13.0 R S R
AB14 A.	baumannii ≤2 0.5 1 0.25 4 8 2 15.1 16.4 11.8 R R R
AB16 A.	baumannii ≤2 1 0.5 0.5 16 16 2 16.0 16.8 12.5 R R R
AB17 A.	baumannii ≤2 0.5 0.25 0.5 64 64 2 16.9 17.2 12.0 R R R
AB25 A.	baumannii 4 0.5 0.5 0.25 2 8 8 16.6 17.4 12.5 R S R
AB26 A.	baumannii 4 1 0.5 0.25 4 4 4 16.7 17.8 11.3 R R R
AB183 A.	baumannii ≤2 0.125 0.5 0.5 1 2 4 17.4 18.7 12.5 S S R
AB184 A.	baumannii ≤2 1 1 0.5 64 64 2 15.4 16.4 13.3 R R R
AB186 A.	baumannii ≤2 0.5 0.5 1 64 128 2 14.3 15.2 12.0 R R R
AB198 A.	baumannii >4 1 1 0.25 4 16 2 17.3 18.7 12.5 R R R
AB199 A.	baumannii 4 0.5 0.5 0.5 8 16 0.5 16.9 18.1 11.8 R R R
AB200 A.	baumannii ≤2 0.5 0.5 0.25 1 4 1 16.5 17.5 13.3 R S R
AB202 A.	baumannii ≤2 0.5 1 0.5 4 8 2 16.5 17.9 13.5 R R R
AB205 A.	baumannii >4 256 >256 256 >256 >256 64 9.3 10.2 8.0 R R R
AB210 A.	baumannii ≤2 0.5 0.5 0.25 1 1 2 15.2 16.2 12.5 S S R
AB211 A.	baumannii ≤2 2 0.5 0.5 256 256 1 15.2 15.9 12.8 R R R
AB213 A.	baumannii ≤2 0.5 0.5 0.5 2 16 2 16.2 17.8 12.8 R S R
AB214 A.	baumannii 4 0.5 0.5 0.25 64 64 2 16.6 17.5 12.0 R R R
AB215 A.	baumannii 4 0.5 0.5 0.5 2 4 2 15.7 16.7 12.5 R S R
AB216 A.	baumannii 4 0.25 1 0.5 4 16 2 16.0 17.0 12.5 R R R
AB219 A.	baumannii >4 128 >256 >256 >256 >256 128 7.8 8.9 7.3 R R R
AB230 A.	baumannii 4 0.125 1 1 1 4 4 15.8 16.9 12.3 R S R
AB231 A.	baumannii ≤2 0.5 0.5 0.5 8 16 2 15.4 16.8 12.3 R R R
AB234 A.	baumannii 4 0.5 0.5 0.25 4 8 2 16.0 16.9 12.5 R R R
AB235 A.	baumannii ≤2 0.125 0.5 0.25 1 4 1 16.3 17.2 13.5 R S R
AB236 A.	baumannii ≤2 0.125 0.25 0.25 1 1 4 15.4 16.3 12.8 S S S
AB238 A.	baumannii ≤2 0.5 0.5 0.25 4 4 2 14.8 15.5 11.5 R R R
AB243 A.	baumannii ≤2 0.5 0.5 0.25 2 4 4 14.7 15.9 12.3 R S R
AB244 A.	baumannii 4 1 1 0.25 2 8 2 15.6 16.5 12.5 R S R
AB285 A.	baumannii 4 0.125 0.5 0.5 2 4 2 14.8 16.0 11.5 R S R
AB287 A.	baumannii >4 4 4 16 128 256 4 15.1 16.0 11.5 R R R
AB292 A.	baumannii ≤2 0.125 0.5 0.5 1 4 1 15.6 16.6 11.8 R S R
AB296 A.	baumannii ≤2 0.5 0.5 0.25 32 32 1 15.6 16.7 12.0 R S R
AB315 A.	baumannii ≤2 1 1 1 1 2 2 15.7 16.8 11.8 S S R
AB5075 A.	baumannii ≤2 1 4 0.125 2 4 8 14.7 16.3 11.4 R S R
NCTC	12156 A.	baumannii ≤2 0.125 0.25 0.25 1 1 0.5 15.9 16.9 12.0 S S S
NCTC	12934 P.	aeruginosa ≤2 4 1 1 4 4 16 15.2 17.0 11.8 R R R
NCTC	12241 E.	coli ≤2 0.5 1 0.25 2 2 2 15.4 16.0 11.8 S S S
NCTC	13376 P.	mirabilis >4 >256 >256 >256 >256 >256 >256 6.0 6.0 6.0 R R R
NCTC	10418 E.	coli ≤2 1 0.5 0.125 2 2 2 15.1 16.0 12.0 S S S
KP6	(2014) K.	pneumoniae >4 16 32 128 >256 >256 32 11.9 12.4 8.9 R R R
Zone	of	inhibition	diameter	(mm)Colistin	MIC/MBC	(mg/L)
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Figure 3-2 Histograms depicting colistin MIC distribution according to susceptibility testing 2827 
method (limited to MIC/MBC methods). 2828 
All methods reporting COL MIC (mg/L), except for MBC. S – susceptible by PAP; R – 2829 
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Figure 3-3 Colistin PAP-AUC ratio graph depiciting the spread of values. 2838 
Blue diamonds (u) – susceptible by broth microtitre dilution (reference method 2839 
recommended by both CLSI and EUCAST, i.e. COL MIC ≤ 2 mg/L); red diamonds (u) – 2840 
resistant (COL MIC > 2 mg/L); Green diamond (u) represents reference COL 2841 
heteroresistant type strain, NCTC 12934 (COL MIC = 1 mg/L). Dashed reference line – PAP- 2842 






























3.1.3.2 Comparison of susceptibility tests with population analysis 2845 
profiles 2846 
3.1.3.2.1 Sensitivity, Specificity, Positive and Negative predictive values 2847 
The most striking observation is the difference between the ability of the conventional 2848 
susceptibility methods (including reference tests, BMD and agar dilution) and PAP to 2849 
predict COL resistance. The sensitivity of the tested methods ranged from 13% (Broth 2850 
microtitre dilution) to 92% (TKMBC and MTKC). These results are summarised in Figure 3-4 2851 
below. The difference between the most sensitive methods (TKMBC and MTKC) and the other 2852 
tested methods were statistically significant (p < 0.05). Apart from TKMIC (p = 0.0005) and 2853 
MTKCS (p = 0.0003), the other p values were < 0.0001.  2854 
Figure 3-4 Sensitivity of susceptibility tests (utilising a susceptibility breakpoint of colistin 2 2855 
mg/L) with population analysis profile as a gold standard. 2856 
 2857 
Only 4 isolates were susceptible by PAP, and as a consequence, comparisons of specificity 2858 
were inconclusive (p > 0.05). See Figure 3-5 for the specificity results. The positive 2859 
predictive value (PPV) of all the methods were high (> 90%), however, the negative 2860 
predictive values (NPVs) did not exceed 57% (highest NPVs for TKMBC and MTKC). The 2861 
NPVs may have suffered from the relative paucity of truly susceptible strains. See Figure 2862 





































































Figure 3-5 Specificity of susceptibility tests (utilising a susceptibility breakpoint of colistin 2 2864 
mg/L) with population analysis profile as a gold standard. 2865 
2866 
Figure 3-6 Positive predictive values (PPV) and negative predictive values (NPV) of the 2867 













































































































































3.1.3.2.2 Categorical agreement, very major error and major error 2870 
Similarly, categorical agreement between the methods studied against PAP was highest for 2871 
the time-kill techniques that assessed the bactericidal activity of colistin, namely TKMBC and 2872 
MTKC (categorical agreement of 92% with PAP). Disappointingly, the commonly used 2873 
reference methods, agar dilution and BMD, were far less accurate with categorical 2874 
agreements of only 24% and 21% respectively. The difference between the categorical 2875 
agreement for TKMBC and MTKC and the other tested methods were statistically significant – 2876 
TKMIC (p = 0.0007), MTKCS (p = 0.0003) and all other methods p < 0.0001.  2877 
Very major error rates were likewise lowest for TKMBC and MTKC (8% for both) and highest 2878 
for Etest (84%), agar dilution (84%) and BMD (87%). The differences between very major 2879 
error rates of TKMBC (and MTKC) and the other methods were statistically significant – TKMIC 2880 
(p = 0.0006), MTKCS (p = 0.0003) and the rest with p values < 0.0001. 2881 
Interpretation of major error rates was difficult owing to the relative lack of truly COL 2882 
susceptible isolates (n = 4) by PAP. All test methods studied reported a specificity of 100%, 2883 
apart from macro Etest (75%). The difference between the specificity for macro Etest and 2884 
all other tested methods was not statistically significant (p > 0.05). The comparison of 2885 
categorical agreement, very major error and major error rates is shown in Figure 3-7.  2886 
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3.1.3.2.3 Essential agreement 2889 
Essential agreement amongst the MIC methods (namely, MicroScan, Etest, agar dilution, 2890 
BMD, MIC by time-kill and macro Etest) was assessed, using agar dilution, broth microtitre 2891 
dilution and MIC by time-kill (TKMIC) as reference methods. The results are reflected in 2892 
Figure 3-8.  2893 
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3.1.3.2.4 Disc diffusion, macro Etest and modified time-kill methods 2896 
Receiver-operator characteristic (ROC) area curves of the disc diffusion and macro Etest 2897 
methods were drawn and compared with population analysis profile as gold standard. The 2898 
ROC areas of the respective tests are shown in Figure 3-9. All 4 tests were significantly 2899 
different from PAP (p > 0.05). No suitable cut-point could be identified for any of these 2900 
tests. Applying ROC analyses to TKMBC and log10 MTK values revealed appropriate 2901 
susceptibility cut-off points to be colistin 2 mg/L for the former (TKMBC ROC area = 0.967), 2902 
and a > 2.5 log10 cfu/mL decrease in bacterial colony count from the starting inoculum for 2903 
modified time-kill assay performed with 2 mg/L of COL for the latter (log10 MTK ROC area = 2904 
0.964). For MTK, this cut-off point was very close to the definition of bactericidal activity in 2905 
time-kill assays previously proposed by NCCLS (270), of ≥ 3 log10 cfu/mL, hence this value 2906 
(i.e. ≥ 3 log10 cfu/mL) was retained for purposes of categorising values into susceptible and 2907 
resistant subgroups.  2908 
Figure 3-9 Receiver-operator characteristic (ROC) curves for disc diffusion methods 2909 
(including with colistin 25 µg disc, colistin 50 µg disc and macro method), macro Etest and 2910 
modified time-kill methods (time-kill assay with colistin 2 mg/L). 2911 
Dotted red reference line denotes equal chances of the test predicting susceptibility or 2912 





































































3.1.3.3 Discrimination between susceptible and resistant populations 2915 
3.1.3.3.1 Comparing means 2916 
Comparisons were made between the groups classified ‘susceptible’ and ‘resistant’ by 2917 
population analysis profile using the values produced by the various test methods. The 2918 
means between the susceptible and resistant populations were not sufficiently different 2919 
from each other for all methods assessed (p > 0.05) apart from TKMBC (p = 0.0119). Strip 2920 
plots reflecting the means and 95% confidence intervals of test values are shown in Figure 2921 
3-10. 2922 
Figure 3-10 Strip plots – Comparisons of means of susceptible versus resistant isolates 2923 
(defined by population analysis profile) by susceptibility test method.  2924 
 (a) Disc diffusion methods (all p > 0.05) 2925 
 2926 
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3.1.3.3.2 Comparing medians 2931 
Additionally, the medians of each pair of susceptible/resistant values were performed by 2932 
quantile regression. Except for TKMBC, where the p value was 0.009, none of the other pairs 2933 
of medians produced a statistically significant difference. All the median comparison 2934 
results, together with the interquartile range, are reflected in Figure 3-11. Levene’s test for 2935 
equal variances were performed on the datasets, and apart from MicroScan and TKMIC, all 2936 
other pairs of values were assumed to fulfil the equal variances criteria (p > 0.05). 2937 
Figure 3-11 Box and whisker plots – Comparisons of medians of susceptible versus 2938 
resistant isolates (defined by population analysis profile) by susceptibility test method. 2939 
(a) Disc diffusion methods (all p > 0.05) 2940 
 2941 
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3.1.4 Discussion 2946 
3.1.4.1 Studying susceptibility of colistin in vitro 2947 
The study of antimicrobial activity in a laboratory setting has been around since the pre- 2948 
antibiotic era. Development and refinement of these techniques, and more importantly 2949 
standardisation, which led to the birth of the prevailing inception of modern-day in vitro 2950 
susceptibility testing methodologies, began in the mid 20th century. The introduction of the 2951 
Kirby-Bauer disc diffusion method in the 1960s was a fundamental cornerstone on which 2952 
antimicrobial susceptibility tests in clinical diagnostic laboratories was built on, to aid in 2953 
clinical management of infection in real time. National and international committees were 2954 
set-up (e.g. NCCLS and later the CLSI in USA, British Society of Antimicrobial 2955 
Chemotherapy (BSAC) in UK, EUCAST in Europe) to coordinate the delivery and use of 2956 
antimicrobial susceptibility tests. (276)  2957 
COL, an old antimicrobial belonging to the class of polymyxins, is presented in a unique 2958 
situation. It was first discovered in 1949 and introduced into clinical use in the 1950s. 2959 
However, due to the relative number and severity of adverse effects (most notably, 2960 
nephrotoxicity) treatment with COL carried compared with newer and safer agents (e.g. 2961 
cephalosporins), it became rarely used clinically by the 1970s. (132, 133, 257) Though COL 2962 
susceptibility testing methodologies were included in most of the antimicrobial guidelines, 2963 
they were rarely updated or revised. The recent renaissance of COL in clinical use due to 2964 
the rise of multi-drug resistant Gram-negative organisms (e.g. carbapenemase-producing 2965 
Enterobacteriaceae, MDR A. baumannii) has revealed the glaring lack of contemporary 2966 
knowledge of the agent, both in the laboratory (susceptibility testing) and in clinical settings 2967 
(dosing regimen). (131, 160, 256, 257) A number of clinical trials have been conducted to 2968 
address the latter issue, many having the foresight to investigate the efficacy of COL- 2969 
combination therapies, due in part, to anecdotal reports of therapeutic failures on COL 2970 
monotherapy. (202) In the laboratory, latest research has begun to provide much needed 2971 
information about COL susceptibility testing, the most vital of which is arguably, the 2972 
accurate prediction of resistance, as COL is currently an agent of last resort in combating 2973 
multi-drug resistant infections.  2974 
COL susceptibility testing is however, fraught with problems. COL, being a large 2975 
amphipathic molecule, binds non-specifically to many materials including those commonly 2976 
used in susceptibility testing. (126) The need for tight quality control of test media and 2977 
compounds used in testing is paramount to COL susceptibility testing for the purposes of 2978 
reproducibility and accurate comparison. ISA or ISB was used for all experiments in this 2979 
study with an aim to make valid comparisons. 2980 
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COL heteroresistance is a phenomenon that has been well documented in literature, and 2981 
hypothesised to be one of the main reasons for likely therapeutic failure on colistin 2982 
monotherapy. (164, 165)  2983 
3.1.4.2 Summary of results 2984 
This study highlights the inadequacies of routine diagnostic tests as well as frequently used 2985 
reference methods for the purposes of detecting COL resistance in A. baumannii. Of the 36 2986 
A. baumannii clinical isolates, only 1 was susceptible by PAP, compared with 33 by BMD 2987 
and 32 by agar dilution. It is important to note that none of the susceptibility test methods 2988 
included in this study fulfill the criteria set out by the US FDA for acceptability as a reliable 2989 
test for predicting COL resistance. (277) The guidance requires any new diagnostic test to 2990 
achieve > 90% categorical agreement (and essential agreement where applicable), ≤ 3% 2991 
major error rate and ≤ 1.5% very major error rate when compared with the reference 2992 
method (here, PAP was used). Of the various test methods, only TKMBC and its surrogate 2993 
MTKC attained a categorical agreement with PAP of > 90%. All methodologies failed to 2994 
meet the very major error rate requirement of ≤ 1.5% (the lowest rates (8%) were observed 2995 
amongst the time-kill methods reflecting the minimum bactericidal concentrations, TKMBC 2996 
and MTKC) and all achieved a major error rate of 0% except for macro Etest (25%). 2997 
Employing the susceptible breakpoint of 2 mg/L on the MBC yields the best correlation 2998 
with PAP, which consequently best predicts COL resistance in this study. A possible 2999 
explanation for this could be the COL dependence that some subpopulations exhibit. (164) 3000 
The concentration of COL required prevent growth of strains harbouring these 3001 
heterogeneous subpopulations are greater than the apparent minimum inhibitory 3002 
concentration. Obtaining bactericidal activity (reflected by the minimum bactericidal 3003 
concentration), or attaining ≥ 99.9% kill could be the new benchmark for ensuring 3004 
treatment success.  3005 
COL heteroresistance has been observed in MDR A. baumannii on multiple occasions. (76, 3006 
164, 165, 262). The inability of conventional susceptibility methods, including BMD 3007 
(reference method recommended by CLSI and EUCAST), to identify these heteroresistant 3008 
strains is of grave concern in this age where optimal use of antimicrobial agents is 3009 
paramount. (163) This study has demonstrated the pitfalls of utilising conventional 3010 
susceptibility methods as the gold standard, which have led to the erroneous conclusions 3011 
by many comparative studies done regarding COL susceptibility. (158, 160-162, 264)  3012 
The distribution of the PAP-AUC ratios in this study shows that most of the ‘heteroresistant 3013 
strains’ (those susceptible by BMD, but resistant by population analysis profile) have a ratio 3014 
between 0.9 and 2. Strains resistant by BMD recorded a PAP-AUC ratio of > 2, including 3015 
the intrinsically COL resistant P. mirabilis type strain NCTC 13376 and a K. pneumoniae 3016 
strain carrying a known pmrB mutation that confers COL resistance (PAP-AUC ratio > 3 for 3017 
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both strains). It is also worth noting that the majority of strains susceptible by broth 3018 
microtitre dilution and resistant by PAP had MICs ranging 0.25 mg/L to 2 mg/L. Reducing 3019 
the susceptible breakpoint of COL (when using BMD) from the current 2 mg/L to 0.25 mg/L 3020 
reduced the percentage error from 79% (n = 33) to 33% (n = 14) without introducing any 3021 
major errors. Application of 0.25 mg/L as the susceptible breakpoint with agar dilution and 3022 
Etest reduced the percentage error from 76% to 7% and 76% to 19% respectively. 3023 
However, in the case of both agar dilution and Etest methodologies, the reduction of the 3024 
susceptible breakpoint increases the major error rate to 50% from 0% (n = 2). The inclusion 3025 
of more susceptible strains by PAP would be needed to fully assess the impact on major 3026 
error rates.  3027 
Disc diffusion methods, though widely implemented in clinical diagnostic laboratories, do 3028 
not produce consistent and reliable results for COL susceptibility. Receiver-operator 3029 
characteristic (ROC) curves drawn against a gold standard of population analysis profile 3030 
produced ROC areas < 0.5 (ROC areas = 0.5 refers to a diagnostic test that is equally likely 3031 
to produce a susceptible or resistant result. i.e. a pointless test.) The ROC areas of all 3 3032 
disc diffusion tests were significantly different (p ≤ 0.0001) from PAP in this study, thereby 3033 
confirming that the disc diffusion is unsuitable for predicting COL resistance. This finding is 3034 
similar with others reported in literature, and the recommendation from CLSI and EUCAST 3035 
is to avoid the use of disc diffusion methods for the purpose of COL susceptibility testing. 3036 
(271, 272)  3037 
ROC areas for macro Etest and modified time-kill colony counts were 0.62 and 0.96 3038 
respectively. Compared with PAP, the former was significantly different with a p value of 3039 
0.01 and the latter was not significantly different (p = 0.2). The macro method for screening 3040 
heteroresistance may be useful for heterogeneous S. aureus with intermediate-level 3041 
resistance to vancomycin (hVISA) and glycopeptides (hGISA), but our findings have found 3042 
them to be inadequate for detecting COL hetero-resistance. Modified time-kill, on the other 3043 
hand, where a single concentration time-kill assay (in this study colistin 2 mg/L, the 3044 
susceptible breakpoint, was chosen) was performed, and the difference between the 24 h 3045 
bacterial colony count and the starting inoculum was taken and assessed against PAP. The 3046 
nature of performing a time-kill assay, which requires constant shaking and thereby mixing 3047 
of the media, bacteria, COL and air, may be the key to enabling its detection of the 3048 
heteroresistant subpopulations. It should be noted that this allows growth within 24 h 3049 
compared with PAP, which is typically performed over 48 h. The slower growth of the 3050 
resistant subpopulations may be due to the relative fitness of the strains in artificial media, 3051 
(75, 278) though they have been reported to be able to cause clinical infection during COL 3052 
therapy. (164, 279)  3053 
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The comparisons of means and medians within each method (the PAP-susceptible strains 3054 
versus the PAP-resistant strains) showed that the differences between them were only 3055 
significant for the time-kill methods that utilised a minimum bactericidal concentration 3056 
definition, at a 95% confidence level. This result further underscores the urgency with 3057 
which we need to address the methods we use for COL susceptibility, to preserve the 3058 
clinical use of COL, an important agent in our fight against antimicrobial resistant infections.  3059 
3.1.4.3 Proposed two-step algorithm for screening colistin resistance 3060 
in A. baumannii 3061 
A two-step algorithm could be employed, whereby the clinical diagnostic laboratory 3062 
performs an initial colistin susceptibility screen by Etest or agar dilution (a simplified version 3063 
could be performed using breakpoint plates 0.25 mg/L and 0.5 mg/L, as well as a growth 3064 
control plate grouped in batches). Subsequently, all isolates screened ‘susceptible’ (i.e. 3065 
MIC ≤ 0.25 mg/L) will have their colistin susceptibility confirmed by BMD, again using a 3066 
breakpoint of 0.25 mg/L. Using this algorithm, the percentage error is reduced to 5% (agar 3067 
dilution à BMD) and 7% (Etest à BMD), with very major error rates 0% and 3% 3068 
respectively, and major error rates 50% for both.  3069 
See Figure 3-12 for the details on the impact of lowering the MIC for screening purposes 3070 
and use of the two-step algorithm on sensitivity and specificity of the aforementioned 3071 
testing modalities. Figure 3-13 depicts details of the categorical agreement, very major 3072 
error and major error rates.  3073 
 177 
Figure 3-12 Comparison of sensitivity, specificity, PPV and NPV of Etest, agar dilution and broth microtitre dilution (versus PAP) using a hypothetical 3074 
screening cut-off of colistin 0.25 mg/L, and proposal of a two-step algorithm. 3075 
(0.25) – using COL 0.25 mg/L cut-off (i.e. isolates screened susceptible if COL MIC ≤ 0.25 mg/L, otherwise resistant); (2) – using COL 2 mg/L cut-off, the 3076 
prevailing susceptible breakpoint concentration (EUCAST version 7.0, CLSI M100-S27); ET – Etest; AD – Agar dilution; ETàBMD – Susceptible isolates by 3077 
Etest (i.e. MIC ≤ 0.25 mg/L) subsequently tested by broth microtitre dilution, only those susceptible by both methods are screened ‘susceptible’; ADàBMD 3078 



































Figure 3-13 Comparison of categorical agreement, very major error and major error rates of Etest, agar dilution and broth microtitre dilution (versus PAP) 3081 
using a hypothetical screening cut-off of colistin 0.25 mg/L, and proposal of a two-step algorithm. 3082 
 (0.25) – using COL 0.25 mg/L cut-off (i.e. isolates screened susceptible if COL MIC ≤ 0.25 mg/L, otherwise resistant); (2) – using COL 2 mg/L cut-off, the 3083 
prevailing susceptible breakpoint concentration (EUCAST version 7.0, CLSI M100-S27); ET – Etest; AD – Agar dilution; ETàBMD – Susceptible isolates by 3084 
Etest (i.e. MIC ≤ 0.25 mg/L) subsequently tested by BMD, only those susceptible by both methods are screened ‘susceptible’. ADàBMD – Susceptible 3085 



































3.1.4.4 Limitations 3088 
The main limitation of this study was the relative lack of truly susceptible strains (n = 4), 3089 
leading to inconclusive results regarding specificity and major error rates. Moreover, the 3090 
total number of isolates used (n = 42), though large for a study using population analysis 3091 
profile as a gold standard, is too small in size to meet the sample size criteria for the FDA 3092 
guidelines (for comparing categorical agreement, essential agreement, very major error and 3093 
major error rates). Furthermore, 23 of the 36 A. baumannii clinical strains in the collection 3094 
included in this study were isolated from patients within the sample institution, where OXA- 3095 
23 UK clone 1 MDR A. baumannii was endemic in the ICU. The extension of this study, 3096 
including strains from diverse sources, preferably with different genotypic profiles, is 3097 
warranted to confirm the findings of this study (i.e. high COL heteroresistance burden 3098 
amongst A. baumannii clinical isolates, and failure of common susceptibility testing 3099 
methods to detect heteroresistance, with possibility of using either a 2-step algorithm for 3100 
screening or time-kill based methods being the best alternatives for detecting COL 3101 
heteroresistance).  3102 
Only Iso-Sensitest media was used for testing across the board. As no other media was 3103 
tested in this study, further work is required to assess if the results presented here can be 3104 
extrapolated to other susceptibility test media.  3105 
3.1.4.5 Conclusions 3106 
COL resistance is often underestimated by conventional susceptibility test methods, which 3107 
could lead to potentially devastating therapeutic failures. PAP, whilst the most sensitive 3108 
method for detection of resistance, particularly in the identification of heteroresistant 3109 
subpopulations, is labour intensive and time-consuming, thus unfeasible to perform on a 3110 
routine basis. There is currently no known method comparable to PAP, although a MBC 3111 
based test (using a susceptible breakpoint of 2 mg/L) or a proposed two-step algorithm 3112 
with agar dilution or Etest followed by confirmation with BMD (using a proposed 3113 
susceptible breakpoint of 0.25 mg/L) could be introduced for the purpose of screening for 3114 
COL resistance (including heteroresistance). COL monotherapy should be avoided if the 3115 
clinical isolate is found to be heteroresistant. Accurate detection of heteroresistance is 3116 
therefore paramount in preserving the usefulness of COL, which is an antimicrobial agent 3117 
heavily relied upon in our struggle with MDR GNB infections.  3118 
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3.2 Screening colistin combinations in vitro 3119 
 181 
3.2.1 Introduction 3120 
3.2.1.1 Background and rationale 3121 
Antimicrobial combination therapy is widely employed to treat infections. Clinicians may 3122 
employ this strategy as empirical therapy, when the identity and/or the susceptibility 3123 
pattern of the infecting organism is not yet known, or as targeted therapy.  3124 
The goal of empirical antimicrobial therapy is to provide adequate treatment of the 3125 
infection, by choosing agents with known activity against the suspected pathogen(s) based 3126 
on the clinical diagnosis and local resistance patterns. Combination therapy is often 3127 
employed in this setting as clinicians strive to broaden the antimicrobial cover in early 3128 
sepsis/infection, as inadequate antimicrobial therapy has been associated with poorer 3129 
clinical outcomes. (201) In addition, pathogens with increasing resistance to traditional first 3130 
line antimicrobial agents in specific patient populations (e.g. cystic fibrosis, returning 3131 
traveller, patients from long-term care facilities) may require the combination therapy 3132 
approach to achieve adequate treatment. Critically ill patients and those with multiple 3133 
comorbid factors often receive combinations of the antibiotics empirically, to attain a 3134 
broad-spectrum of antimicrobial coverage for multiple possible diagnoses as this might not 3135 
be clear from the outset (e.g. severe sepsis presenting with multi-organ failure) or multiple 3136 
sites of infection might be present. (280-283)  3137 
When antimicrobial combinations are used as targeted therapy, the rationale is somewhat 3138 
different, particularly if single agent alternatives are present (based on antibiogram). The 3139 
following assumptions are usually made – combination therapy enhances the antibacterial 3140 
effect, combination required for a difficult to treat site due to poor penetration of 3141 
antimicrobials (e.g. endocarditis, meningitis), particularly virulent organisms with very low 3142 
infecting doses requiring rapid eradication (e.g. S. pyogenes), single agent alternatives not 3143 
available due to host factors (e.g. drug allergy, renal disease). (280, 281, 283-286) 3144 
In vitro combination testing was developed to help optimise combination therapy as well as 3145 
provide a rational approach to its use in clinical management of infections. However, 3146 
consensus on testing methodology and formal guidance on the rules of interpretation are 3147 
currently lacking. Antimicrobial combination susceptibility tests (ACSTs) remain within the 3148 
realm of research, and are not routinely performed in either clinical microbiology 3149 




Contemporary ACSTs methodologies most commonly used and cited in literature fall within 3153 
3 broad categories – checkerboard screening assay, Etest screening method and time-kill 3154 
assays. Time-kill assays benefit from being the only method described within a published 3155 
guideline, (270) which includes both methodology and interpretation of results (See Section 3156 
3.3.1.1 for details). Checkerboard assays are performed in 96-well microtitre plates (see 3157 
Section 3.2.2.7 for details), and are essentially a miniaturised version of an end-point time- 3158 
kill assay. Finally, Etest methods have been developed to provide a simple way of 3159 
performing synergy testing. Both Etest methods require prior ascertainment of the MIC of 3160 
the individual agents by Etest, followed by the synergy test. The 2 methods that have been 3161 
described to date are performed as follows – 2 Etest strips are applied to the even lawn at 3162 
the intersection (perpendicularly) of the MICs; or the first strip is applied to the lawn, and 3163 
left to allow diffusion of the antimicrobial through the agar for 60 min, then removed, after 3164 
which the second strip is applied in the same spot and incubated. All 3 methods are costly 3165 
to perform and labour intensive, moreover, only 1 antimicrobial combination can be tested 3166 
at a time.  3167 
The renaissance of the use of COL in clinical practice has led to the recent increase in 3168 
investigation of COL combinations in vitro. The rationale behind synergistic COL 3169 
combinations lies with the unique property of polymyxins to disrupt the cell membrane 3170 
(including the protective and negatively charged Gram-negative outer membrane), thereby 3171 
potentially allowing the passage of other compounds into the cell that might otherwise be 3172 
excluded. Exclusion could be due to hydrophobicity of the antimicrobial (e.g. macrolides, 3173 
rifamycins, oxalidinones) or size (e.g. glycopeptides). (288, 289) It is hypothesised that 3174 
unorthodox COL combinations (secondary agent not known to efficiently penetrate the 3175 
Gram-negative membrane) could potentially present a new mechanism of antibacterial 3176 
action not encountered by these organisms before, thereby minimising the possibility of 3177 
resistance including against otherwise MDR strains. 3178 
3.2.1.2 Objectives 3179 
The main aim of this part of the study was to systematically screen antimicrobial agents 3180 
(licensed for clinical use and currently available in the British formulary) for synergy in 3181 
combinations with COL against a pre-selected group of Gram-negative isolates with 3182 
defined mechanisms of resistance and virulence, belonging to problematic 3183 
epidemiologically defined clones. 3184 
Other aims were to develop a simple and efficient method of screening the activity of COL 3185 
combinations in vitro and to propose a new method for investigating mutational frequency 3186 
to drugs used singly and in combination. 3187 
 3188 
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3.2.2 Methods 3189 
3.2.2.1 Strain preparation 3190 
Strains used in the study were stored on MicroBank™ beads (Pro-Lab Diagnostics, Austin, 3191 
Texas, USA) at -70°C, and subcultured onto unsupplemented ISA plates (see Section 3192 
3.1.2.1 for details).  3193 
3.2.2.2 Antimicrobial agent preparation 3194 
See Section 3.1.2.2  for details of preparation of colistin sulfate solution. Other antimicrobial 3195 
agents were prepared in a similar manner.  3196 
Fusidic acid sodium salt (Sigma-Aldrich, Poole, Dorset, UK), fosfomycin disodium (Sigma- 3197 
Aldrich, Poole, Dorset), polymyxin B sulfate (LKT laboratories, St. Paul, Minnesota, USA) 3198 
and polymyxin B nonapeptide (Sigma-Aldrich, Poole, Dorset, UK) were each added to 3199 
sterile distilled water to obtain stock solutions of 40 mg/mL (fusidic acid), 10 mg/L 3200 
(fosfomycin, polymyxin B) and 5 mg/mL (polymyxin B nonapeptide). Stock solutions were 3201 
stored in small aliquots at -20°C. Once thawed, stock solutions were used immediately and 3202 
any leftovers were discarded.  3203 
Chloramphenicol (Sigma-Aldrich, Poole, Dorset, UK) was prepared by first dissolving the 3204 
compound in ethanol to yield a concentration of 10 mg/mL, then diluted with sterile distilled 3205 
water to obtain a final stock solution with a concentration of 1 mg/mL. The stock solution 3206 
was stored in small aliquots at 4°C, and used within 7 days.  3207 
Telavancin (Astellas Pharma Europe, lot 07-2460) stock solution of 2 mg/mL was made up 3208 
fresh with 100% DMSO and used on the same day. Vancomycin hydrochloride (Sigma- 3209 
Aldrich, Poole, Dorset, UK) stock solution of 10 mg/mL was made up in sterile distilled 3210 
water and stored in small aliquots at 4°C and used within 7 days. Teicoplanin (Sigma- 3211 
Aldrich, Poole, Dorset, UK) stock solution of 10 mg/mL was made up with sterile distilled 3212 
water and used on the same day.  3213 
3.2.2.3 Media preparation 3214 
See Section 3.1.2.3 for details of preparation of ISA and ISB media used for screening 3215 
colistin combinations. 3216 
3.2.2.4 Reagent preparation 3217 
Resazurin was used as an indicator of viable bacterial growth in broth microtitre dilution to 3218 
improve accuracy of MIC determination over visualisation of turbidity. (290, 291) Resazurin 3219 
is a reduction-oxidation indicator, which is non-toxic and stable, and is blue and non- 3220 
fluorescent in its native form. On addition to bacterial cell culture, it is irreversibly reduced 3221 
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by viable cells to produce a fluorescent (read at λex 520 nm/λem 590 nm) pink metabolite, 3222 
resorufin. (292) Resorufin may be further reduced to a colourless non-fluorescent product, 3223 
hydroresorufin, which may be reversed in the presence of oxygen. (292) 3224 
Resazurin sodium salt (Sigma-Aldrich, Poole, Dorset, UK) was dissolved in sterile distilled 3225 
water to obtain a 0.01% weight/volume solution (10 mg in 100 mL). This was subsequently 3226 
filter sterilised using a 0.2 µm pore size filter, and stored in 10 mL aliquots at -20°C. Each 3227 
aliquot is thawed out at 4°C (kept in use for 1 week at 4°C) 24 h prior to use.  3228 
3.2.2.5 Disc diffusion screening 3229 
Agar dilution was performed on all isolates (as per Section 3.1.2.7) to determine the COL 3230 
MIC of all relevant strains used in the study. The obtained MICs were used to prepare COL 3231 
supplemented ISA plates as described below. 3232 
COL supplemented ISA plates were prepared for each isolate with the following 3233 
concentrations – no COL (i.e. 0 mg/L), 0.25x MIC, 0.5x MIC and 1x MIC. All COL 3234 
supplemented ISA plates were either used on the day they were prepared or kept at 4°C 3235 
and used within 24 h.  3236 
Bacterial suspensions in PBS were prepared as described in Section 3.1.2.4. Even lawns 3237 
were spread across the prepared plates and incubated aerobically at 37°C for 18 h to 3238 
determine the highest concentration of COL that supported growth of a confluent lawn for 3239 
each isolate. This was noted as the maximum sub-inhibitory concentration (MSIC) for COL. 3240 
Disc diffusion tests were then performed in duplicate for each isolate on COL 3241 
supplemented (with MSIC of COL) and unsupplemented ISA plates (as growth control and 3242 
baseline reading) as described in Section 3.2.2.4. 6 discs were applied in a ring formation 3243 
on each plate, and an additional COL 25 µg disc was included on the unsupplemented ISA 3244 
plate in the middle to complete the observations of all antimicrobials being tested. See 3245 
Figure 3-14 for an illustration of the layout. The antimicrobials screened for synergy with 3246 
COL are listed in Table 3-4. 3247 
The absolute difference in the diameter measurements (mm) of the zones of inhibition 3248 
between the supplemented and unsupplemented ISA plates were recorded. ≥ 5mm 3249 
difference suggested potential synergy between colistin and the 2nd agent (5mm difference 3250 
was extrapolated from disc diffusion synergy tests for detection of extended-b-lactamase 3251 
producers in Enterobacteriaceae as per CLSI guidelines. (271) 3252 
Additionally, any ‘keyhole effect’ observed between 2 discs, denoting possible synergy was 3253 
noted and pursued if present on repeat testing and preserved across species. 3254 
 3255 
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Figure 3-14 Disc diffusion screening layout. 3256 
A – F represents individual antimicrobial discs (6 mm in diameter each). A COL 25 µg (CT 3257 
25) disc was added to the unsupplemented ISA plates for each isolate tested. 3258 
 3259 
Table 3-4 Antimicrobial discs used in colistin combination disc diffusion screening. 3260 
 3261 
 3262 
3.2.2.6 Etest® screening 3263 
Etest screening for synergy was performed for the combination of COL-daptomycin (293, 3264 
294) as both paper discs and pure compound (for in vitro susceptibility use), were 3265 




















Etest screening was performed in a similar way to the disc diffusion screen (on ISA), except 3267 
for the application of an Etest strip (bioMérieux, Marcy l’Etoile, France) instead of a paper 3268 
disc on each plate as per Sections 3.2.2.4 (for disc diffusion screen) and 3.1.2.5 (for Etest 3269 
method). The MICs obtained, with and without COL supplementation were noted, and 3270 
synergy was defined as ≥ 4 fold reduction in daptomycin MIC in the presence of COL.  3271 
Daptomycin susceptibility requires calcium supplementation (usually 50 mg/L) of the 3272 
medium used. (294) The calcium supplement needed has been supplied within the Etest 3273 
strip itself, and was not required for this study. (293, 294) 3274 
3.2.2.7 Checkerboard assays 3275 
Checkerboard assays were performed as an additional test to disc diffusion screening to 3276 
ascertain reproducibility of any synergy observed. 3277 
Overnight broth cultures were prepared as described in Section 3.1.2.6. Antimicrobial 3278 
supplemented broth solutions ranging from 0.125 – 256 mg/L in doubling concentrations 3279 
were prepared using fresh stock solutions (in sterile distilled water) and sterile ISB. COL 3280 
supplemented broth solution was similarly prepared with final concentrations from 0.125 – 3281 
8 mg/L. Broth solutions were used within an hour of preparation.  3282 
Checkerboard assays were performed in sterile round-bottom 96-well microtitre plates. 50 3283 
µL aliquots of prepared antimicrobial broth solutions (ISB supplemented with antimicrobial 3284 
stock solutions) were added to the microtitre plates to yield final concentrations of in 3285 
ranges 0.125 – 8 mg/L for colistin and 0.25 – 256 mg/L for the second compound in 3286 
doubling concentration series (in addition, for experiments with fosfomycin, each well was 3287 
suuplemented with glucose-6-phosphate (G6P; bioMérieux, Marcy-l'Étoile, France), yielding 3288 
a final concentration of 25 mg/L in each well (295)). COL concentrations were increased 3289 
down the rows (A-H) and the second compound increases across the columns (1-12) as 3290 
detailed in Figure 3-15. Where appropriate, additional concentrations of either (or both) 3291 
compound are tested. 3292 
100 µL aliquots of the prepared broth cultures are subsequently added to each well, 3293 
obtaining a final volume of 200 µL per well. The plates are then incubated aerobically at 3294 
37°C for 24 h. 20 µL of 0.01% (weight/volume) resazurin was added to each well at the end 3295 
of the experiment and incubated at 37°C for a further 1 h prior to determination of the 3296 
relevant results. 3297 
The lowest concentration of each compound which there was an absence of growth (no 3298 
trace of pink resorufin) was read as the MIC, either singly (in absence of a secondary agent; 3299 
Row A and Column 1) or in combination. These readings were used to calculate indices of 3300 
synergy (see Section 3.2.2.10.2). 3301 
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Figure 3-15 Layout of checkerboard assays. 3302 
 3303 
 3304 
3.2.2.8 Polymyxin permeability hypothesis investigation 3305 
Polymyxin B nonapeptide (PBNP) is a derivative of polymyxin B without a fatty acid tail. It is 3306 
hypothesised that the absence of the fatty acid tail reduces the antibacterial activity of the 3307 
compound, preventing it from causing cell death, (296, 297) whilst retaining its property of 3308 
disrupting the cells membranes, thus allowing the passage of hydrophobic compounds into 3309 
the cell (e.g. fusidic acid). 3310 
Polymyxin B sulfate stock solution (prepared as per Section 3.2.2.2) was added to sterile 3311 
ISB and serially diluted to obtain final concentrations of 0.015625 – 256 mg/L in doubling 3312 
series. Polymyxin B MIC was subsequently performed as per Section 3.2.1.6. Susceptibility 3313 
was determined using CLSI clinical breakpoints (CLSI M100-S27) for P. aeruginosa (S ≤ 2 3314 
mg/; R ≥ 8 mg/L) and A. baumannii (S ≤ 2 mg/L; R ≥ 4 mg/L – for all non P. aeruginosa 3315 
isolates). (271) 3316 
Fusidic acid (FUS) BMD was performed as described in Section 3.2.1.6, with some 3317 
modifications. 50 µL of FUS supplemented ISB was added to each well to yield final 3318 
concentrations ranging 0.25 – 256 mg/L, as well as an antibiotic-free growth control for 3319 
each isolate.  FUS BMD was then performed with or without the addition of PBNP to 3320 
examine the permeabilising effect of polymyxins. 50 µL of ISB (negative control) or PBNP 3321 
supplemented ISB (polymyxin susceptible strains – 2 and 8 mg/L; polymyxin resistant 3322 
strains – 8 – 256 mg/L, at the same or below the concentration as the corresponding 3323 
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polymyxin B MIC) was added to each well, before the addition of 100 µL of the prepared 3324 
bacterial suspension. FUS MICs were recorded with or without PBNP, and the ratio of the 3325 
MICs in the presence of the highest concentration of PBNP used to the MIC in the absence 3326 
of PBNP was determined and recorded as the sensitisation index. 3327 
3.2.2.9 Mutational frequency of A. baumannii when exposed to 3328 
colistin-fusidic acid combination 3329 
A modified serial passage experiment was designed to investigate the mutational frequency 3330 
of combinations. In particular, the experiments were interested in examining the differences 3331 
between the mutational frequencies of the isolate in the presence of the antimicrobial 3332 
agents singly and in combination when subjected to the same test conditions (i.e. in the 3333 
same run). 3334 
Checkerboard assays were performed as described in Section 3.3.2.6. The well with the 3335 
lowest calculated synergy index was identified, and an aliquot from the well containing 0.5x 3336 
the antimicrobial concentration of the lowest synergy index well was taken and diluted 3337 
1:1000 in sterile ISB, and used as the inoculum for the next passage experiment. Each 3338 
passage experiment was a checkerboard assay identical to the initial experiment performed 3339 
on day 1. The microtitre plates were incubated aerobically at 37°C for 24 h with shaking 3340 
(160 rpm). The serial passage was continued for a total of 7 days. The lowest MIC for the 3341 
antimicrobials, singly and in combination were recorded each day.  3342 
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3.2.2.10 Data analysis 3343 
3.2.2.10.1   Definitions of susceptibility 3344 
The clinical susceptibility breakpoint of colistin used in the study was 2 mg/L, as per 3345 
EUCAST v7 and CLSI (M100-S27) guidelines. (271, 272) 3346 
The susceptibility breakpoints used in the checkerboard assay analyses for non-COL 3347 
antimicrobials are listed in Table 3-5. 3348 
Table 3-5 Clinical susceptibility breakpoints used in checkerboard assays – non-colistin 3349 
antimicrobials. 3350 
Green-shaded breakpoint concentrations were used when there are discrepancies between 3351 
the 2 guidelines. 3352 
 3353 
3.2.2.10.2   Checkerboard assays 3354 
The fractional inhibitory index concentration (FICI), first described by Berenbaum (298), was 3355 
used to assess the antimicrobial effect in combination.  3356 
FICI was calculated as follows: 3357 
FICI = 
MIC of A in combination 
+ 
MIC of B in combination 
MIC of A MIC of B 
 3358 
Interpretation of the calculated FICIs were done using parameters recommended by Odds 3359 
in a review of FICI parameters (299) – synergy ≤ 0.5, > 0.5 to ≤ 1 additive, > 1 to ≤ 4 3360 
indifference and > 4 antagonism. (300) 3361 
Antimicrobial SBP (mg/L) Organisms intended SBPI (mg/L) Organisms intended
Chloramphenicol 8 Enterobacteriaceae, 
B. cepacia complex , 
S. maltophilia
8 Enterobacteriaceae
Fosfomycin 64 E. coli 32 Enterobacteriaceae
Fusidic acid 1 Staphylococcus spp.
Teicoplanin 8 Staphylococcus spp. 2 S. aureus
Telavancin 0.12 S. aureus 0.125 MRSA
Vancomycin 2 S. aureus 2 S. aureus
CLSI M100-S27 EUCAST v 7.0
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Additionally, the susceptible breakpoint index (SBPI) was determined for all synergistic 3362 
combinations to determine the clinical relevance of the synergy observed (SBPI >2 refers to 3363 
useful synergy). (300)  3364 
SBPI was calculated as follows: 3365 
SBPI = 
Susceptible breakpoint of A 
+ 
Susceptible breakpoint of B 
MIC of A in combination MIC of B in combination 
 3366 
3.2.2.10.3 Mutational frequency in combination 3367 
The rates of mutational resistance of selected strains were studied by calculating the time 3368 
taken in days (or serial passage experiments) for the strain to raise the MIC 4-fold above 3369 
the baseline (MIC for each agent at the start of the experiment). The rates for combinations 3370 
were compared to their single agent counterparts. Additionally, the MIC for each agent at 3371 
the conclusion of the experiment (i.e. day 7) was compared with baseline to assess the 3372 
magnitude of decrease in susceptibility under drug selection pressure, either singly or in 3373 
combination. 3374 
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3.2.3 In vitro experiments plan for colistin combinations 3375 
 3376 
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3.2.4 Results 3377 
3.2.4.1 Strains used for screening 3378 
The 35 isolates used for screening COL combinations are shown in Table 3-6. A total of 10 3379 
A. baumannii isolates, 5 E. coli, 5 Enterobacter spp., 4 K. pneumoniae, 7 P. aeruginosa, 1 S. 3380 
marcescens and 1 S. maltophilia were included. Of these, 9 were type strains (from the 3381 
National Collection of Type Cultures, Public Health England, UK) and the other 26 were 3382 
clinical isolates. 3383 
Table 3-6 Characteristics of isolates used for screening colistin combinations. 3384 
CF – cystic fibrosis; LES – Liverpool epidemic strain. 3385 
 3386 
 3387 
Isolate Organism Characteristic Colistin in agar (mg/L)
NCTC 12156 Acinetobacter baumannii Type strain 0.125
AB14 Acinetobacter baumannii OXA-51-like, OXA-23 clone 1 0.5
AB16 Acinetobacter baumannii OXA-51-like, OXA-23 clone 2 0.25
AB12 Acinetobacter baumannii OXA-51-like, SE clone 0.25
AB184 Acinetobacter baumannii OXA-51-like, T strain 0.125
AB186 Acinetobacter baumannii OXA-51-like, Burn strain 0.25
AB210 Acinetobacter baumannii OXA-51-like, OXA-23-like, TGC S 0.25
AB211 Acinetobacter baumannii OXA-51-like, OXA-23-like, TGC R (paired with AB210) 0.25
AB205 Acinetobacter baumannii OXA-51-like, OXA-23, TGC R, COL R 32
AB219 Acinetobacter baumannii OXA-51-like, OXA-23-like, TGC R, COL R 64
NCTC 9735 Enterobacter aerogenes Type strain 0.5
EA2 Enterobacter aerogenes TEM-1, CTX-M-1 0.125
EA1 Enterobacter aerogenes Carbapenem-resistant (porin/AmpC) 0.0625
NCTC 10005 Enterobacter cloacae Type strain, COL R 32
NCTC 13380 Enterobacter cloacae Type strain, COL S 0.0625
NCTC 12241 Escherichia coli Susceptibility type strain 0.0625
NCTC 11954 Escherichia coli TEM-1 0.125
EC2 Escherichia coli TEM-1, OXA-1, CTX-M-15, ST131 0.125
EC204 Escherichia coli NDM-1 0.125
EC405 Escherichia coli NDM-5 0.0625
NCTC 9633 Klebsiella pneumoniae Type strain 0.25
KP51 Klebsiella pneumoniae TEM-1, OXA-1, CTX-M-15 0.5
KPC3 Klebsiella pneumoniae KPC-3, TEM-1, SHV-11 0.125
KP1 (2013) Klebsiella pneumoniae VIM-4 64
NCTC 12903 Pseudomonas aeruginosa Susceptibility type strain, COL heteroresistant 0.25
PA01 Pseudomonas aeruginosa Chronic infection virulence profile 0.5
PA14 Pseudomonas aeruginosa Acute infection virulence profile 0.125
PACF1092 Pseudomonas aeruginosa CF isolate, LES 2
PACF593 Pseudomonas aeruginosa VIM-2 0.5
PA8 (2013) Pseudomonas aeruginosa VIM-2  1
PA11 (2013) Pseudomonas aeruginosa VIM-2 0.25
NCTC 13382 Serratia marcescens Type strain 256
NCTC 10258 Stenotrophomonas maltophilia Type strain 1
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3.2.4.2 Disc diffusion screening using colistin supplemented agar 3388 
Of the 17 antimicrobials tested, COL-rifampicin combination appeared to be the most 3389 
active across all isolates (73% synergy, n = 24). This was followed closely by COL- 3390 
meropenem (64%), colistin-chloramphenicol (64%), colistin-fusidic acid (60%) and colistin- 3391 
fosfomycin (52%). The magnitude of synergy (measured by the average increase in zone of 3392 
inhibition with addition of colistin amongst synergistic combinations) was largest in COL- 3393 
fusidic acid combination (16.18 mm), followed by COL-rifampicin (11.44 mm), COL - 3394 
cotrimoxazole (10.19 mm) and COL-cefpodoxime (9.86 mm). COL-meropenem and COL- 3395 
fosfomycin, though synergistic against many strains across diverse species, displayed 3396 
rather more modest effects, with average increases of 8 mm and 8.97 mm respectively.  3397 
Interestingly, commonly employed regimens in clinical practice, COL-tigecycline and COL- 3398 
ciprofloxacin fared considerably worse in vitro, with synergy observed in only 12% of 3399 
isolates in both instances. Of greater concern, is the potential for antagonism – 2 type 3400 
strains with COL-ciprofloxacin including 11 mm decrease in zone of inhibition with K. 3401 
pneumoniae, and 4 COL resistant strains with COL-tigecycline (average decrease in zone of 3402 
inhibition 3 mm).  3403 
Whilst COL-combinations reported some degree of synergy against A. baumannii (except 3404 
for COL-cotrimoxazole) and K. pneumoniae (except for COL-ciprofloxacin), this was not a 3405 
consistent finding across the different species – 82% of combinations synergistic against 3406 
Enterobacter spp. (except with ampicillin, minocycline and tigecycline), 65% against E. coli 3407 
(except with ampicillin, cefpodoxime, cotrimoxazole, vancomycin, ciprofloxacin and 3408 
tigecycline), 65% against P. aeruginosa (except with ampicillin, cefpodoxime, erythromycin, 3409 
vancomycin, linezolid and quinopristin-dalfopristin), 41% against S. marcescens (only with 3410 
b-lactams, cotrimoxazole, chloramphenicol and rifampicin) and 29% against S. maltophilia 3411 
(only with ampicillin, gentamicin, chloramphenicol, fosfomycin and rifampicin).  3412 
Detailed results by organism (A. baumannii, Enterobacter spp., E. coli, K. pneumoniae and 3413 
P. aeruginosa are illustratated in Table 3-7. 3414 
 3415 
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Table 3-7 Results of disc diffusion screening for colistin combinations. 3416 





Disc Antimicrobial Amount in disc (μg) % of isolates Av. diff. (mm) % of isolates Av. diff. (mm) % of isolates Av. diff. (mm) % of isolates Av. diff. (mm) % of isolates Av. diff. (mm)
AMP 10 Ampicillin 10 40% 5.75 0% n/a 0% n/a 25% 13.00 0% n/a
CPD 10 Cefpodoxime 10 40% 7.25 20% 8.00 0% n/a 25% 8.00 0% n/a
AMC 30 Co-amoxiclav 20 (amoxicillin)/10 (clavulanate) 70% 6.57 20% 8.00 20% 7.00 75% 6.67 29% 7.00
MEM 10 Meropenem 10 100% 7.50 40% 6.00 60% 9.67 75% 10.67 29% 6.50
E 5 Erythromycin 5 60% 6.92 60% 8.83 40% 6.00 75% 13.67 0% n/a
CN 10 Gentamicin 10 40% 6.38 60% 5.00 40% 6.25 25% 8.00 14% 8.00
SXT 25 Cotrimoxazole 1.25 (trimethoprim)/23.75 (sulfamethoxazole) 0% n/a 60% 7.67 0% n/a 25% 9.00 43% 10.50
VA 5 Vancomycin 5 90% 7.11 40% 9.00 0% n/a 50% 13.00 0% n/a
CIP 1 Ciprofloxacin 1 10% 18.00 20% 6.00 0% n/a 0% n/a 29% 5.50
FD 10 Fusidic acid 10 90% 16.72 60% 13.50 80% 10.75 75% 26.00 14% 11.50
C 30 Chloramphenicol 30 100% 8.75 60% 12.00 40% 8.25 50% 7.50 29% 9.50
FOT 200 Fosfomycin 200 (fosfomycin)/50 (G6P) 50% 10.30 60% 5.67 40% 7.50 50% 13.00 57% 9.25
LZD 10 Linezolid 10 30% 5.33 20% 7.50 20% 8.00 75% 10.33 0% n/a
QD 15 Quinopristin-dalfopristin 15 70% 6.43 40% 11.75 40% 10.50 75% 16.00 0% n/a
MH 30 Minocycline 30 10% 5.00 0% n/a 20% 5.50 25% 13.00 43% 7.33
TGC 15 Tigecycline 15 20% 9.00 0% n/a 0% n/a 25% 6.50 14% 7.50
RD 5 Rifampicin 5 70% 9.57 80% 12.63 80% 8.63 75% 21.00 57% 9.13
A. baumannii Enterobacter spp. E. coli K. pneumoniae P. aeruginosa
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3.2.4.3 Etest screening using colistin supplemented agar – Colistin- 3422 
daptomycin combination 3423 
Synergy was observed only against A. baumannii that were susceptible to COL (n = 7, 3424 
AB12 not tested during initial screen). Daptomycin MIC was > 256 mg/L against all other 3425 
species, with or without the addition of sub-inhibitory concentration of COL. A further 5 3426 
clinical A. baumannii strains were tested (all susceptible to COL i.e. COL MIC ≤ 2 mg/L) to 3427 
confirm a species-specific finding – synergy was similarly observed in this group. Results 3428 
from COL-daptomycin synergy screening against A. baumannii are detailed in Table 3-8. 3429 
Table 3-8 Colistin-daptomycin Etest screening versus A. baumannii. 3430 
R – resistant; S – susceptible; TGC – tigecycline; No. of dilutions decrease – number of 2- 3431 
fold decrease in daptomycin MIC with the addition of subinhibitory concentration of COL. 3432 
 3433 
Isolate Organism Characteristic Amount	of	colistin	(mg/L) no.	of	dilutions	decrease
NCTC	12156 Acinetobacter	baumannii Type	strain 0.25 7
AB14 Acinetobacter	baumannii OXA-23	clone	1 0.5 5
AB16 Acinetobacter	baumannii OXA-23	clone	2 0.5 6
AB184 Acinetobacter	baumannii T	strain 0.25 6
AB186 Acinetobacter	baumannii Burn	strain 0.5 6
AB198 Acinetobacter	baumannii OXA-23 0.5 4
AB199 Acinetobacter	baumannii OXA-23 0.5 5
AB200 Acinetobacter	baumannii OXA-23 0.5 4
AB202 Acinetobacter	baumannii OXA-23,	TGC	R 0.5 4
AB205 Acinetobacter	baumannii OXA-23	clone	1,	TGC	R,	COL	R 0.75 0
AB210 Acinetobacter	baumannii OXA-23	clone	1,	TGC	S 0.25 3
AB211 Acinetobacter	baumannii OXA-23	clone	1,	TGC	R	(paired	with	AB210) 0.25 4
AB219 Acinetobacter	baumannii OXA-23,	TGC	R,	COL	R 0.75 1
AB292 Acinetobacter	baumannii OXA-23,	TGC	R 0.5 5
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3.2.4.4 Checkerboard assay 3434 
Checkerboard assays were performed on the most promising novel COL combinations 3435 
based on disc diffusion screening, and these were COL-FUS and COL-CHL.  3436 
Additionally, previously reported synergistic pairs, COL-FOS (301) and COL-glycopeptide 3437 
(including lipoglycopeptide, telavancin) combinations (302) were assessed in checkerboard 3438 
assays, to confirm potential synergy observed in disc diffusion screening from this study 3439 
(except telavancin, the activity of which was extrapolated from COL-VAN disc diffusion 3440 
results), and compare the level of activity with the newly described novel combinations 3441 
(COL-FUS, COL-CHL).  3442 
3.2.4.4.1 Colistin-fusidic acid checkerboard assays 3443 
The COL-FUS combination was tested using the checkerboard assay against 12 A. 3444 
baumannii isolates and 60 other Gram-negative organisms. Synergy was observed across 3445 
all A. baumannii isolates, suggesting a likely species-specific effect for this combination, 3446 
which extends to strains displaying high-level resistance to COL (AB219 and AB205 - see 3447 
Section 3.1.3.1). The average FICI for the isolates was 0.059 (range 0.016 – 0.113). The 3448 
corresponding average SBPI was 61 (range 4 – 158).  3449 
Additionally, synergy was also observed in 58% (n = 35) of non A. baumannii Gram- 3450 
negative organisms, with useful synergy (denoted by an SBPI >2) displayed by all but one 3451 
strain (S. marcescens type strain bearing inherent COL resistance). Synergy was observed 3452 
in just over half of all isolates carrying blaNDM and blaOXA-48, and approximately a third of 3453 
isolates carrying blaKPC. COL-FUS combination was more active against CTX-M-15, with 3454 
synergy observed in 88%. More interestingly, synergy was observed against all isolates 3455 
known to carry polymyxin resistant determinants, namely pmrAB mutants and mcr (see 3456 
Figure 3-16 for an example of COL-FUS checkerboard assay against an mcr-producer). 3457 
Importantly, antagonism was not observed against any of the 72 isolates included in the 3458 
study. The details of the results are illustrated in Table 3-9.  3459 
 3460 
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Figure 3-16 Checkerboard assay of colistin-fusidic acid against EC27852 (2016), a colistin- 3461
resistant E. coli strain carrying mcr-1. 3462
Resazurin has been added to all wells, and incubated at 37°C for 1 h before reading. Pink – 3463
growth detected, blue – no growth. 3464
3465
Table 3-9 Colistin-fusidic acid combination against non A. baumannii Gram-negative 3466
isolates by checkerboard assay. 3467
(a) by type of organism and (b) by resistance determinant. Combination effect determined 3468
by fractional inhibitory concentration index (FICI) and interpretated as follows: synergy (≤ 3469
0.5), additive (> 0.5 and ≤ 1), indifference (> 1 and ≤ 4) and antagonism (> 4). Clinically 3470
relevant synergy is assessed by a susceptible breakpoint index (SBPI) > 2. 3471
(a) by type of organism 3472
3473
(b) by resistance determinant 3474
3475
Organism Synergy	%	(n) Additive	%	(n) Indifference	%	(n) Antagonism	%	(n) SBPI	>2	%	(n)
58	(35) 21	(13) 20	(12) 0	(0) 56	(34)
60	(34) 23	(13) 16	(9) 0	(0) 58	(33)
52	(11) 33	(7) 14	(3) 0	(0) 52	(11)
100	(2) 0	(0) 0	(0) 0	(0) 100	(2)
66	(6) 22	(2) 11	(1) 0	(0) 66	(6)
63	(14) 18	(4) 18	(4) 0	(0) 63	(14)
0	(0) 0	(0) 100	(1) 0	(0) 0	(0)
0	(0) 0	(0) 100	(3) 0	(0) 0	(0)








Pseudomonas	aeruginosa	(n = 3) 
Serratia	marcescens	(n = 1) 
Stenotrophomonas	maltophilia	(n	=	1) 100	(1) 0	(0) 0	(0) 0	(0) 100	(1)
Resistance	determinant Synergy	%	(n) Additive	%	(n) Indifference	%	(n) Antagonism	%	(n) SBPI	>2	%	(n)
NDM	(n	=	5) 60	(3) 20	(1) 20	(1) 0	(0) 60	(3)
KPC	(n	=	17) 35	(6) 29	(5) 35	(6) 0	(0) 35	(6)
VIM	(n	=	2) 0	(0) 100	(2) 0	(0) 0	(0) 0	(0)
OXA-48	(n	=	5) 60	(3) 40	(2) 0	(0) 0	(0) 60	(3)
CTXM	(n	=	9) 88	(8) 0	(0) 11	(1) 0	(0) 88	(8)
pmr	mutants	(n	=	2) 100	(2) 0	(0) 0	(0) 0	(0) 100	(2)
mcr	(n	=	6) 100	(6) 0	(0) 0	(0) 0	(0) 100	(6)
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3.2.4.4.2 Colistin-chloramphenicol checkerboard assays 3476
Potential synergy between COL and CHL, particularly against A. baumannii (synergy was 3477
demonstrated against all A. baumannii isolates tested with disc diffusion screening in 3478
Section 3.2.4.2) was further explored with checkerboard assays. Whilst antagonism was 3479
not observed against any of the 8 A. baumannii isolates, the combination was only 3480
synergistic against a third of the isolates (all clinically relevant, with SBPI > 2). The extent of 3481
synergy was considerably lower than with COL-FUS, with FICI ranging 0.13 – 1. A similar 3482
finding was noted against K. pneumoniae (n = 7; FICI 0.25 – 2) and P. aeruginosa (n = 8; 3483
FICI 0.13 – 2). Unlike COL-FUS, colistin-COL-CHL combination was not particularly useful 3484
against carbapenemase producers, with only borderline synergy observed against only 1 3485
isolate carrying blaKPC (K. pneumoniae; FICI 0.5, SBPI 4.1) and 1 isolate carrying blaVIM (P. 3486
aeruginosa; FICI 0.5, SBPI 8). The details of these results are shown in Table 3-10. 3487
Table 3-10 Colistin-chloramphenicol combination against Gram-negative isolates by type of 3488
organism and resistance mechanism. 3489
(a) by type of organism 3490
3491
(b) by resistance determinant 3492
3493
Organism Synergy	%	(n) Additive	%	(n) Indifference	%	(n) Antagonism	%	(n) SBPI	>2	%	(n)
Acinetobacter	baumannii	(n	=	8) 37	(3) 62	(5) 0	(0) 0	(0) 37	(3)
Enterobacter	aerogenes	(n	=	3) 0	(0) 0	(0) 0	(0) 0	(0) 0	(0)
Enterobacter	cloacae	(n	=	2) 0	(0) 0	(0) 50	(1) 0	(0) 0	(0)
Escherichia	coli	(n	=	5) 0	(0) 40	(2) 0	(0) 0	(0) 0	(0)
Klebsiella	pneumoniae	(n	=	7) 28	(2) 42	(3) 14	(1) 0	(0) 28	(2)
Pseudomonas	aeruginosa	(n	=	8) 50	(4) 37	(3) 12	(1) 0	(0) 50	(4)
Serratia	marcescens	(n	=	1) 0	(0) 0	(0) 0	(0) 0	(0) 0	(0)
Enterobacteriaceae	(n	=	18) 11	(2) 27	(5) 11	(2) 0	(0) 11	(2)
All	(n	=	34) 26	(9) 38	(13) 8	(3) 0	(0) 26	(9)
Resistance	mechanism Synergy	%	(n) Additive	%	(n) Indifference	%	(n) Antagonism	%	(n) SBPI	>2	%	(n)
KPC	(n	=	7) 14	(1) 57	(4) 28	(2) 0	(0) 14	(1)
NDM	(n	=	5) 0	(0) 20	(1) 0	(0) 0	(0) 0	(0)
VIM	(n	=	1) 100	(1) 0	(0) 0	(0) 0	(0) 100	(1)
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3.2.4.4.3 Colistin with other agents (checkerboard assays) 3494
3.2.4.4.3.1 Colistin-fosfomycin, colistin-glycopeptides checkerboard assays 3495
A few other previously described unorthodox COL combinations (e.g. COL-glycopeptides, 3496
COL-FOS) were also explored with checkerboard assays. Of note, these were only 3497
explored against COL-susceptible strains (BMD MIC ≤ 2 mg/L), with synergy varying from 3498
44 – 100% of isolates. The activity observed between COL-glycopeptides and COL- 3499
fosfomycin were comparable to previously reported studies, (171, 301, 302) with strain to 3500
strain variability in their interaction. See Table 3-11 for details of these results. 3501
Table 3-11 Colistin in combination with fosfomycin or glycopeptides in checkerboard 3502
assays. 3503
3504
3.2.4.4.3.2 Fosfomycin-chloramphenicol combination, with or without colistin 3505
During the disc diffusion screening stage, ‘keyhole effect’ was noted between the FOS and 3506
CHL discs on a range of isolates, on both COL supplemented and unsupplemented ISA. 3507
The keyhole effect is caused by the expansion of the expected zone of inhibition of one 3508
agent due to the potentiation of the antibacterial effect with another. It is classically used in 3509
clinical microbiology laboratories to screen for the presence of extended-spectrum b- 3510
lactamases (ESBLs) – the potentiation of 3rd generation cephalosporins (e.g. ceftazidime) by 3511
clavulanate (in the form of co-amoxiclav). Examples of this effect are illustrated in Figure 3512
3-17. 3513
Figure 3-17 Keyhole effect between fosfomycin and chloramphenicol. 3514
(a) AB16 with (right) or without COL supplementation (left). Note the potentiation of the FOS 3515
zone of inhibition (FOT 200) by the CHL disc (C 30). 3516
3517
Adjuvant	agent	(no.	of	isolates,	n) Synergy	%	(n) Additive	%	(n) Indifference	%	(n) Antagonism	%	(n) SBPI	>2	%	(n)
Teicoplanin	(n	=	3) 100	(3) 0	(0) 0	(0) 0	(0) 100	(3)
Telavancin	(n	=	9) 44	(4) 11	(1) 44	(4) 0	(0) 44	(4)
Vancomycin	(n	=	8) 87	(7) 12	(1) 0	(0) 0	(0) 87	(7)
Fosfomycin	(n	=	4) 50	(2) 25	(1) 25	(1) 0	(0) 50	(2)
200 
(b) NCTC 13382 type strain (S. marcescens) on unsupplemented ISA. Note the zone of 3518
inhibition around the FOS disc (FOT 200) was only present on the side facing the CHL disc 3519
(C 30). 3520
3521
This was further investigated in checkerboard assays against 33 strains. Synergy was 
3522
mainly observed against P. aeruginosa isolates (75%, n = 6; this is in contrast to COL-FUS 
3523
and COL-CHL combinations) and KPC-producers (57%, n = 4; K. pneumoniae n = 3, E. 
3524
cloacae n =1). FOS-CHL combination was antagonistic against a clinical strain of E. 
3525
aerogenes (carbapenem susceptible phenotype, with FOS MIC = 1 and CHL MIC = 0.25), 
3526
which was otherwise susceptible to both agents when tested singly. See Table 3-12 for a 
3527
summary of the activity of FOS-CHL combination in checkerboard assays by type of 
3528
organism and carbapenemase harboured (if present).  
3529




(a) by type of organism
3532
3533
(b) by resistance mechanism
3534
3535
Organism Synergy	%	(n) Additive	%	(n) Indifference	%	(n) Antagonism	%	(n) SBPI	>2	%	(n)
Acinetobacter	baumannii	(n	=	8) 12	(1) 25	(2) 62	(5) 0	(0) 12	(1)
Enterobacter	aerogenes	(n	=	3) 0	(0) 0	(0) 66	(2) 33	(1) 0	(0)
Enterobacter	cloacae	(n	=	2) 100	(2) 0	(0) 0	(0) 0	(0) 100	(2)
Escherichia	coli	(n	=	4) 0	(0) 100	(4) 0	(0) 0	(0) 0	(0)
Klebsiella	pneumoniae	(n	=	7) 42	(3) 14	(1) 28	(2) 0	(0) 42	(3)
Pseudomonas	aeruginosa	(n	=	8) 75	(6) 25	(2) 0	(0) 0	(0) 50	(4)
Serratia	marcescens	(n	=	1) 100	(1) 0	(0) 0	(0) 0	(0) 100	(1)
Enterobacteriaceae	(n	=	17) 35	(6) 29	(5) 23	(4) 5	(1) 35	(6)
All	(n	=	33) 39	(13) 27	(9) 27	(9) 3	(1) 33	(11)
Resistance	mechanism Synergy	%	(n) Additive	%	(n) Indifference	%	(n) Antagonism	%	(n) SBPI	>2	%	(n)
KPC	(n	=	7) 57	(4) 14	(1) 28	(2) 0	(0) 57	(4)
NDM	(n	=	4) 25	(1) 75	(3) 0	(0) 0	(0) 25	(1)
VIM	(n	=	1) 0	(0) 100	(1) 0	(0) 0	(0) 0	(0)
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Additionally, a triple combination approach with COL, FOS and CHL was investigated with 3536 
a particular focus against P. aeruginosa. 10 isolates were selected – 8 P. aeruginosa, 1 3537 
NDM-1 producing E. coli and 1 KPC-2 producing K. pneumoniae. Subinhibitory 3538 
concentrations of COL were added to the checkerboard assays. The addition of COL 3539 
further potentiated the effect of FOS-CHL against the NDM and KPC strains, leading to 16 3540 
fold and 3 fold drop in FICI (compared to FICI in the absence of COL) respectively (triple 3541 
combination FICI were NDM 0.033, and KPC 0.023). SBPI was similarly raised 16 fold and 3542 
23 fold respectively (triple combination SBPI were NDM 208, KPC 36).  3543 
The magnitude of potentiation by colistin observed against the 2 enterobacteriaceae did 3544 
not, however, extend to all P. aeruginosa strains. Of the 8 P. aeruginosa strains, the 3545 
addition of COL resulted in lower FICI in 62% (n = 5; range 3 – 53 fold). The SBPI rose 2 – 3546 
45 fold (n = 6) and dropped 7 fold (n = 1) against the 7 isolates which displayed synergy 3547 
(FICI ≤ 0.5) in the presence of COL. 1 isolate (Liverpool epidemic strain isolated from a 3548 
cystic fibrosis patient) resulted in raised MICs in the presence of the triple combination 3549 
compared with FOS-CHL (FOS-CHL: FICI 0.5004, SBPI 64; triple combination: FICI 1.06, 3550 
SBPI 16.5).  3551 
 3552 
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3.2.4.5 Examination of permeability hypothesis underlying the colistin- 3553 
fusidic acid combination 3554 
FUS MIC was determined with or without polymyxin B nonapeptide (PBNP) for 35 isolates – 3555 
27 were susceptible to polymyxin B, and 8 were resistant. For polymyxin B susceptible 3556 
isolates, 8 mg/L of PBNP was not sufficient to inhibit growth, except for 4 P. aeruginosa 3557 
strains (where 2 mg/L PBNP was used). For polymyxin B resistant isolates, the 3558 
concentration of PBNP used was the polymyxin B MIC (maximum concentration of 256 3559 
mg/L), and this was subinhibitory for all 8 isolates tested. Sufficient sensitisation was 3560 
defined as a sensitisation index of > 2, allowing for a 2 fold (or sensitisation index of 2) 3561 
margin of error.  3562 
PBNP sensitised 26 of the 35 (74%) isolates tested, including 21 polymyxin B susceptible 3563 
strains (78%), and 5 polymyxin B resistant strains (63%). Among the polymyxin B 3564 
susceptible strains, the sensitisation index ranged from 4 – 256 in those that were 3565 
sufficiently sensitised. Sensitisation was inadequate with an A. baumannii strain, a K. 3566 
pneumoniae type strain and all P. aeruginosa strains apart from a known colistin 3567 
heteroresistant type strain (268). Sensitisation with PBNP was surprisingly observed among 3568 
polymyxin B resistant strains, with 5 strains dropping their FUS MIC by 4-32 fold. 3 strains 3569 
that did not see sufficient sensitisation included intrinsically polymyxin resistant S. 3570 
marcescens and P. mirabilis type strains, as well as a clinical carbapenem-resistant E. 3571 





Table 3-13 Sensitisation study of Gram-negative organisms to fusidic acid with polymyxin B nonapeptide. 3576 
Carb – carbapenem; TGC – tigecycline; CF – cystic fibrosis; LES – Liverpool epidemic strain. 3577 
 3578 
Isolate Organism Characteristic Fusidic acid MIC (mg/L) Polymyxin B MIC (mg/L) PBNP concentration (mg/L) Sensitisation index
NCTC 12156 Acinetobacter baumannii Type strain 256 0.25 8 16
AB12 Acinetobacter baumannii OXA-23 SE clone >256 0.25 8 128
AB14 Acinetobacter baumannii OXA-23 clone 1 256 0.25 8 16
AB16 Acinetobacter baumannii OXA-23 clone 2 >256 0.25 8 1
AB184 Acinetobacter baumannii T strain 256 0.5 8 256
AB186 Acinetobacter baumannii Burn strain 256 0.25 8 128
AB210 Acinetobacter baumannii OXA-23 clone 1, TGC S 256 0.25 8 32
AB211 Acinetobacter baumannii OXA-23 clone 1, TGC R >256 0.25 8 4
AB315 Acinetobacter baumannii OXA-23 clone 1, VAP clinical isolate 256 0.25 8 16
AB5075 Acinetobacter baumannii Animal model virulent strain 256 0.25 8 64
NCTC 12241 Escherichia coli Type strain >256 0.25 8 32
EC2 Escherichia coli CTX-M-15, ST131 >256 0.25 8 32
NCTC 11954 Escherichia coli Type strain, TEM ESBL >256 1 8 16
EC204 Escherichia coli NDM-1 >256 0.25 8 16
EC405 Escherichia coli NDM-5 >256 0.125 8 16
NCTC 13368 Klebsiella pneumoniae Type strain >256 0.5 8 1
KP51 Klebsiella pneumoniae CTX-M-15 >256 1 8 8
KPC-3 Klebsiella pneumoniae KPC-3 >256 0.25 8 4
KP50 Klebsiella pneumoniae NDM-1 >256 0.5 8 4
NCTC 13380 Enterobacter cloacae Type strain >256 0.25 8 32
NCTC 9735 Enterobacter aerogenes Type strain >256 1 8 4
EA2 Enterobacter aerogenes Carb S (pair of EA1) >256 0.25 8 16
NCTC 12903 Pseudomonas aeruginosa Type strain, COL hR >256 1 8 64
PA01 Pseudomonas aeruginosa Chronic infection strain >256 1 2 1
PA14 Pseudomonas aeruginosa Acute infection strain >256 1 2 1
PACF593 Pseudomonas aeruginosa CF isolate, VIM-2 >256 1 2 1
PACF1092 Pseudomonas aeruginosa CF isolate, LES >256 0.5 2 1
AB205 Acinetobacter baumannii OXA-23 clone 1, COL R 64 32 32 4
AB219 Acinetobacter baumannii OXA-23 clone 1, COL R 64 256 256 16
NCTC 9633 Klebsiella pneumoniae Type strain >256 8 8 4
EA1 Enterobacter aerogenes Carb R >256 16 16 2
NCTC 10005 Enterobacter cloacae Type strain, COL R >256 256 256 8
NCTC 13376 Proteus mirabilis Type strain >256 >256 256 1
NCTC 13382 Serratia marcescens Type strain >256 >256 256 1
NCTC 10258 Stenotrophomonas maltophilia Type strain >256 16 16 8
Polymyxin B resistant strains
Polymyxin B susceptible strains
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3.2.4.6 Mutational frequency of A. baumannii exposed to colistin- 3579 
fusidic acid combination 3580 
This was performed to assess the difference in rate of mutational resistance in A. baumannii 3581 
strains with COL-FUS combination compared with their single agent counterparts. The 3582 
pathogen-antimicrobial combination was chosen due to the potency demonstrated in 3583 
checkerboard assays and the consistency across a range of isolates within the species 3584 
(species-specific phenomenon).  3585 
4 A. baumannii strains were selected to investigate the mutational resistance frequency in 3586 
vitro – NCTC 12156 (type strain), AB14 (OXA-23 UK clone 1), AB205 (COL resistant clinical 3587 
strain) and AB315 (ventilator-associated pneumonia, VAP strain). COL-FUS combination 3588 
resulted in a lower frequency of mutational resistance to either agent compared with their 3589 
single agent counterparts. In particular, serial passage of representatives of commonly 3590 
encountered clinical strains in the UK (OXA-23 UK clone 1) AB14 and AB315 in the 3591 
presence of combination therapy resulted in 512 and 1024 fold drop respectively, in 3592 
development of mutational resistance. Details of the serial passage experiment are shown 3593 
in Table 3-14. 3594 
Table 3-14 Serial passage experiment – Colistin-fusidic acid against A. baumannii. 3595 
cCOL – colistin MIC subjected to dual agent exposure; cFUS – fusidic acid MIC subjected 3596 
to dual agent exposure. Combination resistance factor is the ratio of the final MIC (on day 3597 
7) when exposed to the single agents to that obtained when subjected to dual agents.  3598 
 3599 
Isolate Condition Original MIC (mg/L) Final MIC (mg/L)




COL 0.25 4 16
cCOL 0.25 0.5 2
FUS 256 2048 8
cFUS 256 512 2
COL 0.25 2048 8192
cCOL 0.25 4 16
FUS 128 2048 16
cFUS 128 256 2
COL 512 2048 4
cCOL 512 512 1
FUS 64 8192 128
cFUS 64 2048 32
COL 1 1024 1024
cCOL 1 1 1
FUS 128 >16384 >128














3.2.5 Discussion 3600 
Multiple COL combinations can be investigated at once using a disc diffusion screening 3601 
assay. While agar-based methods are unsuitable for testing COL susceptibility (see Section 3602 
3.1.3), they can be used in such a manner to identify likely synergistic combinations, which 3603 
can then be confirmed using broth-based methods. COL-FUS is an example of the 3604 
preservation of the synergistic effect observed across the different platforms used. 3605 
3.2.5.1 Novel synergistic colistin combinations 3606 
3.2.5.1.1 Colistin-fusidic acid 3607 
COL-FUS was identified as the most potent combination from disc diffusion screening 3608 
(average increase in zone of inhibition was 16.2 mm, 40% higher than the next most active 3609 
combination, COL-rifampicin). The in vitro synergistic effect was replicated in checkerboard 3610 
assays against all A. baumannii strains tested (n = 12; FICI 0.016 – 0.113; SBPI 3.8 - 158) 3611 
and over half of all other Gram-negative isolates. It is postulated, much like with other 3612 
synergistic COL combinations, that the mechanism of action underlying the antibacterial 3613 
activity of COL-FUS is a two-step process whereby COL permeabilises the Gram-negative 3614 
outer membrane, thereby allowing the passage of hydrophobic steroidal molecule, FUS into 3615 
the cell interior where it inhibits ribosomal translocation by binding elongation factor G (EF- 3616 
G). See Figure 3-18 for a diagram depicting this putative mechanism of action.  3617 
Recent studies conducted by Rahim et al. and Sharma et al. have illustrated the additional 3618 
damage to the bacterial cell surface under combination therapy (polymyxin B and 3619 
chloramphenicol in the former, and polymyxin B and meropenem in the latter study) using 3620 
scanning electron microscopy. The authors hypothesised that the observation is due to the 3621 
synergistic effect of the combination, the secondary compound utilising the permeabilising 3622 
property of polymyxins. (303, 304)  3623 
FUS, though a substrate for some multidrug efflux pumps common to CHL (e.g. AcrAB- 3624 
TolC in E. coli) (305) and may be enzymatically deactivated by some cat enzymes, (306) 3625 
may have superiority over a number of other possible candidates as the adjuvant to COL 3626 
given its relatively narrow spectrum of activity (and hence clinical application) on its own 3627 
(largely limited to S. aureus), (55) yet possessing an intracellular target (ribosomal 3628 
elongation factor G) that is presumably ubiquitous to all prokaryotes. Its target in Gram- 3629 
negative organisms is relatively unexposed to FUS due to the lack of influx into the cell, and 3630 
hence selective pressure to develop or express clinically relevant fusidic acid resistance is 3631 
low compared to natively active Gram-negative antimicrobial agents. 3632 




3.2.5.1.1.1 Colistin-fusidic acid against colistin-resistant organisms 3636 
Perhaps the most interesting phenomenon observed was the activity COL-FUS had against 3637 
COL resistant strains, including those carrying known polymyxin resistance determinants 3638 
(e.g. pmrAB mutants, mcr-1) and inherently COL-resistant S. marcescens type strain. This 3639 
is an unusual phenomenon, with few reports in literature demonstrating synergy with COL 3640 
combinations against colistin resistant isolates. (307, 308) No antagonism was observed 3641 
against the 15 COL-resistant isolates tested (MIC range 8 to >256 mg/L), and synergy was 3642 
demonstrated against all (FICI 0.0006 – 0.14, SBPI 0.52 – 36) but the P. mirabilis type strain 3643 
(NCTC 13376; FICI 2). Further examination of this phenomenon with polymyxin B 3644 
nonapeptide may suggest that the permeabilising property is preserved against polymyxin 3645 
resistant strains, even if cell death does not occur, whereby combination therapy might still 3646 
prove successful in the face of resistance to polymyxin monotherapy. Vidaillac et al (308) 3647 
noted in their study that COL-resistant subpopulations raised in vitro from susceptible 3648 
strains were more susceptible to COL combinations than their susceptible parent strains. It 3649 
was observed that the higher the potential for selecting for COL heteroresistant 3650 
subpopulations, the greater the chance of synergy with vancomycin or cotrimoxazole. Soon 3651 
et al (309) observed that the degree of surface disruption (using atomic force microscopy to 3652 
map surface roughness by measuring the relative changes to the vertical height of the 3653 
surface studied) of the COL resistant (MIC >128 mg/L) strain was similar to that of the 3654 
parent COL susceptible strain (MIC 1-2 mg/L) when exposed to 4 mg/L and 32 mg/L of 3655 
COL. The authors suggest that some form of interaction between COL and COL-resistant 3656 
A. baumannii was preserved. Further investigation comparing non A. baumannii COL- 3657 
resistant strains, including inherently resistant S. marcescens and P. mirabilis, may reveal if 3658 
COL heteroresistance underlies the observed synergy of the COL-FUS combination. 3659 
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Observations of the degree of surface disruption by atomic force microscopy 3660 
(measurement of average height deviations from the calculated mean) or scanning electron 3661 
microscopy (detection of scatter electrons from surface by primary beam producing image 3662 
of surface morphology) of COL resistant A. baumannii strains during exposure to increasing 3663 
concentrations of COL and FUS, singly and in combination, may reveal potential additional 3664 
membrane altering effects caused by the combination. As the putative target of FUS’s 3665 
antimicrobial action is intracellular following transport into the cell aided by COL, 3666 
transmission electron microscopy imaging (electron beam passes through thin slices of 3667 
specimen producing images of ultrastructure within the cell) during various stages of 3668 
exposure to the combination and its single agent counterparts could elucidate the nature of 3669 
the antimicrobial activity against both COL susceptible and COL resistant strains. The 3670 
combined mechanism(s) of action might differ, given the susceptibility profile to colistin on 3671 
its own.   3672 
3.2.5.1.1.2 Evolution of A. baumannii resistance slowed when exposed to colistin 3673 
and fusidic acid in combination  3674 
One of the rationales for employing antimicrobial combination therapies is to reduce or 3675 
prevent resistance. (282, 284) The in vitro serial passage study of COL-FUS against 4 A. 3676 
baumannii strains revealed the rapid evolution of resistance (or increasing MICs in the case 3677 
of baseline non-susceptibility) when any of the 4 strains were subjected to single agent 3678 
exposure (4-fold increase in MIC: COL – 24 – 96 h, FUS – 48 – 120 h). In contrast, most 3679 
strains did not attain 4-fold increase in COL MIC by the end of the experiment (168 h) when 3680 
exposed to both agents simultaneously, apart from AB14 (MIC increased at 168 h). FUS 3681 
mutational resistance was similarly slowed under dual agent selection, with only AB205 3682 
(COL-resistant strain) reaching 4-fold increase in MIC (144 h) during the study. 3683 
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3.2.5.1.2 Colistin-chloramphenicol 3684 
Likewise, the synergistic activity of COL-CHL and COL-daptomycin observed against 3685 
Gram-negative organisms (limited to A. baumannii in the latter) exploits the same property.  3686 
COL-CHL might be less potent a combination compared with COL-FUS possibly due to the 3687 
presence of multiple resistance genes (e.g. efflux pumps AcrAB-TolC and CmlA, 3688 
chloramphenicol acetyltransferase (cat)), which Gram-negative organisms possess as an 3689 
adaptive feature to CHL exposure over time. (310) 3690 
CHL is a hydrophobic compound, with an intracellular bacterial ribosomal target, inhibiting 3691 
protein synthesis by interrupting the transpeptidation process. The permeabilising property 3692 
of COL increases the influx of CHL across the outer membrane, allowing it to freely diffuse 3693 
through the inner membrane (being a hydrophobic molecule). It is notable that whilst both 3694 
CHL and FUS are substrates of similar multi-drug efflux pumps (e.g. AcrAB, MexAB), (305) 3695 
differences in efflux efficiencies may exist for the various substrates. (311) This may in part 3696 
account for the apparent better activity of COL-CHL against P. aeruginosa (additive effect; 3697 
FICI ≤ 1 against the same 3 P. aeruginosa strains for which there was no COL-FUS effect 3698 
with FICI 2). 3699 
Moreover, whilst COL-FUS combination was synergistic (FICI ≤ 0.5) and potentially 3700 
clinically effective (SBPI > 2) against some COL-resistant strains, this effect did not appear 3701 
to extend to COL-CHL. This likely suggests that in COL-resistant strains, FUS may play an 3702 
important role in the entry of one or both agents into the bacterial cell, a property likely 3703 
unique to FUS and lacking in chloramphenicol, despite similar hydrophobic properties. 3704 
Another possible explanation is the existence of multiple other mechanisms of 3705 
chloramphenicol resistance which could act synergistically to exclude or inactivate CHL in 3706 
these Gram-negative bacterial isolates apart from multi-drug efflux (for which both agents 3707 
are potential substrates).  3708 
 3709 
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3.2.5.1.3 Colistin-daptomycin 3710 
Similarly, daptomycin does not possess any appreciable native Gram-negative activity, and 3711 
was thought to be a good candidate as a COL adjunct utilising this strategy.  3712 
COL-daptomycin was investigated as a possible synergistic combination as both agents 3713 
work in a similar fashion by damage the cell membrane, albeit daptomycin has no activity 3714 
on its own on the Gram-negative outer membrane. COL-daptomycin combination was 3715 
however only active against A. baumannii strains, perhaps suggesting the lack of 3716 
appropriate target or condition (the antibacterial effect of daptomycin is caused by the 3717 
efflux of potassium from the cell and this in turn is calcium-dependent (312)) on the cell 3718 
membrane of non A. baumannii Gram-negative organisms.  3719 
This finding was similarly observed by Galani et al. in time-kill assays (bactericidal against 3720 
9/10 COL-susceptible isolates, and bacteriostatic against COL-resistant strains) (313) and 3721 
Yang et al. in a Galleria mellonella model (survival with combination >80%, and <70% with 3722 
colistin monotherapy). (314) 3723 
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3.2.5.2 Other synergistic colistin combinations 3724 
3.2.5.2.1 Colistin-fosfomycin 3725 
FOS is a small (138 Da) hydrophilic molecule, which binds to MurA, an enzyme involved in 3726 
the biosynthesis of peptidoglycan precursors in the early phase of peptidoglycan synthesis. 3727 
(315) The permeabilising property of COL allows greater influx of FOS through the outer 3728 
membrane (otherwise limited by transport via porin channels), and eventual uptake through 3729 
the inner membrane via the glycerol-3-phosphate transporter (GlpT) and/or glucose-6- 3730 
phosphate transporter (UhpT). GlpT, being the sole transporter of FOS into P. aeruginosa, 3731 
as it lacks UhpT permease. (316) 3732 
Colistin-fosfomycin has been observed to be synergistic in vitro, (317-319) and this was 3733 
similarly observed in this study against COL-susceptible isolates (FICI ≤ 1 in 3/4 isolates 3734 
tested). There was no observed effect (FICI 2) between COL and FOS against a NDM-1 3735 
producing E. coli strain, potentially due to co-carriage of plasmid-encoded inactivating 3736 
enzyme, FosA. (320) Albur et al similarly noted the significant difference in the synergistic 3737 
effect of COL-FOS against FOS-susceptible and FOS-resistant NDM producing strains. 3738 
(317) 3739 
In an open-label randomised controlled study of COL-FOS versus COL monotherapy for 3740 
the treatment of carbapenem-resistant A. baumannii infections (n = 94), 28-day crude 3741 
mortality was similar in both arms (p = 0.41), although microbial eradication was superior in 3742 
the group who received combination therapy (100% vs 81.2%, p = 0.001). Although not 3743 
explicitly reported, the authors noted that the COL MICs from the isolated strains were 3744 
mostly ≤ 2 mg/L, and FOS MIC in A. baumannii their country (Thailand) were high, MIC90 3745 
128 mg/L). (207)  3746 
3.2.5.2.2 Colistin-glycopeptide and colistin-lipoglycopeptide combinations 3747 
Glycopeptides (vancomycin, teicoplanin) and related antimicrobial agents, 3748 
lipoglycopeptides (e.g. telavancin), are large hydrophobic molecules that are effectively 3749 
excluded from Gram-negative bacteria by the outer membrane. (302) 3750 
The permeabilising property of COL is thus ideally exploited in these combinations, 3751 
allowing the entry of these large molecules, which bind to the D-Ala-D-Ala terminus of the 3752 
pentapeptidic peptidoglycan precursor, thereby inhibiting the transpeptidation stage 3753 
(cross-linking) of cell wall formation. This leads to the loss of turgidity and positive osmitic 3754 
pressure, eventually resulting in lysis and cell death. (321) Telavancin is a semisynthetic 3755 
derivative, with an additional hydrophobic tail, and a hydrophilic phosphonate group, and 3756 
inhibits both cell wall synthesis (peptidoglycan formation) and depolarises the cell 3757 
membrane. (321) 3758 
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Several studies have reported on the synergistic relationship between COL and 3759 
glycopeptides or lipoglycopeptides in vitro and in vivo. (302) Synergy was limited to COL- 3760 
susceptible strains, suggesting that the effect of the combination is contingent on the 3761 
antibacterial effect of COL. To date, there has yet to be a RCT conducted investigating the 3762 
efficacy of COL in combination with either glycopeptides or lipoglycopeptides, but 2 3763 
retrospective observational studies have been performed, and whilst both were small 3764 
studies (n = 57 Garnacho-Montero; n = 166 Petrosillo), mortality rates were similar between 3765 
COL monotherapy and COL-glycopeptide groups. The burden of nephrotoxicity was higher 3766 
in the combination therapy arm in the study conducted by Garnacho-Montero et al (p = 3767 




3.2.5.3 Other novel synergistic combinations – Fosfomycin- 3771 
chloramphenicol 3772 
P. aeruginosa presented a problem, against which potent synergy was not consistently 3773 
observed with any of the other COL combinations tested (best combinations on disc 3774 
diffusion screen were with fosfomycin or rifampicin, and only against half the isolates 3775 
tested).  3776 
FOS-CHL combination, however, showed potential promise against P. aeruginosa (n = 8), 3777 
with the combination demonstrating synergy (75%) or additive effect, and useful synergy in 3778 
50% (SBPI 0.4 – 64). In the presence of sub-inhibitory concentration of COL, the triple 3779 
combination was synergistic against 7 of the 8 strains, and all 7 displayed useful synergy 3780 
(SBPI >2).  3781 
It is unclear what the underlying mechanism of the observed synergy is, with all 8 P. 3782 
aeruginosa strains resistant to FOS with (MIC ≥ 128 mg/L) or without subinhibitory COL 3783 
(MIC ≥ 512 mg/L), and CHL with (MIC ≥ 16 mg/L) or without subinhibitory COL (MIC ≥ 32 3784 
mg/L). Similarly, all 8 isolates were susceptible to COL (MIC ≤ 1 mg/L), and with the 3785 
exception of 1 LES isolate (where the addition of 0.25x MIC of COL resulted in rise of FOS 3786 
MIC from 0.5 to 1024 mg/L, decrease in CHL MIC from 128 to 16 mg/L, and a FOS-CHL 3787 
FICI rise from 0.625 to 1.06), the addition of subinhibitory COL potentiated the synergy 3788 
between FOS and CHL.  3789 
Examination of the keyhole effect demonstrated in this study between the 2 antimicrobials 3790 
reveal a potentiation of FOS zone of inhibition with chloramphenicol, and in the case of S. 3791 
marcescens type strain, exposure to additional chloramphenicol appeared to inhibit 3792 
possible spontaneous FOS mutants (zone of lower density bacterial growth compared to 3793 
surrounding areas).  3794 
Further studies are warranted to elucidate the basis of the synergy between FOS and CHL, 3795 
and to assess the bactericidal activity of the combination compared to the respective single 3796 
agent counterparts at clinically relevant concentrations of both agents.   3797 
3.2.5.4 Limitations 3798 
The main limitation of the study is the methods used for screening combinations. Disc 3799 
diffusion susceptibility testing has drawbacks including poor COL diffusion across agar, 3800 
prone to measurement error (±	1 mm could decide susceptibility versus resistance, and in 3801 
this study, could rule in or rule out potential synergy) and assessment of combination effect 3802 
only at a fixed concentration for each drug pair. Checkerboard assays, whilst allowing a 3803 
defined range of drug concentrations to be tested, is limited by being an end-point assay. 3804 

































antimicrobial agents, are useful as screening tools due to the relative ease in performing the 
assays. Confirmation of any synergy observed requires further assessment in the form of 
time-kill assays. 
3.2.5.5 Conclusions 
Extension of the antimicrobial activity of COL by combining it with other antimicrobial 
agents already licensed for use in clinical practice has the potential to (a) preserve the 
clinical efficacy of COL and (b) present viable therapeutic options against organisms that 
prove to be otherwise resistant. By exploiting the unique property of permeabilising the 
Gram-negative memebrane that polymyxins possess, novel antimicrobial pathways (e.g. 
COL-glycopeptideCOL-FUS) are presented against these MDR Gram-negative organisms. 
These synergistic combinations serve to refresh the Gram-negative antimicrobial pipeline 
with probable novel antimicrobial mechanisms of action, with licensed agents already at 
our disposable, whilst we continue our efforts to develop new therapeutic options. Utility of 
already licensed drugs has the upperhand in that safety, pharmacometrics and optimisation 
in humans have already been studied, and new data continues to be available routinely. 
Synergistic COL combinations with existing antimicrobials (e.g. glycopeptides, FUS, 
daptomycin) may be employed presently against Gram-negative infections for which viable 
options are few to none, compared to promising new therapies that may take up to 10 
years in development before they enter clinical use.  
The proposed screening strategy, utilising an inexpensive and high throughput disc 
diffusion screening process, followed by confirmation of synergy using checkerboard 
assays help to identify potential synergistic COL combinations. COL-FUS combination has 
been found to be the most potent synergistic pair from this screen, and was found to 
demonstrate synergy across a number of species (including A. baumannii, E. coli, K. 
pneumoniae, Enterobacter spp.) and resistance mechanisms, with unexpected activity 
against colistin-resistant organisms. This pair, in particular, warrants further examination of 
its synergistic activity over time, to better predict its potential clinical utility. As previously 
mentioned (see Section 3.1), endpoint assays fail to detect heteroresistance, and though 
mutational frequency of A. baumannii strains against COL-FUS combination therapy was 
found to be markedly lower than that of their single agent counterparts, it is prudent to 
subject the combination to time-course assay assessment to observe its post-antibiotic 
effect and activity against hetero-resistant subpopulations. (322)  3837
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3.3 In vitro confirmation of the activity of 3838
colistin and fusidic acid combination by 3839
time-kill assays 3840
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3.3.1 Introduction 3841 
3.3.1.1 Background and rationale 3842 
MIC methodologies, including broth microtitre dilution and their dual agent counterpart, 3843 
checkerboard assays, whilst convenient to perform thus suitable for high throughput 3844 
screening are ultimately end-point assays. The only result available, in most cases, is the 3845 
minimum concentration of each drug (or drug combination) required to inhibit the growth of 3846 
a specific organism at a particular inoculum after a specified period of time (usually 18-24 3847 
h). Time-course assays, on the other hand, provide more information regarding the drug- 3848 
organism interaction over time, including whether the antibacterial activity at a given 3849 
concentration is bactericidal or bacteriostatic, the rate and pattern of bacterial killing over 3850 
time, maximum growth of an organism in the absence of any drug and maximum effect of 3851 
the drug. (322) This drug-organism relationship allows for mathematical modelling of the in 3852 
vitro pharmacodynamics (effect of an antibiotic on the rate of growth of an organism), 3853 
which more accurately captures the antibacterial effect of an agent, even discriminating 3854 
between strains that apparently have similar MICs to the same agent. (323) This in turn is 3855 
helpful with designing clinically relevant dosing regimens by combining it with 3856 
pharmacokinetic parameters (derived separately by studying the elimination kinetics of the 3857 
drug in humans), optimising the dose and frequency to allow for maximal effect on the 3858 
pathogen with minimal toxicity in humans.     3859 
As previously observed in COL PAP (see Section 3.1), COL heteroresistant subpopulations 3860 
of A. baumannii isolates have been selected for and detected in time-course assays. 3861 
Several authors have noted that the concentrations of COL required to suppress the 3862 
development of heteroresistant subpopulations far exceed the concentration of COL 3863 
attainable in humans (clinical susceptibility breakpoint set by EUCAST and CLSI being 2 3864 
mg/L, (271, 272) which despite high-dose regimens may be difficult to achieve in some 3865 
individuals). (135, 146, 324)  3866 
Time-course assays are conducted by comparing the viable bacterial counts over the 3867 
duration of antimicrobial exposure at specific concentrations. They may be static or 3868 
dynamic. Static time-course assays are set up with a specific concentrations and inoculum 3869 
set at the beginning of the assay, and small samples are removed at various time-points 3870 
over the course of the experiment (usually limited to 24 h for aerobic Gram-negative 3871 
organisms). (270, 325, 326) Dynamic assays seek to mimic the conditions in vivo, 3872 
incorporating clinical pharmacokinetic parameters, thereby allowing the study of 3873 
antimicrobial activity in the context of changing concentrations (e.g. multiple dosing, 3874 
continuous infusion regimens) over time. (322) Time-course assays are predictably 3875 
 216 
extremely time-consuming, costly and labour intensive to perform, and not feasible to 3876 
perform within the constraints of the clinical diagnostic laboratory.  3877 
3.3.1.2 Objectives 3878 
Here, the most promising combination (COL-FUS) identified from the screening study was 3879 
further investigated in static time-kill assays to better understand the nature of the 3880 
relationship over time, in particular to examine the post-antibiotic effect and any 3881 
observations of bacterial regrowth when exposed to COL versus to COL-FUS.  3882 
Time-kill assays assessing the activity of the combination versus wild type strains 3883 
belonging to representative Gram-negative species will be performed in the first stage. The 3884 
organism most susceptible to the combination will be used to conduct further studies, 3885 
incorporating well characterised strains including those expressing multiple AMR 3886 
mechanisms. 3887 
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3.3.2 Methods 3888 
3.3.2.1 Strain selection 3889 
7 representative type strains were chosen for the initial time-kill experiments to assess the 3890 
relationship of the colistin-fusidic acid (COL/FUS) combination and Gram-negative 3891 
organisms. The isolates selected (COL MIC determined by BMD) were – NCTC 9735 (E. 3892 
aerogenes; COL MIC 1 mg/L), NCTC 10005 (E. cloacae; COL MIC >256 mg/L), NCTC 3893 
12241 (E. coli; COL MIC 0.25 mg/L), NCTC 9633 (K. pneumoniae; COL MIC 2 mg/L), NCTC 3894 
10258 (S. maltophilia; COL MIC 4 mg/L), NCTC 13382 (S. marcescens; COL MIC >256 3895 
mg/L), NCTC 12156 (A. baumannii; COL MIC 0.25 mg/L). The clinical susceptible 3896 
breakpoint for COL against Enterobacteriaceae (EUCAST v7) and Acinetobacter spp. 3897 
(EUCAST v7, CLSI M100-S27) was 2mg/L, (271, 272) and this concentration of COL was 3898 
used as the backbone for all the COL/FUS versus non S. marcescens type strain 3899 
experiments (apart from NCTC 12156, in which COL 2 mg/L alone prevented growth 3900 
sufficiently, and discrimination between COL and COL/FUS could not be assessed; COL 3901 
0.5 mg/L i.e. 2x MIC was used instead). For intrinsically COL-resistant S. marcescens type 3902 
strain, concentrations of drugs used were COL 256 - 512 mg/L and FUS 64 mg/L, to 3903 
assess if synergy observed in the checkerboard assays was likewise present by time-kills 3904 
as a proof of concept.  3905 
6 A. baumannii strains (NCTC 12156 type strain, and 5 MDR strains – AB12, AB14, AB16, 3906 
AB205, AB315; refer to Section 3.1.2.1 Table 3-1 for their respective characteristics) were 3907 
subsequently chosen to conduct further time-kill experiments to ascertain the minimum 3908 
concentrations of COL and FUS that resulted in synergy and bactericidal activity.  3909 
All strains were stored on MicroBank™ beads (Pro-Lab Diagnostics, Austin, Texas, USA) at 3910 
-70°C. Prior to each experiment, the strains were freshly subcultured onto ISA plates 3911 
(prepared as per Section 3.1.2.3) and incubated aerobically at 37°C for 18 h.  3912 
3.3.2.2 Antimicrobial agent preparation 3913 
COL and FUS stock solutions were prepared and stored prior to use in each experiment as 3914 
per Sections 3.1.2.2 (COL) and 3.2.2.2 (FUS).  3915 
3.3.2.3 Media preparation 3916 
ISB is prepared and stored as per Section 3.1.2.3.  3917 
3.3.2.4 Time-kill assay protocol 3918 
Static time-kill assays were set up as described in the guideline published by the National 3919 
Committee for Clinical Laboratory Standards (NCCLS)(270).  3920 
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3-5 colonies of each organism were subcultured from the ISA plates into 10 mL of sterile 3921 
ISB (in 50 mL sterile FalconTM conical centrifuge tubes; Fisher Scientific, Loughborough, 3922 
UK), and incubated aerobically at 37°C for 18 h with shaking (at 224 rpm). Aliquots of the 3923 
overnight culture were subsequently used to inoculate 10 mL sterile ISB (in 50 mL FalconTM 3924 
tubes), adjusted to yield final inocula of approximately 106 cfu/mL. COL and FUS stock 3925 
solution were added to experimental tubes to obtain concentrations including the clinical 3926 
susceptibility breakpoint (i.e. 2 mg/L (Enterobacteriaceae and A. baumannii) for COL and 1 3927 
mg/L (for S. aureus) for FUS), and/or the BMD MIC of COL and the attainable 3928 
serum/plasma concentration for FUS (>20 mg/L after the first oral dose, accumulation 3929 
occurs with each subsequent dose, reaching levels in excess of 100 mg/L by day 5 of a 3930 
500 mg 8 hourly regimen). (327) A growth control per organism for each experimental run 3931 
was set up alongside the antimicrobial arms (inoculated, but untreated). All tubes were 3932 
incubated aerobically at 37°C for 24 h (with shaking at 224 rpm), with 100 µL aliquots 3933 
removed at 0 h, 2 h, 4 h, 6 h and 24 h, and plated onto unsupplemented ISA plates for 3934 
viable bacterial counts (with or without serial dilutions in sterile PBS). Colony counts in 3935 
cfu/mL were determined after aerobic incubation at 37°C for 18 3936 
h. Additional samples were taken for representative organisms, AB14 (MDR OXA-23 UK 3937 
clone 1), AB205 (COL resistant strain) and AB315 (VAP MDR strain) to obtain more 3938 
information regarding the changes in bacterial load between 6 h and 24 h.  3939 
High inoculum experiments were set up using AB14 as the representative strain, as OXA-23 3940 
UK clone 1 is the most prevalent strain in the UK, specifically the cause of nosocomial 3941 
outbreaks in critical care facilities. (328) Overnight ISB broth culture of AB14 was 3942 
transferred to each experimental tube containing 10 mL of sterile ISB (including a growth 3943 
control), and adjusted to obtain inocula of 108 cfu/mL. Experiments were set up as 3944 
described for the lower inocula runs. Additional samples were taken at 0.5 h and 1 h to 3945 
study the effect of the COL and COL-FUS combination during the early phase of the 3946 
experiment.  3947 
3.3.2.5 Data analysis and definitions 3948 
Clinical susceptibility breakpoints for COL (2 mg/L for Enterobacteriaceae and A. 3949 
baumannii; Same breakpoints extrapolated to S. marcescens, P. mirabilis and S. maltophilia 3950 
in this study) and FUS (1 mg/L for S. aureus) used in the study were as per published 3951 
guidelines by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 3952 
version 7. (272)  3953 
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Bactericidal and bacteriostatic activity were interpreted as described in the NCCLS 3954 
guidelines – > 3 log10 cfu/mL decrease in viable bacterial count at 24 h (end of experiment) 3955 
compared with 0 h (start of experiment) was taken to be bactericidal, and a decrease in 3956 
viable count of < 3 log10 cfu/mL or no change in viable count (excepting regrowth) was 3957 
defined as bacteriostatic activity. (270) Synergy between COL and FUS was defined at ≥ 2 3958 
log10 cfu/mL decrease in viable bacterial count at 24 h compared with the 24 h viable count 3959 
of their single agent (either COL or FUS) component during the same experimental run.  3960 
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3.3.3 Results 3961 
3.3.3.1 Colistin-fusidic acid versus type strains time-kill curves 3962 
COL alone was rapidly bactericidal against COL susceptible E. coli and E. aerogenes type 3963 
strains at 2 mg/L and A. baumannii type strain at 0.5 mg/L, with sustained activity through 3964 
to the 6 h time-point. COL 2 mg/L inhibited the growth COL susceptible K. pneumoniae 3965 
type strain, though this activity was only bacteriostatic. Amongst the COL resistant strains, 3966 
COL 2 mg/L was only bacteriostatic against S. maltophilia (none were bactericidal), 3967 
sustained through to 6 h. None of the antibacterial activity observed at early in the 3968 
experiment was sustained through to 24 h, with regrowth to match the colony counts 3969 
observed in the antibiotic-free growth control. COL 256 – 512 mg/L inhibited growth of S. 3970 
marcescens only in the initial phase (2 h) of the experiment with rapid regrowth thereafter. 3971 
Antibacterial activity was not observed with FUS alone at any concentration, with the 3972 
growth trajectory of FUS alone against all strains following the respective antibiotic-free 3973 
growth controls.  3974 
Synergy at 24 h (≥ 2 log10 cfu/mL decrease in colony counts in COL-FUS arm compared 3975 
with COL or FUS alone) was observed in all combinations against all strains apart from COL 3976 
2 mg/L + FUS 4 mg/L against K. pneumoniae and COL 2 mg/L + FUS 2 mg/L against S. 3977 
maltophilia. Combination with FUS appeared to retard the antibacterial activity of COL at 3978 
the early time-points (up to 4 h), with greater colony counts in the combination arm 3979 
compared with COL alone against COL susceptible isolates. This was not the case with the 3980 
COL resistant isolates, however, the addition of FUS had a greater antibacterial effect 3981 
compared with COL alone at all time-points, although the attainment of synergy was only 3982 
observed later in the experiment – from 4 h onwards for NCTC 10005 (E. cloacae), and from 3983 
6 h onwards for NCTC 13382 (S. marcescens). See Figure 3-19 for illustrations of the time- 3984 
kill curves. 3985 
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Figure 3-19 Colistin and fusidic acid singly and in combination against 7 type strain 3986 
organisms in static time-kill assay. 3987 
Col-Fus – colistin and fusidic acid in combination. 3988 
 3989 
 3990 
(a) NCTC 9735 (E. aerogenes)
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(b) NCTC 10005 (E. cloacae)
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(c) NCTC 12241 (E. coli)
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(d) NCTC 9633 (K. pneumoniae)
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(e) NCTC 10258 (S. maltophilia)
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(f) NCTC 13382 (S. marcescens)



































(g) NCTC 12156 (A. baumannii)


































3.3.3.2 Colistin-fusidic acid versus A. baumannii 3996 
The antibacterial effect of the COL-FUS combination against A. baumannii was further 3997 
investigated by performing additional static time-kill experiments on 5 other clinical strains. 3998 
The strains used were AB12, AB14, AB16, AB205 and AB315. The characteristics of these 3999 
strains were detailed in Table 3-1. See Figure 3-20 for time-kill curves. 4000 
Figure 3-20 Colistin and fusidic acid singly or in combination against A. baumannii isolates 4001 
– time-kill assays. 4002 







































(b) AB12 (SE clone)









































(c) AB14 (OXA-23 clone 1)
















Fusidic acid 1 mg/L
Fusidic acid 2 mg/L






















(d) AB16 (OXA-23 clone 2)



































(f) AB315 (VAP strain)
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Amongst COL-susceptible strains, the MICs (by broth microtitre dilution) ranged 0.25 – 1 4010 
mg/L. 1 COL-resistant isolate was included, AB205, and its MIC was 256 mg/L. All strains, 4011 
with the exception of type strain NCTC 12156, were COL heteroresistant by PAP (using the 4012 
PAP-AUC method described by Wootton et al. (267)). In the presence of COL monotherapy, 4013 
up to 8x MIC, COL-susceptible isolates were rapidly killed, bactericidal activity achieved 4014 
within 2 h (all except NCTC 12156) of exposure and sustained through to 6 h (AB12 and 4015 
AB315). Additional time-points examined with AB14 and AB315 revealed that this sustained 4016 
killing was also observed through to 10 h (at COL concentration equivalent to the 4017 
susceptible breakpoint of 2 mg/L). However, the antibacterial effect of COL alone did not 4018 
persist till 24 h (time-kill end-point) against most isolates, with regrowth observed 4019 
compared with starting inocula. COL 2 mg/L was bacteriostatic against AB12 (4x MIC) and 4020 
AB315 (2x MIC), with < 1 log10 cfu/mL reduction in bacterial colony counts. Additional time- 4021 
points obtained for AB14 and AB315 (colistin 1 mg/L) showed that the regrowth had 4022 
occurred (above that of the starting inocula) by 20 h. COL alone did not appear to be 4023 
effective against any of the COL-susceptible isolates at 24 h, with end-point colony counts 4024 
similar to drug-free growth controls. Bacterial growth of COL-resistant AB205 in the 4025 
presence of COL 2 mg/L followed the trajectory of the drug-free control. Likewise, the 4026 
growth patterns of all strains (except for AB205) in the presence of FUS alone were similar 4027 
to those of their counterpart drug-free controls. AB205 was inhibited by 8 mg/L of FUS at 2 4028 
h, but regrowth was observed soon after and colony counts were on par with the drug-free 4029 
control by 6 h.  4030 
Synergy was observed between COL and FUS against all strains tested. For each strain 4031 
tested, the lowest concentration of COL resulting in synergy was determined in 4032 
combination with a clinically achievable concentration of fusidic acid (329) (up to 8 mg/L). 4033 
All drug concentrations used in the time-kill assays were clinically attainable, and as close 4034 
to published susceptible breakpoints (271, 272) (2 mg/L for COL against A. baumannii; 1 4035 
(f) AB315 (VAP strain)
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mg/L for FUS against S. aureus) as possible. The combinations resulting in synergy with the 4036 
lowest concentrations of drugs used are listed in Table 3-15. 4037 
Table 3-15 Lowest concentrations of colistin and fusidic acid that are synergistic in 4038 
combination against A. baumannii. 4039 
Synergy - ≥ 2 log10 cfu/mL decrease in colony count with combination compared to either 4040 
drug alone; Bactericidal synergy – synergy with ≥ 3 log10 cfu/mL decrease compared with 4041 
starting inoculum. 4042 














NCTC 12156 0.5 1 0.5 1 
AB12 0.5 1 0.5 1 
AB14 1 4 2 1 
AB16 2 1 2 1 
AB205 2 8 2 8 
AB315 0.5 2 2 1 
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High inocula experiments were conducted using AB14, a representative strain (OXA-23 UK 4044 
clone 1) from the most common lineage amongst clinical isolates from the UK. Time-kill 4045 
curves from these experiments are depicted in Figure 3-21 below. COL alone demonstrated 4046 
similar activity at higher inocula, achieving bactericidal activity at 1 h that persists through 4047 
to 6 h. Regrowth was similarly observed by the end of the experiments, at the 24 h time- 4048 
point. Closer examination of the earlier time-points (i.e. 0 – 2 h) revealed more rapid kill with 4049 
combination compared to COL alone at 30 min, but this early activity plateaued with 4050 
combination, with some acceleration between 6 – 24 h. COL alone, on the other hand, 4051 
achieved the greatest kill rate between 30 min and 1 h, with some slowing towards 6 h, and 4052 




Figure 3-21 Colistin and fusidic acid singly or in combination against high-inocula AB14 in 4056 
static time-kill experiments. 4057 
Col-Fus – Colistin and fusidic acid in combination. 4058 
 4059 
AB14 High inocula reads
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3.3.4 Discussion 4060 
Of the 7 type strains tested, COL resistance was detected at 24 h in all including those with 4061 
MIC ≤ 2 mg/L by broth microtitre dilution (i.e. susceptible by EUCAST). The rapid 4062 
antimicrobial activity demonstrated by COL against ‘COL-susceptible’ type strains, as 4063 
observed by the bacterial kill at 2 h (reaching bactericidal levels against E. aerogenes and 4064 
E. coli, and bacteriostatic against A. baumannii, S. maltophilia and K. pneumoniae), was 4065 
shortlived, and eventually paved the way for the growth of COL-resistant subpopulations. 4066 
The growth of these resistant subpopulations was slowed in the presence of added FUS, 4067 
and in the case of A. baumannii type strain NCTC 12156, this resulted in marked 4068 
bactericidal activity (> 4 log 10 cfu/mL reduction with COL at 2x MIC (0.5 mg/L) and fusidic 4069 
acid at clinical susceptibility breakpoint of 1 mg/L).  4070 
Further examination of the potent COL-FUS activity against A. baumannii demonstrated 4071 
that this activity extended to MDR and XDR phenotypes, including a strain that is COL- 4072 
resistant. Similar to its activity against NCTC 12156 type strain, COL demonstrated rapid 4073 
antimicrobial activity against all COL-susceptible A. baumannii strains, likely reflecting the 4074 
majority of the COL-exposure naïve population being composed of COL-susceptible 4075 
subpopulations. A similar observation was made by Li et al, where COL-resistant 4076 
subpopulations made up just 0.000023% of the wild-type NCTC 12156 type strain, and 4077 
eventually 100% in the presence of 10 mg/L of COL. (165) The growth of the COL-resistant 4078 
subpopulations was hindered from growth and proved bactericidal (> 3 log10 cfu/mL 4079 
reduction) at concentrations of COL and FUS attainable with recommended dosing 4080 
regimens. From the time-kill assays in this study, it is noted that there is no single ‘optimal’ 4081 
combination concentration (lowest concentration of both antimicrobials resulting in 4082 
bactericidal activity) that worked across all A. baumannii isolates, although, it could be 4083 
postulated that attaining serum COL concentration of 2 mg/L and FUS concentration of 8 4084 
mg/L would likely result in successful suppression of COL-resistant subpopulations, and 4085 
therefore likelihood of therapeutic cure. Closer examination of additional sampling time- 4086 
points and expanded concentrations against AB14 (representative MDR OXA-23 UK clone 4087 
1 isolate), revealed the growth patterns of the breakthrough resistant subpopulations. 4088 
Whilst the antimicrobial activity (if at all) in the first 6-10 h was rather predictable, where the 4089 
fall in bacterial count was most marked in the early hours (within the first 2 h), with continual 4090 
slowing of activity approaching a plateau towards the 10 h time-point. This was the trend of 4091 
bacterial killing kinetics for both COL and COL-FUS arms, with FUS single agent arm 4092 
closely mimicking the untreated growth control (reaching saturation or maximum growth by 4093 
4 h, sustained through to the end of experiment at 24 h). However, the trends for the COL 4094 
and COL-FUS arms diverge in the latter half. In conditions where regrowth occurred in the 4095 
presence of COL-FUS, the growth kinetics were slow, and did not reach maximal growth by 4096 
the end of the experiment. In contrast, regrowth occurred at a faster rate in the COL arms, 4097 
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almost matching the speed of kill seen in the early phases of the experiment. The best 4098 
antimicrobial activity against AB14 was obtained with COL 2 mg/L combined with either 2 4099 
mg/L or 4 mg/L of FUS, both resulted in marked kill within the first 4 h, and a slowed but 4100 
sustained kill from 6 – 24 h in a linear fashion. The combination with higher FUS 4101 
concentration of 4 mg/L saw a quicker drop in bacterial load at 2 h (by approximately 1.5 4102 
log10 cfu/mL), but was otherwise similar in activity to that observed at 2 mg/L. The 4103 
differences in bacterial killing seen between COL 2 mg/L + FUS 1 mg/L and COL 2 mg/L + 4104 
FUS 2 mg/L were rather in the latter half of the experiment, where a slight regrowth was 4105 
observed with the lower FUS concentration, and continued suppression with the higher 4106 
FUS 2 mg/L. This trend proposes that for COL 2 mg/L, the critical concentration of FUS 4107 
required for continued sustained killing through to 24 h would be 2 mg/L, though 4108 
bactericidal activity (defined as > 3 log10 cfu/mL decrease compared with starting inoculum) 4109 
was observed at 24 h depiste the marginal regrowth seen with FUS 1 mg/L. And any 4110 
additional FUS beyond 2 mg/L did not further suppress the growth of the resistant 4111 
subpopulations, but rather appeared to accelerate the rate of kill of heteroresistant initial 4112 
population (augmenting the antimicrobial effect of COL on COL-susceptible A. baumannii 4113 
or potentially killing COL-resistant A. baumannii via a novel mechanism). A similar picture 4114 
was observed for the killing kinetics against the VAP strain, AB315 (the clinical case and 4115 
treatment outcomes are described in Section 6.3). COL 0.5 mg/L and 1 mg/L resulted in 4116 
rapid kill and subsequent regrowth, eventually reaching maximal growth at 24 h. COL 2 4117 
mg/L was rather more efficient (compared with the lower COL concentrations) at 4118 
suppressing the growth of the COL-resistant subpopulations, and was close to 4119 
bacteriostatic against AB315 at the 24 h time-point. Interestingly, the addition of 2 mg/L of 4120 
FUS to both COL 0.5 mg/L and COL 1 mg/L resulted in a similar post-antibiotic effect at 24 4121 
h. The addition of FUS 1 mg/L to COL 2 mg/L sustained bacterial kill through to 24 h. The 4122 
observed synergy between COL and FUS was maintained against a higher inoculum of 4123 
AB14, final bacterial load at the end of the experiment was similar for COL and FUS at 4124 
susceptibility breakpoint concentrations of 2 mg/L and 1 mg/L respectively, though there 4125 
was a paradoxical relative decrease in bactericidal activity with increase in FUS 4126 
concentration from 2 mg/L to 4 mg/L in combination with COL 2 mg/L. Further experiments 4127 
including COL and FUS at an expanded range of concentrations and against different 4128 
strains of A. baumannii would be needed to shed light on this observation. It would also be 4129 
interesting to observe the COL-FUS post-antibiotic effect beyond 24 h.  4130 
The most notable observation with regards to the COL-FUS combination is its antimicrobial 4131 
activity against COL-resistant isolates in vitro. The proposed mechanism of synergistic 4132 
antimicrobial activity underpinning colistin combinations against Gram-negative bacteria 4133 
lies with the permeabilising ability of COL, thereby allowing numerous compounds 4134 
including other antimicrobials previously excluded by the effective Gram-negative outer 4135 
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membrane to enter the cell. This cooperative effect on the bacteria has been proposed by 4136 
some authors to be limited to COL susceptible organisms, as the first step of the 4137 
permeabilising effect of COL is the electrostatic interaction of the drug (carrying a strong 4138 
net positive charge) and the Gram-negative outer membrane (negatively charged). The 4139 
Gram-negative outer membrane differs from the phospholipid cytoplasmic membrane (or 4140 
inner membrane) due to the presence of LPS on its outer leaflet, which confers an overall 4141 
negative charge. Changes to the lipid A component of LPS, including the addition of L- 4142 
Ara4N or PEtN, decreases this negative charge, resulting in COL resistance. (330) 4143 
Differences between the surface electrostatic charges on the outer membrane of COL 4144 
susceptible and COL resistant strains estimated by the measured zeta potentials (the 4145 
absolute values of which are often somewhat higher than actual surface charge) in a study 4146 
by Soon et al revealed relative decrease in the magnitude of the negative surface charge in 4147 
colistin resistant isolates compared to their susceptible counterpart. (331) As COL binding 4148 
to Gram-negative outer membrane is initiated by the electrostatic attraction of the cationic 4149 
polypeptide to the negatively charged outer membrane, the relative decrease in the 4150 
negative charge of the outer membrane consequently reduces its interaction with COL, and 4151 
hence the antimicrobial activity. FUS, on the other hand, is a hydrophobic steroidal 4152 
molecule, which carries a net negative charge at physiological pH (7.4). (329, 332) Despite 4153 
this, Helle et al found high retention rates of FUS in vesicles composed of lipids extracted 4154 
from E. coli bacterial membranes. The authors observed a high degree of membrane 4155 
disruption with the addition of FUS in the membrane, and postulate that FUS largely 4156 
remains within the lipid bilayer and interacts with intracellular EF-G at the inner surface of 4157 
the cytoplasmic membrane, rather than the relatively more inefficient method of free 4158 
diffusion into the bacterial cytoplasm itself. (333) The decrease in the magnitude of the 4159 
negative charge as a result of COL resistance may reach a specific level with which 4160 
interaction with FUS is possible (critical threshold), thereby allowing its entry into the lipid 4161 
bilayer, and possibly into the periplasmic space and into the cytoplasmic membrane. It has 4162 
been shown that cationic peptides such as polymyxins lower the surface charge of the 4163 
Gram-negative bacteria on binding, (334) and the role of COL in the case of COL resistant 4164 
organisms could be to interact with the still negatively charged outer membrane and lower 4165 
its charge to the critical threshold needed for FUS to interact with the membrane. 4166 
Moreover, Soon et al noted increased hydrophobicity of the outer membrane with COL 4167 
resistance, theoretically increasing the affinity for hydrophobic molecules like FUS and the 4168 
lipophilic tail of COL. (335) FUS could further disrupt the outer membrane, allowing both 4169 
agents to enter the periplasmic space and eventually diffuse through the cytoplasmic 4170 
membrane to exert their bacterial killing effect.  4171 
There was a degree of strain to strain variability in the antimicrobial activity of the COL-FUS 4172 
combination against Gram-negative bacteria in this study. Whilst COL 2 mg/L and FUS 1 4173 
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mg/L (clinical breakpoint concentrations) were bactericidal against COL susceptible A. 4174 
baumannii strains, higher concentrations of FUS (8-32 mg/L) were required in combination 4175 
with COL 2 mg/L to attain sufficient antimicrobial activity at 24 h. The COL-FUS activity 4176 
against COL-resistant strains tested were rather more diverse in potency, with high COL 4177 
and FUS concentrations beyond achievable serum concentration (COL 256 mg/L and FUS 4178 
64 mg/L) for bacteriostatic effect against intrinsically COL resistant S. marcescens. The 4179 
variability observed in the study may reflect differences in FUS activity once it gets past the 4180 
outer membrane. Indeed, well described multi-drug efflux transporters from the resistance- 4181 
nodulation-division (RND) superfamily such as AcrAB-TolC in E. coli and MexAB-OprM in P. 4182 
aeruginosa are efficient at expulsion of a number of hydrophobic antimicrobials including 4183 
FUS, amongst other substrates. (336) Both AcrAB-TolC and MexAB-OprM respond to 4184 
antimicrobial exposure by overexpression, thereby further increasing the rate of efflux of 4185 
their respective substrates. (337) This is particularly useful to P. aeruginosa, as it possesses 4186 
a comparatively (to most other Gram-negative organisms) impermeable outer membrane, 4187 
with few influx channels, and an active indiscriminate drug efflux system would rapidly 4188 
result in high-level multi-drug resistance, as is the phenotype of many pathogenic P. 4189 
aeruginosa strains encountered in clinical medicine today. (337) AcrAB-TolC RND efflux 4190 
pumps are chromosomally encoded across multiple strains and species of 4191 
Enterobacteiaceae including E. coli (best described here), Enterobacter spp. and K. 4192 
pneumoniae, though strain to strain variation of FUS efflux have been described. (338) 4193 
Additionally, Perez et al described the presence of non-AcrAB fusidic acid efflux in an E. 4194 
cloacae clinical strain, contributing to intrinsic FUS resistance. (339) The major RND efflux 4195 
pump in A. baumannii is AdeABC, while being efficient at expulsion of numerous antibiotics 4196 
including b-lactams, tetracyclines (e.g. tigeyclcine) and aminoglycosides, does not number 4197 
FUS amongst its substrates. AdeIJK, a relatively less efficient RND efflux pump does 4198 
however extrude fusidic acid from the cell, though its overexpression may prove toxic for 4199 
the bacterium. (340) The differences in the efficacies of these efflux mechanisms to FUS 4200 



























The time-kill assays in this study was limited to 7 type strains (E. coli, E. cloacae, E. 
aergoenes, K. pneumoniae, S. marcescens, S. maltophilia, A. baumannii) and 5 additional 
MDR A. baumannii clinical strains. Further time-course assays across more isolates with 
defined mechanisms of resistance, including those with/without knockout mutants of efflux 
pumps and/or known COL resistance genes may be helpful in further delineating the 
potential utility of the COL-FUS combination. 
This study has been conducted using static time-kill assays, and whilst it has provided 
useful information regarding the killing kinetics of COL monotherapy and in combination 
with FUS, the experiments did not reflect in vivo drug concentrations (e.g. variations due to 
elimination profiles) or conditions (e.g. protein binding). Additional investigations by way of 
time-course assays and/or animal models is warranted to further assess the potential 
clinical utility of the combination. 
3.3.6 Conclusions 
The COL-FUS combination continues to demonstrate potency against a range of Gram-
negative bacteria in vitro, in the time-kill experiments. The contrast in its post-antibiotic 
effect as compared with COL alone is marked, and conserved across all species tested. 
COL-FUS combination was demonstrated to be useful against both COL-susceptible and 
COL-restistant MDR and XDR isolates in this study, mirroring the findings from the disc 
diffusion and checkerboard screening assays, showing its potential as a therapeutic 
strategy in Gram-negative infections where treatment options are few or completely absent. 
COL-FUS combination, thus warrants urgent onward assessment to assess its efficacy and 
pharmacokinetics/pharmacodynamics (PKPD) in vivo, as well as investgations into the 
underlying mechanism of action(s). 4226
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3.4 Chapter summary 4227 
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3.4.1 In vitro susceptibility of Acinetobacter baumannii to 4228 
colistin – Comparison of methods against population 4229 
analysis profile 4230 
o In vitro susceptibility of A. baumannii to COL difficult, and has undergone numerous 4231 
methodology guideline changes. Current recommendation by EUCAST and CLSI 4232 
suggest use of broth microtitre dilution method to determine MIC, and hence 4233 
susceptibility. 4234 
o Reports of colistin heteroresistance raised concerns regarding potential therapeutic 4235 
failure in vivo despite apparent COL susceptibility by MIC (current susceptibility 4236 
breakpoint 2 mg/L).  4237 
o PAP is considered the ‘gold standard’ for detection of these heteroresistant strains 4238 
in vitro, although time/labour intensive and expensive to perform. (341, 342) 4239 
o Conventional susceptibility methods (disc diffusion, BMD, agar dilution, Etest, 4240 
automated system), proposed simplified methods for detection of heteroresistance 4241 
(‘macro’ Etest and ‘macro’ disc diffusion) (342) and methods based on time-kill 4242 
assays (determination of MIC and MBC) were compared with a PAP method (PAP- 4243 
AUC) to determine their ability to detect COL resistance (including 4244 
heteroresistance) from 42 isolates with a range of phenotypic and genotypic 4245 
characteristics, including ‘COL susceptible’ type strains (E. coli NCTC 12241, A. 4246 
baumannii NCTC 12156) and known COL heteroresistant type strain (P. aeruginosa 4247 
ATCC 27853).  4248 
o None of the conventional susceptibility methods were able to reliably predict COL 4249 
heteroresistance/resistance, test sensitivity <50% in all cases. Macro Etest 4250 
sensitivity was approximately 30%, and only the time-kill methods that equated 4251 
bactericidal activity at COL 2 mg/L with susceptibility were useful at detecting 4252 
resistance (sensitivity >90%).  4253 
o Categorical agreement was poor with broth microtitre dilution (21%), with very 4254 
major error rate of 87%. This is of particular concern, as it is the recommended 4255 
susceptibility test method for COL, and could lead to therapeutic failure on a wide 4256 






o A modified time-kill method for predicting COL resistance, including 4262 
heteroresistance might be useful in the clinical diagnostic laboratory as a surrogate 4263 
for MBC, MTKC – where bactericidal activity (> 3 log10 cfu/mL decrease compared 4264 
with 0 h) at 24 h with COL 2 mg/L is taken to be susceptible, and the rest predict 4265 
resistance. In this study, the very major error rate was 8% for this method, far 4266 
better than any other method compared (TKMIC 40%, conventional methods 42- 4267 
87%) with population analysis profile. 4268 
o A 2-step algorithm using Etest or agar dilution (2 breakpoint plates containing COL 4269 
0.25 mg/L and 0.5 mg/L), followed by broth microtitre dilution could be used to 4270 
screen for heteroresistance. The screening cut-offs used are proposed to be as 4271 
follows – ≤ 0.25 mg/L for susceptibility to COL, and > 0.25 mg/L for resistance. 4272 
Percentage error rates were reduced using the 2-step method are far lower 4273 
compared to any conventional method on its own – 7% (Etest à BMD), and 5% 4274 
(agar dilution à BMD).  4275 
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3.4.2 Screening colistin combinations in vitro 4276 
o Simple 3-step process for screening COL combinations in a high throughput 4277 
fashion, with subsequent confirmatory assays to identify novel and potent COL 4278 
combinations against Gram-negative bacteria. 4279 
 4280 
o Disc diffusion – multiple COL pairs screened against a well characterised strain 4281 
collection including MDR Gram-negative pathogens and type strains. 4282 
o Checkerboard assays – COL combinations displaying best in vitro synergy from the 4283 
disc diffusion screen are further assessed in microtitre checkerboard assays to 4284 
confirm their activity, using fractional inhibitory concentration (FICI) and 4285 
susceptibility breakpoint concentration (SBPI) indices. 4286 
o Time-kill assays – Most potent synergy (with demonstrable potential clinical utility, 4287 
SBPI >2) are investigated via time-kill assays for their antimicrobial activity over 4288 
time, as COL is known to have little to no post-antibiotic effect, allowing the growth 4289 
of heteroresistant subpopulations, ultimately resulting in potential therapeutic 4290 
failure.  4291 
o Novel COL combinations identified – COL-CHL, COL-FUS, COL-daptomycin (the 4292 
last of which was specifically assayed by a different Etest method due to lack of 4293 
commercial availability of compound or antimicrobial discs at the time of study).  4294 
o Col-FUS demonstrated most potent synergy (FICI ≤0.5) in checkerboard assays 4295 
across the majority of Gram-negative species tested (50-100% of isolates within 4296 
each species-specific class were synergistic), with the exception of P. aeruginosa 4297 
and P. mirabilis. COL-FUS was synergistic against carbapenemase-producing 4298 
organisms (60% NDM, 35% KPC, 60% OXA-48, 100% OXA-23), and COL-resistant 4299 
phenotypes (synergy demonstrated against 2 pmrB mutants, and 6 mcr-1 4300 
producing organisms).  4301 
o COL-CHL was less active, with synergy noted in 37% of A. baumannii, 50% P. 4302 
aeruginosa and 28% K. pneumoniae strains tested. Additionally, synergy was 4303 
observed against 14% of KPC strains tested, and against a single P. aeruginosa 4304 
isolate carrying blaVIM-2.  4305 
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o The addition of sub-inhibitory concentration of COL reduced its daptomycin MIC by 4306 
≥4 fold against all COL-susceptible A. baumannii tested. No activity was observed 4307 
against other Gram-negative species.  4308 
o The theory that polymyxins act as a permeabiliser of the Gram-negative outer 4309 
membrane was tested in a permeability assay, using PBNP (cationic cyclic peptide 4310 
lacking the fatty acyl tail of polymyxin B, and hence antimicrobial activity) as a cell 4311 
permeabiliser and fusidic acid as the representative hydrophobic antibiotic normally 4312 
excluded by the negatively charged Gram-negative outer membrane. A decrease in 4313 
FUS MIC ≥4 fold was seen against 26 of the 35 isolates tested (21 were susceptible 4314 
to polymyxin B ≤ 2 mg/L, the rest were resistant), demonstrating the influx of FUS 4315 
into the cell due to permeabilising action of PBNP.  4316 
o A novel assay investigating the mutational frequencies of A. baumannii strains 4317 
exposed to COL-FUS singly and in combination was developed in this study. 4 A. 4318 
baumannii strains (1 type strain, 3 MDR clinical strains including an XDR COL- 4319 
resistant strain) tested showed higher MICs to COL and FUS when exposed to their 4320 
single agent components (≥ 4 fold difference in day 7 MIC) compared with 4321 
combination exposure. The novel COL-FUS combination may provide a new 4322 
strategy against MDR Gram-negative infections, which not only acts synergistically 4323 
against the pathogen as a potent therapeutic option, may additionally slow or halt 4324 
the development of resistance due to antibiotic selection pressure. 4325 
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3.4.3 In vitro confirmation of the activity of colistin and 4326






















o Addition of FUS (2-32 mg/L) to 2 mg/L of COL resulted in better antimicrobial 
activity than COL alone at 24 h against 5 type strains (E. coli NCTC 12241, E. 
aerogenes NCTC 9735, E. cloacae NCTC 10005, S. maltophilia NCTC 10258, and
K. pneumoniae NCTC 9633). COL 0.5 mg/L and FUS 1 mg/L combination 
demonstrated bactericidal synergy against A. baumannii type strain (NCTC 12156). 
Addition of FUS 64 mg/L to COL (256 – 512 mg/L) against intrinsically COL 
resistant S. marcescens type strain (NCTC 13382) was bacteriostatic at 24 h.
o Potent bactericidal synergy was seen against 5 additional MDR A. baumannii 
clinical strains, with all strains displaying synergy at or below clinically attainable 
serum concentrations of COL (0.5 – 2 mg/L) and FUS (1 mg/L for all strains except 
COL resistant strain requiring 8 mg/L).
o COL alone at MIC or susceptibility breakpoint concentration was either inactive or 
displayed only early killing effect (2 – 4 h) against the strains tested, suggesting little 
post-antibiotic effect. This finding is consistent with others reported in literature, 
and likely to be due to COL heteroresistance.
o Activity of COL-FUS combination against COL-resistant isolates may be due to 
increased hydrophobicity and decrease in negative charge of the outer membrane 
as a result of alterations to the LPS component, reversing the fortunes of 
hydrophobic FUS, which would be otherwise be excluded by the highly negatively 
charged outer membrane (in COL susceptible isolates). This might also suggest a 
different mechanism of action for COL-FUS against COL-resistant isolates 
compared to COL-susceptible organisms. 
4349
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4 In vivo activity of colistin and 4350 
fusidic acid combination therapy 4351 
against A. baumannii infections 4352 
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4.1 Introduction 4353 
4.1.1 Background -  Animal models in the development of 4354 
antimicrobial therapy 4355 
Animal studies are an integral part of antibiotic development, enabling host response to 4356 
candidate compounds at specific sites of infection and pharmacometric parameters, prior 4357 
to human trials. Although appreciable differences exist between animal models and 4358 
humans (e.g. PK of drugs, immunological responses, virulence and pathogenicity of 4359 
specific organism, toxicity of drugs), the importance of pre-clinical testing of antibacterials 4360 
cannot be understated. Animal models are vital in the study of the efficacy and safety 4361 
profile of new compounds in a living organism, often providing the first crucial PKPD 4362 
profiles, aiding the translation of promising compounds (from in vitro experiments) into 4363 
clinically useful antimicrobials. (343, 344) In fact, assessment in animal models following 4364 
successful demonstration of antimicrobial activity in vitro became an essential next step in 4365 
developing new antimicrobial compounds prior to clinical trials. (345, 346) In general, 4366 
testing of new antibacterial compounds or combination therapies in animal models can be 4367 
divided into the intended study endpoints or outcomes. Screening models investigate 4368 
mortality as a definitive study endpoint usually with a short study time-frame, 4369 
monoparametric (only one outcome studied) and discriminative (complex models 4370 
incorporating multiple outcomes and measures usually reserved for more advanced phases 4371 
of animal trials, with ideal models most closely mimicking human-microbe-antimicrobial 4372 
interactions) models on the other hand are reserved for assessing other outcomes (most 4373 
often nonfatal) including PK, decrease in bacterial load and toxicity studies. (344, 347) 4374 
Screening models are often used as the first in vivo study of a new anti-infective, with the 4375 
primary objective of translating an in vitro antimicrobial effect into in vivo therapeutic cure. 4376 
The criteria for selection of a good screening model were described by O’Grady (348): 4377 
1) Efficient and effective delivery of pathogen in a suitably high inoculum to induce 4378 
disease/death within a short time-frame 4379 
2) Ease of delivery of antimicrobial therapy, with high repeatability and reproducibility 4380 
to site of infection 4381 
3)  An outcome measure that can be easily assessed and reproduced 4382 
A good screening model for anti-infective agents has long been typified by the septicaemia 4383 
mouse model, whereby susceptible mice (oftentimes immunosuppressed) are given large 4384 
inocula of the pathogen of interest intravenously/intraperitoneally, and then given the 4385 
antimicrobial therapy (treatment regimen) soon after, or just prior to infection (prophylactic 4386 
regimen). Survival analyses are then studied to assess the in vivo efficacy of the regimen. 4387 
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There have been numerous criticisms of these screening models, in particular, due to the 4388 
artifice of the infection (as opposed to infection occurring spontaneously in nature) and 4389 
oftentimes in very high inocula, do not provide accurate correlation with human clinical 4390 
infection. (344, 347) This is especially critical, as rising awareness regarding the use of 4391 
animal models in healthcare research has led to a radical shift in the way it is conducted. 4392 
The core tenets of the 3Rs (replacement, reduction and refinement) are now firmly 4393 
embedded in healthcare research. Briefly, this is a guiding principle to replace animal 4394 
models for viable alternatives (e.g. tissue cell cultures, mathematical modelling) where 4395 
possible (where animals are replaced with alternatives not presently considered to 4396 
experience suffering, is known as ‘partial replacement), reduce the number of animals used 4397 
in animal trials by priori accurate sample size calculation for the effect being studied, and 4398 
refinement is the practice of optimising the trial process to minimise harm and suffering the 4399 
animals may experience. (349, 350)  4400 
As a result, antimicrobial research has made great strides in recent years to follow the 4401 
guidance set out in the 3Rs. The replacement of higher mammalian models during the initial 4402 
screening phase in animal studies has received much attention. With the rise of 4403 
antimicrobial resistance, and calls to revitalise the antimicrobial development pipeline with 4404 
viable novel therapeutic options, there has been much scrutiny on the testing process. The 4405 
use of invertebrate models for initial phase in vivo testing of antimicrobial agents has been 4406 
seen to fulfil the core tenets of 3Rs, as well as aid in the process of translation of novel 4407 
antimicrobial therapies to clinical practice. Indeed, the National Centre for Replacement, 4408 
Reduction and Refinement (NC3Rs) has been funding research utilising these models in 4409 
recent years. One such model uses the larvae of the greater wax moth, Galleria mellonella. 4410 
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4.1.2 Galleria mellonella as a model for assessing the 4411 
activity of antimicrobial therapy 4412 
G. mellonella are insects belonging to the order Lepidoptera and family Pyralidae. They are 4413 
found naturally in climates that support bee populations, and feed on beeswax and pollen. 4414 
As such, they are considered pests to honeybees. (351) They are however, reared as pet 4415 
food for reptiles and fishing bait, due to the relative ease of breeding and caring for the 4416 
larvae. The final instar (larval stage prior to pupation) is approximately 2 cm in length and 4417 
200-300 mg in weight, (351) making it ideal for direct inoculation of its haemolymph (by 4418 
injecting the pathogen of interest through one of its prolegs). (352) Like other more 4419 
established insect larvae in medical research (e.g. Drosophila melanogaster), G. mellonella 4420 
larvae possess innate immunity capable of reacting to infection. (353) The haemolymph 4421 
comprises 4 cell types, namely the plasmatocyte, granulocyte, oenocytoids and 4422 
spherulocyte. Plasmatocytes and granulocytes form part of their cellular immune system, 4423 
undertaking the crucial roles of phagocytosis, encapsulation and nodulation. (352-354) This 4424 
is similar in function to that of higher mammalian models. Together with melanisation, the 4425 
larval coagulation cascade which promotes wound healing, pathogens are trapped in 4426 
capsules, effectively neutralising them. (352, 354) Oenocytoids produce prophenoloxidase, 4427 
an enzyme released in response to insult, including infection. Intermediaries 4428 
(dihydrophenylalanine, quinons and free radicals) produced within the phenoloxidase 4429 
cascade are not only toxic to foreign bodies such as pathogens, they likewise harmful 4430 
towards the larval cells. (352, 354) They are therefore closely regulated by serpins. Melanin 4431 
is a product of the phenoloxidase cascade, and central to melanisation. Melanin also helps 4432 
recruit antimicrobial molecules. Some stimulate the activity of phenoloxdiase (positive 4433 
feedback, e.g. apolipophorin III) whilst others create a negative feedback loop on 4434 
phenoloxidase activity (e.g. lysozyme). (352, 354) The larvae are also found to possess 4435 
other immune-related proteins and peptides including antimicrobial peptides, protease 4436 
inhibitors, insect metalloproteinase inhibitor, pattern recognition proteins and Gram- 4437 
negative binding proteins, to name a few. These molecules form part of the G. mellonella 4438 
humoral immune system, and work together with the cellular immune system to combat 4439 
infection. (354) 4440 
The immune system of the G. mellonella larvae mirror those of higher mammalian models in 4441 
acute infection, thus making G. mellonella an attractive candidate as a surrogate during the 4442 
early phase of translational research. (352) Moreover, the larvae are easy to obtain and 4443 
breed, several orders of magnitude cheaper than higher mammalian models (e.g. mice), 4444 
easy to handle and maintain, require relatively little space and housing either prior or during 4445 
the experimental phase, of the appropriate size and weight (compared with some other 4446 
smaller invertebrate models for example the smaller nematode Caenorhabditis elegans or 4447 
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fruit fly D. melanogaster, where direct injection is either impossible (C. elegans) or 4448 
technically difficult and requiring specialist equipment (D. melanogaster) (353)) to allow 4449 
efficient and accurate delivery of pathogen and antimicrobial, ability to maintain the larvae 4450 
at 37°C during the experiment and larval death is clearly and easily observed. (352, 355) 4451 
These attributes adhere to the core principles of optimal selection of an appropriate animal 4452 
screening model, whilst fulfilling the spirit of the 3Rs. Indeed, the rise in the use of G. 4453 
mellonella in antimicrobial research, providing more robust information prior to either more 4454 
complex animal models or clinical trials, allows for better refinement of the antimicrobial 4455 
development process, in turn bettering our efforts in our fight against AMR. G. mellonella 4456 
assays have been particularly well developed for the study of Gram-negative bacteria. A. 4457 
baumannii has been successfully assessed in both G. mellonella virulence and treatment 4458 
assays, and their results have been shown to correlate with those of higher mammalian 4459 
models. (356, 357)  4460 
4.1.3 Objectives 4461 
The G. mellonella model was used as a simple preliminary study of assessing the in vivo 4462 
viability of novel COL combination therapies against MDR A. baumannii infections. The 4463 
model was tested in 3 stages: 4464 
1) Inoculum test – where the optimal infective bacterial inoculum was identified for 4465 
each strain prior to each experiment. 4466 
2) Toxicity study – the candidate antimicrobial agents were given in increasing 4467 
concentrations to uninfected larvae to determine the safety/toxicity of the agents 4468 
tested. 4469 
3) Treatment assay – finally, the therapeutic efficacy of the candidate combination is 4470 
assessed, using larval survival as the primary outcome measure. 4471 
Additionally, a small pilot study was conducted to investigate the efficacy of the COL-FUS 4472 
combination compared to COL monotherapy in a murine lung infection model using one of 4473 




4.2 Methods 4477 
4.2.1 Galleria mellonella in vivo experiments 4478 
4.2.1.1 Strain preparation 4479 
All isolates (see Table 4-1 for details of the individual strains included) were stored on 4480 
Microbank™ beads (Pro-Lab Diagnostics, Merseyside, UK) at -70°C, and subcultured onto 4481 
unsupplemented ISA plates prior to each experiment. NCTC 12156 (also known as 4482 
American Type Culture Collection, ATCC 19606) pmrB gene knockout mutant (358) was 4483 
kindly donated by Alejandro Beceiro (A Coruña, Spain).  4484 
Luria-Bertani broth base (10 g/l tryptone, 10 g/l NaCl, 5 g/l yeast extract), obtained from 4485 
Sigma-Aldrich (Dorset, UK), was used to make up sterile LB broth according to 4486 
manufacturer’s instructions as follows – 25 g of the base was suspended in 1 L of distilled 4487 
water, and sterilised in a steam autoclave at 121°C for 15 min. The sterilised LB broth was 4488 
allowed to cool to room temperature prior to use. 4489 
3-5 colonies were selected at random for inoculation of 10 mL aliquots of sterile LB broth. 4490 
The cultures were then incubated aerobically at 37°C with shaking (224 rpm) for 18-24 h. 4491 
Overnight broth cultures were prepared for each experiment, and kept at 4°C until use. 4492 
Overnight broth cultures were stored at 4°C for a maximum of 24 h, and discarded 4493 
thereafter. 4494 
Table 4-1 A. baumannii strains used in the G. mellonella assays. 4495 
MICs determined by BMD in ISB. OM – osteomyelitis; ICC – international clonal complex. 4496 
(356) 4497 
Isolate Characteristics COL MIC (mg/L) FUS MIC (mg/L) 
NCTC 12156 Type strain 0.25 128 
AB12 SE clone 0.5 64 
AB14 OXA-23 UK clone 1 0.25 32 
AB16 OXA-23 UK clone 2 0.5 > 256 
AB5075 ICC 1, hypervirulent OM strain 0.125 32 
NCTC 12156 ΔpmrB pmrB mutant of type strain > 256 8 
AB205 OXA-23 UK clone 1 256 16 
 4498 
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4.2.1.2 Antimicrobial agent preparation 4499 
Stock solutions of antimicrobials were prepared as described in Sections 3.1.2.2 and 4500 
3.2.2.2. The injections were then made up to final required concentrations using sterile PBS 4501 
as a diluent. 4502 
4.2.1.3 Animal preparation – G. mellonella model 4503 
Galleria mellonella larvae were procured from Livefoods (http://www.livefoods.co.uk, 4504 
Somerset, UK) and kept at 15°C on dry wood shavings for a maximum of 7 days before 4505 
using in experiments (see Figure 4-1). Larvae weighing 250 ± 25 mg, in their final instar of 4506 
development, were used for G. mellonella assays.  4507 
Figure 4-1 G. mellonella larvae on wood shavings (left), 25 µL Hamilton™ syringe used for 4508 
injections (right). 4509 
 
 
4.2.1.4 Inoculum preparation 4510 
1 mL aliquots were removed from the prepared LB broth cultures and washed twice in 4511 
sterile PBS prior to injection. Washing was achieved by centrifugation at 6,500 rpm for 10 4512 
min (Biofuge Pico, Heraeus Instruments, DJB Labcare Limited, Buckinghamshire, UK), 4513 
discarding the supernatant and resuspending the pellet in sterile phosphate-buffered saline 4514 
to make up a final volume of 1 mL. Prepared inocula were either used neat or diluted in 4515 
sterile PBS prior to injections. G. mellonella were injected within an hour of inocula 4516 
preparation.  4517 
4.2.1.5 Dose selection 4518 
Doses used in G. mellonella treatment assays were based on human intravenous dosing 4519 
regimens. 4520 
COL is given as a pro-drug, CMS, in humans. In the UK, the British National Formulary 4521 
(BNFC 2016-2017; https://www.bnf.org/) recommends a maximum dose of 75,000 4522 
units/kg/day of CMS for children up to 60kg in weight. This equates to approximately    4523 
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2.25 mg/kg/day of CBA (based on 30 mg CBA for every 1 mu of CMS). (134) Contemporary 4524 
PK studies in humans have argued for a change in the current COL dosing guidelines to 4525 
maximise efficacy of the drug, as the prevailing recommended doses lead to under dosing 4526 
and therapeutic failure. Concerns regarding nephrotoxicity, however, limits the maximum 4527 
recommended dose to 5 mg/kg/day. (134) COL comprises several polypeptides, with 4528 
colistin A and B described as the predominant forms. (140) COL solution in sterile PBS (for 4529 
larval treatment) was analysed by LC-MS/MS (Analytical chemistry department, 4530 
GlaxoSmithKline, Stevenage, UK) and found to contain approximately 90% of colistin A and 4531 
B (34% and 55% respectively). Doses of COL (using colistin sulfate solutions as prepared 4532 
in Section 4.2.1.2) given in treatment assays therefore equate to 2.5 mg/kg (‘usual dose’) or 4533 
5 mg/kg (‘maximum dose’) as a single bolus injection. 4534 
FUS is given orally in the UK (either as fusidic acid or sodium fusidate), with the injectable 4535 
form withdrawn from use since 2012. Package insert of the commercially available (in 4536 
countries outside of the UK including Australia and USA) product, Fucidin® (Leo Pharma, 4537 
Berkshire, UK; 4538 
http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1487918907487.pdf) 4539 
suggest an intravenous dose of 20 mg/kg/day. Oral suspension doses for children range 4540 
from 45 mg/kg/day (BNFC 2016-2017) to 20-50 mg/kg/day (Fucidin® Oral suspension 4541 
SPC, Leo Pharma; http://www.medicines.ie/medicine/5743/SPC/Fucidin+Suspension/). The 4542 
doses used in the treatment assays equate to 20 mg/kg (or less) as a single bolus injection.  4543 
4.2.1.6 Experimental set-up 4544 
4.2.1.6.1 Equipment and injection procedure 4545 
22s gauge 25 µL Hamilton™ syringes (1702N, Fisher Scientific, Loughborough, UK) were 4546 
used to inject the G. mellonella larvae (see Figure 4-1). Syringes were sterilised with 70% 4547 
ethanol between injections. 4548 
An ‘injection table’ was constructed using a 90 mm petri dish and a 1000 µL pipette tip to 4549 
facilitate the injection procedure. See  4550 
Figure 4-2 for details. (Please find included in Appendix C, a video of the injection 4551 
procedure and a simulation of the speed of distribution throughout the larvae of either 4552 
bacterial inoculum or treatment using green food dye.) 4553 
4.2.1.6.2 Inoculum test 4554 
An inoculum test was conducted prior to every G. mellonella experiment. Bacterial 4555 
suspensions obtained in Section 4.2.1.4 were adjusted with sterile PBS to obtain final 4556 
inocula in 10-fold dilutions ranging 102 – 107 cfu/mL. 150 µL aliquots of each dilution was 4557 
transferred to a sterile 96-well microtitre plate to obtain relevant optical density at 600nm 4558 
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(OD600), using a BioTek™ ELx800™ Absorbance Microplate Reader. Bacterial colony 4559 
counts were determined for each inoculum by plating 100 µL aliquots (with dilution in PBS, 4560 
where appropriate) onto unsupplemented ISA and incubating in air at 37°C for 18 h. 10 4561 
larvae were injected per inocula, each with 10 µL of the prepared suspension into the first 4562 
left proleg. Additionally, 10 larvae were injected with 10 µL sterile phosphate-buffered 4563 
saline (control) for each isolate tested. Each 10 larvae group were housed in a 90 mm triple- 4564 
vented petri dish (Sterilin™, Thermo Fisher Scientific, Waltham, MA, USA) on Whatman™ 4565 
Grade 2 filter paper, and incubated aerobically in the dark at 37°C for a maximum of 96 h. 4566 
Survival data was recorded at 24 h intervals for each condition. Absence of response within 4567 
2-3 min to touch stimulus (using a sterile 1000 µL pipette tip) was taken to represent larval 4568 
death.  4569 
Figure 4-2 Procedure for injecting G. mellonella. 4570 
(a) Underside of G. mellonella larva, depicting 4 pairs of prolegs. Haemocoel injections are 4571 
performed through the 1st pair (closest to the larval head). (b) Haemocoel injection through 4572 
the first right proleg, on an injection table, with a 25 µL Hamilton™ syringe. (c) Close up of 4573 








Appropriate inocula for the treatment assays were defined as the bacterial inoculum 4576 
(cfu/larva) required to result in 75% larval death (LD75) at 24 h. Separately, the inoculum at 4577 
which 50% death occurred (LD50) for each strain was determined, for comparison of relative 4578 
virulence. The inocula were first log-transformed (base 10), and x-y “dose-response” curves 4579 
were plotted to examine the nature of the relationship. Probit regression analysis 4580 
(transforms sigmoidal dose-response relationships with binomial responses into linear 4581 
plots, on which the best fit linear association and thus predictions of dose-related 4582 
responses are made) was performed in Stata. LD75 values were interpolated for each isolate 4583 
for each experimental run, and LD50 values determined for each strain across all 4584 
experiments. One-way ANOVA analysis was performed to determine if the mean LD50 4585 
values from the different organisms were equal (i.e. null hypothesis). Additionally, 4586 
differences between the overall LD50 (summated over all experiments performed) were 4587 
assessed using unpaired t test analysis in Stata.  4588 
4.2.1.6.3 Toxicity assay 4589 
Toxicity assays were conducted to ensure antimicrobial compounds used did not result in 4590 
excess mortality.  4591 
5 larvae were used for each concentration of COL and FUS tested. Concentrations tested 4592 
were as follows – COL 1.25 – 1000 mg/kg and FUS 16.7 – 2000 mg/kg. The weight of each 4593 
larva was taken to be 250 mg for the purposes of drug dosing calculations. A drug-free 4594 
(PBS only) control was included for each compound tested. 10 µL of the prepared solutions 4595 
were delivered as a bolus injection into the first right proleg of each larva. The larvae were 4596 
incubated under similar conditions to those described for the inoculum test (Section 4597 
4.2.1.6.2), and incubated for a total of 72 h. Pooled larval survival was plotted against time. 4598 
4.2.1.6.4 Treatment assay 4599 
The inoculum used for infecting the larvae was determined by a prior inoculum test (Section 4600 
4.2.1.4). A similar dilution step with sterile PBS was performed to prepare the inoculum 4601 
used for the treatment assay. Bacterial colony counts were performed (as per Section 4602 
4.2.1.6.2) to determine the exact inoculum used to infect the larvae in the treatment assays.  4603 
10 µL of the prepared inoculum was injected into the first left proleg of each larva. 4604 
Treatment with either 10 µL of control (sterile PBS) or antimicrobial solution (in PBS) was 4605 
then injected into the first right proleg of the larva within 15 – 30 min of infection. Separate 4606 
syringes were used for injecting the inoculum and delivering the antimicrobials. The larvae 4607 
were then housed and incubated under conditions described for inoculum tests (Section 4608 
4.2.1.6.2). A minimum of 3 experiments performed on separate occasions was conducted, 4609 
and pooled larva survival was determined for each treatment arm every 24 h for a maximum 4610 
of 168 h. 4611 
250 
4.2.1.7 Data analysis of G. mellonella treatment assays 4612
4.2.1.7.1 Overall pooled survival data analysis 4613
Pooled survival data was analysed by plotting Kaplan-Meier curves, and estimating hazard 4614
ratios with Cox regression analyses in Stata (StataCorp. 2011. Stata Statistical Software: 4615
Release 12. College Station, TX: StataCorp LP). Hazard ratio (HR) with p values (two-tailed) 4616
of < 0.05 were considered significant. Comparators included larvae treated with PBS 4617
(placebo control), or either of the single agents. Tests of proportionality were performed 4618
prior to Cox regression to satisfy the main assumption (i.e. proportionality) of the model.  4619
4.2.1.7.2 Relative risk reduction (by time-point) 4620
Additionally, relative risk (of mortality) reduction (RRR) was determined for each time-point 4621
to investigate any time-dependent differences in mortality between the combination therapy 4622
arm and comparators. Relative risk reduction and corresponding 95% confidence intervals 4623



































4.2.2 Mouse lung infection model – pilot study 
A small pilot study was performed in a murine lung model to assess the comparability of 
the G. mellonella data. This pilot study was performed by Daniel V. Zurawski and Crystal L. 
Jones (Walter Reed Army Institute of Research, Maryland, USA). Animal experimental 
procedures were approved by the Institutional Animal Care and Use Committee at the 
Walter Reed Army Institute of Research, and conducted in accordance to the guidelines set 
out by the National Research Council. (359) 
4.2.2.1 Animal preparation 
12 6-week old BALB/c mice (National Cancer Institute, Fredrick, Maryland) were each given 
2 intraperitoneal doses of cyclophosphamide (150 mg/kg 4 days prior to infection, and 100 
mg/kg 1 day prior to infection) to induce neutropenia.  
BALB/c mice are a successively inbred lineage used widely in infectious diseases and 
toxicology research due to its susceptibility to infections, able to mimic the systemic 
responses to infections (e.g. septicaemia, pneumonia (360-362)) in humans. (363) 
Cyclophosphamide temporarily suppresses the host immune responses in the BALB/c 
mice, allowing A. baumannii infection to develop in the lungs. (364)  
4.2.2.2 Strain selection 
AB5075, a known pathogenic strain in both G. mellonella and in a murine lung model 
previously described by Jacobs et al (356). In a comparative study of A. baumannii 
virulence, infection with AB5075 in the murine pulmonary model resulted in a 70% mortality 
rate by day 2 post-infection. The 6-day survival was 25%. (356) 
4.2.2.3 Experimental set-up 
AB5075 was cultured in LB broth (see Section 4.2.1.1 – strain preparation for G. mellonella 
model), and subsequently washed and resuspended in PBS, in preparation for inoculation. 
COL and FUS were prepared as per Section 4.2.1.2.  
The mice were first anaesthetised with oxygenated isoflurane, then infected with 5 x 106 cfu 
of AB5075 (in 25 µL bolus) intranasally. (356, 365) They were then randomly allocated into 4 
treatment groups (3 mice each) – COL 5 mg/kg/day, COL 5 mg/kg/day + FUS 50 
mg/kg/day, FUS 50 mg/kg/day or COL 2.5 mg/kg/day + FUS 50 mg/kg/day. Antimicrobial 
therapy was given intraperitoneally in 2 divided doses for 3 days (first dose delivered 4 h 
post infection to allow for establishment of pulmonary infection).  
The mice were assessed once a day and followed up for a period of 7 days post-infection. 
Moribund animals were humanely euthanised. Study outcomes included survival and 
weight changes (as compared with weight at the start of the study) on treatment days and 4658
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day 6 post-infection. Severity of infection with increased bacterial load has been associated 4659 
with greater weight loss, and consequently weight gain associated with better response to 4660 
antimicrobial treatment. (366, 367) 4661 
4.2.2.4 Data analysis 4662 
Pooled survival analysis was done by plotting Kaplan-Meier curves, and comparisons of 4663 
hazard ratios were done by Cox regression analysis in Stata. Relative risk reduction in 4664 
mortality were determined in Stata as described in Section 4.2.1.7.2. 4665 
 4666 
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4.3 Results 4667 
4.3.1 Comparative virulence of A. baumannii at 24 h in G. 4668 
mellonella  4669 
The 50% lethal doses (LD50) at 24 h of 7 strains were compared with each other. See Figure 4670 
4-3 and Table 4-2 for the means and 95% confidence intervals for each isolate. The 4671 
differences observed between the LD50 of the various strains was statistically significant (p 4672 
< 0.0001), and pairwise comparisons of their means were similarly significantly different (p < 4673 
0.05). Of note, the LD50 for the pmrB mutant of the NCTC 12156 type strain (resulting in 4674 
COL-resistance with BMD MIC > 256 mg/L) was lower than the LD50 for wild-type NCTC 4675 
12156, suggesting that virulence was not only not attenuated with the development of 4676 
COL-resistance, it may be increased in the G. mellonella model (p < 0.0001). Despite this, 4677 
the LD50 for the clinical COL-resistant strain, AB205, was the highest amongst all tested 4678 
isolates, which may be the result of other factors mitigating its biological fitness or perhaps 4679 
suggesting that biological costs of COL-resistance may be dependent on the specific 4680 
underlying mechanism involved. 4681 
The most virulent strain, with the lowest LD50, was AB5075, which is a hypervirulent strain 4682 
specifically adapted for studying A. baumannii infection in G. mellonella and a murine 4683 
pulmonary model, as described by Jacobs et al. (356) 4684 
Figure 4-3 Comparative LD50 at 24 h post-inoculation of A. baumannii infected G. mellonella 4685 
larvae. 4686 




























Table 4-2 Characteristics and LD50 at 24 h post-inoculation of the A. baumannii strains 4689 
tested in G. mellonella, in cfu/larva. 4690 
Isolate Characteristics Mean 95% confidence interval 
NCTC 12156 Type strain 4.97E+05 2.26E+05 1.09E+06 
AB12 SE clone 6.98E+04 3.47E+04 1.40E+05 
AB14 OXA-23 UK clone 1 4.94E+04 2.14E+04 1.14E+05 
AB16 OXA-23 UK clone 2 1.20E+06 4.82E+05 3.00E+06 
AB5075 ICC 1, hypervirulent OM strain 1.29E+04 3.41E+03 4.89E+04 
NCTC 12156 ΔpmrB pmrB mutant of type strain 1.81E+05 1.24E+05 2.65E+05 




4.3.2 Toxicity of colistin and fusidic acid in G. mellonella 4693 
All G. mellonella larvae given COL doses of 1.25 – 100 mg/kg and FUS doses of 1.5 – 200 4694 
mg/kg (including doses used in the treatment assays, reflecting achievable serum levels of 4695 
both drugs in humans) survived to the end of the experiment (72 h post-inoculation). Larval 4696 
death was observed at higher doses of both agents, with 20% death at 24 h in larvae given 4697 
200 mg/kg of COL, 60% death at 24 h in those given 100 mg/kg of FUS, and 100% death 4698 
at 24 h for those given either 1000 mg/kg of COL or 2000 mg/kg of FUS. Interestingly, 4699 
significant mortality associated with toxicity due to high doses of either agent occurred 4700 
within the first 24 h, perhaps suggesting an acute response mounted by the larvae, either 4701 
resulting in rapid successful limitation or containment of the insult or failure and hence 4702 
death. The effects of toxicity did not appear to extend beyond the initial 24 h period in this 4703 
study. See Figure 4-4 and Figure 4-5 for summary plots of COL and FUS G. mellonella 4704 
toxicity assays.  4705 
Figure 4-4 Colistin toxicity assay in G. mellonella - Pooled larval survival plot. 4706 
Colistin doses in mg/kg. PBS – negative control.  4707 




























Figure 4-5 Fusidic acid toxicity assay in G. mellonella - Pooled larval survival plot. 4710 
Fusidic acid doses in mg/kg. PBS – negative control.  4711 



























4.3.3 Colistin-fusidic acid therapy for systemic A. baumannii 4714 
infection in G. mellonella – Survival data 4715 
4.3.3.1 G. mellonella treatment assays – Overall pooled larval survival 4716 
analysis 4717 
From the Kaplan-Meier survival curves (Figure 4-6), pooled larval survival appeared to 4718 
favour COL-FUS combination therapy compared with either placebo (PBS) or monotherapy 4719 
(COL or FUS) against all 7 strains tested. Cox regression analyses revealed significantly (p 4720 
< 0.05) greater reduction of mortality with COL-FUS combination therapy compared with 4721 
placebo against A. baumannii infection by all experimental strains. In contrast, COL 4722 
monotherapy was only better than placebo when treating larvae infected with NCTC 12156 4723 
(type strain) and AB5075 (hazard ratios were 0.5 and 0.34 respectively). Unsurprisingly, FUS 4724 
monotherapy did not improve survival (p > 0.05), with hazard ratios ranging 0.65 – 1.329 4725 
(compared with placebo). See Figure 4-7 for comparative hazard ratios (HR) and their 4726 
relevant p-values and 95% confidence intervals per isolate.  4727 
When compared with COL monotherapy, COL-FUS combination significantly increased 4728 
survival, with a minimum of 50% reduction in mortality (p < 0.01).  4729 
Likewise, significantly lower larval mortality (p ≤ 0.05) was observed in the combination 4730 
therapy groups compared with FUS monotherapy.  4731 
Figure 4-6 Kaplan-Meier survival curves of A. baumannii infected G. mellonella treated with 4732 
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Figure 4-7 Forest plots depicting mortality hazard ratios of the various treatment arms in A. baumannii infected G. mellonella larvae. 4742
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(b) Colistin-fusidic acid combination therapy versus colistin monotherapy 4745 
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 4747 
(c) Colistin-fusidic acid combination therapy versus fusidic acid monotherapy (colistin-resistant strains only) 4748 
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4.3.3.2 G. mellonella treatment assays – Comparative relative risk 4750 
reduction in mortality at individual time-points 4751 
In general, the RRR in mortality with COL-FUS combination therapy (compared with either 4752 
placebo or monotherapy) was greatest in the first 48 h. This effect then slowed and 4753 
plateaued in most cases towards the end of the experiment. This would suggest that the 4754 
protective effect of the combination does not extend beyond this period. The exceptions 4755 
were observed with wild-type type strain, NCTC 12156, where there was a linear decline in 4756 
RRR rate from 48 h onwards with COL-FUS combination, compared with placebo; and with 4757 
COL-resistant clinical strain, AB205, where RRR remained constant throughout the 4758 
experiment (up to 168 h post-infection). See details of the RRR in mortality for G. mellonella 4759 
larvae infected with each of the 7 strains in Figure 4-8. 4760 
All RRR in mortality were statistically significant, with two-tailed p values < 0.05, with the 4761 
following exceptions – NCTC 12156 (COL vs PBS, 168 h, p = 0.11), AB12 (COL vs PBS, all 4762 
time-points, p > 0.7), AB14 (COL vs PBS, all time-points, p > 0.3), AB16 (COL vs PBS, all 4763 
time-points, p > 0.19), NCTC 12156 DpmrB (COL vs PBS, all time-points, p > 0.5; FUS vs 4764 
PBS, 24 h 144 h and 168 h, p > 0.06) and AB205 (COL vs PBS, all time-points, p > 0.29; 4765 
FUS vs PBS, all time-points, p > 0.41).  4766 
RRR with COL monotherapy (compared with placebo only) likewise peaked in the early 4767 
phase of the experiment, where there was appreciable decrease in mortality (against 4768 
infection with NCTC 12156 and AB5075). COL monotherapy was no different to placebo at 4769 
all time-points against all other strains tested. Similarly, FUS monotherapy was no different 4770 
to placebo against the COL-resistant strains.  4771 
Although FUS MICs were comparatively lower with COL-resistant strains, AB205 and NCTC 4772 
12156 DpmrB, 16 and 8 mg/L respectively, this did not translate to an overall protective 4773 
effect in vivo. Significant differences in RRR was only noted with FUS monotherapy 4774 
between 48 – 120 h time-points (p < 0.05) against the wild-type mutant, NCTC 12156 4775 
DpmrB, which did not extend to the end of the experiment. 4776 
 4777 
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Figure 4-8 Relative risk reduction in G. mellonella larval death by colistin-fusidic acid 4778 
combination compared with all other treatment arms, or colistin monotherapy compared 4779 
with placebo. 4780 
C2.5 – COL 2.5 mg/kg; C5 – COL 5 mg/kg; F20 – FUS 20 mg/kg; C2.5F20 – COL 2.5 mg/kg 4781 
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4.3.4 Efficacy of colistin-fusidic acid combination therapy – 4790 
Murine lung infection model vs G. mellonella model 4791 
In the murine lung infection model, COL monotherapy (5 mg/kg/day) was the best 4792 
treatment arm, being the only group with surviving mice at 168 h (end of experiment), and 4793 
indeed at any time-point beyond 72 h. See Figure 4-9 for graphs of the survival curves. 4794 
Unsurprisingly, the corresponding hazard ratios of mortality of the other treatment arms 4795 
compared with COL monotherapy were extremely large in this small pilot study of 12 mice 4796 
– fusidic acid monotherapy (HR 2 x 1010, p < 0.001), COL-FUS combination therapies 4797 
(identical survival in both arms; HR 7 x 109, p < 0.001).  4798 
Figure 4-9 Kaplan-Meier survival curves of murine pulmonary infection with AB5075, 4799 
treated with colistin and fusidic acid, singly or in combination. 4800 
Note: COL combination therapies (both colistin 2.5 mg/kg or colistin 5 mg/kg, with fusidic 4801 
acid 50 mg/kg) had identical survival curves. 4802 
 4803 
This is in stark contrast to the observation in G. mellonella systemic infection model, and 4804 
the in vitro studies. Comparing the murine lung infection model survival data with the G. 4805 
mellonella model infected with the same strain, AB5075, it is reasonable to conclude that 4806 
COL monotherapy significantly improves host survival of AB5075 infection (RRR in mortality 4807 
with COL monotherapy compared with placebo 1.5 – 2.6 fold, p < 0.0001 in G. mellonella 4808 
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model with AB5075 reported 20 - 25% survival at day 6 post-infection. (356) Due to the 4810 
small numbers of mice in each treatment arm in this pilot study, and a lack of placebo 4811 
group, the effect of each treatment was difficult to assess with statistical certainty. RRR in 4812 
mortality was not statistically significant with any of the 4 treatment arms compared to 4813 
another.  4814 
It is possible that FUS given systemically at 50 mg/kg/day is potentially toxic to mice, given 4815 
the greater proportion of deaths in the FUS treatment arm (all dead at 48 h post-infection), 4816 
compared with expected 25% survival at 6 days post-infection in untreated mice. (356) A 4817 
comparison of HR of all fusidic acid containing regimens in both G. mellonella and mouse 4818 
models demonstrates a preponderance towards survival with the addition of colistin. 4819 
Survival was significantly increased in the G. mellonella model (12.3 fold, p < 0.001), the 4820 
difference was not significant in the mouse model (p = 0.272). See Figure 4-10 for forest 4821 
plot of HR of fusidic acid containing regimens. 4822 
Body weight changes were recorded over the course of the experiment, and the average 4823 
results (and standard deviation) are shown in Figure 4-11. Decrease in the total body weight 4824 
of mice is expected in infection, and has been shown to correlate with severity of illness 4825 
due to infection. (367) Successful antimicrobial treatment has been associated with weight 4826 
gain during the course of infective illness, and better outcomes. (366) It is interesting to 4827 
note that whilst the mouse model survival data propose that the most active treatment is 4828 
COL monotherapy, the weight gain was slow over time, whilst the combination arms saw 4829 
rapid weight increments (almost 4 fold between days 1 and 2 post-infection with COL 2.5 4830 
mg/kg and FUS 50 mg/kg). This could suggest that combination therapy might have been 4831 
more effective at reducing bacterial burden in the mice, but that the animals ultimately 4832 
succumbed to the toxic effects of FUS.  4833 
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Figure 4-10 Hazard ratios of mortality in AB5075 infected animals treated with colistin-fusidic acid compared with fusidic acid monotherapy. 4834 
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4.4 Discussion 4839 
4.4.1 G. mellonella as a model of A. baumannii infection 4840 
G. mellonella larva has been used as a simple invertebrate infection model to investigate 4841 
both virulence of target pathogens and efficacy of antimicrobials. (352, 355) G. mellonella 4842 
larvae possess an innate immunity including haemocytes and antimicrobial peptides that 4843 
respond to bacterial infection, which mimic higher mammalian models of acute infection. 4844 
(352, 368-371) This property allows for an efficient way to further investigate infection 4845 
models within a living organism prior to either animal studies or clinical trials. Another 4846 
strength of the model is the ability to incubate the larvae at optimal human physiological 4847 
temperatures (i.e. 37°C), allowing for closer clinical predictions of pharmacodynamic 4848 
response of antimicrobials made from the model. (352, 355) 4849 
A. baumannii has previously been reported to be reliably studied in G. mellonella, with 4850 
comparable results to higher mammalian models. (356, 357) In this study, there was 4851 
considerable strain to strain differences in LD50 (differences between the 7 strains were 4852 
significant, with corresponding p < 0.0001), and clear reproducible demonstration of the 4853 
efficacy of the antimicrobial regimens investigated was best achieved by infecting larvae 4854 
with an inoculum that resulted in 75% death at 24 h in the untreated (or placebo) arm.  4855 
Due to some variation between batches of larvae, even when acquired from the same 4856 
supplier, inoculum tests were performed prior to every experimental run. A spin-off 4857 
company from the University of Exeter, BioSystems Technology Ltd (Devon, UK) has 4858 
recently produced research adapted G. mellonella larvae, TruLarvTM, which are of a 4859 
consistent age and weight for studying virulence and drug efficacy/toxicity, and are 4860 
additionally surface-decontaminated and bred in a controlled environment without 4861 
exposure to antibiotics or other drugs. There have been 2 projects with the company 4862 
funded through the NC3Rs’ CRACK IT programme (competitive fund to enable new 4863 
technologies for the goal of reducing the use of animals in research), which have 4864 
successfully used TruLarvTM as a screening assay for antimicrobial activity from 4865 
actinomycete extracts (372) and as a reliable surrogate to clinical studies of cell 4866 
cytotoxicity. (373) BioSystems are offering their G. mellonella larvae for £50 per 50 larvae, 4867 
which is comparable to the cost (after accounting for attrition, and the numbers needed 4868 
within the right weight range) of procuring them from fish bait and pet food stores. In 4869 
addition, the company is currently working on developing transgenic models, which if 4870 
successfully bred, will further aid antimicrobial drug development with assays that are 4871 
better able to predict in vivo outcome in higher mammalian models as well as in humans.  4872 
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4.4.2 Study of colistin combination therapy in G. mellonella 4873 
The G. mellonella model enables the study of antimicrobial efficacy over a relatively short 4874 
time-frame (≤ 1 week), suitable for high throughput screening and assessment of multiple 4875 
bug-drug combinations, in contrast with the limitations underpinning some higher 4876 
mammalian models. Treatment of Gram-negative bacteria infected G. mellonella larvae with 4877 
COL is well documented in literature, with multiple authors reporting superior larval survival 4878 
in combination with other antimicrobials (e.g. glycopeptides, rifampicin, tigecycline, 4879 
doripenem, daptomycin) compared with monotherapy. (314, 374-382) See Table 4-3 for 4880 
details of larval survival data for infected G. mellonella larvae treated with COL containing 4881 
regimens to date (excluding this study). COL combination therapy was noted to significantly 4882 
improve larval survival (compared with colistin monotherapy) against COL-susceptible 4883 
strains, however, strain to strain variability of activity was observed against COL-resistant 4884 
strains. Against COL-resistant strains, promising COL combinations include COL-rifampicin 4885 
(against 2 S. maltophilia strains) (375) and COL-doripenem (against 3 A. baumannii strains). 4886 
(379) In their study, O’Hara et al noted that whilst all 3 A. baumannii strains were resistant 4887 
to doripenem (MIC > 32 mg/L), in addition to COL (MIC 4 mg/L for 1 strain, > 256 mg/L for 4888 
the other 2), improved larval survival was noted with doripenem monotherapy (p < 0.006). In 4889 
fact, the addition of COL to doripenem tended towards increased mortality compared with 4890 
doripenem monotherapy, although the differences were not significant (p > 0.05). (379) A 4891 
similar phenomenon was observed with vancomycin monotherapy against A. baumannii by 4892 
Hornsey et al, and both groups of authors postulate that the improved larval survival may 4893 
be the result of priming of the G. mellonella immune system (treatment was delivered to 4894 
larvae 30 min post-infection), rather than as a direct antimicrobial effect of the drug on A. 4895 
baumannii. (377, 379) It would be interesting to study the effects of these drugs (doripenem 4896 
and vancomycin) on G. mellonella survival against infections by other pathogens, and the 4897 
impact of delayed treatment delivery (i.e. doses given at various time-points > 30 min post- 4898 
infection) to allow for the establishment of infection in the larvae, comparing this with a 4899 
‘prophylaxis’ or ‘pre-emptive therapy’ model (where the drug is given before, at the time of, 4900 
or soon after infection).  4901 
COL was well tolerated in G. mellonella larvae in this study, with no decrease in survival 4902 
with doses up to 100 mg/kg compared with uninoculated controls at 72 h post-inoculation 4903 
(see Figure 4-4 for details). Yang et al similarly observed that COL given at a dose of 2.5 4904 
mg/kg was not toxic to G. mellonella larvae. (382) In this study, fusidic acid was not found 4905 
to be toxic to G. mellonella larvae at doses up to 200 mg/kg (Figure 4-5). 4906 
Establishing the inoculum resulting in 24 h lethality of approximately 75% was crucial to 4907 
enable clear discrimination between the different treatment arms studied, and accurately 4908 
assess the survival outcome. The combination of COL with FUS in the treatment of A. 4909 
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baumannii infected G. mellonella larvae was shown to be clearly superior to either 4910 
monotherapy arms, overall throughout the experiment (as evidenced by the Cox regression 4911 
analysis), and at each 24 h interval time-point (as demonstrated by the significantly reduced 4912 
relative risk of mortality) for all strains tested, including the hypervirulent OM strain 4913 
(AB5075), and COL-resistant strains (AB205 and NCTC 12156 DpmrB).  4914 
Strain to strain variations were observed in the magnitude of the protective effect with COL 4915 
monotherapy and COL-FUS combination therapy against A. baumannii infection. Amongst 4916 
the 7 strains, overall larval survival with COL monotherapy was only significantly increased 4917 
(compared with placebo) in G. mellonella larvae infected with NCTC 12156 (mortality HR 4918 
0.5, p = 0.004) or AB5075 (HR 0.33, p < 0.001). COL monotherapy was not observed to 4919 
have a negative impact on larval survival, including in larvae infected with COL-resistant 4920 
strains. This suggests that whilst successful treatment of A. baumannii infection may not 4921 
always be possible with COL monotherapy in G. mellonella larvae, it has not been 4922 
associated with excess deaths from either toxicity in infected larvae or increased 4923 
pathogenicity with COL exposure in vivo. 4924 
COL-FUS combination was comparatively more active than COL monotherapy. The HRs for 4925 
mortality over the experimental period (168 h) compared with COL monotherapy were 4926 
consistently ≤ 0.5 (p < 0.01). The greatest protective effect offered by COL-FUS 4927 
combination was demonstrated during the first 48 h (as seen by the gradual plateau of RRR 4928 
in mortality over the course of the experiment). This is likely due to the observation that 4929 
untreated or inappropriately treated A. baumannii infection leads to acute and rapid larval 4930 
death, often manifesting within the first 24 h (a secondary smaller decrease in survival up to 4931 
72 h with COL-resistant strains). Another possibility may be the employment of a single 4932 
bolus dose of treatment delivered within 15 – 30 min of infection. Elimination of COL and 4933 
FUS may have occurred over the first 48 h, with minimal residual concentrations within the 4934 
haemolymph beyond this point. The effect of the COL-FUS combination in multiple dosing 4935 
regimens, utilising lower inocula may be warranted to examine impact on survival over 4936 
several days. Additionally, PK studies of COL and FUS haemolymph concentrations could 4937 
be investigated in further studies to assess the relationship between drug concentrations 4938 
and larval survival of A. baumannii infection. Hill et al have described using a bioassay to 4939 
determine pharmacokinetic parameters in G. mellonella, observing a Cmax 11.2 µg/mL, t1/2     4940 
1 h and AUC0-24 20.1 µg×h/mL with a single bolus of COL 5 mg/kg. (383) A recently 4941 
published study by Zhao et al observed the PK parameters of CMS and colistin following a 4942 
single-dose infusion (over 1 h) of CMS (2.5 mg of CBA) in healthy volunteers (n = 12) and 4943 
noted a COL Cmax 0.687 ±	0.074 mg/L, t1/2 4.49 ±	0.56 h, AUC0-12 5.87 ±	0.76 mg×h/L, AUC0- 4944 
¥ 7.6 8±	1.3 mg×h/L. (384) Assuming a proportional effect of doubling COL doses, the 4945 
apparent haemolymph concentrations obtained were in excess of those expected in 4946 
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humans, although Hill et al utilised a bioassay method for determining COL haemolymph 4947 
concentrations, and there are various pitfalls associated with this methodology, including 4948 
poor COL agar diffusion (authors used a ditch well method, similar in principle to disc 4949 
diffusion assay), (383) and the potential presence of other antimicrobial peptides and/or 4950 
colonising bacteria within the haemolymph, all of which could affect the reliability of the 4951 
COL measurements. In line with recommendations for determination of human serum COL 4952 
concentrations for therapeutic drug monitoring purposes, (140) studies to assess the PK of 4953 
COL and FUS in G. mellonella should be determined using a LC/MS-MS platform, (140, 4954 
385) for both single bolus dosing and multiple dosing regimens, to better inform future 4955 
clinical management where the COL-FUS combination could be employed for the treatment 4956 
of XDR A. baumannii infections.  4957 
Overall, this study demonstrated greatly reduced larval death in the COL-FUS treated 4958 
groups compared with placebo or either monotherapies – numbers needed to treat (NNT) 4959 
were 2 – 5 fold lower with COL-FUS compared with COL monotherapy against COL- 4960 
susceptible strains, and 4.5 – 5.8 fold lower compared with COL monotherapy and 3.2 – 4961 
12.6 fold lower compared with FUS monotherapy against COL-resistant strains.  4962 
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Table 4-3 Colistin combination therapies in G. mellonella model. 4963 
Author Year Isolates tested Colistin 
susceptibility 
Colistin dose Additional 
agent(s) and 
dose(s) 




Betts 2014 NDM-1 E. coli 
CTX-M-15 E. coli 
OXA-48 K. pneumoniae 
CTX-M-15 K. pneumoniae 
E. aerogenes 





2.5 mg/kg Tigecycline  
1 mg/kg 
48 Combination better than colistin 
monotherapy against all strains  
(p < 0.05) 
373 





2.5 mg/kg Tigecycline  
1 mg/kg 
48 Combination better (p < 0.05) than 
colistin monotherapy against 1/2 
strains (with colistin MIC 4 mg/L, 
tigecycline MIC 2 mg/L; not 
significantly better in strain with 
colistin MIC 32 mg/L and 
tigecycline MIC 8 mg/L) 
374 
    
2.5 mg/kg Rifampicin 
10 mg/kg 
48 Combination better than colistin 
monotherapy against both strains  
(p < 0.05) 
 
Hornsey 2013 A. baumannii type strain 





2.5 mg/kg Telavancin 
10 mg/kg 
48 Combination better than colistin 
monotherapy against both strains  
(p < 0.001) 
375 
Hornsey 2011 A. baumannii type strain 





2.5 mg/kg Teicoplanin 
10 mg/kg 
48 Combination better than colistin 
monotherapy against both strains  
(p < 0.05) 
376 
    
2.5 mg/kg Vancomycin 
10 mg/kg 
48 Combination better than colistin 
monotherapy against both strains  
(p < 0.05) 
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Author Year Isolates tested Colistin 
susceptibility 
Colistin dose Additional 
agent(s) and 
dose(s) 




Krezdorn 2014 VEB-1, VIM-1 P. 
aeruginosa type strain 
Colistin MIC 2-4 
mg/L 










30 Dual agent colistin combinations no 
better than colistin monotherapy. 
 
Triple agent colistin combinations 
that were better than colistin 
monotherapy included (p < 0.05): 
- Colistin + meropenem + 
piperacillin 
- Colistin + meropenem + amikacin 
- Colistin + meropenem + 
levofloxacin 
- Colistin + piperacillin + amikacin 
- Colistin + piperacillin + 
levofloxacin 
- Colistin + amikacin + levofloxacin 
377 
O'Hara 2013 3 MDR A. baumannii 





2.5 mg/kg Doripenem 
7.5 mg/kg 
60 Combination better than colistin 
monotherapy against all strains  
(p ≤ 0.01) 
378 
    2.5 mg/kg Vancomycin 
15 mg/kg 
60 No difference between combination 
and colistin monotherapy 
 





60 Combination better than colistin 
monotherapy against all strains  
(p < 0.05) 
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Author Year Isolates tested Colistin 
susceptibility 
Colistin dose Additional 
agent(s) and 
dose(s) 




Wei 2017 A. baumannii type strain 
A. baumannii type strain 
derived colistin-resistant 
mutant 
2 MDR A. baumannii 
clinical strains 
Type strain and 1 
clinical strain 
susceptible to 
colistin, the others 
were resistant 
2.5 mg/kg Levofloxacin 
6.7 mg/kg 
48 Combination better (p < 0.05) than 
colistin monotherapy for 1/4 strains 
(clinical isolate susceptible to 
colistin MIC 2 mg/L) 
379 
Yang 2015 A. baumannii type strain 
MDR A. baumannii clinical 




2.5 mg/kg Daptomycin 
4 mg/kg 
48 Combination better than colistin 
monotherapy against both strains  
(p < 0.05) 
313 





2.5 mg/kg Imipenem  
15 mg/kg 
48 Combination better than colistin 
monotherapy against both strains  
(p ≤ 0.0001) 
380 
Yang 2016 A. baumannii type strain 
A. baumannii type strain 
derived colistin-resistant 
mutant 
2 MDR A. baumannii 
clinical strains 
Type strain and 1 
clinical strain 
susceptible to 
colistin, the others 
were resistant 
2.5 mg/kg Vancomycin 
15 mg/kg 
48 Combination better than colistin 
monotherapy against all strains  
(p < 0.05) 
381 
         
         
         
4964 
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4.4.3 Comparative efficacy of colistin and fusidic acid singly 4965 
and in combination against A. baumannii in a murine 4966 
lung infection model 4967 
A mouse A. baumannii lung infection model described by Eveillard et al, (365) and later 4968 
optimised by Jacobs et al using a well-characterised hypervirulent strain (AB5075), (356) 4969 
was used to study the efficacy of colistin and fusidic acid in vivo. The main purpose of this 4970 
small pilot study was to assess any differences in survival with the addition of FUS to COL 4971 
for the treatment of AB5075 pneumonia, and how the difference (if any) compared with the 4972 
observations in the G. mellonella systemic infection model. Jacobs et al had previously 4973 
reported 25% 6-day survival in untreated AB5075 lung infection. (356) In comparison with 4974 
untreated AB5075, 67% of the COL monotherapy treated mice infected with AB5075 4975 
survived to the end of the experiment (day 7 post-infection). It is probable that COL 4976 
monotherapy is sufficiently bactericidal against AB5075, resulting in better chances of 4977 
survival in vivo, both in the G. mellonella model and in mice.  4978 
Perhaps somewhat surprisingly, the addition of FUS 50 mg/kg, given in 2 divided doses 4979 
every day for 3 days, increased mortality in AB5075 infected mice. This was observed in 4980 
AB5075 infected mice treated with either FUS monotherapy, or in combination with low 4981 
dose COL (2.5 mg/kg/day) or high dose COL (5 mg/kg/day). Rapid elimination of FUS in 4982 
mice requires large doses to be given systemically, to attain clinically relevant 4983 
concentrations. (386, 387) Bellahsene et al noted the LD50 of orally administered (via gastric 4984 
tube) fusidic acid in mice was in excess of 1000 mg/kg, and oral doses of up to 500 mg/kg 4985 
were well tolerated (i.e. absence of toxic side effects). (388) Payne et al, however, reported 4986 
problems with toxicity when FUS was given intraperitoneally at doses of 30 mg/kg/day or 4987 
60 mg/kg/day. (387) This may be the reason for the excess death in mice observed with 4988 
FUS-containing regimens – all mice perished 48 h post-infection in the FUS monotherapy 4989 
group, and all mice given FUS-containing therapies were dead by 72 h. There was no 4990 
significant difference between the HR in mortality between FUS monotherapy and COL- 4991 
FUS combination therapy arms (p = 0.272). In their study, Payne et al noted that 4992 
subcutaneously delivered FUS was better tolerated by mice, at 60 mg/kg/day given in 3 4993 
divided doses, with few adverse effects apart from mild local reaction at the injection site. 4994 
(387) Further investigation of COL-FUS efficacy in mice should avoid delivery of FUS 4995 
intraperitoneally, and could explore the use of subcutaneous delivery instead. A separate 4996 
arm with PBS-treated (placebo group) infected control should also be included to better 4997 
discern the impact of the various treatment regimens.  4998 
COL-FUS combination therapy may have resulted in greater reduction of the AB5075 4999 
bacterial load, with the observation of greater weight gain (amongst surviving mice) within 5000 
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the first 48 h post-infection compared with COL monotherapy. The magnitude of weight 5001 
loss in mouse models have been used as a marker of severity of sepsis, (389) and 5002 
successful treatment associated with subsequent weight gain. (366) Further studies are 5003 
warranted to confirm this finding, including direct measurement of bacterial load in murine 5004 
lung tissue from each experimental arm.  5005 
4.4.4 Limitations 5006 
The main limitation of the G. mellonella model lies in the probable heterogeneity of innate 5007 
host factors present between larvae, which may have led to variance in response to 5008 
infection regardless of type of treatment received. COL-FUS therapy was only investigated 5009 
against A. baumannii infection in the G. mellonella model in this study. Further studies 5010 
including diverse species with varying COL-susceptibility and different MDR mechanisms 5011 
are needed to investigate if the efficacy observed here extends to infections by other 5012 
pathogens as demonstrated in the in vitro experiments. PK parameters were not measured 5013 
in this study, and the “humanised doses” employed in G. mellonella may have delivered 5014 
COL and FUS therapy in excess of attainable serum concentrations in humans.  5015 
The murine lung infection model was performed using very few animals as part of an 5016 
exploratory study, and differences in survival observed were difficult to interpret in this 5017 
setting. However, even within this small cohort, the issue of FUS toxicity (when delivered 5018 
systemically) in mice cannot be ignored, and may be ameliorated by use of a different 5019 
mode of FUS delivery (e.g. subcutaneously, orally) in future studies with more animals in 5020 
each treatment group. 5021 
4.4.5 Conclusions 5022 
The G. mellonella model appears to be better suited for the study of COL-FUS efficacy 5023 
compared with the murine lung infection model, the larvae less susceptible to the toxic 5024 
effects of FUS, compared with their higher mammalian counterpart. G. mellonella was a 5025 
useful model for studying the in vivo impact (on survival) of systemic A. baumannii infection, 5026 
with clear differentiation in virulence between the strains tested. The results of the COL- 5027 
FUS G. mellonella treatment assays mirror the potent synergy observed in vitro, and 5028 
demonstrates the efficacy of the combination in vivo.  Although the results from the pilot 5029 
study in mice was disappointing, it may be further pursued with different routes of FUS 5030 
administration that are less toxic to the animals.  5031 
COL-FUS represents a promising treatment option in the face of dwindling viable 5032 
antimicrobial therapies. The potent synergy between COL and FUS has been consistently 5033 
observed in vitro with numerous testing methods, and in an invertebrate model of infection. 5034 
Moreover, the COL-FUS combination employs antimicrobial agents that are currently 5035 
available for clinical use, allowing for adoption in the treatment of Gram-negative infections 5036 
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for which there may be no other, today, in contrast to new agents that require years of 5037 
development and testing prior to routine clinical use. The COL-FUS combination should be 5038 
considered as an option for the treatment of infections where no other viable options are 5039 
available, and further studies by way of clinical trials are needed to assess the wider clinical 5040 
efficacy of the regimen.  5041 
 5042 
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5 Case reports 5043 
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5.1 Introduction 5044 
The identification of potent synergy between COL and teicoplanin or FUS has been put to 5045 
practice in 2 separate cases, for the treatment of MDR A. baumannii infections. In both 5046 
cases, COL remained the only antimicrobial agent which retained any activity against the 5047 
organism in vitro, although COL heteroresistance was demonstrated by COL PAP (see 5048 
Section 3.1.3.1). Clinical decisions to treat these patients with the novel COL combinations 5049 
were made collectively (intensive care/nephrology physician, antimicrobial pharmacist, 5050 
infectious disease/clinical microbiologist) and the patients otherwise managed as per 5051 
standard protocol. 5052 
MDR A. baumannii has emerged as an endemic problem in most healthcare institutions, 5053 
most commonly in the critical care setting. (112, 390) The predominant strain in the UK, 5054 
OXA-23 EU clone II (UK PFGE clone 1), is usually an MDR phenotype, resistant to multiple 5055 
classes of antimicrobials including quinolones, carbapenems, aminoglycosides and 5056 
cephalosporins, and variably susceptible to COL, FOS and tigecycline. (328) The MDR 5057 
profile, coupled with the ability to persist in the environment for extended periods of time, 5058 
makes A. baumannii particularly suited to establishment as a nosocomial pathogen, of 5059 
which it does with great success. Indeed, MDR A. baumannii infection is frequently cited as 5060 
risk factor for mortality, carrying with it high economic costs. (391-393)  5061 
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5.2 Colistin-teicoplanin 5062 
5.2.1 Background and diagnosis of MDR A. baumannii 5063 
infection 5064 
COL-glycopeptide combination therapy has been used in our institution for the treatment of 5065 
MDR A. baumannii infections with a reasonable measure of success in the recent past. 5066 
Here, we detail the utilisation of COL-teicoplanin combination therapy for the treatment and 5067 
eradication of persistent MDRAB from the urinary tract associated with indwelling 5068 
prosthetic devices.  5069 
A 66-year-old gentleman, with chronic renal impairment due to obstructive nephropathy 5070 
(previously refused surgical correction of external sphincter stricture), underwent multiple 5071 
urological procedures for insertion of ureteric and/or prostatic stents to treat sphincter 5072 
strictures over a 2 year period. An episode of acute on chronic renal failure resulted in 5073 
admission to the critical care unit at a tertiary teaching hospital and was commenced on 5074 
regular haemodialysis. During his admission, he was treated for multiple episodes of sepsis 5075 
with broad-spectrum antibiotics including co-amoxiclav, piperacillin-tazobactam and 5076 
imipenem. On day 27 of his ICU admission, he was found to be colonised with MDR A. 5077 
baumannii. Despite eventual recovery and discharge from hospital, MDR A. baumannii 5078 
colonisation persisted in his urinary tract. He continued to be dialysis dependent upon 5079 
discharge from hospital, and his renal function showed a slow decline over the following 18 5080 
months. Multiple exchanges of the prosthetic stents (with or without CMS 1 million units 5081 
(mu) as antibiotic prophylaxis prior to the procedures) over this time period did not help 5082 
with eradication of the organism.  5083 
The MDRAB organism isolated belonged to the OXA-23 UK clone 1 strain, which was 5084 
endemic in the ICU of his admitting hospital. The organism was resistant to multiple classes 5085 
of antibiotics including quinolones, cephalosporins, carbapenems and aminoglycosides. 5086 
Additionally, it was resistant to tigecycline (Etest minimum inhibitory concentration (MIC) = 5087 
1 mg/L). (394) COL susceptibility varied depending on the test method (clinical 5088 
susceptibility breakpoint of 2 mg/L used, as per British Society of Antimicrobial 5089 
Chemotherapy (BSAC) guidelines version 10.2 (394)) – Etest MIC 0.38 mg/L (susceptible), 5090 
MicroScan WalkAway automated system MIC > 4 mg/L (resistant, but COL susceptibility 5091 
not validated on this platform) and BMD MIC 16 mg/L (resistant).  5092 
Clinical deterioration due to persistent MDR A. baumannii urinary tract infection prompted 5093 
the investigation of alternative therapies. Following demonstration of negative gut carriage 5094 
of MDR A. baumannii, and a decision was made to commence targeted treatment with 5095 
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COL-glycopeptide combination therapy just prior to stent exchange, to maximise the 5096 
chance of success. 5097 
5.2.2 In vitro colistin combination studies 5098 
Synergy between COL and teicoplanin was demonstrated by checkerboard assays – 5099 
average FICI 0.062, and SBPI 4.1. The interaction between COL and vancomycin was less 5100 
positive, with a FICI of 0.78 (additive).  5101 
The synergy observed in the checkboards (COL-teicoplanin) was further assessed by time- 5102 
kill assays. Rapid bactericidal activity was noted within the first 4 h of treatment with either 5103 
COL monotherapy or colistin-teicoplanin combination therapy. Regrowth was noted in both 5104 
arms at 24 h, however, there is a 5 log10 cfu/mL decrease in bacterial load with the 5105 
combination compared to COL alone (bacterial load at 24 h was similar to that of the 5106 
untreated growth control), demonstrating synergy. This synergy was not bactericidal, 5107 
however, with a final inoculum yield in the combination arm of 5 log10 cfu/mL. 5108 
5.2.3 Treatment history and clinical progress 5109 
Treatment with COL and teicoplanin was commenced on the morning of the stent 5110 
exchange procedure (approximately 2 h prior). Due to the recommendations made by a 5111 
landmark PK study by Garonzik et al regarding optimisation of COL therapeutic dosing by 5112 
Garonzik et al, (134) the patient was given a loading dose of 7.5 mu of CMS. He was also 5113 
started on teicoplanin therapy (as per standard British Formulary recommendations – 400 5114 
mg twice daily for the first 3 doses, and subsequently 400 mg once daily on dialysis days). 5115 
On the second day of therapy (day 1 post-procedure), he was given 1 mu of CMS in the 5116 
morning prior to dialysis, and 1.3 mu post-dialysis. 1 mu of CMS was given twice (12 h 5117 
apart) on the third day. Thereafter, he was given 1 mu in the morning, and 1.3 mu in the 5118 
afternoon post-dialysis on dialysis days (3 times a week). Therapy was continued for 9 days 5119 
in total. Trough serum levels of COL and teicoplanin were taken on dialysis days and these 5120 
ranged 1.3 – 3.1 mg/L (target level 2 mg/L) and 15 – 22 mg/L (target level 20-40 mg/L) 5121 
respectively. Urine samples obtained on dialysis days during treatment and twice weekly 5122 





































5.3 Colistin-fusidic acid 
5.3.1 Background 
A 19-year-old female, sustained multiple traumatic injuries following a high-speed collision 
between the car she was in and a lorry. She did not have any underlying comorbid factors 
prior to the accident. The injuries she sustained were extensive, though mainly confined to 
her upper body. These included bilateral haemothoraces and rib fractures, large right-sided 
acute extradural haematoma resulting in dense left-sided hemiparesis and multi-level 
thoracic spinal fractures. Following emergency decompressive right-sided hemicranectomy 
and insertion of bilateral chest drains, she was transferred to the intensive care unit for 
cardiopulmonary support including mechanical ventilation.  
5.3.2 Diagnosis of MDR A. baumannii infection 
Fifteen days after admission, a clinical diagnosis of VAP was made based on clinical 
features of fever (38.3⁰C), purulent sputum production, peripheral leucocytosis (13.2 x 109 
cells/L) and rising ventilatory support requirements. (395) A chest radiograph revealed left-
sided collapse/consolidation (see Figure 5-1) and a pure culture of A. baumannii was 
isolated from an endotracheal aspirate the following day.  Susceptibility testing using the 
MicroScan Walk-Away® system (Dade Behring, West Sacramento, CA), interpreted 
according to Clinical Laboratory Standards Institute (CLSI) guidelines (396) revealed 
resistance to aminoglycosides, fluoroquinolones, cephalosporins and carbapenems. The 
MIC of tigecycline (0.5 mg/L; resistant using non-species related susceptibility breakpoint 
set by the British Society for Antimicrobial Chemotherapy (BSAC), version 12) and COL 
(0.19 mg/L; susceptible) (397) were determined by Etest® (bioMérieux SA, Marcy l'Etoile, 
France). Molecular analysis of the A. baumannii isolate revealed that this was an MDR 
strain belonging to OXA-23 UK clone 1. PCR and sequencing of antimicrobial resistance 
genes identified blaOXA-51, and blaOXA-23 β-lactamases accounting for cephalosporin and 
carbapenem resistance and the 16S methyltransferase armA that promotes pan-
aminoglycoside resistance.  
5.3.3 In vitro synergy studies 
FUS was chosen as the second agent in the COL combination for treatment of the MDR A. 
baumannii VAP as COL-FUS synergy was most marked against the OXA-23 UK clone 1 
representative isolate in the in vitro studies. Moreover, FUS has been noted to demonstrate 
reasonable lung penetration, (398, 399) and demonstrates higher potency in acidic 
environments (metabolic acidosis is a well-established consequence of sepsis (400)). (401) 
Synergy was observed between COL and FUS against the MDR A. baumannii isolated from 
the endotracheal aspirate by checkerboard assays done in triplicate (average FICI = 0.2 5159
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representing synergy, and average SBPI = 42 representing potential clinical relevance of 5160
the synergy observed.  5161
Time-kill assays identified that the COL-FUS combination was rapidly bactericidal, a 5.6 5162
log10 cfu/mL reduction in bacterial count was seen using target therapeutic levels of COL 2 5163
mg/L and FUS 1 mg/L (see Figure 5-2). The COL-FUS combination was bactericidal at 6 5164
hours with no regrowth 24 hrs after the initial kill, suggesting it may suppress the 5165
emergence of resistant mutants. In the in vitro assessment of mutational frequency to COL, 5166
the COL MIC derived at the end of the experiment from colistin single agent exposure was 5167
1024 fold higher than that observed in the organisms exposed to both COL and FUS (see 5168
Section 3.2.4.6).  5169
Figure 5-1 Chest radiographs depicting radiological progress of VAP. 5170
Left – taken on day 15 of admission showing left-sided collapse/consolidation. Right – 5171
taken 1 month after completion of treatment showing resolution of radiological signs of 5172
infection. 5173
5174
Figure 5-2 Time-kill graphs using target serum concentrations of colistin and fusidic acid 5175
against VAP MDR A. baumannii isolate (AB315). 5176
5177
AB315 case report











































5.3.4 Treatment history and clinical progress 
Following review of additional microbiological data and due to the patient’s deteriorating 
clinical condition, therapy was commenced with intravenous CMS (Colomycin®; Forest 
laboratories, Dartford, UK) 2 mu given 8 hourly and sodium fusidate (Fucidin®; LEO 
Pharma, Berkshire, UK) 500 mg given 8 hourly via naso-gastric tube on day 21.  Serum 
trough COL level was measured on day 4 of the COL-FUS combination therapy. 
A treatment regimen consisting of intravenous CMS and oral FUS was found to be 
beneficial in the case highlighted. Clinical response was rapid, with marked improvement in 
both systemic (fever, tachycardia, respiratory support requirement) and biochemical 
markers of infection (normalisation of WBC) within 48 hours of therapy. Sustained clinical 
cure and microbiological eradication was achieved after 5 days of treatment, the patient 
was weaned off ventilation and was breathing spontaneously with FiO2 28 %.  
Radiological evidence of resolution was also attained (see chest radiographs in Figure 
5-1). Post-therapy surveillance cultures for MDRAB (sputum, rectal swabs and swabs from 
wound sites) remained consistently negative.  Serum trough level of colistin measured 
during the treatment period was < 2 mg/L. 5193
291 
5.4 Discussion 5194
Both cases illustrate the success of novel COL combination therapies in practice. The use 5195
of COL combination therapies here were ‘targeted’ at the MDR organism being treated, as 5196
opposed to the more common empirical approach (i.e. to increase the antimicrobial 5197
spectrum prior to microbiological confirmation of infection and/or susceptibility of 5198
organism). In both instances, the synergy observed in vitro was translated across to the 5199
bedside, resulting in clinical improvement and cure. In particular, both demonstrate not only 5200
treatment success, but also the eradication of MDRAB with sustained culture negativity 5201
post-treatment.  5202
Additionally, in the 2nd case, the COL-FUS combination led to eradication of MDRAB from 5203
all sites, including gut carriage. Eradication of MDRAB is notable, as A. baumannii has 5204
established itself as one of the foremost nosocomial pathogens partly due to its ability to 5205
infect virtually any site in the human body and persist in the clinical environment (e.g. 5206
medical equipment, prosthetic devices, bedding, surfaces). (402) Even with the best 5207
disinfection and sterilisation efforts, patients remain inexhaustible reservoirs of the 5208
organism, limiting infection control practices. If eradication is made possible, coupled with 5209
effective environment cleaning and healthcare hygiene protocol, the demise of MDRAB as a 5210
scourge of critical care facilities around the world could potentially be realised. Further 5211
study, by way of prospective clinical trials would be useful in assessing not just the 5212
traditional clinical outcomes of mortality, cure and adverse effects of the combination, but 5213
also the eradication rates (e.g. cross-sectional data pre and post intervention, longitudinal 5214
surveillance study) and economical impact of the combination in both low and high 5215
colonisation/infection settings.  5216
The specific mechanism by which both COL-teicoplanin and COL-FUS works against these 5217
MDR organisms should be elucidated in further in vitro studies, with particular focus on the 5218
mechanism of action of COL-FUS against COL-resistant organisms. 5219
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6 Discussion 5220 
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6.1 Overview and background 5221 
Antimicrobial resistance in the 21st century has been hailed as one of the foremost crises 5222 
facing modern medicine, threatening to undo healthcare’s crowning achievement of the last 5223 
century, antibiotics. Much focus has been given to tackling this issue with concerted efforts 5224 
made to tighten controls on use of our existing antimicrobials in medicine (humans and 5225 
veterinary), agriculture and manufacturing industries, develop rapid diagnostic platforms for 5226 
infections, improve antimicrobial resistance surveillance, optimise infection prevention and 5227 
control and develop novel antimicrobial agents effective against multi-drug resistant 5228 
organisms. (1, 2, 6) The development of new agents for MDR Gram-negative infections has 5229 
suffered from decades of underinvestment, mainly due to the diminishing returns (high cost 5230 
of research & development met with low usage and eventual disuse due to rapid 5231 
development of resistance) received by pharmaceutical companies on any promising agent. 5232 
This has led to an effectively dry antimicrobial developmental pipeline, in which no novel 5233 
class active against Gram-negatives (particularly MDR Gram-negative pathogens) has been 5234 
brought to market in decades. The last antimicrobial representing a novel class active 5235 
against Gram-negative bacteria was trimethoprim in 1968. (403) Most Gram-negative 5236 
agents brought to market in the past 30 years have been incremental modifications or 5237 
additions to already existing agents, with the majority being either b-lactams or quinolones. 5238 
(403) The concern here is the ease with which microbes may adapt to the ‘new’ agent, in 5239 
itself a slight modification of an existing agent it has encountered before and is able to 5240 
either inactivate or bypass. (22) Strategies to combat this include the use of combinations, 5241 
or development of novel classes of antimicrobials, preferably with multiple targets, in an 5242 
effort to slow the development of resistance and retain its antimicrobial activity. (22) 5243 
COL, is an old antimicrobial that has been brought back to clinical use globally for the 5244 
treatment of MDR and XDR Gram-negative infections, for which therapeutic options are 5245 
extremely limited. Due to problems with heteroresistance resulting in potential treatment 5246 
failure with monotherapy, and ad hoc efforts to increase the efficacy of the treatment 5247 
regimen (additive or synergistic effect of combination therapies), clinicians have been 5248 
employing COL in combination with other agents, usually broad-spectrum antibiotics such 5249 
as meropenem or tigecycline. (177) There is however, a legitimate concern regarding the 5250 
continued use of broad-spectrum antibiotics (e.g. carbapenems, quinolones) whether singly 5251 
or in combination, as they are thought to be risk factors for multi-drug resistance, including 5252 
the feared carbapenemase-producing enterobacteriaceae. (404) The permeabilising effect 5253 
COL has against the Gram-negative outer membrane allows it to be uniquely placed for 5254 
unusual or unorthodox combinations (agents normally excluded by the Gram-negative 5255 
outer membrane due to size or hydrophobicity), (405, 406) introducing potential novel 5256 
antimicrobial mechanisms against multi-drug resistant organisms. Combination with an 5257 
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agent that does not normally possess activity against Gram-negative organisms may also 5258 
have the added advantage of the absence of exposure and hence prior selective pressure, 5259 
allowing for a slower adaptive response by the microbe to circumvent the effects of the 5260 
non-traditional combination. 5261 
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6.2 Summary of chapters 5262 
6.2.1 A systematic review of colistin combination therapies 5263 
for Gram-negative infections 5264 
6.2.1.1 Clinical outcome – Mortality 5265 
The meta-analyses performed in this study underscored the relative paucity of robust 5266 
clinical trial data needed to draw evidence-based conclusions about the clinical outcomes 5267 
following colistin combination therapies. Of the 51 studies included in the meta-analyses, 5268 
only 4 were randomised-controlled trials, and none of them were double-blind in design, 5269 
attributing considerable bias into the results generated. Nonetheless, the summative results 5270 
showed that colistin combination therapies that have been employed thus far, were no 5271 
superior in successfully treating Gram-negative infections compared with all other 5272 
prevailing standard treatment regimens (all-cause mortality odds ratio – RCTs p = 0.455, 5273 
non-RCTs p = 0.113; infection-related mortality – RCTs p = 0.083, non-RCTs p = 0.903; 5274 
positive clinical response to treatment – RCTs p = 0.443, non-RCTs p = 0.967), nor was 5275 
there a significant excess burden of nephrotoxicity (RCTs p = 0.295, non-RCTs p = 0.546). 5276 
Subgroup analyses of the non-RCT studies (this was not possible with the RCTs as there 5277 
were only 4 eligible studies included) revealed better survival with colistin combinations in 5278 
bacteraemic patients (OR 0.6, p = 0.001), particularly in those with K. pneumoniae 5279 
bacteraemia (OR 0.42, p < 0.001). Whilst all-cause mortality appeared to be lower with 5280 
colistin combination therapies in these groups of patients, this did not translate to lower 5281 
infection-related mortality. Similarly, no single subclass of colistin combination (grouped 5282 
according to the antimicrobial class of the additional agent(s)) resulted in significantly better 5283 
or worse mortality rates (both all-cause and infection-related) compared with either colistin 5284 
monotherapy or non-colistin therapies. Once again, a closer look at the bacteraemic cases 5285 
revealed better odds of survival (all-cause mortality only) with colistin-tigecycline compared 5286 
with colistin monotherapy (OR 0.42, p = 0.04) and interestingly, all cases were due to 5287 
carbapenemase-producing organisms. Of the 5 studies included in the subgroup, only the 5288 
Spanish study by Navarro-San Francisco et al assessing outcomes of bacteraemia due to 5289 
OXA-48 producing Enterobacteriaceae reported higher mortality with colistin-tigecycline 5290 
compared with colistin monotherapy (OR = 11, 95% CI 0.28-433.8, n = 7). (237) The other 4 5291 
studies were conducted in patients with K. pneumoniae bacteraemia positive for either KPC 5292 
and/or VIM carbapenemases, and mortality between the 2 arms were either indifferent 5293 
(Papadimitriou-Olivgeris #1033) or lower in the colistin-tigecycline group. This may suggest 5294 
a potential niche for the use of colistin-tigecycline targeted therapy KPC-producing K. 5295 
pneumoniae bacteraemia, although it should be noted that colistin-tigecycline was not 5296 
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associated with significantly better clinical response or lower infection-related mortality 5297 
rates.  5298 
6.2.1.2 Clinical outcome – Clinical improvement 5299 
Subgroup analysis of bacteraemic cases (BSI) or respiratory tract infections (LRTI) did not 5300 
show any significant differences in positive clinical response to treatment with colistin 5301 
combination therapies compared with all comparators (BSI p = 0.965, RTI p = 0.686), 5302 
colistin monotherapy (BSI p = 0.785, RTI p = 0.382), or non-colistin therapies (BSI p = 5303 
0.518, LRTI p = 0.112). Likewise, there were no significant differences observed between 5304 
specific colistin combination classes and comparator arms, or by type of organism isolated. 5305 
This observation may in part be due to the variation in determination of ‘positive clinical 5306 
response’ between studies (varying definitions of ‘cure’, ‘success’, ‘response’, with few 5307 
relying on objective biochemical or radiological parameters), or indeed within studies 5308 
between outcome assessors (many studies were observational in nature, and clinical 5309 
response was defined by different clinicians, some were difficult to ascertain from written 5310 
records due to their retrospective design). Unlike a clear outcome measure such as all- 5311 
cause mortality, defining good clinical response to therapy is difficult, with considerably 5312 
more uncertainty than determination of mortality attributable to infection (in itself subject to 5313 
a degree of ambiguity compared with all-cause mortality), serving a possible explanation for 5314 
the discrepancies in observation between these outcome measures.  5315 
6.2.1.3 Clinical outcome - Nephrotoxicity 5316 
Excess burden of nephrotoxicity from an additional agent to colistin (i.e. colistin 5317 
combination therapy versus colistin monotherapy) was not significant, for both pooled 5318 
analyses from RCTs (p = 0.295) and non-RCTs (p = 0.341). The trends though were 5319 
interesting, with the pooled OR from non-RCT studies associated with marginally higher 5320 
rates of nephrotoxicity (OR = 1.25) with colistin combination therapies, compared with 5321 
lower rates in RCTs (OR = 0.78). Nephrotoxicity rates were observed to be lower in the 5322 
colistin combination arms of all 3 RCTs included (colistin-fosfomycin #743 OR = 0.77; 5323 
colistin-rifampicin #757 OR = 0.77; colistin-antipseudomonal agent #857 OR = 0.84), 5324 
compared with only 3 of 8 non-RCTs reporting lower rates in the colistin-combination arms 5325 
(OR 0.6-0.94). This may suggest that whilst anecdotally, addition of another agent to 5326 
colistin could potentiate the adverse renal toxicity effects, this observation may be subject 5327 
to several confounding factors. Firstly, due to the observational nature of the 8 non-RCT 5328 
trials (additionally, 6 of 8 were retrospective studies), inconsistencies of estimation and/or 5329 
lack of information could lead to inaccurate baseline renal function, with most studies (6/8, 5330 
2 studies #753 and #990 did not include a definition) estimating this from a single 5331 
measurement of serum creatinine on initiation of therapy. The underlying differences in 5332 
demographics and disease severity/characteristics between the colistin combination and 5333 
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colistin monotherapy arms of non-RCT trials could thus affect the risk of nephrotoxicity 5334 
developed during therapy/infective episode.  Therapeutic choices were made by individual 5335 
physicians in the non-RCT studies, and factors such as severity of illness and pre-existing 5336 
comorbid conditions (e.g. immunosuppression) could result in greater likelihood of the use 5337 
of additional agents in the hope of synergy against a specific organism, or to broaden 5338 
empirical therapy, all of which have previously been shown to be independent risk factors 5339 
for nephrotoxicity. (407-409) Moreover, varying doses and durations of antimicrobial 5340 
therapies could further impact the observation of nephrotoxicity. Although there is 5341 
insufficient evidence to suggest that the addition of other antimicrobial agents to colistin 5342 
has led to increased nephrotoxicity, the lack of difference in mortality and clinical response 5343 
rates between colistin combination therapies and other standards of therapy including 5344 
colistin monotherapy (save for a small subset of bacteraemic patients where colistin- 5345 
tigecycline combination is associated with better all-cause survival) contravenes in vitro 5346 
observations of synergy, (410) and the expectation that broadening the spectrum of activity 5347 
by way of combination therapies in sepsis could lead to superior clinical outcomes. (169, 5348 
411) 5349 
6.2.1.4 Sample size problems 5350 
The summative evidence may show indifference due to the paucity of well-designed clinical 5351 
trials with sufficient sample size. There were only 4 randomised controlled trials included in 5352 
this study, none were double-blinded, and sample sizes varied from n = 43 – 209. 5353 
Gutiérrez-Gutiérrez et al recently published results from a retrospective multi-centre cohort 5354 
study (INCREMENT) assessing the effects of any appropriate combination therapy and 5355 
appropriate monotherapy for the treatment of carbapenemase-producing 5356 
enterobacteriaceae bacteraemia on all-cause 30-day mortality. (412) The impact of the 5357 
various treatment regimens on all-cause 30-day mortality were as follows – inappropriate 5358 
therapy (60.6%, 57/94), all appropriate therapy (38.5%, 132/343), appropriate monotherapy 5359 
(40.8%, 85/208), appropriate combination therapy (34.8%, 47/135). Appropriate therapy 5360 
was defined as receipt of ≥ 1 microbiologically active agent (susceptible in vitro) within 5 5361 
days of infection. Based on the mortality rates of monotherapy and combination therapy 5362 
from this study, an appropriate sample size with a type II error rate of 5% (probability of 5363 
incorrectly rejecting the null hypothesis of no difference between the 2 arms) and power of 5364 
80% (probability of a significant result, rejecting the null hypothesis) should be 2116 (n = 5365 
1058 in each arm). If the assumption is made that colistin combination is the only 5366 
‘appropriate therapy’, and all other regimens (e.g. colistin monotherapy) are not, the sample 5367 
size required to detect significance based on the observations in the INCREMENT study 5368 
would be 176 (n = 88 in each arm), which is considerably more than the study population of 5369 
2 out of 3 RCTs with all-cause mortality as an outcome measure. Small sample sizes may 5370 
lead to type I errors of incorrectly not rejecting the null hypothesis, or false negative finding, 5371 
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due to the inability to detect smaller differences. (413) It is however difficult to recruit 5372 
suitable patients into trials for colistin combination therapies, as these are often options of 5373 
last resort, reserved for patients with MDR (often XDR) Gram-negative infections, usually 5374 
occurring in the critical care setting. It is unethical to withhold treatment knowing that harm 5375 
could potentially occur, and hence true randomised placebo-controlled (or controlled with 5376 
‘inappropriate therapy’) double-blinded clinical trials investigating the outcomes of colistin 5377 
combination therapies should never be performed in the present day. Randomised designs, 5378 
are thus restricted to less critically ill patients, and probably underestimates the efficacy of 5379 
combination therapies, particularly colistin combination therapies, where the additional 5380 
burden of toxicity cannot be ignored. (19) 5381 
6.2.1.5 Trial design 5382 
Part of the response to tackling the problem of antimicrobial resistance has been calls for 5383 
updates on the design of clinical trials for antibacterials, (18) focussing on trial designs to 5384 
aid external validity of results as well as recruitment of patients (e.g. pragmatic clinical 5385 
studies), (180) demonstration of superiority rather than non-inferiority (useful for assessing 5386 
treatments of last resort), (18, 178) assessment of multiple outcomes with clearer 5387 
consensus guidelines for case definition and outcome measures, (19, 413, 414) and new 5388 
models/designs for assessment of efficacy (e.g. cure-death multistate model). (415) These 5389 
redesigns and adapted improvements for anti-infective trials may help to bolster the current 5390 
evidence base, providing physicians a much-needed decision making tool thereby 5391 
maximising the benefit of the currently available antimicrobials and minimising their misuse, 5392 
and will be crucial in optimising the research and development phases of drug discovery 5393 
and new regimens. (18) 5394 
6.2.1.6 Colistin dosing regimens 5395 
Moreover, COL or rather CMS (sulphomethylated, therefore less toxic pro-drug) dosing has 5396 
been the focus of much debate in recent years. Due to the history of the clinical use of 5397 
colistin (introduction in 1960s, falling into disuse a decade later due to ‘excessive toxicity’ 5398 
compared to its contemporaries in a crowded antibacterials market, only to return to more 5399 
regular clinical use in the era of rising Gram-negative multi-drug resistance – See Section 5400 
1.1.5 for further details), when COL was ‘reintroduced’ more recently to treat systemic MDR 5401 
infections, relatively low doses (e.g. 1-2 mu of CMS) (416) based on evidence gleaned from 5402 
studies conducted decades ago. COL has suffered from the lack of use in clinical medicine 5403 
compared with other agents introduced at a similar time (e.g. aminoglycosides, quinolones) 5404 
with considerably less information about its safety or efficacy. Contemporary PK studies 5405 
have alluded to the improbability of achieving a target COL serum concentration of 2 mg/L 5406 
(clinical susceptibility breakpoint, and epidemiological cut-off (separating susceptible ‘wild- 5407 
type’ strains from the resistant) values for Enterobacteriaceae and A. baumannii) with 1-2 5408 
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mu (or the equivalent in mg) of CMS, recommending instead a higher dose of 9 mu (in 2-3 5409 
divided doses), with a loading dose of 9 mu, in the absence of renal impairment. (134, 146, 5410 
417) Additionally, Garonzik et al suggested that optimisation of COL dosing for critically ill 5411 
patients hinges on close monitoring of renal function (i.e. creatinine clearance) and target 5412 
serum concentrations required from in vitro determination of MIC. (134) The wide range of 5413 
CMS dosing regimens used in the studies included in the pooled analyses may account for 5414 
the inter-study differences observed (different regimens used in different institutions), as 5415 
well as contribute to clinical efficacy for individual patients, as CMS dosing regimens were 5416 
not tailored to the MIC of the infecting organism or their specific creatinine clearance. 5417 
6.2.1.7 Colistin heteroresistance 5418 
Another factor that may lead to clinical failure following COL therapy may lie with the 5419 
difficulty in ascertaining COL susceptibility in vitro. None of the 51 studies included patients 5420 
with infecting organisms that were resistant to colistin in vitro, although varying rates of 5421 
clinical success and associated mortality were reported, despite some being given COL 5422 
combination therapies (e.g. COL-rifampicin, COL-carbapenems, COL-tigecycline). A 5423 
possible explanation could be due to the inherent problem of COL heteroresistance, which 5424 
have been reported in Enterobacteriaceae, (418-420) A. baumannii, (164, 165, 262, 421) 5425 
and P. aeruginosa. (204) COL heteroresistance is difficult to detect with conventional 5426 
susceptibility testing methods (often only detected with PAP – See Sections 3.1.3 and 3.1.4 5427 
for details), and reliable genotypic methods have yet to be described to date. COL 5428 
heteroresistant strains often appear susceptible, with a far higher proportion susceptible to 5429 
COL prior to exposure, and resistant subpopulations selected for with colistin treatment. 5430 
(165) As PAP was not performed in any of the clinical trials, it is unknown what the potential 5431 
impact of this is on the prediction of positive outcomes with COL combinations over their 5432 
comparators could be. A recent in vitro PKPD study demonstrated the superiority of COL in 5433 
combination with doripenem compared with COL monotherapy against 2 COL 5434 
heteroresistant strains of P. aeruginosa, (204) suggesting the addition of a second agent to 5435 
colistin may prove beneficial where infecting organisms are COL heteroresistant.  5436 
6.2.1.8 Colistin combinations – Time to explore new combinations? 5437 
Whilst the lack of evidence to advocate for COL combination therapy (Section 2, and 3 5438 
other meta-analyses (177, 202, 203)) may be due to the relative poor quality of the trials 5439 
conducted to date, the lack of expected efficacy may lie with the choice of agent(s) 5440 
selected for combination with COL. Carbapenem therapy has been cited in numerous 5441 
studies as an independent risk factor for infection with carbapenem-resistant and 5442 
carbapenemase-producing organisms. (422-426) Despite this, COL-carbapenem 5443 
combinations remain a popular treatment option for treating carbapenemase-producing 5444 
Gram-negative infections. This may seem counter-intuitive from a mechanistic point of 5445 
 300 
view, given the addition of COL does not offer a significant advantage to carbapenems as 5446 
their antimicrobial target site and site of enzymatic inactivation are within the periplasm (for 5447 
the major carbapenemases (KPC, VIM, OXA-48) apart from NDM, which is a lipoprotein b- 5448 
lactamase bound to the inner leaflet of the outer membrane),  and increasing their influx 5449 
through the outer membrane may not have any additional net activity, (427) whilst 5450 
potentially increasing the production of the carbapenemases, resulting in rising 5451 
carbapenem resistance, leading to treatment failure. (428) This is similarly reflected by the 5452 
observation of higher infection-related mortality observed in 2 of the 3 studies (Navarro-San 5453 
Francisco #1088, Bergamasco #1308; none of the infections treated with COL containing 5454 
regimens resulted in infection-related mortality in the study by Souli #1208) comparing 5455 
COL-carbapenem combinations with COL monotherapy, although the pooled OR was not 5456 
statistically significant (OR = 2.8, p = 0.424).  5457 
Of note, a recently concluded multi-centre RCT investigating the clinical outcomes between 5458 
COL-meropenem combination therapy (n = 208) and COL monotherapy (n = 198) have 5459 
failed to demonstrate any significant differences in mortality or clinical cure. (429) The 5460 
relative risk for clinical failure with COL-meropenem compared with COL monotherapy at 5461 
14 days was 0.93 (p = 0.172), with 28-day all-cause mortality numerically worse (RR 1.03, p 5462 
= 0.78), and higher relative risk of microbiological failure (RR 1.1, p = 0.489). The clinical 5463 
failure rate with either treatment regimen was alarmingly high – 79% with monotherapy, and 5464 
73% with COL-meropenem combination therapy, compared with clinical failure rates of < 5465 
60% with either COL monotherapy or COL combinations (rifampicin or fosfomycin) in 2 5466 
other RCTs (207, 215), despite optimisation of COL dosing in the COL-meropenem trial.  5467 
 Interestingly, acquisition of new carbapenem-resistant bacteria was higher in the 5468 
combination therapy arm, with RR 1.73 (p = 0.146), in keeping with the observation that 5469 
carbapenem therapy increases the likelihood of being colonised/infected with carbapenem- 5470 
resistant organisms. The infecting pathogen in the majority of cases in both arms was A. 5471 
baumannii (76% in COL monotherapy arm, and 77% in combination arm), and 5472 
carbapenem-resistance was high amongst all isolates in this study (meropenem MIC > 8 5473 
mg/L in 97% across both arms). The dosing regimens used in this study were based on 5474 
recommendations by contemporary PK studies, (134, 430) utilising a loading dose of 9 mu 5475 
of CMS followed by 4.5 mu twice daily (with adjustment for patients with creatinine 5476 
clearance of < 50 mL/min), and meropenem 2g (over a 3 h infusion) thrice daily (renally 5477 
adjusted where appropriate). Incidence of nephrotoxicity (determined by RIFLE score) was 5478 
higher with COL monotherapy (48% vs 29%, p = 0.001) at day 14, which was partially 5479 
reversed over time as evidenced by lower rates by day 28 (35% vs 20%, p = 0.075), 5480 
consistent with reports from observational studies. (430) Diarrhoea was observed more 5481 
often with COL-meropenem combination therapy, compared with COL monotherapy 5482 
(although incidence of confirmed Clostridium difficile diarrhoea was low in both arms 1% 5483 
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with monotherapy, 3% with combination therapy, p = 0.174), 27% versus 16% (p = 0.009). 5484 
Meropenem possesses a broad-spectrum of activity against a number of enteric organisms 5485 
to which COL is inactive (anaerobes, Gram-positive bacteria), and treatment with 5486 
meropenem would predictably affect the gut microbiome more than COL, potentially a key 5487 
reason for the higher incidence of diarrhoea in the combination therapy arm. This study has 5488 
highlighted the lack of evidence to recommend the addition of carbapenems to COL for the 5489 
treatment of carbapenem-resistant Gram-negative infections, in particular A. baumannii 5490 
infections. It is important to note that all isolates tested were susceptible to COL in vitro 5491 
(MIC ≤ 2 mg/L), suggesting the pitfalls of reliance on COL as the sole active agent in clinical 5492 
treatment of MDR Gram-negative infections.  5493 
Although the lack of clinical activity of COL and carbapenems may be disappointing, it is at 5494 
least in part due to the inability of polymyxins to efficiently overcome the activity of b- 5495 
lactamases (in the case of carbapenems, carbapenemases), and this may be the prevailing 5496 
reason for clinical and microbiological failure in the COL-meropenem RCT reported by Paul 5497 
et al (although not explicitly tested in all isolates, the authors note a high rate of 5498 
carbapenemase-producers amongst Gram-negative clinical infections in the institutions the 5499 
trial was conducted (i.e. Israel, Italy and Greece). (429) If the mechanism of carbapenem- 5500 
resistance were due to porin loss and/or efflux, (431) the permeabilising property of 5501 
polymyxins may be employed more effectively in the polymyxin-carbapenem combination.  5502 
Polymyxins, do however, provide an excellent opportunity for creating completely novel 5503 
antimicrobial effects on Gram-negative pathogens, and this should be fully exploited in 5504 
polymyxin combination therapies to maximise the use of this class of antimicrobials. As 5505 
detailed in Section 1.1.1, whilst the pipeline for anti-Gram-negative agents has dwindled, 5506 
there have been considerably more anti-Gram-positive agents brought to market in the 5507 
recent past. Antimicrobials with sole activity against Gram-positive agents are unable to 5508 
enter the Gram-negative cell envelope often due to size (hydrophilic molecules enter via 5509 
porin channels provided they are smaller than 600 Daltons) (432) and/or molecular charges 5510 
(the outer membrane of the Gram-negative cell envelope carries a strong negative surface 5511 
charge), and whilst the lipid bilayer structure of the outer membrane allows the passive 5512 
diffusion of lipophilic molecules, this is process is slow and inefficient (10-100 fold lower 5513 
diffusion rates of steroids) compared to the diffusion cross the phospholipid bilayer 5514 
cytoplasmic membrane. (433) A number of hydrophobic antimicrobials (e.g. macrolides, 5515 
CHL, FUS, novobiocin) are extruded from the Gram-negative cells by multi-drug efflux 5516 
pumps, and the combination of these efflux mechanisms and the relatively impermeable 5517 
outer membrane act synergistically to exclude these antimicrobials, hence resulting in 5518 
phenotypic resistance. (337, 433, 434) It has been shown that the balance between the 5519 
influx of these hydrophobic antimicrobials and the speed of efflux dictates the level 5520 
phenotypic resistance, and theoretically, if the permeability is increased (e.g. in the 5521 
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presence of polymyxins), the speed of efflux might not be able to keep pace with the influx 5522 
and susceptibility is potentially restored. (337) Vaara et al and Ofek et al observed the 5523 
marked reduction of MIC of hydrophobic antimicrobials with the addition of permeabilising 5524 
agent, PBNP (a derivative of polymyxin B without the fatty acyl tail, with no demonstrable 5525 
antimicrobial activity whilst retaining the outer membrane permeabilising property), (297, 5526 
435) and Ofek noted that the addition of PBNP to novobiocin and erythromycin 5527 
successfully treated mice infected with P. aeruginosa (10/10) and K. pneumoniae (10/18) in 5528 
a septicaemic mouse model.  5529 
The current climate of multi-drug resistance in Gram-negative infections leaves physicians 5530 
with few choices, and the emphasis on preserving the activity of the agents that remain 5531 
active against these pathogens cannot be understated. The optimisation of therapy is an 5532 
important facet in meeting this objective, and may be aided by new rational combination 5533 
approaches to maximise efficacy and potency of treatment, whilst minimising the excess 5534 
burden of resistance incurred.   5535 
 5536 
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6.2.2 Colistin in vitro susceptibility tests 5537 
6.2.2.1 Overview of susceptibility test methods 5538 
Table 6-1 Overview of currently available susceptibility testing methods. 5539 
(Adapted from Jorgensen et al and Louie et al) (436, 437) 5540 
All phenotypic test methods are subject to accuracy of inoculum determination (e.g. 0.5 5541 
McFarland standard needed in most cases, with appropriate dilution for organisms with 5542 
different growth requirements – 1:100 dilution for Enterobacteriaceae).  5543 
Disc diffusion and MIC methods benefit from being in general use and international 5544 
consensus guidelines for performance and interpretation (EUCAST, CLSI), with constant 5545 
updates and rapid incorporation of new agents. (271, 272) 5546 
*  Agar dilution has been adapted to resource-poor settings to determine susceptibility 5547 
versus resistance, by performing a truncated dilution series across the susceptibility and 5548 
resistance breakpoints. 5549 
** Macrodilution methods are largely superceded by microdilution, based on similar 5550 
principle but performed in individual tubes or flasks instead of multiple wells on a 96-well 5551 
microtitre plate. Far more time and labour-intensive, and more expensive to perform.  5552 
 5553 
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 Advantages Disadvantages 
Agar-based 
methods 
Visualise colony morphology 
 
Accuracy hindered by swarming 
organisms (e.g. Proteus spp.) 
 
 Disc diffusion Cheap 
 
Scalability (volume and agents 
tested) 
 
Low hands-on time on set-up 
 
Suitable for automation 
 
Skill requirement low 
 
Elaborate equipment not required 
(except for automation) 
 
Commercially prepared media and 
antimicrobial agents widely 
available 
 
MIC not determined 
 
Poor diffusion of certain agents may 
impact on accuracy and reliability 
(e.g. teicoplanin, colistin) 
 
Degree of subjectivity in 
measurement of zone sizes, 
resulting in errors 
 
May be more time-consuming to 
read and interpret than MIC 
methods 
 
Not suitable for anaerobic bacteria 
(lack of correlation between zone 
sizes and MICs) 
 Gradient strip 
method 





Lower ascertainment error than disc 
diffusion 
 
Suitable for automation 
 
Elaborate equipment not required 
(except for automation) 
 
Commercially prepared media and 





Costlier than disc diffusion – both 
test strip and number of plates per 
organism 
 
Less scalable than disc diffusion 
 
Poor diffusion of certain agents may 
impact on accuracy and reliability 





Agar dilution* MIC method 
Compared to Etest, better suited for 
high volume work in a large set-up 
(e.g. reference laboratory) 
Suitable for automation 
Flexible platform, with ability to 
change drug concentrations and 
ratios easily within existing set-up 
Expensive 
Labour-intensive 
Long set-up time, prone to errors at 
multiple stages (reduced if 
automated) 
Moderate skill level required for set-
up and result ascertainment 
Compound instability (once 
incorporated into media), may lead 
to inaccurate results 
Difficult to judge inoculum effect on 




Not dependent on diffusion of drug 
across agar 
Not affected by swarming 
Growth media suitable for most 
human pathogenic organisms 
Prone to errors by contamination or 
mixed cultures (unless parallel 
purity plate set-up) 
Inoculum effect on result difficult to 





MIC method (current recommended 
‘gold standard’ susceptibility test 
method) 
Flexible platform, with ability to 
change drug concentrations and 
ratios easily within existing set-up 
Suitable for automation (basis of 
most widely used automated 
susceptibility test systems) 
Auccrate and reliable (provided 
performed to optimal standards) 
Expensive 
Labour-intensive (staff time and 
skills requirement) 
Long preparation / set-up time, 
prone to errors at multiple stages 
Result ascertainment subjectivity 
(e.g. manual judgement of turbidity) 
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5554
6.2.2.2 Other methods for detection of antimicrobial resistance 5555
6.2.2.2.1 Molecular (DNA) methods  5556
o Rapid turnaround of results (usually 2 – 3 h from sample receipt) as growth of 5557
bacteria not required (phenotypic methods usually require incubation of a minimum 5558
of 18 – 24 h) 5559
o Useful for resistance screening and provides rapid results for infection control 5560
purposes 5561
o Relatively higher skill requirements compared with most phenotypic methods, 5562





Reduced errors in the sample 
preparation stage by minimising 
handling and manipulation 
Standardisation of inoculum 
MIC method possible 
Less subjectivity with result 
ascertainment compared with 
manual methods 
Lower skill requirement compared 
with broth microtitre dilution 
Real-time results direct to end-user 
possible (dependent on system / 




Panels combining identification and 
susceptibility available 
Expensive (high up-front costs for 
equipment and IT set-up; relatively 
higher costs incurred with 
maintenance and consumables 
compared with manual methods) 
Dedicated laboratory space 
required for platform(s) and IT 
system 
Customisation of panels restricted 
compared with broth microtitre 
diltuon (not economical unless 
ordered in bulk) 
Compromise between expanded 
MIC range per drug and number of 
drugs tested per panel 
Scalability per platform limited 
(compared with manual methods) 
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o Qualitative PCRs provide binary results with far less subjectivity compared with 5565 
most phenotypic methods 5566 
o Dedicated facility and expensive equipment required 5567 
o May be scaled up for high throughput settings (although limited by capacity of 5568 
thermocycler and/or DNA extraction platforms) 5569 
o Detection of resistance genes may not always result in phenotypic resistance (due 5570 
to varying levels of expression) – leading to false resistance or major errors 5571 
o Negative test does not definitively rule out resistance either (e.g. different 5572 
mechanism of resistance present but not tested for, genetic variant of resistance 5573 
determinant present) 5574 
o Current platforms unable to provide MIC information (useful for clinical 5575 
management) 5576 
6.2.2.2.2 Detection of hydrolytic enzymes 5577 
o E.g. lateral flow immunoassays, (438, 439) biochemical hydrolysis (440, 441) 5578 
o Rapid turnaround (usually < 2 h), but results are inconsistent from neat samples. 5579 
(442) 5580 
o Simple to use, additional dedicated laboratory equipment not usually required. 5581 
o Some level of subjectivity involved in result ascertainment and interpretation, may 5582 
lead to errors in measurement. 5583 
o Expensive, but often cheaper to perform than similar molecular methods. 5584 
6.2.2.2.3 Detection of altered target 5585 
o E.g. latex agglutination test for PBP2’ (test for MRSA) (443) 5586 
o Similar to lateral flow immunoassays (monoclonal antibodies to target) 5587 
o Rapid turnaround, but cannot be done on neat samples 5588 
o Relatively more hands-on time compared with lateral flow immunoassays 5589 
o Cheaper than molecular methods 5590 





6.2.2.2.4 Mass spectrometry 5595 
o Matrix-assisted laser desorption/ionisation time of flight mass spectrometry 5596 
(MALDI-TOF) mainly used in modern clinical microbiology laboratories for 5597 
identification of organisms (each organism produces a unique peptide fingerprint) 5598 
(444) 5599 
o Adapted to detect resistance (e.g. different fingerprints generated for MRSA and 5600 
VRE compared to their susceptible counterparts) 5601 
o Detection of specific b-lactamases by comparing the ratio of intact and hydrolytic 5602 
metabolites of the b-lactam antibiotic before and after incubation with the bacterial 5603 
culture.  5604 
6.2.2.3 Comparative results – Population analysis 5605 
Of the 36 clinical A. baumannii isolates tested in this study, only 1 (AB236) was susceptible 5606 
by PAP. Antibiotic-susceptible type strains NCTC 12156 (A. baumannii), NCTC 12241 (E. 5607 
coli) and NCTC 10418 (E. coli) were likewise susceptible to COL by PAP (i.e. colistin 5608 
heteroresistance not detected). In stark contrast with BMD, where only 5/42 isolates tested 5609 
were resistant to COL (MIC range 16 to > 256 mg/L), 38/42 strains tested were resistant to 5610 
COL by PAP. This perhaps reflects the inadequacy of conventional susceptibility methods 5611 
for the detection of heteroresistance, and hence prediction of treatment failure. (341) 5612 
Amongst the A. baumannii strains studied here, 2 clinical strains (AB183, AB213) with low 5613 
COL MICs (0.5 mg/L by BMD) comprised of subpopulations that were highly selected for in 5614 
the presence of colistin, demonstrating high PAP-AUC ratios. See Figure 6-1 for details of 5615 
the PAP for these phenotypes compared with the reference COL-heteroresistant strain 5616 
(NCTC 12934) and a representative COL-susceptible type strain (NCTC 12156). These 5617 
strains with highly inducible COL resistance may represent hypermutator phenotypes, as a 5618 
survival advantage to adverse external conditions such as antibiotic treatment. Mutation 5619 
frequencies of hypermutator subpopulations have been demonstrated to be 10-100 fold 5620 
greater than the original strain, conferring a considerable adaptive advantage. (445) AB183 5621 
and AB213 may also harbour COL-dependent subpopulations. The survival of these 5622 
subpopulations was contingent on the presence of COL in a study by Hong et al, and the 5623 
authors noted higher rates of mortality with COL in the 18 patients infected with COL- 5624 
dependent A. baumannii strains compared with patients with COL-susceptible (n = 27) 5625 
infections (67% vs 37%, p = 0.05). (446) The underlying molecular mechanisms of COL- 5626 
dependence in A. baumannii have yet to be fully elucidated, (446) and indeed may be 5627 
multifactorial, although some authors have noted mutations in pmrB (447) and lpxACD (448) 5628 
on in vivo (COL therapy) and in vitro (COL 10 mg/L selection from clinical isolates) 5629 
respectively.  5630 
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Figure 6-1 Representative colistin versus A. baumannii population analysis profiles. 5631 
AB183 and AB213 – COL heteroresistant clinical A. baumannii isolates, with highly 5632 
inducible COL-resistant phenotypes (BMD MIC 0.5 mg/L); NCTC 12156 (COL-susceptible 5633 
A. baumannii type strain; BMD MIC 0.25 mg/L); NCTC 12934 (COL heteroresistant P. 5634 
aeruginosa type strain; BMD MIC 1 mg/L). Dashed line denotes susceptible breakpoint for 5635 
COL (2 mg/L).  5636 
 5637 
6.2.2.4 Conventional susceptibility test methods for the detection of 5638 
colistin resistance in A. baumannii 5639 
The sensitivity of the commonly employed susceptibility test methods for detecting COL 5640 
resistance was low, when compared with a gold standard of PAP – BMD 13.2%, agar 5641 
dilution 15.8%, Etest 15.8% and MicroScan 42.1%. Categorical agreement was similarly 5642 
low with BMD 23.4%, Etest and agar dilution 23.8% and MicroScan 47.6%. Very major 5643 
error rates were very high – BMD 86.8%, E test and agar dilution 84.2% and MicroScan 5644 
57.9%. No major errors were detected in the study with unexpectedly few truly susceptible 5645 
isolates (n = 4). To the best of my knowledge, this is the first study comparing BMD, Etest, 5646 
agar dilution and an automated system (MicroScan) against PAP for the detection of COL 5647 
resistance in A. baumannii. A number of studies have noted detection of COL 5648 
heteroresistance with PAP despite susceptibility by the BMD reference method (i.e. COL 5649 
MIC ≤ 2 mg/L). (164, 165, 262, 419) Additionally, Hawley et al observed higher proportion of 5650 
COL resistant subpopulations in A. baumannii strains isolated from patients with prior 5651 
exposure to COL therapy (approximately 4 fold higher) compared with controls who were 5652 
colistin therapy naïve. (164) Similarly, Srinivas et al noted that in their small cohort of 24 5653 
patients with A. baumannii bloodstream and respiratory tract infections, the infection- 5654 
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related mortality rate was 21% (n = 5), and 4 of the 5 patients harboured COL- 5655 
heteroresistant strains.  5656 
This study emphasises the pitfalls of relying on BMD as a reference standard for COL 5657 
susceptibility testing. The sensitivity of the test was by far the worst of all the conventional 5658 
methods tested, resulting in an unacceptably high very major error rate of 86.8%. Although 5659 
the number of isolates tested was small (n = 42), and only included 36 clinical A. baumannii 5660 
strains, the results of the comparative study done here highlighting the inadequacies of 5661 
routine susceptibility test methods, could potentially explain the observation of treatment 5662 
failure with COL monotherapy. (163, 258)  5663 
6.2.2.5 Time-kill assays improve detection of colistin resistance in A. 5664 
baumannii 5665 
In contrast to routine susceptibility methods, sensitivity and categorical agreement were 5666 
higher with time-kill methods, reflecting superior detection of COL resistance – TKMIC 5667 
(60.5%, 64.3%), TKMBC (92.1%, 92.9%), MTKCS (57.9%, 61.9%) and MTKC (92.1%, 92.9%). 5668 
Consequently, very major error rates were likewise low, TKMIC 39.5%, TKMBC 7.9%, MTKCS 5669 
42.1% and MTKC 7.9%. No major errors were detected with the time-kill methods.  5670 
It is interesting to observe the difference in resistance detection rates between BMD and 5671 
TKMIC. This might be due to relative subjectivity in determination of MIC in BMD (manually 5672 
determined by eye – lowest concentration with ‘absence of turbidity’ [see Section 3.1.2.6]), 5673 
compared with difference in viable colony counts for time-kill methods (see Section 5674 
3.1.2.9). Determination of turbidity by eye may not be possible at colony counts much lower 5675 
than » 1 x 108 cfu/mL (approximately 0.5 McFarland standard). For this study, TKMIC 5676 
corresponded to the lowest concentrations supporting a maximum growth of » 106 cfu/mL. 5677 
This may lead to underestimation of the true inhibitory concentration of COL by visual 5678 
turbidity. Furthermore, the time-kill methods were performed with continuous shaking (224 5679 
rpm) of the reaction tubes as is the convention, ensuring constant mixing of medium, 5680 
oxygen, bacteria and antimicrobials (where present). BMD and the automated methods 5681 
(based on BMD), though subject to similar incubation conditions (e.g. temperature, oxygen 5682 
content) and tested with the same growth medium (i.e. ISB, were performed without 5683 
shaking, and indeed would be difficult to handle on shaking platforms or in a shaking 5684 
incubator, given the relative volume of contents (usually 150 – 200 µL) to that of the 5685 
individual wells (usually ≤ 500 µL). (449) Kravanen et al examined the extent of COL loss in 5686 
a variety of broth-based experimental conditions and found that use of polystyrene reaction 5687 
vessels resulted in high COL loss (due to high binding affinity and capacity) compared with 5688 
glass or polypropylene, and this was markedly higher in polystyrene microplates (used in 5689 
BMD, including this study) than in large tubes (used in time-kill experiments, but not in this 5690 
study – polypropylene tubes were used instead). (450) The authors noted that the 5691 
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percentage of COL lost to adsorption was notably higher at lower concentrations, 5692 
potentially resulting in greater degree of errors made in MIC determination for susceptible 5693 
organisms. This however, would have led to overestimation of resistance (i.e. false 5694 
resistance or major errors) rather than under detection, compared with the time-kill 5695 
methods.  5696 
The surrogate markers proposed by this study – MTKCS (for TKMIC) and MTKC (for TKMBC) 5697 
used a simplified time-kill protocol (only one colistin concentration needed, at the 5698 
susceptibility breakpoint of 2 mg/L), with similar results to TKMIC and TKMBC. The biggest 5699 
drawback of the time-kill methodology was the need to obtain viable bacterial colony 5700 
counts at the start and the end (at 24 h) of the experiments, although this allowed for 5701 
determination of MBC and more accurate MICs (defined by the lowest concentration that 5702 
inhibited growth at 24 h, or bacteriostatic effect). This unfortunately precludes the use of 5703 
time-kill methods in routine clinical diagnostic laboratories, limiting its use. 5704 
6.2.2.6 Other experimental methods for detection of colistin resistance 5705 
A macro Etest method first proposed by Walsh et al for the detection of glycopeptide 5706 
heteroresistance in S. aureus, (265) was performed alongside an adaptation of the method 5707 
using COL discs instead of Etest strips in this study. See Section 3.1.2.10 for details of 5708 
both methods.  The macro Etest method was noted to be a useful screening test for 5709 
glycopeptide-heteroresistance in S. aureus, (265, 267) however, this test could not be 5710 
recommended for purposes of COL-heteroresistance detection in A. baumannii based on 5711 
the results from this study. Sensitivity and categorical agreement (using COL 2 mg/L as the 5712 
cut-off) were slightly better than the standard Etest method, 31.6% (vs. 15.8%) and 35.7% 5713 
(vs. 23.8%), but this introduced the only major error of the entire study (false resistance 5714 
with MIC = 4 in an isolate susceptible by PAP). This suggested that raising the cut-off value 5715 
to increase sensitivity could potentially create more major errors. The ROC curves for both 5716 
macro Etest and disc diffusion methods similarly demonstrated their inability to reliably 5717 
predict COL resistance.  5718 
The macro methods rely on high inocula (2 McFarland standard, approximately 6 x 108 5719 
cfu/mL) and prolonged incubation (48 h) to detect glycopeptide-resistant subpopulations in 5720 
S. aureus. These adjustments alone were however unable to overcome the poor diffusion of 5721 
COL across agar, likely due to its amphipathic nature.  5722 
6.2.2.7 Two-step algorithm to screen for colistin resistance 5723 
Potential two-step algorithms are proposed here based on the results from this study, 5724 
utilising routine susceptibility methods to improve sensitivity and hence screening for COL 5725 
resistance, with the assumption that a time-kill or PAP method would be used as a 5726 
confirmatory test in the absence of other suitable methods. 5727 
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Utilising an agar-based MIC method (i.e. Etest, agar dilution) followed by a BMD 5728 
(commercially prepared BMD panels have been shown to be comparable (159, 160)) 5729 
method, coupled with lowering the COL MIC cut-off for screening purposes to 0.25 mg/L 5730 
improved the detection of colistin resistance, depicted by the improved sensitivity (97.4% 5731 
for Etest à BMD, 100% for agar dilution à BMD) and categorical agreement of > 90% and 5732 
very major error rates of ≤ 3% for both algorithms. (See Section 3.1.4.3 for details) The 5733 
latter 2 conditions fulfilling 2 of 3 criteria set by the US FDA for acceptability of a reliable 5734 
test. (277) The major error rate was 50% for both algorithm, which is considerably higher 5735 
than the guidelines of ≤ 1.5%, (277) although it is difficult to draw conclusions about major 5736 
error rates reported from this study due to the underrepresentation of truly COL susceptible 5737 
isolates (35 of 36 clinical A. baumannii isolates in this study were COL heteroresistant).         5738 
6.2.2.8 Mechanisms of colistin resistance in A. baumannii 5739 
The prevailing theory underlying COL resistance in A. baumannii is due to the reduction of 5740 
the net negative charge borne by its outer membrane. The initial phase of polymyxin action 5741 
on Gram-negative bacteria including A. baumannii is the binding of the cationic portion of 5742 
the amphipathic peptide with the negatively charged outer membrane (conferred by the 5743 
lipid A portion of the LPS molecules that make up the outer leaflet of the lipid bilayer outer 5744 
membrane). The addition of phosphoethanolamine (PetN) to the phosphate groups of lipid 5745 
A reduces its negative charge, thus decreasing binding affinity of polymyxins to the outer 5746 
membrane. (451-453) The addition of PetN is mediated by the expression of pmrCAB 5747 
operon, which is auto-regulated by pmrA. Alterations to pmrA and pmrB genes resulting in 5748 
COL resistance by the addition of PetN or galactosamine (454) to lipid A phosphate groups 5749 
have been described in A. baumannii. (451, 453) Plasmid-mediated COL resistance 5750 
determinant, mcr-1, which has received global attention due to the potential of its rapid 5751 
dissemination, subsequently obliterating a crucial agent of last resort. The addition of PetN 5752 
to lipid A was observed in isolates carrying mcr-1, and although there have yet to be 5753 
reports of A. baumannii carrying mcr-1, Liu et al successfully transformed COL-susceptible 5754 
(MIC 0.25 – 1 mg/L) type strains and clinical isolates with mcr-1 carrying plasmids, resulting 5755 
in COL resistance (MIC 16 mg/L in the type strain, and > 128 mg/L in clinical strains), (455) 5756 
clearly demonstrating the potential and consequence of spread to A. baumannii.  5757 
COL resistance has also been observed in A. baumannii strains with modifications in LPS 5758 
biosynthesis genes, lpxACD. (76) The modifications may be due to mutations or insertions, 5759 
leading to complete loss of LPS. Compared to lipid A modifications, complete loss of LPS 5760 
conferred high-level COL resistance, with MIC often > 128 mg/L. (330) 5761 
Another oft cited mechanism of COL resistance in Gram-negative pathogens is the addition 5762 
of the positively charged L-Ara4N moiety to the phosphate groups of lipid A. This is 5763 
mediated by the expression of arnBCADTEF operon (both synthesis and addition), which is 5764 
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in turn upregulated by the PmrAB two-component system. (330) However, the 5765 
arnBCADTEF operon is absent in A. baumannii. (451, 453)  5766 
6.2.2.9 In vitro detection of colistin resistance – evidence to date 5767 
COL susceptibility testing has received a considerable amount of attention in recent years 5768 
as the antimicrobial makes its return in clinical medicine as agent of last resort. (155, 456- 5769 
458) The physiochemical properties of the drug, whilst making it a potent antimicrobial 5770 
agent (cationic polypeptide with molecular mass of approximately 1200 Da 5771 
(https://pubchem.ncbi.nlm.nih.gov/compound/44144393)), may hinder accuracy of current 5772 
susceptibility tests. Indeed, the performance of COL susceptibility by disc diffusion has 5773 
been found to be unreliable due to its poor diffusion across solid agar. (459, 460) The 5774 
common consensus by international agencies has recommended broth microtitre dilution 5775 
as a reference standard for determining COL susceptibility. This however may fall foul of 5776 
problems arising from heteroresistance, notably in A. baumannii strains. (458) COL 5777 
heteroresistance was noted in strains that were COL susceptible by BMD (susceptible 5778 
clinical breakpoint 2 mg/L), (165) and more alarmingly, was found to be biologically fit in a 5779 
murine model of infection by Band et al resulting in treatment failure with COL (similar 5780 
survival time to untreated controls infected with either COL heteroresistant or susceptible 5781 
strains of carbapenem-resistant K. pneumoniae). (461) Moreover, Choi et al found that COL 5782 
concentrations of up to 64 mg/L were unable to prevent the in vitro selection of COL 5783 
resistant subpopulation (in single-step experiments) in 40 A. baumannii clinical isolates. In 5784 
this study, apart from one isolate with pmrB mutation corresponding to COL resistance, no 5785 
other known resistance determinants (pmrAB, lpxACD) were detected. (462) At present, the 5786 
‘gold standard’ method for detecting heteroresistance is population analysis profiling. (463) 5787 
This method studies the proportion of resistant subpopulations within each strain by 5788 
prolonged (often 48 h) incubation under selection pressure (drug at higher than MIC 5789 
concentrations). (341, 464) PAP, however is extremely labour intensive, and time- 5790 
consuming procedure, and not suited for routine clinical laboratories. (341, 464) Similar 5791 
detection of COL heteroresistance on COL exposure were noted in time-kill studies, and 5792 
may potentially be used to detect heteroresistance in lieu of PAP. (165, 324, 465) Time-kill 5793 
assays are similarly time-consuming, although results may be available marginally sooner 5794 
(often conducted over a 24 h period). Unfortuately, no reliable rapid diagnostic or genotypic 5795 
method exists for detection of COL heteroresistance. A recent review by Giske et al 5796 
concluded that a recently developed rapid method for detection of COL resistance, Rapid 5797 
Polymyxin NP (based on detection of growth in the presence of 3.75 mg/L of COL after 2 h 5798 
of incubation), was insufficiently sensitive (compared with broth microtitre dilution) to be 5799 
recommended as a reliable platform for detection of COL resistance. (466) Similarly, reliable 5800 
genotypic methods have yet to be uncovered for detection of COL heteroresistance in A. 5801 
baumannii. Some reports have noted mutations in pmrAB, phoPQ, mgrB and lpx genes in 5802 
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K. pneumoniae, (419, 467) but thus far, a reliable genotypic detection method for COL 5803 
heteroresistance in A. baumannii remains elusive. (76) A study comparing the zeta potential 5804 
(surrogate of outer membrane surface charge) of COL-susceptible and COL-resistant 5805 
mutants of A. baumannii strains, Soon et al noted a relative decrease in net surface charge 5806 
in COL-resistant mutants compared with their susceptible parent strains. (331) Though the 5807 
exact underlying molecular determinant was unknown, they propose that the observations 5808 
were likely the result of alterations to the lipid A component of LPS, similar to those seen in 5809 
strains with mutations to pmrAB or lpxACD giving rise to insertion of PetN and loss of LPS 5810 
biosynthesis respectively. (331) Zhang et al observed alterations in pmrAB and/or lpxACD 5811 
in COL-resistant and COL-dependent clinical strains, with associated changes in outer 5812 
membrane integrity seen on transmission electron microscopy (increasing levels of 5813 
disruption amongst COL susceptible, resistant and dependent strains) and its long chain 5814 
fatty acid composition (particularly C12 reduction in COL resistant and COL dependent 5815 




6.2.3 Colistin combination therapy – strategy to overcome 5819 
problems with colistin resistance and heteroresistance 5820 
As previously mentioned in Section 2.1.1, combination therapies have been used in the 5821 
clinical management of infections, either empirically (prior to knowledge of in vitro 5822 
susceptibility profile of the infecting organism) or as targeted therapy (less common 5823 
approach, generally only in severe sepsis, and often based on the concept of synergy 5824 
observed in vitro). Although there has been a considerable body of in vitro evidence for 5825 
synergy, suggesting potential benefit of employing more than one agent, this has generally 5826 
not translated into better clinical outcomes. (406, 469)  5827 
COL-carbapenem, COL-rifampicin and COL-sulbactam combinations were shown to be 5828 
synergistic in vitro and in animal/invertebrate models (against strains either susceptible to 5829 
or with low level COL resistance), (470) analysis of pooled survival and clinical response 5830 
data from clinical trials did not confirm this effect (see Section 2.3). Aside from the 5831 
aforementioned problems with types of trials conducted and trial design/parameters, 5832 
potential problems might stem from the choice of ‘partner’ antimicrobial agent(s) used with 5833 
COL, as well as the strain characteristics (synergism/antagonism could be better predicted 5834 
if stratified by PAP characteristics i.e. susceptible, heteroresistant and/or high-level COL 5835 
resistance). Pragmatic clinical trials assessing the ‘real world’ use of novel COL 5836 
combinations (shown to be synergistic in vitro) could be focussed on strains where no other 5837 
therapeutic options are available (i.e. PDR strains, including COL-heteroresistant strains) to 5838 
study the benefit of COL-combinations as a viable treatment regimen in lieu of new 5839 
antimicrobial agents. COL monotherapy may be useful in a subset of patients infected with 5840 
Gram-negative pathogens that are truly susceptible to COL alone (non-heteroresistant 5841 
strains), with optimised dosing to attain a therapeutic target steady-state serum 5842 
concentration of 2 mg/L. However, with increasing use of COL in practice, and 5843 
consequently reports of selection of COL resistant strains during COL therapy, (164, 258, 5844 
446, 447, 461) the burden of COL heteroresistance necessitates alternative options, 5845 
including the use of additional agents in combination with COL.  5846 
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6.2.4 Novel colistin combinations – in vitro study 5847 
The screening process used in this study identified 3 potential novel colistin combinations: 5848 
1) Colistin-daptomycin 5849 
2) Colistin-chloramphenicol 5850 
3) Colistin-fusidic acid 5851 
 5852 
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6.2.4.1 Colistin-daptomycin combination 5853 
The synergistic activity of COL-daptomycin combination was observed only against A. 5854 
baumannii strains. Daptomycin is a cyclic lipopeptide targeting the cytoplasmic membrane, 5855 
in a similar fashion (calcium-bound daptomycin acts like a cationic peptide) (471) to the 5856 
binding of COL to the Gram-negative outer membrane. It was thus hypothesised that the 5857 
combination of 2 membrane-active agents might exert a synergistic effect (Figure 6-2). In 5858 
addition to the synergy described in this study, (472) Galani et al similarly observed 5859 
bactericidal synergy between COL and daptomycin against COL-susceptible A. baumannii 5860 
in time-kill assays (313) and Wang et al noted improved survival (81% vs 35%, p < 0.05) of 5861 
XDR A. baumannii (COL MIC = 1 mg/L) infected G. mellonella larvae treated with colistin- 5862 
daptomycin compared to COL alone, in additional to bactericidal synergy in time-kill 5863 
assays. (314) 5864 
It is interesting that COL-daptomycin activity was only seen against A. baumannii, perhaps 5865 
suggesting the similarities of A. baumannii cytoplasmic membrane to Gram-positive 5866 
pathogens, compared to other Gram-negative species. Furthermore, COL-daptomycin 5867 
combination was not synergistic (although antagonism was not observed either) against 5868 
COL-resistant A. baumannii strains. This finding proposes the theory that colistin acts as a 5869 
permeabiliser of the outer membrane, co-transporting daptomycin (otherwise excluded 5870 
from the cell) to its eventual target site in COL-susceptible strains. Alternatively, there may 5871 
exist a distinct novel target in A. baumannii for the combination, which warrants further 5872 
study. 5873 
Figure 6-2 Putative mechanism of action for colistin and daptomycin in combination. 5874 
 5875 
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6.2.4.2 Colistin-chloramphenicol combination 5876 
COL and CHL combination was noted to be synergistic against diverse Gram-negative 5877 
pathogens, as compared with COL-daptomycin, namely K. pneumoniae (2/7 strains tested), 5878 
P. aeruginosa (4/8) and A. baumannii (3/8). No antagonism was noted against any strain, 5879 
including those expressing high-level COL resistance. CHL, like COL, is another example of 5880 
an old antimicrobial agent (first introduced in 1949), which is seeing a surge in use in recent 5881 
days due to problems with multi-drug resistance. Though unlike COL, it boasts a broader- 5882 
spectrum of activity ranging Gram-positive, Gram-negative and anaerobes, and excellent 5883 
tissue penetration including into the central nervous system, and include multiple 5884 
formulations (i.e. oral, topical, parenteral). (473) However, severe toxicity issues (e.g. 5885 
idiosyncratic aplastic anaemia, dose-dependent bone marrow suppression, ‘gray baby’ 5886 
syndrome due to cardiovascular collapse with high-dose therapy) has led to declining use 5887 
in favour of alternatives with safer toxicity profiles, although its efficacy and availability as 5888 
an oral formulation sees its continued use in resource-poor regions of the world. (473, 474) 5889 
CHL is a relatively small (323 Da) hydrophobic molecule, which binds (competes with 5890 
aminoacyle-tRNA) to peptidyltransferase domain of the bacterial 50S ribosomal subunit 5891 
inhibiting the transpeptidation reaction thereby halting protein synthesis. (473-475) High 5892 
concentrations of CHL may also result in inhibition of the mitochondrial ribosome (70S, 5893 
similar to prokaryotic bacterial ribosome), resulting in toxic side effects, the most 5894 
pronounced of which occur in erythropoeitic cells. (475) 5895 
CHL resistance is most often ascribed to deactivation (acetylation) by CHL 5896 
acetyltransferase (cat) enzymes, which are encoded on plasmids. Gram-negative 5897 
pathogens may also possess chromosomal and acquired resistance determinants resulting 5898 
in efflux, reduced permeability and alterations of the CHL binding site. (310) In a recent 5899 
review by Civljak et al assessing the evidence for use of CHL for infections by ESKAPE 5900 
pathogens (see Section 1.1.4.2), the authors concluded that CHL monotherapy may be 5901 
more useful against MDR Gram-positive pathogens than their Gram-negative counterparts. 5902 
(476) The authors noted high levels of in vitro resistance to K. pneumoniae (overall 57%, 5903 
carbapenemase-producers 70-100%), Enterobacter spp. (10-40%, but 80% in 5904 
carbapenemase-producers), P. aeruginosa (overall 13%, but half the studies 100%) and A. 5905 
baumannii (< 20%). The authors speculate that the higher resistance rates seen in 5906 
carbapenemase-producing organisms may harbour plasmids encoding multiple resistance 5907 
mechanisms, including those resulting in CHL resistance (e.g. cat). (476)  5908 
Similarly, the variability in susceptibility to COL-CHL observed in this study may be due to 5909 
strain to strain differences in burden of CHL resistance determinants. It is interesting that 5910 
though susceptibility to CHL is extremely low amongst A. baumannii and P. aeruginosa, 5911 
(476) the addition of COL was synergistic in 37% of A. baumannii and 50% of P. aeruginosa 5912 
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isolates in this study (all with SBPI > 2), and the effect was otherwise at least additive (FICI 5913 
≤ 1) in all but one P. aeruginosa strain (indifferent, FICI ≤ 2; blaIMP-15). This suggests that for 5914 
at least a proportion of A. baumannii and P. aeruginosa isolates, impermeability could be 5915 
the major determinant of CHL resistance, and susceptibility may be restored with the 5916 
addition of COL to varying degrees, dependent on whether other factors of CHL resistance 5917 
are present and/or the COL heteroresistance profile of the strain.  5918 
Two other studies have reported synergy between COL and CHL. (477, 478) Wei et al 5919 
observed synergy between COL and CHL against XDR A. baumannii (16/50) in 5920 
checkerboard assays, and again in time-kill assays (n = 4, including ATCC 19606 type 5921 
strain, 1 COL-heteroresistant clinical strain, and 2 COL-resistant strains with MIC ≥ 4 mg/L) 5922 
with COL 2 mg/L and CHL 32 mg/L. (478) It should be noted that the concentration of CHL 5923 
required in combination exceeds both ideal peak (10 – 20 mg/L) and trough (5 – 10 mg/L) 5924 
serum concentrations in humans, and in fact persistent peak concentrations of ≥ 25 mg/L 5925 
and trough concentrations of ≥ 10 mg/L has been associated with bone marrow 5926 
suppression, with high levels of ≥ 40 mg/L associated with ‘gray baby syndrome’. (479) A 5927 
further study by Rahim et al observed improved bacterial killing with polymyxin B and CHL 5928 
combination compared with either polymyxin B or CHL alone against 4 NDM-producing K. 5929 
pneumoniae. (304) All 4 strains studied were susceptible to polymyxin B (MIC = 0.5 mg/L), 5930 
although heteroresistance was noted on PAP, and it was notable that 2 of the 3 clinical 5931 
strains were resistant to CHL (MIC ≥ 16 mg/L, proposed by authors to be due to CHL 5932 
efflux).  Similar to Wei et al, the concentrations of CHL used in the time-kill assays were 5933 
high (8 – 32 mg/L). (304) Additionally, the authors detected the presence of several CHL 5934 
efflux determinants in the 4 strains tested (including ATCC BAA-2146 type strain) – RND 5935 
multi-drug efflux (acrA, eefB, oqxA, oqxB) and major facilitator superfamily (MFS; emrA, 5936 
mdfA), with eefB, oqxA and oqxB notably absent in the CHL susceptible clinical strain (MIC 5937 
= 4 mg/L). (304, 480, 481) The permeabilising action of polymyxins may circumvent the 5938 
action of efflux, allowing the influx of CHL to outpace its extrusion by the organism, thereby 5939 
expressing either additive or synergistic antimicrobial effect in combination. See Figure 6-3 5940 
for the putative mechanism of action for the COL-chloramphenicol combination.  5941 
Although COL-CHL combination appears to be promising against diverse Gram-negative 5942 
pathogens, its activity against COL-resistant organisms is variable at best, and requires 5943 





Figure 6-3 Putative mechanism of action for colistin-chloramphenicol combination against 5948 






6.2.4.3 Colistin-fusidic acid combination 5954 
COL-FUS combination was the most active novel COL combination tested in this study. 5955 
Synergy by checkerboard assays was demonstrated against all A. baumannii isolates (n = 5956 
12), and 58% of non A. baumannii strains. The synergy observed (FICI ≤ 0.5) was 5957 
additionally suggestive of potential clinical benefit, with SBPI < 2 noted in all cases apart 5958 
from a S. marcescens type strain. Although antagonism was not observed against any of 5959 
the organisms tested, indifference (i.e. no effect from addition of 2nd agent) was noted 5960 
against P. aeruginosa and P. mirabilis. This could suggest possible additional permeability 5961 
barriers and/or efflux (of one or both agents) mechanisms carried by these organisms.  5962 
FUS is a relatively large molecule (516 Da, but less than half the size of polymyxins) that is 5963 
largely hydrophobic (similar in structure to steroids) in nature, although carrying an overall 5964 
weak negative charge at physiological pH. (55, 329, 482) FUS is an ‘old’ antimicrobial 5965 
agent, derived from the fermentation broth of the fungus, Fusidium coccineum, and 5966 
introduced into clinical use in the 1960s. (55, 327) It has been used primarily as a narrow- 5967 
spectrum agent against S. aureus, usually as part of combination therapy (due to high rate 5968 
of spontaneous mutation), (483) with virtually no antimicrobial activity against aerobic 5969 
Gram-negative organisms (55), hypothesised to be excluded by the Gram-negative outer 5970 
membrane. (297) FUS is available in multiple formulations including intravenous, oral and 5971 
for topical applications (e.g. ointment, ophthalmic), with excellent bioavailability reported 5972 
with newer oral formulations (up to 91% compared with intravenous preparation), and it 5973 
accumulates with repeated dosing leading to increased levels during the course of 5974 
treatment. (329, 484) Compared with polymyxins and chloramphenicol, FUS boasts a better 5975 
safety profile, with few reports of associated severe adverse events, including 5976 
hepatotoxicity, myopathy and blood dyscrasias, none of which were definitively linked to 5977 
FUS therapy. (485)  5978 
The combination of COL and FUS was the most antimicrobially active pair found in this 5979 
study. Similar to other observations with hydrophobic antibiotics (e.g. rifampicin, CHL), 5980 
(406, 478) COL likely permeabilises the Gram-negative outer membrane, allowing greater 5981 
influx of FUS into the cell, and eventually to its target site on the bacterial ribosome. Unlike 5982 
most other COL combinations, FUS is a narrow-spectrum antimicrobial agent, with no 5983 
reported phenotypically expressed anti-Gram-negative activity. Whilst intuitively, this might 5984 
represent an advantage over broader-spectrum agents from a resistance evolution 5985 
perspective, FUS however, is a substrate for a number of multi-drug efflux pumps (e.g. 5986 
AcrAB-TolC, AdeIJK), and may drive their overexpression resulting in greater extrusion and 5987 
eventually phenotypic resistance. (486, 487) This probably contributes to the heterogeneity 5988 
of activity observed amongst the different Gram-negative strains tested.  5989 
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In the time-kill experiments, it was noted that the COL-FUS combination resulted in less 5990 
rapid bacterial kill compared with COL alone (against COL-susceptible A. baumannii 5991 
strains), although sustained inhibition of growth and/or killing was maintained only in 5992 
combination. This could suggest an interaction between COL and FUS against COL- 5993 
susceptible subpopulations, which may include competition for binding to the outer 5994 
membrane (cationic COL binds to the negatively charged outer membrane; and even 5995 
though FUS carries a weak negative charge at physiological pH, it has an affinity for 5996 
negatively charged membranes), (126, 333) or interaction between COL and FUS molecules 5997 
(both are amphipathic bearing opposing charged groups) could potentially slow the 5998 
eventual binding of COL to the anionic outer membrane.  5999 
In addition to the study presented here, (488) other authors have subsequently observed 6000 
similar in vitro activity of COL and FUS against COL-susceptible strains of MDR A. 6001 
baumannii. (489, 490) Fan et al additionally demonstrated significantly reduced bacterial 6002 
load at 24 h and 48 h with COL-FUS combination therapy compared with COL alone (p < 6003 
0.05) in a murine thigh model of infection. The authors observed that of the 6 COL 6004 
combination therapies investigated (combination agents were meropenem, FOS, 6005 
tigecycline, FUS, rifampin and sulbactam), COL-FUS and COL-rifampin were the most 6006 
active against XDR A. baumannii both in vitro and in the murine model. (489, 490) It should 6007 
be noted that among the 6 combinations tested, FUS and rifampin are hydrophobic (FUS 6008 
though carrying a weak net negative charge, is structurally similar to steroids) molecules 6009 
that do not appear to have any direct route of entry into the Gram-negative cell (e.g. porin 6010 
channels), perhaps suggesting superiority from a mechanistic perspective of combining the 6011 
permeabilising activity of COL with hydrophobic antimicrobials. In contrast with the findings 6012 
in this study, Bowler et al observed strain to strain differences in activity of COL-FUS 6013 
against 3 pairs (each pair isolated from the same patient before and after COL exposure) of 6014 
clinical MDR A. baumannii strains belonging to distinct pulse-field clusters in static time-kill 6015 
experiments, all harboured blaOXA-23 and the addition of PetN to the lipid A components was 6016 
demonstrated with each corresponding COL-resistant strain. (489, 491) Synergy was 6017 
observed against all COL-susceptible strains from each pair (although bactericidal synergy 6018 
was only noted in 2 of 3), and 2 of 3 COL-resistant strains (bactericidal only in 1 of 3 with an 6019 
MIC = 4 mg/L). The concentrations used by the authors were COL 1 – 2 mg/L, and FUS 8 6020 
mg/L. (489, 491) This likely reflects additional mechanisms (e.g. efflux, target site 6021 
alterations) that could affect the activity of the combination, which may be partially 6022 
ameliorated in vivo by higher concentrations of FUS due to accumulation of the drug 6023 
intracellularly (401), and lower drug clearance with repeat dosing. (327, 329, 492)  6024 
 323 
6.2.4.3.1 Colistin and fusidic acid synergy against colistin-resistant strains 6025 
Synergy between COL and FUS against COL-resistant strains was not limited to A. 6026 
baumannii, and was demonstrated in checkerboard assays against enterobacteriaceae (n = 6027 
13) and a Stenotrophomonas maltophilia type strain (NCTC 10258; COL MIC 8 mg/L), 6028 
including strains harbouring resistance determinants associated with COL resistance 6029 
(mutations in pmrAB or plasmidic mcr-1). (453) Apart from the P. mirabilis type strain (NCTC 6030 
13376) that is intrinsically resistant to COL (MIC > 256 mg/L), COL-FUS synergy was 6031 
observed against all other COL-resistant (COL BMD MIC > 2 mg/L) enterobacteriaceae 6032 
tested. The FICI values were unexpectedly low, with an average of 0.045 (range 0.0006 – 6033 
0.14), with potential clinically relevant activity (SBPI >2 in 12 of 13 isolates; SBPI was 0.52 6034 
against the S. marcescens type strain NCTC 13382, despite a FICI = 0.1). S. marcescens, 6035 
similar to P. mirabilis, is intrinsically resistant to COL, both bearing chromosomally encoded 6036 
genotypic determinants that are associated with the addition of L-Ara4N and/or PetN to 6037 
LPS, thereby resulting in COL resistance. (330) Furthermore, the presence of RND multi- 6038 
drug efflux, AcrAB-TolC, may contribute to FUS resistance in P. mirabilis (Visalli et al 6039 
observed high-level resistance to known AcrAB-TolC substrates (e.g. erythromycin, 6040 
novobiocin, chloramphenicol) in a wild-type P. mirabilis strain that was reduced with 6041 
inactivation and only marginally increased with overexpression, suggesting the efficiency of 6042 
native AcrAB-TolC in P. mirabilis). (493) The relative susceptibility of the S. marcescens type 6043 
strain to COL and FUS combination compared with P. mirabilis may be due to the 6044 
difference in efficiency/native expression of their main multi-drug efflux, with the S. 6045 
marcescens homologue, SdeAB, (494, 495) possibly being less efficient at extrusion of 6046 
FUS. The activity of COL and FUS against COL-resistant strains appears promising, with 6047 
the ability to bypass the deleterious effect of a less negatively charged outer membrane (in 6048 
this study, the known mechanisms studied were limited to the addition of PetN, although 6049 
others may exist in strains that were susceptible to the combination), potentially offering a 6050 
viable therapeutic option against otherwise PDR Gram-negative infections. There exists, 6051 
however, strain to strain variation in the activity of the COL-FUS combination, and further 6052 
understanding of its underlying mechanism would go a long way to aid optimisation of use 6053 
of this combination in clinical practice. It is likely that the COL-FUS combination exerts its 6054 
antibacterial effects in multiple ways, the predominant mechanism may be dictated by the 6055 
structure and integrity of the Gram-negative outer membrane.  6056 
6.2.4.3.2 Protein synthesis and antimicrobial action of fusidic acid 6057 
Bacterial protein biosynthesis is a necessary process for cell growth and survival, and is an 6058 
energy driven operation. The hydrolysis of GTP by GTPases generates the energy required 6059 
for the peptide translocation in a two-step process. Firstly, elongation factor Tu (EF-Tu) 6060 
brings aminoacyl-tRNA and GTP to the A-site, and interaction of the mRNA with the 6061 
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corresponding anti-codon catalyses the GTPase activity. Upon dissociation of the EF- 6062 
Tu×GDP complex (amminoacetylated-tRNA left bound to ribsome then reacts with peptidyl- 6063 
tRNA via transpeptidation), and switching GTPase associated centre (GAC) to the ‘closed’ 6064 
conformation, EF-G×GTP binds to the pre-translocation ribosomal complex, ready for 6065 
peptide translocation from A-site to P-site. After GTP hydrolysis, EF-G×GDP dissociates 6066 
from the post-translocation ribosomal complex, switching GAC to a ‘half-open’ 6067 
conformation, ready for binding with EF-Tu×aa-tRNA×GTP. (496, 497) 6068 
FUS forms a strong stable complex with EF-G×GDP (after one round of peptide 6069 
translocation), leaving GAC in the ‘open’ conformation, preventing further cycles of peptide 6070 
translocation. (497, 498) It has also been proposed that FUS interrupts ribosomal recycling 6071 
by preventing disassembly following termination of protein translation far more efficiently 6072 
than it does inhibiting peptide translocation. (499) Additionally, Borg et al demonstrated the 6073 
ability of FUS to inhibit multiple stages of the peptide elongation process, and noted the 6074 
relative efficiency of inhibition in the early stages of translocation compared to later stages 6075 
(FUS dissociates slowly, and may rebind to EF-G×GDP downstream), corresponding to a 6076 
rapid increase in peptide elongation time with addition of low concentrations of FUS, and a 6077 
more gradual rise in effect with increasing concentrations. (500) 6078 
In a proteomic study of COL resistant mutants (raised in vitro from parent wild type strain 6079 
ATCC 19606 in presence of COL 36 mg/L), upregulation of EF-G and downregulation of EF- 6080 
Tu was observed. (501) This served to slow the overall protein synthesis and therefore 6081 
bacterial growth of the COL resistant mutant compared to its parent strain, (501) with 6082 
potential increased susceptibility to the antimicrobial effects of FUS.  6083 
It was noted that A. baumannii strains in this study with high-level COL resistance (e.g. 6084 
AB205, AB219, NCTC 12156 DpmrB) were more susceptible to FUS, with lower FUS MICs 6085 
(8 – 64 mg/L), compared with COL susceptible strains. In particular, the pmrB knockout 6086 
mutant (by insertional inactivation) of NCTC 12156 type strain was >32 times more 6087 
susceptible to FUS than its parent strain.  6088 
6.2.4.3.3 Colistin resistance disrupts the integrity of the outer membrane 6089 
Addition of L-Ara4N, PetN or glucosamine to phosphate groups in the lipid A component of 6090 
LPS reduces the overall net negative charge of the outer leaflet of the Gram-negative 6091 
membrane, thereby weakening bonds with divalent cations (these bonds contribute to the 6092 
overall stability and integrity of the outer membrane) resulting in looser packing of the LPS 6093 
molecules. (502) This may increase its permeability to a number of hydrophobic agents, 6094 
usually halted in its ingress by a strongly anionic layer formed by the lipid A core. (288) It is 6095 
hypothesised that the reduction or complete loss of LPS (in the case of mutations in LPS 6096 
biosynthesis genes, lpxACD, observed in COL-resistant A. baumannii strains) (76, 468) may 6097 
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consequently see the cell replace these with glycerophospholipid segments (akin to the 6098 
cytoplasmic or inner membrane layer) that are more permeable to hydrophobic 6099 
compounds. (288)  6100 
Fusidic acid, an amphipathic molecule (although largely hydrophobic due to similarities in 6101 
structure to steroids, but carries a net negative charge at physiological pH), would benefit 6102 
from such membrane alterations, allowing its incorporation into the outer membrane, and 6103 
eventual transport through the cell. Helle et al demonstrated the affinity fusidic acid has for 6104 
negatively charged phospholipid membranes, and its retention within the membrane bilayer 6105 
raises the overall negative surface charge. (333) This interesting observation may offer a 6106 
potential explanation for the perceived synergy between COL and FUS. FUS could 6107 
potentially partially restore binding affinity for cationic COL to the outer membrane by 6108 
temporarily increasing the net negative surface charge, thereby further disrupting the 6109 
integrity of the membrane and the eventual demise of the cell.  6110 
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6.2.5 In vivo activity of colistin and fusidic acid combination 6111 
therapy against A. baumannii infections 6112 
6.2.5.1 G. mellonella model 6113 
G. mellonella larva has been identified as a suitable surrogate in vivo model for studying 6114 
pathogen virulence and anti-infective efficacy. (352, 355) This simple invertebrate model 6115 
possesses host factors that mount an immune response to acute infection mimicking 6116 
higher mammalian models, (354, 355, 357) providing useful initial assessment of 6117 
antimicrobial activity observed in vitro, in a in vivo model, (353, 355, 357) whilst avoiding the 6118 
use of higher mammalian models, in keeping with the principles set out by NC3Rs. (349, 6119 
350)  6120 
A number of studies investigating A. baumannii virulence and pathogenesis have utilised 6121 
the G. mellonella model, with the authors reporting on its suitability for assessment of this 6122 
pathogen, (356, 357, 503-505) and Jacobs et al have additionally demonstrated similar 6123 
trends in response to different strains of A. baumannii with distinct virulence profiles in both 6124 
G. mellonella larvae and in a mouse lung infection model. (356) Significant differences were 6125 
noted in the lethality (determined by LD50 at 24 h) amongst the 7 A. baumannii strains 6126 
studied here (see Section 4.3.1), reflecting distinct virulence profiles that were effectively 6127 
observed in this model of infection. Moreover, the G. mellonella model demonstrated the 6128 
differences between relative virulence in 2 COL-resistant strain – whilst the pmrB knockout 6129 
mutant of type strain NCTC 12156 was surprisingly more virulent than its parent strain, the 6130 
COL-resistant clinical strain, AB205 (with unknown underlying COL-resistance mechanism), 6131 
was the least virulent of all 7 strains studied with the highest LD50. The observation that 6132 
pmrB mutants have little or no impact on the biological fitness and virulence of A. 6133 
baumannii was also noted by Wand et al in G. mellonella. (505) 6134 
G. mellonella has also been used to study the efficacy of antimicrobials, and several 6135 
authors have used this model to investigate the effects of colistin combination therapies for 6136 
the treatment of A. baumannii infections. (314, 376, 377, 379, 380, 382) Of note, whilst 6137 
several colistin combinations resulted in lower larval mortality at 96 h, including COL- 6138 
telavancin, COL-glycopeptides, COL-daptomycin, against COL-susceptible A. baumannii 6139 
infections, only COL-doripenem (only in 1 study, n = 3, O’Hara et al) demonstrated 6140 
consistent significant activity against COL-resistant infections. The mortality rate observed 6141 
in the COL-doripenem group was no different to that of the doripenem monotherapy group 6142 
(all isolates were doripenem resistant with MIC > 32 mg/L), leading the authors to postulate 6143 
that doripenem may in fact prime the immune system of the larvae, and not entirely due to 6144 
antimicrobial activity alone. (379)  6145 
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COL-FUS combination therapy was demonstrably superior to either COL or FUS 6146 
monotherapy for the treatment of A. baumannii infections in the G. mellonella systemic 6147 
infection model, regardless of the COL susceptibility of the infecting strain (p < 0.01). Larval 6148 
mortality following A. baumannii infection was most marked within the first 24 – 48 h period, 6149 
and consequently the greatest RRR in mortality from successful treatment was observed 6150 
during the first 48 – 72 h post-infection/treatment, likely suggesting that the increased larval 6151 
survival in these treatment arms were the result of antimicrobial activity in vivo. Unlike 6152 
doripenem and vancomycin, (377, 379, 382) FUS monotherapy did not have any 6153 
appreciable impact on larval survival, including strains with lower FUS MICs (NCTC 12156 6154 
DpmrB, AB205), further suggesting that the RRR and lower hazard of mortality observed 6155 
with COL-FUS combination therapy may be due to the direct result of decreased bacterial 6156 
burden from synergistic antibacterial activity (mirroring the results of the in vitro studies).  6157 
The addition of FUS to COL has reduced the NNT in G. mellonella 2 – 5 fold, suggesting an 6158 
appreciable and significant increase in activity for the treatment of A. baumannii infection.  6159 
6.2.5.2 Murine lung infection model 6160 
The A. baumannii mouse lung infection model was developed to study the pathogenesis of 6161 
A. baumannii pneumonia with the direct inoculation of the candidate strain into the 6162 
respiratory tract of the test mice. (365) Jacobs et al have previously demonstrated the 6163 
suitability of a ‘hypervirulent’ A. baumannii strain, AB5075, belonging to ICC I and isolated 6164 
from a patient with osteomyelitis, for the study of lung infection in mice, and the efficacy of 6165 
antibacterials in said model. (356) Disappointingly, this study noted higher mortality in mice 6166 
treated with FUS-containing regimens, whilst COL monotherapy successfully treated mice 6167 
with A. baumannii lung infection (2 of 3 survived till the end of experiment, at day 7). COL 6168 
monotherapy was similarly associated with better larval survival compared with placebo in 6169 
the G. mellonella model for the treatment of AB5075 infection, with significantly lower HR of 6170 
0.33 (p < 0.001), perhaps emphasising that this strain is particularly susceptible to COL 6171 
despite being COL heteroresistant (although COL AUC-ratio was low, 1.19).  6172 
FUS has been a difficult antimicrobial to study in mice, due to an extremely short t1/2 when 6173 
delivered systemically, thereby necessitating higher doses than would be used in humans, 6174 
and have been associated with numerous adverse effects when given systemically. The 6175 
observation of higher mortality in mice treated with FUS monotherapy (3 of 3 dead by 48 h, 6176 
or 2 days post-infection) compared with expected (in untreated AB5075 infected mice, 6177 
mortality rate was noted to be 75 – 80% by 72 h by Jacobs et al (356)), was likely a major 6178 
contributor to unexpectedly poor survival in the COL-FUS combination treatment arm. FUS 6179 
toxicity was likewise noted by Payne et al, where the authors noted particularly that 6180 
intraperitoneally administered FUS (used in this COL-FUS study) was particularly toxic to 6181 
mice, and better tolerability observed with the subcutaneous route of administration. (387) 6182 
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Similarly, Bellahsene et al noted better tolerability with oral administration, with an LD50 > 6183 
1000 mg/kg. (388) The relative increase in weight gain amongst surviving mice in the COL- 6184 
FUS arm on day 2 post-infection compared with COL monotherapy could suggest some 6185 
benefit afforded by the combination therapy against the infecting pathogen, prior to 6186 
succumbing to FUS toxicity on day 3.  6187 
Further study of the COL and FUS combination therapy using an alternative route of FUS 6188 
administration (e.g. subcutaneous injections), or investigation in a local infection model (Fan 6189 
et al observed superior reduction in bacterial load with COL-FUS combination compared 6190 
with COL monotherapy in a murine thigh infection model of XDR A. baumannii (490), for the 6191 
treatment of diverse GNB infections should be undertaken. It is however probable that FUS 6192 
toxicity and/or PK in mice may preclude successful study of FUS-containing therapy in 6193 
mice, and perhaps the G. mellonella larval model is better suited for the purpose of 6194 
investigating the efficacy of the COL-FUS combination therapy. As both COL and FUS are 6195 
antimicrobial agents with a several decades of history of clinical use, the COL-FUS 6196 
combination therapy could be put into practice for the targeted therapy of GNB infections 6197 
where no other viable therapeutic options exist, and this data collated and analysed as part 6198 
of a wider clinical study, employing pragmatic trial design principles.  6199 
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6.2.6 Case reports 6200 
In a full circle from bench to bedside, two patients were treated with unorthodox COL 6201 
combination therapies that were investigated as part of this study. Here, we describe the 6202 
successful treatment of XDR A. baumannii infections with COL-teicoplanin combination 6203 
therapy (urinary tract infection associated with indwelling prosthetic device), and COL-FUS 6204 
combination therapy (VAP). In both cases, the strain was only susceptible to COL in vitro 6205 
(BMD MIC 0.5 mg/L for the urinary tract infection strain, and MIC 1 mg/L for the VAP 6206 
strain), although both were COL heteroresistant. 6207 
Both treatment regimens utilised recommended doses of CMS (high-dose regimen with the 6208 
use of a loading dose in the COL-teicoplanin combination, (134) and ‘regular’ low-dose 6209 
regimen (416) for the COL-FUS combination), and COL-related toxicity was notably absent 6210 
in either case during the course of treatment and in the immediate follow-up period.  6211 
Both treatment regimens were demonstrably successful, resulting a rapid clinical 6212 
improvement, and in the case of COL-FUS combination therapy, sustained microbiological 6213 
eradication (including from gut carriage) of the pathogen was achieved.  6214 
These case reports highlight the clinical applicability of the synergistic antimicrobial effect 6215 
of unorthodox COL combinations (where COL is combined with another agent that does 6216 
not possess any tangible Gram-negative activity on its own, effectively ‘sensitising’ or ‘re- 6217 
sensitising’ the agent to the targeted pathogen with COL) observed in vitro and in the G. 6218 
mellonella model. Unorthodox COL combination therapy, in particular, COL-FUS 6219 
combination therapy, is a potentially viable therapeutic option for the treatment of GNB 6220 
infections for which no other active monotherapies are available. In addition, COL-FUS 6221 
combination therapy, comprising 2 old and licensed antimicrobial agents, have proven 6222 
safety profiles in humans, and are widely available at relatively low costs, making this 6223 
combination a suitable therapeutic option for treatment of MDR GNB infections today.  6224 
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6.3 Antibiotics in development with activity 6225 
against MDR Gram-negative bacteria 6226 
The WHO, in a report published in February 2017, identified a list of ‘priority pathogens’ to 6227 
help guide the antimicrobial research and development efforts. Of the priority pathogens, 6228 
carbapenem-resistant A. baumannii, carbapenem-resistant P. aeruginosa and carbapenem- 6229 
resistant or 3rd-generation cephalosporin resistant Enterobacteriaeceae (including E. coli, K. 6230 
pneumoniae, Enterobacter spp., Serratia spp., Morganella spp., Proteus spp. and 6231 
Providencia spp.) were considered to be of ‘critical’ importance. (506) As of May 2017, 6232 
there were 13 agents in Phase I – III clinical trials with activity against these ‘critical priority 6233 
pathogens’, with only 5 of these fulfilling the criteria for being possibly ‘innovative agents’ (2 6234 
definitive and 3 inconclusive), meeting ≥ 1 of the following criteria – new chemical class, 6235 
new target or binding site, new mechanism of action, and no cross-resistance with any 6236 
other known antibiotic classes. (507) See Figure 6-4 for an overview of these 13 agents by 6237 
phase of clinical trials currently underway (of as May 2017). Of these 5 agents, it is perhaps 6238 
somewhat disappointing to note that 4 comprise a b-lactam backbone (either as part of a 6239 
b-lactam and b-lactamase inhibitor combination, or linked with a siderophore), which the 6240 
molecule or combination relies upon for its antimicrobial effect, and only 1 truly novel 6241 
antibiotic class represented by murepavadin (currently recruiting patients to a multi-centre 6242 
Phase III RCT comparing treatment outcome of P. aeruginosa nosocomial pneumonia with 6243 
murepavadin and an anti-pseudomonal antibacterial combination versus 2 anti- 6244 
pseudomonal antibacterials in combination, as of March 2018). Murepavadin is an 6245 
antimicrobial peptide mimic, targeting LptD, (508, 509) an outer membrane protein 6246 
responsible assembly of LPS in the Gram-negative outer membrane. (510) There are 2 6247 
siderophore-bound cephalosporins (Shionogi’s cefiderocol, in Phase III development; 6248 
GSK’s GSK-3342830 in Phase I) in clinical trials, which utilised a ‘Trojan horse’ approach to 6249 
bacterial cell entry, whereby the siderophore (normally produced by bacteria to scavenge 6250 
for extracellular iron that the cell requires for survival) component allows the compound to 6251 
be actively taken up by the cell into the periplasm (511) for the cephalosporin component to 6252 
bind to its target penicillin-binding protein. (512) However, being essentially a b-lactam, 6253 
these siderophore-cephalosporins remain vulnerable to the activity of b-lactamases, and 6254 
resistance may be selected for soon after introduction, as has been the case with many 6255 
other b-lactams throughout the history of their development. (513) An exciting new 6256 
compound in the pre-clinical phase of development improves upon this by linking linezolid 6257 
(an oxazolidinone antibiotic) to the siderophore-cephalosporin. (514) The siderophore 6258 
component brings the entire molecule into the periplasmic space, whereupon encountering 6259 
hydrolysing b-lactamases, the cephalosporin component is cleaved, detaching the linezolid 6260 
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portion from the original compound, free to diffuse through the cytoplasmic membrane and 6261 
eventually bind to its intracellular ribosomal target. (514) 6262 
Figure 6-4 Antibacterial compounds in Phase I - III trials with activity against WHO critical 6263 
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6.4 Conclusions 6268 
AMR poses one of the biggest challenges facing modern medicine, as the use of antibiotics 6269 
is deeply entrenched in diverse medical fields ranging from surgery to oncology, from use 6270 
in minor dental and wound infections to treatment of severe sepsis in critically ill patients. 6271 
There is a global acute crisis caused by the dual problem of rising AMR and lack of 6272 
investment in antimicrobial research and development that has lasted several decades 6273 
resulting in an essentially empty developmental pipeline (with novel antibiotic classes, in 6274 
particular).  6275 
COL therapy represents an agent of last resort, retaining some level of antimicrobial activity 6276 
against MDR and XDR GNB. However, clinical failures due to COL monotherapy has 6277 
highlighted myriad problems associated with the clinical use of COL, including issues 6278 
regarding CMS dosing and PK, as well as COL AST. Strategies to combat these problems, 6279 
as well as attempts to preserve COL activity for the foreseeable future has led to 6280 
considerable interest in COL combination therapies. 6281 
COL has been used frequently in combination with agents that possess broad-spectrum 6282 
activity against Gram-negative pathogens (e.g. carbapenems, tigecycline, fosfomycin), as 6283 
well as in a few instances, in combination with unorthodox agents (without innate Gram- 6284 
negative activity alone) such as glycopeptides and rifampicin due to promising results 6285 
noted in vitro. However, pooled clinical outcomes including mortality and cure did not 6286 
reveal any differences between COL combinations and other comparators (including COL 6287 
monotherapy). This may be due to the low quality of evidence available to date (few RCTs, 6288 
almost all studies were observational in design with non-comparable cohorts based on 6289 
baseline characteristics and severity of illness), or suggest these secondary agents being 6290 
poor candidates for combination with COL for the treatment of MDR and XDR GNB 6291 
infections. 6292 
The systematic screening protocol designed here have identified 3 novel COL combinations 6293 
– COL-FUS, COL-CHL and COL-daptomycin. COL-FUS was the most active combination 6294 
observed in vitro, with activity against most GNB tested (with the exception of P. 6295 
aeruginosa), including against strains known to be COL-resistant. The potent activity of 6296 
COL-FUS was similarly demonstrated in vivo, in an invertebrate model of systemic A. 6297 
baumannii infection (against both COL-susceptible and COL-resistant strains), and was 6298 
used to successfully treat a case of VAP caused by an XDR A. baumannii strain (only 6299 
susceptible to COL by BMD) in a critically ill patient. 6300 
The COL-FUS combination is a viable therapeutic option for targeted treatment of MDR, 6301 
XDR and possibly PDR GNB infections that can be used right now, whilst we await novel 6302 
antibacterials that are currently in development. Urgent studies are needed to elucidate the 6303 
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underlying mechanism of action of this promising combination, as well as pragmatic trials 6304 
to collate clinical data on the clinical outcome of COL-FUS combination for the treatment of 6305 
diverse sites of infection with varying etiologies.  6306 
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6.5 Future development 6307 
Further studies to investigate the extent of COL-FUS combination activity against MDR 6308 
GNB, including but not limited to, static time-kill studies against larger collection of GNB 6309 
strains particularly Enterobacteriaceae harbouring MDR determinants including COL- 6310 
resistant determinants, dynamic time-kill studies using the hollow-fibre infection model to 6311 
mimic human PK of both drugs and COL-FUS treatment of non A. baumannii GNB 6312 
infections in G. mellonella.  6313 
An ongoing collaboration is currently underway using PKPD modelling to investigate the in 6314 
vitro COL-FUS synergy observed against A. baumanni in static time-kill assays and in G. 6315 
mellonella larvae (in collaboration with Institute of Child Health, University College London; 6316 
and Medicines Research Centre, GlaxoSmithKline).  6317 
Mechanistic studies investigating the combined antimicrobial activity of COL-FUS, using 6318 
scanning electron microscopy (to study membrane integrity) and transmission electron 6319 
microscopy (to observe intracellular changes) at various stages of static time-kill 6320 
experiments under single and dual agent exposure. Additionally, labelled FUS (515) could 6321 
be used to investigate if binding to EF-G occurs in COL-resistant strains – as the 6322 
mechanism of action against COL-susceptible and COL-resistant strains may be quite 6323 
distinct from each other.  6324 
Finally, the use of COL-FUS combination therapy should be used as targeted therapy for 6325 
XDR or PDR GNB (for which no other viable monotherapy exists currently), with central 6326 
collation of baseline characteristics, clinical treatment and outcome as well as any relevant 6327 
TDM information. The analysis of this data could subsequently be used to inform clinical 6328 
guidelines for treatment of XDR/PDR GNB infections, or as a basis for design of a 6329 
pragmatic clinical trial to investigate the efficacy of COL-FUS in combination compared 6330 
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Abstract The activity of colistin in combination with
daptomycin was assessed using 30 Gram-negative type strains
and multidrug-resistant isolates with defined mechanisms of
resistance. Daptomycin minimum inhibitory concentrations
(MICs) were determined with and without sub-inhibitory con-
centrations of colistin. The activity of daptomycin was not
affected with respect to Escherichia coli, Klebsiella
pneumoniae or Pseudomonas aeruginosa. For colistin-
susceptible Acinetobacter baumannii, sensitisation factors
ranged from 8 to 128 (median 32), with the daptomycin MIC
being reduced to the Clinical and Laboratory Standards
Institute (CLSI) enterococci susceptibility breakpoint of
4 μg/ml for the ATCC 19606 type strain. A combination of
daptomycin and colistin may be useful for the treatment of A.
baumannii but not infections due to other Gram-negative
species.
Introduction
The emergence and spread of antimicrobial resistance
amongst bacterial pathogens presents major challenges for
the practice of modern medicine. In recent years, the problem
has gained increasing attention due to a paucity of new agents
available for clinical use, combined with the lack of com-
pounds in the later stages of development. The problem is
especially acute with respect to the treatment of Gram-
negative bacterial infections, where the rise of multidrug-
resistant (MDR) and pandrug-resistant organisms threatens
to render common infections untreatable [1]. Clinicians are
resorting to the use of older agents such as polymyxins, which
had previously fallen out of routine use due to concerns over
toxicity, or employing unorthodox combinations of licensed
drugs in the hope that this might bridge the current develop-
mental gap.
The potential to exploit the properties of cationic peptide-
like molecules, either those already in use as antimicro-
bials (polymyxins) or by the construction of novel analogues
(e.g. polymyxin nonapeptide, NAB 739, 741 and 7061) [2],
has been highlighted by a number of groups [3].
Colistin (polymyxin E) retains good in vitro activity against
most Enterobacteriaceae, Pseudomonas aeruginosa and
Acinetobacter baumannii, including MDR strains [4].
Although colistin is increasingly used as a last-resort treat-
ment, there are concerns over its efficacy, toxicity and poten-
tial to drive resistance when used as a monotherapy [5]. The
antimicrobial activity of colistin is thought to be mediated via
an electrostatic interaction with components of bacterial lipo-
polysaccharide (lipid A), leading to depolarisation and disrup-
tion of the outer membrane, and subsequent cell death via
osmotic lysis and the generation of toxic hydroxyl radicals [6].
At high concentrations, colistin is rapidly bactericidal, while
its effects on the outer membrane at lower concentrations
serve to permeabilise Gram-negative bacteria to com-
pounds that are usually excluded. These include hydro-
phobic drugs such as rifampicin, macrolides [7] and
glycopeptides (including, telavancin) [8], compounds that
are usually inactive against Gram-negative bacteria alone but
show potent synergistic activity when combined with colistin.
The results of this study were presented at the 52nd Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
San Francisco, California, USA, September 2012.
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These in vitro findings may have therapeutic implications, as
has been shown in a number of animal models of infection and
a limited number of clinical studies assessing the activity of
colistin and other permeabilising agents in combination with
other agents [9, 10].
In this study, we report on the in vitro activity of the
cyclic lipopeptide daptomycin when combined with colistin
against a collection of important Gram-negative bacteria, in
an attempt to determine whether such a combination should
be considered for clinical use.
Materials and methods
Bacterial isolates and routine antimicrobial susceptibility
testing
Thirty Gram-negative isolates (A. baumannii, E. coli,
Klebsiella pneumoniae, Enterobacter cloacae, P. aeruginosa)
were studied (Table 1). These were selected to represent
antibiotic-susceptible type strains and MDR clinical isolates
with critical resistance mechanisms to β-lactams, including
Table 1 Characteristics of the organisms tested









ATCC 19606 Antibiotic-susceptible type strain 0.25 1 4 128
AB16 Carbapenem-resistant, OXA-23 clone 2 0.5 1 6 85
AB184 ‘T’ strain 0.25 1 6 85
AB186 ‘Burn’ strain 0.5 2 8 64
AB14 Carbapenem-resistant, OXA-23 clone 1 0.5 1 12 42
AB199 Carbapenem-resistant, clinical isolate 0.5 2 16 32
AB292 TGC-resistant, clinical isolate 0.5 1 16 32
AB198 Carbapenem-resistant, clinical isolate 0.5 2 24 21
AB202 TGC-resistant, clinical isolate 0.5 2 24 21
AB200 Carbapenem-resistant, clinical isolate 0.5 2 32 16
AB211 TGC-resistant counterpart of AB210 0.25 2 32 16
AB210 TGC-susceptible, OXA-23 clone 1 0.25 2 64 8
AB219 COL-resistant. OXA-23 clone 1 0.75 64 192 2
AB205 COL-resistant, OXA-23 clone 1 0.75 256 >256 1
Escherichia coli
NCTC 12241 Antibiotic-susceptible type strain 0.125 0.25 >256 1
NCTC 11954 Type strain, TEM-1 producer 0.25 0.5 >256 1
EC204 NDM-1 producer 0.25 2 >256 1
EC207 NDM-1 producer 0.25 0.5 >256 1
EC208 NDM-1 producer 0.25 1 >256 1
EC405 NDM-5 producer 0.25 0.5 >256 1
EC421 NDM-1 producer, TGC-resistant 0.25 1 >256 1
Klebsiella pneumoniae
NCTC9633 Antibiotic-susceptible type strain 0.125 1 >256 1
KPC3 TEM-1, SHV-11 and KPC-3 producer 0.25 2 >256 1
KP50 SHV-11, OXA-1 and NDM-1 producer 0.25 2 >256 1
Enterobacter cloacae
NCTC 13380 Colistin-susceptible type strain 0.125 0.25 >256 1
NCTC 10005 Colistin-resistant type strain 0.75 >256 >256 1
Pseudomonas aeruginosa
ATCC 27853 Antibiotic-susceptible type strain 0.75 1 >256 1
PACF593 VIM-2 producer 0.75 4 >256 1
CF1092 Cystic fibrosis isolate: ‘Liverpool
epidemic strain’
0.5 1 >256 1
PAO1 Virulence profile for chronic infection 0.75 4 >256 1
1292 Eur J Clin Microbiol Infect Dis (2013) 32:1291–1294
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carbapenems, colistin and tigecycline, and/or members of
important epidemiologically defined clones. Clinical isolates
were identified by matrix-assisted laser desorption/ionisation
time-of-flight (MALDI-TOF) mass spectrometry (Bruker
Daltonik, Bremen, Germany). Antibiograms were determined
using the MicroScan WalkAway System (Siemens Healthcare
Diagnostics Inc., Deerfield, Illinois, USA) NM36 panel,
interpreted according to Clinical and Laboratory Standards
Institute (CLSI) guidelines. Genes encoding resistance to
β-lactams (blaTEM, blaSHV, blaOXA-1/4/30, blaCTX-M, blaKPC,
blaNDM) were identified by polymerase chain reaction (PCR)
and sequencing, as previously described [11].
Isolates were routinely propagated on Iso-Sensitest (ISO)
(Oxoid, Basingstoke, UK) medium at 37 °C. The minimum
inhibitory concentrations (MICs) of daptomycin and colistin
alone were determined using the Etest method (bioMérieux,
Marcy l’Etoile, France) on ISO agar after incubation at
37 °C for 18 h under aerobic conditions.
Colistin/daptomycin synergy studies
The activity of daptomycin in combination with colistin was
assessed using an Etest agar dilutionmethod. Colistin sulphate
(Sigma-Aldrich, Poole, UK) was added to ISO agar at con-
centrations of 0.125–0.75 μg/ml. The highest sub-inhibitory
concentration of colistin capable of supporting a confluent
lawn of growth from a 0.5 McFarland standard suspension
was determined for each isolate. Daptomycin MICs were then
determined by the Etest on ISO agar supplemented with the
optimal concentration of colistin sulphate. The MICs of
daptomycin on colistin-supplemented and -unsupplemented
agar were compared and used to calculate the ‘sensitisation
factor’ (ratio of the daptomycin MIC alone to that in combi-
nation with colistin) (Table 1) [12]. A sensitisation factor ≤2
denotes a likely lack of any useful synergy. DaptomycinMICs
in combination with colistin were also compared to currently
available Gram-positive susceptibility breakpoints [British
Society for Antimicrobial Chemotherapy (BSAC) for staphy-
lococci and streptococci, 1 μg/ml for both; CLSI for entero-
cocci, 4 μg/ml].
Results and discussion
The collection consisted of six type strains and 24 clinical
isolates. These included carbapenem-resistant, tigecycline
and colistin-resistant strains of A. baumannii belonging to
the ‘OXA-23’, ‘T’ and ‘Burn’ lineages, MDR strains of E.
coli, K. pneumoniae and P. aeruginosa producing CTX-M,
NDM and VIM β-lactamases and a representative of the
Liverpool epidemic strain of P. aeruginosa associated with
aggressive infections in cystic fibrosis patients.
The daptomycin MIC for all 30 isolates determined by the
Etest was >256 μg/ml, indicating a lack of in vitro activity of
(a) (b)
Fig. 1 Minimum inhibitory





(ISO) agar (a) and on ISO agar
supplemented with 0.25 μg/ml
of colistin (b)
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the drug as a single agent against any of the type strains or
MDR clinical isolates. A reduction in the MIC of daptomycin
in the presence of colistin was observed against all of the
colistin-susceptible A. baumannii isolates but none of the
other Gram-negative isolates tested. In the case of the ATCC
19606 type strain, this was reduced to the CLSI susceptibility
breakpoint for enterococci of 4 μg/ml (Fig. 1). The sensitisa-
tion factor (calculated using a presumptive daptomycin MIC
of 512 μg/ml) for A. baumannii isolates in which synergy was
observed ranged from 8- to 128 (median 32), with daptomycin
MICs ranging from 4 to 64 μg/ml, in the presence of sub-
inhibitory concentrations of colistin.
Daptomycin is a cyclic lipopeptide, and is the only drug of
its class to be used in clinical practice to date. The antimicrobial
activity against Gram-positive bacteria is achieved by disrup-
tion of the bacterial cytoplasmic membrane via a calcium-
mediated interaction with membrane phospholipids [13]. It
has previously been proposed that daptomycin is inactive
against Gram-negative bacteria, a large molecule (molecular
weight 1,620 Da) which cannot penetrate the outer membrane
[13, 14]. There is increasing interest in the use of colistin, which
retains the activity against many MDR Gram-negatives, but
also acts as an effective permeabiliser of the Gram-negative cell
envelope [4]. In this study, we observedmarked increases in the
activity of daptomycin in the presence of sub-inhibitory con-
centrations of colistin against most strains of A. baumannii but
not againstE. coli,K. pneumoniae,E. cloacae orP. aeruginosa.
It is interesting to note that, unlike previously studied
colistin/glycopeptide combinations, colistin/daptomycin syner-
gywas only observed inA. baumannii. This suggests that, apart
from being unable to penetrate the Gram-negative outer mem-
brane, the target required for daptomycin to assert its antimi-
crobial activity on the cytoplasmic membrane might be absent
in other Gram-negative species. This is supported by a recent
study in which the activity of daptomycin in combination with
polymyxin nonapeptide was assessed against chemically gen-
erated protoplasts of E. coli, E. cloacae, K. pneumoniae,
Moraxella catarrhalis and Salmonella typhimurium lacking a
cell wall [15]. In accordance with our findings, daptomycin was
found to be inactive against these species, either alone or in
combination.
In summary, colistin appeared to enhance the activity of
daptomycin towards A. baumannii, but not other Gram-
negative pathogens. Due to the lack of treatment options
for MDR A. baumannii [16], a colistin/daptomycin treat-
ment regimen might be therapeutically useful against some
strains, although further in vivo and clinical outcome data
are needed before it can be recommended.
Conflict of interest All authors declare that they have no conflict of
interest.
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Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for
Treatment of Multidrug-Resistant Acinetobacter baumannii Infections
Lynette M. Phee,a,b Jonathan W. Betts,a Binutha Bharathan,b David W. Warehama,b
Antimicrobial Research Group, Centre for Immunology and Infectious Disease, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary
University of London, London, United Kingdoma; Division of Infection, Barts Health NHS Trust, London, United Kingdomb
The spread of multidrug-resistant Acinetobacter baumannii (MDRAB) has led to the renaissance of colistin (COL), often the
only agent to which MDRAB remains susceptible. Effective therapy with COL is beset with problems due to unpredictable phar-
macokinetics, toxicity, and the rapid selection of resistance. Here, we describe a potent synergistic interaction when COL was
combined with fusidic acid (FD) against A. baumannii. Synergy in vitro was assessed against 11 MDRAB isolates using disc dif-
fusion, checkerboard methodology (fractional inhibitory concentration index [FICI] of < 0.5, susceptibility breakpoint index
[SBPI] of >2), and time-kill methodology (>2 log10 CFU/ml reduction). The ability of FD to limit the emergence of COL resis-
tance was assessed in the presence and absence of each drug alone and in combination. Synergy was demonstrated against all
strains, with an average FICI and SBPI of 0.064 and 78.85, respectively. In time-kill assays, COL-FD was synergistic and rapidly
bactericidal, including against COL-resistant strains. Fusidic acid prevented the emergence of COL resistance, which was readily
selected with COL alone. This is the first description of a novel COL-FD regimen for the treatment of MDRAB. The combination
was effective at low concentrations, which should be therapeutically achievable while limiting toxicity. Further studies are war-
ranted to determine the mechanism underlying the interaction and the suitability of COL-FD as an unorthodox therapy for the
treatment of multidrug-resistant Gram-negative infections.
Infections due to the Gram-negative bacterium Acinetobacterbaumannii are increasingly challenging to treat and control. The
organism has emerged worldwide as a major nosocomial patho-
gen in critical care units responsible for bloodstream, respiratory,
skin and soft tissue, and device-related infections (1). Clinical iso-
lates are often resistant to multiple antimicrobial drugs and be-
long to successful epidemiologically defined clones that, once es-
tablished, are extremely difficult to eradicate from the hospital
environment (2). As a result, outbreaks are common, typically last
for months, and may cost institutions in excess of $500,000 to
curtail (3). Treatment of infected individuals is equally hampered
by a seemingly endless capacity of the organism to acquire and
maintain large numbers of antimicrobial resistance genes (4).
Carbapenems, once considered the treatment of choice, are in-
creasingly found to be ineffective, leaving polymyxins (polymyxin
B and colistin [COL]) as the treatment of last resort (5).
Although polymyxins have been widely employed in the treat-
ment of A. baumannii infections, there are still concerns about
their efficacy and safety. These include the unreliable methods for
performing susceptibility testing, inadequate population pharma-
cokinetic data, uncertainties around appropriate dosing regi-
mens, and the availability of the licensed formulations of colistin
only as the inactive prodrug colistimethate sodium (6).
Despite this, polymyxins have frequently been shown to en-
hance the activity of other antimicrobial agents against resistant
Gram-negative pathogens in vitro. Synergy has been shown not
only with -lactams, carbapenems, aminoglycosides, quinolones,
and tetracyclines but also with agents with little intrinsic Gram-
negative activity (macrolides, rifamycins, fosfomycin, glycopep-
tides, and oxazolidones) (7, 8). Given that any new drugs with
unique modes of action are unlikely to become available for clin-
ical use within the next decade, the use of unorthodox combina-
tions of existing agents may be a rational approach for the therapy
of resistant Gram-negative infections. Although a meta-analysis of
data from historical studies has not yet revealed a clear benefit for
polymyxin combination regimens, a number of prospective trials
have recently been initiated (9).
Here, we describe a highly active and potent combination of
COL and fusidic acid (FD) against multidrug-resistant A. bau-
mannii (MDRAB).
(Part of this work was presented at the 54th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Washing-
ton, DC, 5 to 9 September 2014.)
MATERIALS AND METHODS
Bacterial isolates. Characteristics of all isolates used in this study are listed
in Table 1. Antimicrobial resistance determinants were identified by se-
quencing of PCR products obtained using a number of multiplex PCRs, as
described previously (10). Isolates were classified as multidrug-resistant
(MDR), extensively drug-resistant (XDR), or pandrug-resistant (PDR) A.
baumannii according to the classification of Magiorakos et al. (11). Mo-
lecular typing of all A. baumannii strains was performed by pulsed-field
gel electrophoresis (PFGE) and variable-number tandem-repeat (VNTR)
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analysis at the Antimicrobial Resistance and Healthcare Associated Infec-
tions Reference Unit (by J. Turton, Public Health England).
Antimicrobial susceptibility and synergy tests. Colistin sulfate
(COL; Sigma-Aldrich, St. Louis, MO) and fusidic acid (FD; Sigma-
Aldrich, St. Louis, MO) were dissolved in sterile distilled water to obtain
stock solutions of 50 mg/ml. The MICs of COL and FD were determined
by broth microtiter dilution (BMD) and by agar dilution (for COL) ac-
cording to the Clinical and Laboratory Standards Institute (CLSI) (12)
and the British Society for Antimicrobial Chemotherapy (BSAC) (13)
methodologies. Breakpoints used to interpret MICs were based on pub-
lished CLSI (14) and European Clinical Antimicrobial Susceptibility Test-
ing (EUCAST) (15) guidelines (Acinetobacter spp. for COL; Staphylococ-
cus spp. for FD).
A screening test for potential synergy between COL and FD was
performed using a disk diffusion assay. Bacterial suspensions of each
isolate were prepared in a phosphate-buffered saline (PBS) solution
adjusted to 0.5 McFarland standard. An even lawn was spread onto 2
Iso-Sensitest agar plates (ISA; Oxoid, Basingstoke, United Kingdom),
one supplemented with 0.5 the MIC of COL. After application of FD
10-g discs (Oxoid, Basingstoke, United Kingdom), the plates were
incubated in air at 37°C for 18 h. Potential synergy was inferred when
the zone of inhibition around the FD disc was 5 mm on the COL-
supplemented plate (Fig. 1).
Synergy using the BMD method was assessed in checkerboard assays
(16) using Iso-Sensitest broth (ISB; Oxoid, Basingstoke, United King-
dom). The plates were set up with serial doubling dilutions of COL and FD
at concentrations ranging from 0.008 to 512 mg/liter. Following incuba-
tion, inhibition of growth in each well was confirmed by recording tur-
bidity and by the addition of 20 l of alamarBlue (Invitrogen Corpora-
tion, San Diego, CA, USA) as a marker of bacterial viability. The fractional
inhibitory concentration indices (FICI) [which equals (MIC of A in com-
bination/MIC of A)  (MIC of B in combination/MIC of B)] were calcu-
lated using the wells with the lowest fractional inhibitory concentration
(FIC), and synergy was defined according to standard criteria (0.5, syn-
ergy; 0.5 to 1, additive; 1 to 4, indifference; 4, antagonism). The
susceptible breakpoint index (SBPI; 2, useful synergy) [which equals
(susceptible breakpoint of A/MIC of A in combination)  (susceptible
breakpoint of B/MIC of B in combination)] was also calculated as a means
to assess the likely clinical relevance of any synergistic activity observed
(17, 18).
Time-kill studies. Six representative A. baumannii isolates were se-
lected for further assessment in time-kill assays to investigate the bacteri-
cidal activity of the combination. COL was used at a final concentration at
or below the clinical pharmacodynamic breakpoint (2 mg/liter), and FD
was added at 1 mg/liter or 0.5 the MIC (in the case of isolate AB 205).
These concentrations were chosen to reflect clinically achievable plasma
levels using standard dosing regimens. Each experiment was performed in
10 ml of ISB supplemented with COL and FD (alone and in combination)
as well as with an unsupplemented growth control. A starting inoculum of
106 CFU/ml was used in each broth and incubated aerobically at 37°C in a
shaking incubator at 224 rpm for 24 h. At 2, 4, 6, and 24 h time points,
100-l aliquots were taken and serially diluted prior to plating onto ISA
with overnight incubation to obtain viable colony counts for each condi-
tion at the selected time points. A 2 log10 CFU/ml reduction in the
colony count in the COL-FD condition at 24 h compared to the most
active single agent was used to define synergy. Additionally, a 3 log10
CFU/ml reduction in the COL-FD colony count compared to the starting
inoculum denoted bactericidal activity with the combination (19).
Colistin heteroresistance was determined by population analysis pro-
filing (PAP). Briefly, 5 ml of ISB containing colistin sulfate (concentration
range, 0.5 to 512 mg/liter) and a drug-free control were inoculated with
106 CFU/ml of each isolate. Following incubation, 100-l aliquots were
spread onto ISA to obtain colony counts. The interpretation of heterore-
sistance was made according to the criteria proposed by El-Halfawy et al.
(20).
Mutational resistance to colistin-fusidic acid. The potential for rapid
emergence of resistance to COL and FD in vitro was assessed by serial
passage in increasing concentrations of the drugs alone and in combina-
tion. These experiments were performed using 3 COL-susceptible (ATCC
19606, AB 14, AB 315) and one COL-resistant (AB 205) A. baumannii
strains, using previously published methods with some modifications (21,
22). Briefly, overnight cultures in ISB were diluted to obtain inocula of 105
CFU/ml and then used in COL-FD checkerboard assays. Following aero-
bic incubation at 37°C for 24 h with continuous shaking (160 rpm), the







FD COL FICIc SBPIc
ATCC 19606 Antibiotic-susceptible type strain 128 0.25 16 0.006 155
AB 12 MDR PFGE-defined UK South East Clone; OXA-51 producer 64 1 16 0.1 43
AB 14 XDR PFGE-defined UK OXA-23 clone 1; OXA-51 and OXA-23
producer; IMP R
128 0.5 15 0.23 42
AB 16 XDR PFGE defined UK OXA-23 clone 2; OXA-51 and OXA-23
producer; IMP R
512 0.5 9.5 0.11 37
AB 184 MDR PFGE-defined UK “T strain”; OXA-51 producer 32 0.5 6.5 0.04 158
AB 186 MDR PFGE-defined UK “Burn strain”; OXA-51 producer 32 0.5 17 0.06 82
AB 205 PDR PFGE-defined UK OXA-23 clone 1; OXA-51 and OXA-23
producer; IMP R and TGC R
32 512 (R) 21.5 0.02 8
AB 210 XDR PFGE-defined UK OXA-23 clone 1; OXA-51 and OXA-23
producer; IMP R
64 0.5 18 0.04 101
AB 211 PDR PFGE defined UK OXA-23 clone 1; OXA-51 and OXA-23
producer; IMP R and TGC R
256 4 (R) 16 0.03 35
AB 219 PDR PFGE-defined UK OXA-23 clone 1; OXA-51 and OXA-23
producer; IMP R and TGC R
64 512 (R) 21.5 0.02 4
AB 315 XDR PFGE-defined UK OXA-23 clone 1; OXA-51 and OXA-23
producer; IMP R and TGC R
256 1 10 0.2 42
a PFGE, pulsed-field gel electrophoresis; IMP, imipenem; R, resistant; TGC, tigecycline; MDR, multidrug resistant; XDR, extensively drug resistant; PDR, pandrug resistant.
b COL, colistin; FD, fusidic acid. MIC results shown are averages from experiments done in triplicate. MICs have been rounded up to the higher 2-fold dilution when falling
between dilutions.
c FICI, fractional inhibitory concentration index; SBPI, susceptible breakpoint index. FICI and SBPI results shown are averages from experiments done in triplicate.
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MICs of COL and FD were recorded together with the well with the lowest
FIC for the combination. Aliquots from wells containing 0.5 the MIC of
the single agents and from wells with growth at 0.5 the MIC of the
COL-FD well with the lowest FIC were diluted 1:1,000 in ISB and used as
the inoculum in the next serial passage experiment for a total of 7 days.
The number of days required for either a 4-fold or 8-fold increase in the
MIC of COL and FD above baseline was used as a measure of the likeli-
hood that resistance would readily emerge.
RESULTS
Synergy was observed between COL and FD against all A. bau-
mannii isolates examined. In disc screening assays, the average
increase in zone diameter around FD discs was 15.7 mm (range,
6.5 to 21.5 mm) (Table 1; Fig. 1A and B). Of note, the largest
increases in zone diameters on COL-supplemented plates were
seen against PDR isolates with COL resistance (MIC, 4 to 512
mg/liter). Synergy was subsequently confirmed in checkerboard
assays for every strain, and the interaction appeared to be partic-
ularly strong, with an average FICI of 0.07 (range, 0.02 to 0.23)
recorded (Table 1). The potency of the combination was reflected
in very high SBPI values (mean, 66.5; range, 4 to 158) and the
potential to achieve efficacy against COL-resistant strains (MIC,
512 mg/liter; SBPI, 4). As no correlation was seen between zone
sizes observed in disc diffusion assays and FICI or SBPI values
derived from checkerboards, a cutoff value (mm) for predicting
likely synergy in a disc diffusion test could not be established.
Time-kill assays identified that the COL-FD combination was
rapidly bactericidal, again versus both COL-susceptible and COL-
resistant strains of MDRAB (Fig. 2). With the exception of AB 205
(a colistin-resistant isolate), all tested isolates exhibited heterore-
sistant properties (23), with regrowth at 24 h despite exposure to
COL at concentrations in excess of the MIC (2 to 4 the MIC) in
time-kill studies. This was confirmed by PAP analysis for ATCC
19606, AB 12, AB 14, and AB 16. This phenomenon was abolished
when FD was added in combination. Resistance to either COL or
FD was easily selected when A. baumannii was exposed to increas-
ing concentrations of either drug alone, with 4-fold to 8-fold in-
creases in COL and FD MICs reached after just 1 to 4 days of
passage (Tables 2 and 3). In contrast, there was little increase in the
FIG 1 (A and B) Disc diffusion synergy screen for isolate AB 205. (A) FD 10-g disc applied onto an unsupplemented ISA plate. (B) Same assay performed on
an ISA plate supplemented with 0.5 the MIC of COL. (C) COL-FD checkerboard for isolate AB 315.
Phee et al.
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MIC above baseline after 7 days of serial passage in the presence of
both drugs compared with the single-agent selection pressure.
Prevention of mutational resistance was particularly marked in
those isolates with a COL-heteroresistant phenotype.
DISCUSSION
A. baumannii is a member of the ESKAPE (Enterobacter, Staphy-
lococcus aureus, Klebsiella, A. baumannii, Pseudomonas, Enterococ-
cus) group of bacterial pathogens for which there is an urgent need
to find new or repurpose existing treatments (24). Finding inno-
vative ways to tackle Gram-negative members of this group is a
priority, given the current trajectory and predicted importance of
these infections over the next decade (25). Many strains of A.
baumannii are already XDR, with polymyxins often the only drug
with any useful activity demonstrated in vitro. Clinical experience
with polymyxin monotherapy in the treatment of MDRAB and
other ESKAPE organisms has been mixed, with the rapid emer-
gence of resistance (26) and frequent reports of clinical failures.
While there remains uncertainty over the optimal treatment of
MDR, XDR, and PDR infections, clinicians frequently resort to
the use of antibiotics in combination.
There are numerous data supporting enhanced antimicrobial
activity when polymyxins are added to other antimicrobial agents
in vitro. A recent meta-analysis concluded that, versus A. bauman-
FIG 2 Time-kill assays conducted with COL and FD versus 5 A. baumannii isolates. Strains (concentrations of COL) used were as follows: ATCC 19606 (0.5
g/ml), AB 12 (2 g/ml), AB 14 (2 g/ml), AB 16 (2 g/ml), AB 205 (2 g/ml), and AB 315 (2 g/ml). Strains (concentrations of FD) used were as follows: ATCC
19606 (1 g/ml), AB 12 (1 g/ml), AB 14 (1 g/ml), AB 16 (1 g/ml), AB 205 (8 g/ml), and AB 315 (1 g/ml).
TABLE 2 Effects of exposure to COL and FD alone and in combination on susceptibility (MIC) of A. baumannii in serial passage experiments
Day Passage condition
MIC (mg/liter) of:
ATCC 19606 AB 14 AB 205 AB 315
COL FD COL FD COL FD COL FD
0 Unexposed 0.25 256 0.25 128 512 64 1 128
7 Single-agent pressure 4 2,048 2,048 2,048 2,048 8,192 1,024 16,384
Combined selection pressure 0.5 512 4 256 512 2,048 1 128
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nii, this activity was most pronounced when polymyxins were
partnered with a carbapenem, rifampin, or glycopeptides (7).
Here, we identified COL and FD as another unorthodox combi-
nation with potent activity against MDRAB. We consistently ob-
served synergy against strains with MDR, XDR, and PDR charac-
teristics belonging to important epidemic MDRAB clones using a
range of assays (agar, microtiter dilution, time-kill). Using static
methods, synergy could be readily shown in a simple disc diffusion
assay, and FIC indices denoting the strength of the interaction
were noted to be particularly low. The combination also pro-
moted sustained bacterial killing when assessed using a time-kill
methodology. Due to the degree of heterogeneity in methodology
and the interpretation of in vitro synergy studies, there is still de-
bate about the relevance of these data to clinical practice (27). This
applies also to our findings, although it should be noted that, when
using SBPI as a marker for useful synergy, values many magni-
tudes above the theoretical pharmacodynamic breakpoint were
observed.
The mechanism of synergy between COL and FD remains to be
determined. In Gram-positive bacteria, FD acts to inhibit protein
synthesis, binding to elongation factor G (EF-G) and locking it to
the ribosome (28). Resistance may arise due to point mutations in
the gene encoding EF-G (fusA) and/or by acquisition and expres-
sion of genes (fusB-fusF) encoding proteins able to act as alterna-
tive substrates (29). Gram-negative bacteria are considered to be
intrinsically resistant due to impermeability (30). Polymyxins act
via an electrostatic interaction with lipopolysaccharide (LPS), dis-
rupting the integrity of the Gram-negative outer membrane and
promoting cell lysis. This may increase permeability to com-
pounds that are usually excluded and is hypothesized to be the
mechanism behind the synergy observed with glycopeptides and
other hydrophobic antimicrobials (31). An inverse relationship
between resistance to polymyxins and susceptibility to other anti-
microbials has been reported (32). Among the COL-resistant
strains studied here, slightly lower MICs were observed for FD (16
to 256 mg/liter). Although overcoming permeability may be im-
portant for the activity of FD against A. baumannii, it is notable
that the combination retained, and even had enhanced, activity
against all the COL-resistant strains. Acquired resistance to COL is
a complex adaptive response involving multiple regulatory path-
ways leading to modifications, loss/alteration of LPS, and changes
to the net charge on the outer membrane (33). High-level resis-
tance in clinical isolates is rare, often unstable, and accompanied
by fitness costs (34), while heteroresistance is frequently observed
and easily maintained with ongoing selective pressure (26).
The potential for FD to limit the emergence of COL resistance
when used in combination was therefore investigated by us. In
time-kill studies, FD prevented the regrowth of COL-heteroresis-
tant strains and, in serial passage experiments, limited the emer-
gence of COL-resistant mutants. This suggests that a COL-FD
combination might limit the emergence of resistance during ther-
apy and be an effective treatment. As the EF-G target is essential
and highly conserved among bacterial species (see Fig. S1 in the
supplemental material), FD-containing combination treatments
might also be useful in combating infections with other resistant
Gram-negative pathogens.
Clinical outcome data on combination therapies for XDR and
PDR A. baumannii strains are sparse and often conflicting. A re-
cent retrospective review of MDR Gram-negative infections
treated with COL in combination with glycopeptides found that
this combination improved survival (35), while another linked it
with only an increased risk of renal impairment (36). Fusidic acid
is licensed in the United Kingdom and Europe, where it is avail-
able as an oral preparation, sodium fusidate. It is widely used as an
adjunctive agent in the treatment of Staphylococcal infections of
the skin and soft tissue, bone and joint, and bloodstream (includ-
ing for infective endocarditis) and against methicillin-resistant
Staphylococcus aureus pneumonia. In the United States, an FD
preparation, CEM-102 (Taksta; Cempra Pharmaceuticals), has
undergone phase II trials for the treatment of Staphylococcal skin
and soft tissue and prosthetic joint infections. The development of
a unique loading-dose regimen has passed a number of regulatory
and financial hurdles, and CEM-102 may be available as a licensed
product in the near future (37).
There may be a number of other advantages, in addition to the
antimicrobial effects we have shown in vitro, in partnering FD
with polymyxins for the treatment of MDRAB. The drug has ex-
cellent bioavailability and widespread tissue penetration into skin,
bone, and the respiratory tract. Unlike polymyxins, it is metabo-
lized in the liver and excreted in the bile (38), potentially reducing
the risk of nephrotoxicity with coadministration. Although FD is
highly protein bound, the free concentrations of both FD and
COL required for synergy appear to be very low and, therefore, are
likely achievable at sites of infection. Adequate penetration into
respiratory tissue and epithelial lining fluid gives the possibility of
combining it with aerosolized COL for the treatment of ventila-
tor-associated pneumonia. FD has also been reported to have
some immunomodulatory effects in terms of cytokine and inter-
leukin production, which may be advantageous in critically ill or
septic patients (39).
The need to administer multiple antimicrobial agents is well
recognized in a number of chronic infectious diseases (mycobac-
terial diseases, bacterial endocarditis, HIV, hepatitis) but less so
with acute bacterial infections. Dual therapy has not often been
TABLE 3 Effects of exposure to COL and FD alone and in combination on preventing the emergence of resistance (time to MIC increase) of A.
baumannii in serial passage experiments
Increase in MIC Passage condition
Time to MIC increase (days)
ATCC 19606 AB 14 AB 205 AB 315
COL FD COL FD COL FD COL FD
4 Single-agent pressure 3 4 2 5 4 2 1 2
Combined selection pressure NRa NR 7 NR NR 6 NR NR
8 Single-agent pressure 4 7 3 7 NR 2 1 4
Combined selection pressure NR NR 7 NR NR 7 NR NR
a NR, not reached by the final day (day 7) of experiment.
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shown to be superior to monotherapy when given empirically for
the treatment of Gram-negative sepsis (9). However, in the setting
of MDR, XDR, and PDR infections where the organism is already
known, combinations as a targeted definitive therapy may be
more appropriate. A fuller understanding of the properties and
efficacy of FD combinations in dynamic (hollow fiber) and animal
models, along with more clinical data, is needed before this ap-
proach can be recommended. However, FD is another example of
an old antimicrobial that may be fit for repurposing and develop-
ment as an adjunctive agent for use in the treatment of MDR
Gram-negative infections.
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8.3 Appendix C (CD rom) – Video clip 7785 
demonstrating injection of a G. mellonella 7786 
larva, and simulation of the distribution of 7787 
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